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Short Abstract 
 
Nucleoside, nucleotide and nucleic acid researches have been attracting much attention in 
recent years for their useful and promising biological and therapeutical application. This 
class of molecules results                 
in efficient tools not only as “molecular sensors”, but also to modulate well identified 
cellular activities, introducing an interdisciplinary approach going from the biomedical and 
biotechnological research to the clinical treatment of many diseases, until technological 
applications in nanoscience field. 
Synthetic oligonucleotides (ON) of 15-17 bases having characteristic sequences can be 
efficient gene expression inhibitors or, more generally, regulators, selectively interfering 
with the normal biological functions of nucleic acids or of specific proteins. 
Oligonucleotides, addressed to the control of a specific gene expression, can be 
catalogued, on the base of their target and mechanism of action, in “antisense” or 
“antigene”, when they target a specific mRNA or a tract of duplex DNA, respectively, or as 
“aptamers”, when selectively recognize a specific protein. 
The first part of my research work has been addressed to synthesize and study two main 
classes of ON analogues, with potential biological  properties: 
1) ON analogues able to form stable triple helices 
2) ON analogues able to form new monomolecular quadruplex complexes 
Then, special attention has been devoted to structural investigation on the complexes 
formed by the synthesized oligonucleotides. 
Pharmacological structural investigations on complexes formed by modified ONs and 
synthetic models of their natural targets (mRNA, DNA or proteins), essentially carried out 
by NMR spectroscopy associated with mechanic and molecular dynamics calculations, 
allow a better comprehension of specific recognition mechanisms. This is useful to design 
new rational structural modifications to be introduced in synthetic  ONs.                 
Recently, medicinal chemistry research emphasizes the need of nucleoside and nucleotide 
analogues in high number and diversity, to be used as building blocks in the synthesis of 
new ON generations. Apart from being the genomic building blocks, nucleosides interact 
with roughly one-third of protein classes in the human genome, all targets of therapeutic 
importance in biological systems. Many nucleoside and nucleotide synthetic analogues 
have been the cornerstone of antiviral therapy over the past 30 years, and many others 
also exhibit anti-proliferative, antibiotic and antifungal properties. The rapid development of 
drug resistance and high toxicity that characterize the use of these agents, suggest the 
novel nucleoside drug discovery for critical medical needs. The availability of high-
throughput  screening capabilities together with the combinatorial synthesis of small 
organic molecule libraries offers a unique  opportunity to accelerate the discovery in these 
fields. 
The usefulness of mimics in this field  is not only as a pharmacological tool, but also in the 
elucidation of the mechanism of natural analogues action, labelling of binding proteins or 
antagonizing of their activities. 
In these contests, the second part of my research has been employed and addressed on 
such targets: 
3) Synthesis of combinatorial libraries of nucleosides, specifically inosine      
     analogues 
4) Synthesis of new cIDPR (cyclic hypoxanthine-diphospho-ribose) analogues,   
     designed  as novel stable mimics of cADPR, a potent Ca2+-mobilizing second            
     messenger.                                                                                                                   
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Long Abstract 
 
Il principale obiettivo delle ricerche in campo farmaceutico-farmacologico è l’ottenimento di 
un farmaco che sia in grado di interagire col suo bersaglio in modo specifico o, almeno, 
altamente selettivo. La progettazione di un tale farmaco su base razionale richiede una 
conoscenza dettagliata del suo bersaglio, che non sempre è disponibile nel caso in cui 
esso sia una proteina. La situazione è certamente più favorevole quando il bersaglio è un 
DNA o un RNA perché la struttura e le funzioni di tali classi di molecole sono meglio 
conosciute nelle grandi linee e, soprattutto, perché sono certamente più chiari i 
meccanismi di riconoscimento molecolare in cui esse sono coinvolte. Perché una 
molecola, quale potenziale farmaco, sia in grado di interagire specificamente con un 
particolare acido nucleico, deve essere capace di “leggere” una sequenza non più breve di 
16-18 basi. L’unica molecola capace di fare ciò è un altro acido nucleico. Per questo 
motivo, nell'ultimo decennio l'interesse verso gli oligonucleotidi sintetici (ON) è cresciuto. 
Gli ON deputati a queste funzioni, possono essere catalogati in base al tipo di bersaglio e 
al loro meccanismo d’azione. Essi possono agire come molecole “antisenso” o “antigene”, 
i cui target sono, rispettivamente, uno specifico mRNA ed un tratto di DNA a doppia elica, 
o come aptameri, cioè riconoscere in maniera assolutamente selettiva una proteina. 
La strategia antisenso si basa sul riconoscimento specifico della sequenza bersaglio di 
uno specifico mRNA da parte di un ON avente sequenza complementare mediante 
formazione di un ibrido DNA-RNA stabilizzato da legami Watson-Crick[1] .  
La formazione di tale ibrido porta, attraverso vari meccanismi, al blocco della sintesi della 
relativa proteina. Nel secondo caso, l'ON agisce ancora più a monte, avendo come 
bersaglio un tratto di DNA con il quale forma una tripla elica legandosi nel solco maggiore 
del DNA duplex. La formazione di questi complessi localizzati a tripla elica può impedire le 
interazioni dei geni con i necessari fattori di trascrizione o fisicamente bloccare l’iniziazione 
o l’elongazione del complesso di trascrizione[2]. 
Il processo di riconoscimento molecolare alla base di questa strategia è estremamente 
selettivo, essendo assicurato dalla formazione di triplette di basi stabilizzate da legami 
idrogeno, secondo schemi di tipo Hoogsteen o reverse Hoogsteen[3].Oltre alla elevata 
specificità d’azione, un ON rappresenta un farmaco ideale dal punto di vista 
farmacodinamico, perché può agire ad una concentrazione cellulare molto bassa. Tuttavia, 
l’impiego terapeutico è limitato da diversi problemi farmacocinetici, come la loro scarsa 
capacità di penetrare le membrane cellulari e la  veloce degradazione ad opera delle 
nucleasi cellulari. Per ovviare a questi inconvenienti, sono stati progettati e sintetizzati vari 
ON analoghi e, dopo circa un ventennio di studi, si è oggi arrivati all’approvazione dei primi 
ON antisenso come farmaci antivirali, mentre altri sono in avanzata fase di 
sperimentazione clinica come antitumorali. Le applicazioni antigene sono ulteriormente 
limitate dal fatto che, sul DNA duplex bersaglio, è necessaria la presenza di tratti 
omopurinici-omopirimidinici lunghi almeno 16-18 coppie di basi. Per ampliare il numero di 
sequenze di DNA riconoscibili mediante formazione di strutture triplex, Horne e Dervan[4], 
seguiti poi da altri gruppi di ricerca, hanno proposto l'utilizzazione di ON contenenti 
un'inversione di polarità, per il riconoscimento di duplex a sequenza mista del tipo 
(purina)m(pirimidina)n.  
Un'ulteriore applicazione terapeutica degli ON sintetici è costituita dal loro potenziale 
impiego come aptameri[5]. Un aptamero è un ON in grado di assumere una conformazione 
che gli consenta di interagire specificamente con una particolare proteina, modulandone la 
funzione. La dimostrazione che corti frammenti di DNA o di RNA sono in grado di legare 
specificamente alcune proteine, fa sì che essi non vengano più considerati solo come 
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trasportatori dell'informazione genetica ma anche come biomolecole coinvolte in diversi 
processi cellulari.  Gli ON aptameri, sono acidi nucleici a doppio o a singolo filamento 
capaci di legare e quindi inibire particolari proteine coinvolte nei processi di controllo 
genico. In questa classe rientrano anche gli ON con sequenze poli-G, formanti quadruple 
eliche di DNA caratterizzate dalla strutturazione di quartetti di guanine. Il crescente 
interesse verso tali strutture è legato alla scoperta dell'attività inibitoria che alcuni ON 
sintetici, in grado di formare quadruplex, mostrano nei confronti di alcune importanti 
proteine quali la trombina e l'integrasi dell'HIV-1[6-7], quest'ultima responsabile 
dell'integrazione del DNA virale in quello della cellula ospite. L’importanza e l’attualità degli 
studi in questo campo deriva anche dal fatto che, sequenze telomeriche del gene, ricche 
di deossiguanosine, possono formare complessi a quadrupla elica[8]. Queste strutture, 
probabilmente presenti all'estremità 3' dei telomeri degli eucarioti e dei procarioti, 
potrebbero giocare un ruolo importante nella regolazione dell'attività telomerasica. 
L’epressione ubiquitaria della telomerasi nelle cellule tumorali e la sua ridotta attivita’ nelle 
cellule normali ha suggerito l’ipotesi del coinvolgimento di questo enzima nel processo di 
carcinogenesi. E’ stato ipotizzato che le sequenze telomeriche del gene, strutturandosi in 
quadrupla elica (quadruplex), riescono a regolare l’attivita’ della telomerasi[9]. In tale 
ambito le G-quadruplex risultano utili aptameri[5] per le proteine che regolano la lunghezza 
dei telomeri dei geni nelle cellule eucariote, influenzando i meccanismi di senescenza e 
carcinogenesi cellulare. Di qui, il duplice interesse farmacologico verso le strutture 
quadruplex del DNA, inibizione specifica di alcune proteine (funzionamento come 
aptamero) o bersaglio per l’azione di farmaci antitumorali[10]; inoltre esse rappresentano  
validi modelli di studio per le interazioni aptamero-proteina. Recenti studi ne hanno inoltre 
evidenziato un’applicazione “non farmacologica” suggerendo che strutture G-quadruplex 
possano essere utilizzate come micro-conduttori di elettricità, grazie alla capacità di 
trasferire elettroni lungo la quadrupla elica[11-12]. Inoltre, queste strutture, in ragione della 
capacità di selezionare particolari conformazioni e della loro elevata stabilità, sembrano 
ottime candidate nella costruzione di nano-materiali e nano-meccanismi, questi ultimi 
basati su cambi conformazionali controllati e ripetitivi.  Tutte queste promettenti possibilità 
di utilizzo degli ON rendono necessaria la progettazione e la sintesi di nuove generazioni 
di  ON  opportunamente modificati, allo scopo di individuare nuove e piu’ efficaci 
applicazioni in campo biochimico e biomedico. Studi strutturali, eseguiti mediante tecniche 
di risonanza magnetica nucleare (NMR)  associate a calcoli di meccanica e dinamica 
molecolare, sugli ON naturali e/o modificati e sui vari complessi  che questi possono 
formare con i relativi bersagli, permettono una migliore comprensione dei meccanismi di 
riconoscimento che regolano le interazioni tra queste molecole. Le informazioni, così 
ottenute, possono essere utilizzate per una più razionale progettazione delle modifiche 
strutturali da introdurre sugli ON sintetici, al fine di ottimizzarne le proprietà biologiche. In 
tale ambito, la ricerca medica piu’ recente enfatizza il bisogno di sintetizzare nucleosidi e 
nucleotidi in elevato numero e diversità, per poter realizzare una vasta collezione di ON 
opportunamente modificati. Più che la sintesi classica, sembra che le metodiche sintetiche 
combinatoriali in fase solida possano soddisfare tale esigenza. Questa strategia permette, 
inoltre, di ottenere classi di molecole che differiscono in maniera puntiforme intorno ad una 
struttura centrale con potenziale attività farmacologica,  rivestendo notevole interesse nella 
realizzazione di nuovi farmaci antivirali e antitumorali. L’elevata rapidità di sviluppo di 
fenomeni di resistenza dei virus, nonchè la tossicità che si registra in concomitanza 
all’impiego di antivirali e antitumorali, sono indicativi di un crescente bisogno di ottenere 
nuove molecole in tale ambito. L’enorme versatilità dei nucleosidi, legata non solo al fatto 
che costituiscono le unità base del patrimonio genetico, ma anche alla loro capacità di 
interagire con piu’ di un terzo delle proteine umane, tra cui polimerasi, chinasi, reduttasi, 
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recettori di membrana e proteine strutturali, spiega il notevole bisogno di avere nuovi 
analoghi nucleosidici, terapeuticamente attivi contro tutti questi target biologici. La natura 
stessa offre diversi esempi di  analoghi nucleosidici capaci di agire selettivamente come 
inibitori della sintesi proteica (puromicina), inibitori della glicosil transferasi  (tunicamicina), 
ed inibitori della metil transferasi (sinefungina). 
Da piu’ di 30 anni, analoghi sintetici dei nucleosidi trovano impiego nella terapia delle 
infezioni virali. Attualmente, i nucleosidi e nucleotidi analoghi presenti sul mercato sono 
circa 50, mentre piu’ di un’ottantina sono in fase di studio (pre) clinico non solo come 
antivirali ma anche con attività antitumorale, antifungina, etc. Tra questi annoveriamo 
l’arabinosilcitidina e la 5-aza-citidina utilizzate per il trattamento di leucemie e la 5-
iodouridina utilizzata per le infezioni da virus Herpes Simplex; inoltre l’aciclovir, un farmaco 
antivirale appartenente alla classe degli aciclonucleosidi;  la 3’-tiocitidina (3TC), inibitrice 
della trascrittasi inversa virale, usata contro le infezioni di epatite B; ed il 3’ -azido-3’-
deossitimidina (AZT) il più importante  nucleoside anti-HIV. Sebbene la ricerca sui 
nucleosidi modificati sia fortemente finalizzata alla possibilità di una loro applicazione 
diretta  nella pratica clinica, non è da trascurare il fatto che numerosi nucleosidi e 
nucleotidi  svolgono anche un ruolo centrale nel metabolismo cellulare, come modulatori 
endogeni delle funzioni cellulari.  Ciò presuppone la possibilità di utilizzo di tali molecole 
come utili modelli per meglio comprendere i meccanismi relativi a processi biochimici a cui 
prendono parte analoghi nucleosidici naturali. Un esempio è rappresentato dall’adenosina 
- 5' -  difosfato – ribosio - ciclico (cADPR), un metabolita endogeno intimamente coinvolto 
nella regolazione della concentrazione dello ione calcio intracellulare [ Ca+2]i , in misura 
maggiore dell’ inositolo-1,4,5-trifosfato (IP3) ed in maniera indipendente da esso. Poiché lo 
ione Ca2+ è coinvolto nella regolazione di diverse funzioni cellulari, come la contrazione 
muscolare, la secrezione di neurotrasmettitori, di ormoni ed enzimi responsabili della 
fertilizzazione degli ovociti, nonché nell’attivazione e proliferazione dei linfociti T[13], la 
cascata dei segnali modulata dal cADPR diventa un interessante target farmacologico. 
L’interesse verso il cADPR non è limitato solo alle sue potenzialità farmacologiche, esso 
infatti sembra essere utile nella delucidazione del suo meccanismo d’azione, nello 
screening delle proteine coinvolte nel suo metabolismo e nella sua attività regolatoria, 
nonché nello studio e nel design di analoghi del cADPR. Tutto questo potenziale pool di 
applicazioni risulta inficiato dalla sua scarsa stabilità in condizioni fisiologiche (t1/2= 24h). Il 
cADPR è caratterizzato da un  legame N-1-glicosidico fortemente labile, suscettibile a 
rapida idrolisi sia enzimatica, ad opera della cADPribosio-idrolasi, sia non-enzimatica, con 
formazione del prodotto di idrolisi ADP-ribosio, già in soluzione acquosa neutra[14]. Tuttavia 
il suo importante coinvolgimento biologico rappresenta uno stimolo forte verso la 
progettazione e la sintesi di nuovi analoghi sufficientemente stabili e farmacologicamente 
utili. In questo contesto si inserisce il mio programma di ricerca svolto nei tre anni di 
dottorato. 
In sintesi, la mia attività di ricerca è stata indirizzata ed ha prodotto risultati nel campo 
della : 
 
• Sintesi di librerie combinatoriali di nucleosidi  (nella fattispecie analoghi 
dell’inosina). 
Obiettivo di questo lavoro di ricerca è stato la realizzazione di una metodologia 
sintetica versatile ed efficace mirata, in un primo momento, all’ottenimento di una 
collezione di analoghi N-1-alchilati dell’ inosina e poi estesa  ai corrispondenti 2’,3’-
seco-N1-alchil-inosina derivati, i quali, in virtù dell’analogia strutturale con composti 
a riconosciuta attività antivirale, quali  il ganciclovir, il penciclovir ed altri, potrebbero 
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costituire target molecolari estremamente interessanti nell’ambito della 
chemioterapia antivirale. 
La disponibità di strategie sintetiche basate su una chimica semplice ed efficiente, 
quale la chimica combinatoriale e sull’utilizzo di materiali di partenza poco costosi e 
facilmente reperibili costituisce un obiettivo molto ambito per la sintesi di mimetici di 
composti naturali. 
La  ricerca attuale nel campo dei nucleosidi ad attività antivirale, ma anche 
antitumorale, antifungina, etc. è indirizzata verso la scoperta di nuovi analoghi 
caratterizzati da un’ampio spettro di attività biologiche e da un’elevata specificità 
d’azione al fine di minimizzare gli effetti collaterali di queste molecole. Per 
rispondere all’esigenza di avere, in tempi brevi, un elevato numero di analoghi 
nucleosidici  da saggiare nelle loro eventuali proprietà farmacologiche , in questa 
tesi  è stata messa a punto una strategia di sintesi in fase solida di una collezione di 
analoghi ciclici e aciclici (2’,3’-seco-) dell’inosina, differenziati per la lunghezza della 
catena alchilica lineare in posizione N-1 della base ipoxantina. In letteratura sono 
riportati diversi esempi di strategie combinatoriali in fase solida per la preparazione 
di librerie di nucleosidi e piccoli oligonucleotidi analoghi. In ogni caso, qualunque sia 
l’approccio seguito, un requisito fondamentale è la scelta di un linker appropriato 
che funga da ponte tra il nucleoside e il supporto solido. Esso deve essere 
sufficientemente stabile alle condizioni di reazione usate durante la sintesi, ma allo 
stesso tempo abbastanza labile nelle condizioni di rimozione dal supporto solido 
senza inficiare l’integrità dei prodotti d’interesse.  
La strategia seguita per la sintesi combinatoriale in fase solida di derivati N-1-
alchilati dell’inosina è basata su studi[15], condotti in precedenza dal gruppo di 
ricerca presso cui ho svolto il lavoro di ricerca, sulla reattività dell’ N-1-dinitrofenil-2’-
deossi-inosina nei confronti di nucleofili all’azoto, al fine di ottenere inosine N-1 
sostituite e AICAR derivati. Questo approccio è stato utilizzato anche da altri gruppi 
di ricerca per introdurre una base purinica modificata all’interno di oligonucleotidi. 
Per estendere queste reazioni alla strategia combinatoriale in fase solida, si è usato 
un supporto polistirenico, disponibile commercialmente, a cui è legato 
covalentemente il gruppo MMTCl (monometossi-tritil-cloruro). Questo tipo di 
supporto, già utilizzato efficientemente, come riportato in letteratura, per legare 
nucleosidi o zuccheri, ha la peculiarità di essere stabile in condizioni alcaline, e 
viceversa molto labile in condizioni acide. A tale supporto è stato ancorato 
l’ossigeno 5’ del ribosio della 2’,3’-O-isopropiliden-N-1-(2,4-dinitrofenil)-inosina, con 
formazione del corrispondente legame etereo 5’-O-tritilico. 
Ancorato il nucleoside al supporto solido, è stata saggiata la reattività al carbonio C-
2 dell’anello purinico nei confronti di diversi nucleofili amminici al fine di costruire 
una prima libreria di nucleosidi modificati. La procedura ha fornito, previo distacco 
dal supporto solido, i prodotti desiderati in ottima resa. 
Passo successivo è stato quello di studiare la reattività dell’anello ribosidico 
modificando le posizioni 2’ e 3’. Questo ha previsto l’aggancio diretto alla resina del 
nucleoside N-1-(2,4-dinitrofenil)-inosina non protetto alle funzioni ossidriliche 2’ e 3’, 
vista l’instabiltà del legame 5’-O-etereo alle condizioni di rimozione 
dell’isopropilidene. La condensazione tra il nucleoside e il supporto solido è risultata 
selettiva a carico delle funzioni alcoliche primarie, in accordo con quanto riportato in 
letteratura. Dopo alchilazione della posizione N-1 dell’ inosina, seguendo la 
strategia prima descritta, è’ stata presa in esame la reazione di scissione del 
legame C-C 2’-3’ da parte di composti ossidanti come il periodato (IO4-). L’azione 
del periodato di sodio (NaIO4) sui nucleosidi deprotetti è ben conosciuta[16]. La 
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dialdeide risultante non è stata isolata, ma ridotta direttamente con sodio boroidruro 
(NaBH4). I prodotti di interesse sono stati ottenuti in buona resa. 
Lo studio ha riguardato quindi la sintesi di nuovi nucleosidi analoghi quali potenziali 
agenti terapeutici ed ha condotto all’ottenimento di derivati che verranno poi 
sottoposti a saggi biologici per poterne testare l’eventuale attività terapeutica[17]. 
 
• Sintesi di nuovi derivati del cIDPR (ipoxantina-difosfo-ribosio ciclico) 
progettati come nuovi analoghi del cADPR, un potente secondo messaggero 
coinvolto nella mobilizzazione dello ione [Ca+2]i 
 
Nell’ambito di tale tematica mi sono interessata della sintesi di nuovi analoghi del 
cADPR, al fine di saggiarne le eventuali proprietà farmacologiche, di comprendere 
la relazione tra la struttura e l’attività di tale molecola, intimamente coinvolta nella 
regolazione della concentrazione di calcio intracellulare. Il cADPR esplica una 
funzione fondamentale nella regolazione del Ca+2 , pertanto risulta di grande 
interesse disporre di un numero maggiore di informazioni circa i meccanismi 
attraverso i quali quest’ azione viene regolata. Purtroppo lo studio del ruolo 
fisiologico del cADPR è fortemente limitato dal ruolo transiente di tale molecola[18]. 
Allo scopo di ottenere analoghi del cADPR di pari attività, ma caratterizzati da un 
più stabile legame N-1 ribosidico, sono stati sintetizzati numerosi composti 
strutturalmente correlati ad esso, da utilizzarsi sia come modelli per comprendere la 
relazione struttura-attività, sia per le loro eventuali proprietà farmacologiche. 
In letteratura sono riportati diversi esempi di analoghi stabili del cADPR, in alcuni 
casi anche più attivi dell’analogo naturale stesso. Uno dei primi è stato l’ N-1-
aristeromicina-adenina-difosforibosio ciclico[19]  in cui l’ossigeno del ribosio in N-1 è 
sostituito da un gruppo metilenico. Questo composto risulta essere resistente sia 
all’ idrolisi chimica, sia a quella enzimatica dal momento che non c’è piu’ il legame 
N-1glicosidico presente nel cADPR. Alcune modifiche strutturali sull’adenina 
forniscono derivati più potenti del cADPR, è il caso del 3-deaza-cADPR avente  
un’attivita 70 volte superiore[20]. Ulteriori modifiche strutturali includono il legame 
pirofosfato:  il cATPR  è,  non solo più stabile, ma anche più attivo nell’indurre il 
rilascio di Ca+2 ( 20 volte maggiore) rispetto alla controparte cADPR[21]. Ulteriori 
studi struttura-attività, eseguiti utilizzando derivati opportunamente modificati al 
ribosio in posizione N-1 e alla funzione amminica in C-6 dell’ adenina, indicano che 
questi  non sono punti critici  nell’attività del cADPR. Pertanto il cIDPR e diversi suoi 
analoghi sono stati sintetizzati. Essi mostrano possedere un’aumentata stabilità 
rispetto al cADPR e sembrano conservarne l’attività in alcuni sistemi cellulari, come 
le cellule-T, in cui sono stati saggiati[22]. Pochi studi sono stati condotti per provare 
la farmacoforicità del ribosio in posizione N-9 della base adenina. Preliminari studi 
suggeriscono che il gruppo 3’-ossidrilico è essenziale nell’attività di rilascio del 
[Ca+2]i. Risulta interessante, pertanto, investigare ulteriormente su tale residuo, allo 
scopo di verificare se l’attività del cADPR sia legata  solo alla presenza dei gruppi 
OH sul ribosio in N-9 o necessiti anche della rigidità dell’ unità ribosidica.  La sintesi 
di nuovi analoghi N-9-aciclici che conservano solo le funzioni ossidriliche del ribosio 
ma non la rigidità dell’anello, è parte del mio lavoro di ricerca svolto nei tre anni di 
dottorato[23]. 
 
• Sintesi di TFO (oligonucleotidi formanti tripla elica) coniugati ad un residuo di 
acridina in prossimità del sito di inversione 3’-3’, che, fungendo da 
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intercalante, stabilizzi la struttura triplex, compensando eventuali 
destabilizzazioni dovute alla giunzione 3’-3’. 
 
Per quanto concerne questo punto, l’unica metodica sintetica finora proposta risulta 
alquanto complessa e di non facile applicazione. Con questo lavoro si vuole 
proporre un’alternativa sintetica più semplice che consenta la realizzazione di ON-
coniugati ad un residuo di cloro-metossi-acridina. 
A tale scopo si è pensato di sfruttare la reattività all’alchilazione mostrata dall’N-3 di 
una timidina fiancheggiante il legame fosfodiestereo 3’-3’ e la stabilità dimostrata 
dai complessi a doppia e tripla elica di DNA contenenti intercalanti, o altri gruppi 
legati all’N3 di un residuo di timidina[24]. Tra le varie molecole note per le loro 
proprietà intercalanti e stabilizzanti triplex, la scelta è ricaduta sull’acridina sia per 
l’elevato numero di derivati commercialmente disponibili, ma anche perché quando 
coniugata a sequenze ON  è capace di indurre un più selettivo  cleavage del DNA, 
in presenza di  ioni metallici e per esposizione a fotoirradiazione. La formazione e la 
stabilità dei complessi a tripla elica, ottenuti usando come TFO l’ON-coniugato 
all’acridina, su descritto, sono state valutate  a diversi pH, nell’intervallo 5.5-7.0, 
mediante  studi di denaturazione termica UV e CD (dicroismo circolare), risonanza 
magnetica nucleare e studi di meccanica e dinamica molecolare[25]. La stabilità di 
tali complessi è stata confrontata con quella ottenuta utilizzando le corrispondenti 
sequenze oligonucleotidiche naturali[25]. Le informazioni provenienti da tali studi 
forniscono altresì valide indicazioni per la razionalizzazione delle modifiche 
chimiche più adatte per gli ON. 
 
• Sintesi e caratterizzazione di nuovi analoghi oligonucleotidici capaci di    
     formare quadruple eliche di DNA monomolecolari, o “oligonucleotidi a    
     grappolo”. 
 
 Le strutture a quadrupla elica sono caratterizzate dalla formazione di quartetti di 
guanine connesse da legami idrogeno di tipo Hoogsteen (quadruplex parallele) o 
reverse- Hoogsteen (quadruplex antiparallele). Questi complessi possono essere 
classificati in base al numero dei filamenti oligonucleotidici che li compongono (uno, 
due, quattro) e in base all’orientamento degli ON formanti il complesso (parallelo o 
antiparallelo). Benché la maggior parte delle strutture G-quadruplex con attivita’ 
biologica siano di tipo antiparallelo, recenti studi hanno evidenziato interessanti 
attività anche per quadruplex parallele. Infatti quadruplex parallele interagiscono 
selettivamente con alcune proteine[26], inoltre, è stata osservata per alcuni di questi 
complessi, una attività anti-HIV[5] ed anche attivita’ di aptamero verso 
l’ematoporfirina[5]. Quadruplex parallele si formano quasi esclusivamente in 
complessi tetramolecolari. Sfortunatamente, in vivo, la formazione intermolecolare 
di complessi quadruplex e’ molto lenta e necessita di alte concentrazioni di ON, non 
facilmente raggiungibili in condizioni fisiologiche. Gli sfavorevoli parametri cinetici e 
termodinamici sono quindi un ostacolo alla potenziale utilizzo farmacologico di 
questo tipo di complessi. Di qui l’interesse per  la sintesi e la caratterizzazione 
strutturale di un nuovo tipo di quadruplex parallela monomolecolare formata da 
oligonucleotidi legati a “grappolo”[27]. In particolare, la struttura oligonucleotidica a 
grappolo prevede che i quattro filamenti, formanti il complesso quadruplex, siano 
legati reciprocamente per le estremità 3’ attraverso una molecola ramificata 
simmetricamente. Questa nuova tipologia di quadruplex dovrebbe essere 
caratterizzata da una maggiore stabilita’ e da una veloce cinetica di strutturazione 
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rispetto ai corrispondenti complessi tetramolecolari,  ipotesi confermate dai risultati . 
La sintesi della molecola “linker” tetraramificata (catene dialchilfosfato) avviene su 
supporto polimerico insolubile. Ogni ramificazione contiene una funzione alcolica 
terminale a cui è possibile legare la catena oligonucleotidica. Studi iniziali sono stati 
effettuati sintetizzando ON a grappolo aventi sequenza TGGGT. Modulando 
opportunamente i gruppi protettori delle funzioni alcoliche delle struttura ramificante 
e la tipologia di accrescimento della catena oligonucleotidica, sono state ottenuti 
ON a grappolo formanti strutture quadruplex con orientamento dei filamenti 
predefiniti (paralleli, antiparalleli o con orientazione mista) [28-29]. La maggiore 
stabilità ipotizzata per questa nuova classe di analoghi e confermata mediante 
esperimenti NMR e CD (dicroismo circolare), ha condotto ad estendere lo studio 
anche relativamente a  sequenze oligonucleotidiche naturali formanti strutture 
quadruplex caratterizzate da bassa stabilità , ad esempio contenenti A-tetradi e T-
tetradi[30-31]. Questa nuova tipologia di quadruplex sarà inoltre estesa a complessi 
contenenti filamenti ibridi DNA-PNA. L’accresciuta stabilità delle quadruplex 
monomolecolari potrebbe portare alla formazione di stabili quartetti di guanine nei 
tratti di PNA, finora mai osservati. 
Il mio progetto di ricerca, in tale ambito, ha previsto, inoltre, l’ottimizzazione della 
lunghezza del linker tetraramificato ai fini sia di una maggiore stabilizzazione  della 
struttura quadruplex, sia per poter selezionare quadruplex antiparallele da strutture 
sintetizzate a filamenti pre-orientati a polarità inversa[32]. E’ noto che la polarità dei 
filamenti in una quadruplex riveste fondamentaleimportanza nelle interazioni  con 
proteine o altre molecole. Una quadruplex può essere parallela o antiparallela in 
ragione della sua molecolarità, della sequenza di basi e, in alcuni casi, in ragione 
della sequenza e tipologia dei loop di connesione che si realizzano tra i filamenti 
formanti la quadruplex. La strategia degli ON a grappolo trascende da tutte queste 
limitazioni e consente di preparare quadruplex antiparallele,  purchè si utilizzino 
linker di opportuna lunghezza. L’eccessiva  lunghezza del linker tetraramificato, 
infatti, sembra compromettere la formazione della quadruplex antiparallela 
favorendo la formazione della struttura parallela per ripiegamento dei loop alchilici, 
come dimostrano i dati ottenuti da calcoli di meccanica molecolare condotti in tale 
ambito. La lunghezza del linker sembra anche giocare un ruolo di cruciale 
importanza sulla riproducibilità e velocità dei meccanismi di melting e refolding delle 
strutture quadruplex a grappolo. Preliminari studi CD/T (dicroismo circolare al 
variare della temperatura), eseguiti su vari analoghi caratterizzati da una diversa 
lunghezza del linker, indicano che la specie con l’unità tetraramificante più corta sia 
il deputato migliore su cui fare studi su nanomotori. Infine una particolare attenzione 
è stata rivolta alle indagini strutturali sui complessi formati dagli oligonucleotidi 
sintetizzati. I dati ottenuti mediante impiego di tecniche spettroscopiche, quali CD, 
NMR mono- e bidimensionale, eseguiti a diverse temperature ed in vari tamponi, 
hanno consentito di caratterizzare le strutture di tali complessi. 
E’ stato inoltre valutato anche il diverso effetto stabilizzante dovuto alla presenza di 
cationi potassio e sodio. I dati ricavati dalla spettroscopia NMR, inseriti in metodi di 
calcolo (Cyana e Dyana) consentiranno di proporre valide strutture per i complessi 
studiati.  
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Prefaction 
 
In these  researches, carried out in  three years of PhD in Biotechnology, (Molecular-
Biotechnology), I focused my attention on Nucleic Acid chemistry. Particularly, I 
investigated two main aspects of this field: the chemistry and the structural 
characterization  of some nucleic acid derivatives  and the synthesis of several new 
nucleoside and nucleotide analogues. 
For a greater convenience of exposition, I wish to report the results  arranged in two main 
sessions: 
 
• Synthesis and structural characterization of oligonucleotides (ON) analogues.  
• Synthesis of nucleosides and nucleotides analogues. 
 
To these researches the publication of the following articles ensues: 
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Chapter 1 
 
“General Introduction” 
 
1.1. Synthesis and structural characterization of oligonucleotide (ON) analogues  
 
In recent years, the most important goal of researches in the field of medicinal chemistry is 
the achievement of a drug capable to interact with its target in a specific or, at least, highly 
selective way. The rational design of such a drug requires a detailed knowledge of its 
target, which is not always available if this is a protein. More favourable is certainly the 
case where the target is a DNA or a RNA, since structures and functions of these classes 
of molecules are better known and, above all, mechanisms of molecular recognition in 
which they are involved have been clarified in details. In order that a molecule, as a 
potential drug, may specifically interact with a particular nucleic acid, it has to be able to 
read a sequence not shorter than  16-18 bases. At the best of the present knowledge, the 
only molecule capable to do this is another nucleic acid. This is the reason why, in the last 
decade, interest towards synthetic oligonucleotides (ONs) has been growing, in 
consideration of their use as selective regulators of genetic expression. Oligonucleotides, 
addressed to the control of a specific gene expression, can be catalogued on the base of 
their target and mechanism of action, in “antisense” or “antigene”, when they target a 
specific mRNA or a tract of duplex DNA, respectively, or as “aptamers”, when selectively 
recognize a specific protein. Antisense strategy, for gene regulation, is based on the 
specific recognition of the target mRNA sequence by synthetic ONs having complementary 
sequence by formation of a duplex structure stabilized by Watson-Crick hydrogen bonds. 
In this way the formation of duplex DNA-RNA hybrids is achieved, which can give rise to 
various processes through which the translation of the message is efficiently inhibited. In 
antigene strategy, an ON acts at a higher level, having as a target a double-stranded DNA, 
with which it forms a triple helix (triplex) blocking its transcription. The recognition of a 
double stranded DNA by an ON is highly specific, being based on the formation of base 
triplets stabilized by hydrogen bonds, according to Hoogsteen or reverse Hoogsteen 
schemes. An ON represents an ideal drug from a pharmacodynamic point of view, being 
capable to act in an absolutely specific way and at low cellular concentration. On the other 
hand, an ON, as a drug, is characterized by a number of pharmacokinetic drawbacks. 
Potential therapeutic applications of natural ONs are, in fact, limited by the poor cellular 
uptake and the rapid degradation promoted by cellular nucleases. To overcome these 
problems, several ON analogues have been designed and synthesized and, after more 
than two decades of studies, the first antisense ONs have been recently introduced in 
therapy as antiviral drugs, while others are currently in clinical trials as antitumor agents. 
Antigene applications, in addition to showing the same problems as the antisense strategy, 
are further limited by the request of homopurine-homopyrimidine tracts of 16-18 bases on 
the target, namely a double-stranded DNA. To expand the number of biologically relevant 
DNA sequences, as targets by triplex structures formation, Horne and Dervan, then 
followed by other research groups, proposed the use of ONs containing an inversion of 
polarity motif, i.e. a 3'-3' internucleosidic linkage, to target mixed sequence duplexes of the 
type (purine)m(pyrimidine)n. In order to stabilize the 3'-3' internucleosidic linkage, my 
research work was addressed into synthesis of oligonucleotides with a 3’-3’ inversion 
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of polarity, containing an acridine moiety attached to the nucleotide base flanking the 3’-3’ 
phosphodiester bond, able to form more stable alternate strand triple helix complexes. 
These have been investigated by UV melting studies and CD experiments.  
A further therapeutical application of synthetic ONs is their potential use as aptamers.  An 
aptamer is an ON able to adopt a proper conformation allowing it to specifically interact 
with a particular protein, thus modulating its function. The evidence that short DNA and 
RNA fragments are able to specifically bind several proteins lead to the consequence that 
they are no longer considered as only passive carriers of genetic information, but also as 
bio-molecules involved in many key cellular processes. ONs as aptamers are single, 
double or quadruple strand nucleic acids able to selectively recognize, bind and inhibit 
specific proteins involved in gene control expression or in the development of particular 
disease.  ONs characterized by a G-rich sequence and adopting a G-quadruplex structure, 
could be considered useful aptamers for the control of the cellular senescence and 
carcinogenesis. Furthermore, recent studies on biological activities of synthetic ONs 
forming quadruplex structures, suggest that these molecules can act as inhibitors of 
important proteins such as thrombine and HIV integrase. However, the biological 
importance of these complexes lies in their possible presence in gene telomeric 
sequences. Quadruplex structures (G-quadruplex), generated by a DNA tract containing a 
G-rich sequence, are located at the 3’-end of telomeres, where they probably play an 
important role in the regulation of the telomerase activity. Telomerase is the most 
important enzyme involved in telomere maintenance in tumour cells, identified so far. The 
high activity of this enzyme inhibits the senescence and the death  of tumour cells. This 
hypothesis has originated a large number of studies on the inhibition of the telomerase by 
ONs forming quadruplex structures (G-quadruplex-aptamers). Quadruplex complexes are 
characterized by the formation of G-quartets connected by Hoogsteen hydrogen bonds. G-
quadruplexes can be classified depending on the number of self-associating strands that 
form the structure (one, two or four strands) and are further distinguished by the 
orientation of the strands (parallel or antiparallel). Even though most of the G-quadruplex 
structures involved in biomolecular events belong to the antiparallel type, yet evidences 
have been provided that some proteins are able to interact with parallel G-quadruplex as 
well. Biological relevance of such structures has further risen due to the discovery of ONs 
forming parallel quadruplexes, including aptamers characterized by an anti-HIV activity 
and hematoporphyrine binding aptamers. Parallel quadruplex are found almost exclusively 
in tetramolecular complexes. Unfortunately, the in vivo formation of intermolecular 
quadruplexes is very slow, requiring high ONs concentration. These unfavourable kinetic 
and thermodynamic parameters could be disadvantageous in view of their potential 
therapeutic use. In this contest, another  goal of my research program has been aimed to 
the synthesis and the structural characterization of a new kind of monomolecular G-
quadruplex formed by ONs linked through a tetra-end-linked (TEL) structure. Particularly 
the structural feature of this TEL-ON, forming the quadruplex, is the presence of four ON 
strands whose 3’-ends are linked together by a symmetric tetra-branched spacer. The 
formation of a monomolecular quadruplex could be characterized by favourable kinetic and 
thermodynamic parameters and the complex could be more stable than the corresponding 
tetramolecular counterpart. Preliminary results, on the synthesis and stability of this new 
kind of quadruplexes, carried out in our laboratory, confirmed this hypothesis. The 
synthesis of the symmetric tetra-branched linker have been carried out on polymeric 
support. This branched structure bears four primary alcoholic functions prone to ON chain 
assembly (for example TGGGT o TGGXGGT, where X is a variable base). By choosing 
appropriate alcoholic protecting groups of the linker structure and the ON chain assembly 
procedure, TEL-ONs having predetermined strand orientation (parallel, antiparallel or both) 
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or containing modified bases, have been obtained. Moreover, quadruplex complexes, 
containing less stable quartets such as A-tetrads, C-tetrads, T-tetrads, mixed tetrads, as 
well as tetrads formed by modified nucleosides could be synthesized. In this contest, the 
chemical synthesis of TEL-oligonucleotides prone to form quadruplex structures containing 
G- and T-tetrads has been performed. This new kind of stable quadruplex structure could 
be extended to the complexes containing DNA-PNA hybrid strands. It is reasonable to 
hypothesize that the  increased stability of these new monomolecular quadruplexes could 
permit the formation of PNA guanine quartets, not observed so far. Pharmacological 
structural investigations on complexes formed by synthesized ONs and synthetic models 
of their natural targets (mRNA, DNA or proteins), have been essentially carried out by 
NMR spectroscopy associated with mechanic and molecular dynamics calculations, in 
order to allow a better comprehension of specific recognition mechanisms. This is useful to 
design new rational structural modifications to be introduced in synthetic ONs, to optimize 
their properties and the related biological response.  
Briefly, the first session of my thesis research have been employed and addressed on :  
 
• Synthesis of TFO (Triplex Forming Oligonucleotides) containing a 3’-3’ polarity 
inversion site conjugated to moieties (acridine residue) capable to stabilize  the 
triple helix complexes or to supply particular biological activities. 
 
• Synthesis and characterization of new kind ON analogues able to form stable  
monomolecular quadruple helices DNA complexes (Tetra-End-Linked  
Oligonucleotides TEL-ON).  
In this contest, studies on the length of tetra-end-linked linker on the orientation of 
the ON strands aimed  at of obtaining  stable quadruplex structures and studies on 
quadruplex complexes, containing less stable quartets such as T-tetrads, have 
been performed, too. 
 
Then, special attention has been devoted to structural investigation on the complexes 
formed by the synthesized oligonucleotides. The use of spectroscopy methods, nuclear 
magnetic resonance (NMR) and mass spectrometry (MS) above all, associated with 
molecular mechanism and dynamic studies, result fundamental to allow a deep insight into 
molecular recognition mechanism in which the synthesized molecules are involved. 
Particularly, all synthesized molecules have been purified by HPLC and structurally 
characterized by MS spectrometry, NMR spectroscopy and CD analysis. The stability of 
triple helix complexes have been evaluated by thermal denaturation studies using both UV 
and circular dichroism spectroscopy (at several pH and buffer composition). Furthermore, 
the stabilization effect of Na, K cations for quadruplex complexes, have been evaluated. 
The obtained data have been allowed a further insight into specific recognition 
mechanisms. Physico-chemical studies on the stability of triple and quadruple helices have 
been also carried out. These studies provide detailed information on the energetic of DNA 
high-order structure formation on changing the pH, temperature and base composition. 
Differential scanning calorimetry (DSC), circular dichroism (CD) and computational 
methods have been used to characterize triple and quadruple helices formation. Finally, 
studies are currently in progress in order:  i) to extend the synthetic strategy employed to 
link  other agents near to 3’-3’ phosphodiester linkage, thus furnishing a convenient 
method to stabilize alternate strand triple helices; ii) to assay TEL-ON in their potential 
wide range of biological properties. 
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1.2.  Synthesis of nucleoside and nucleotide analogues 
 
The second part of my research thesis has been aimed to the synthesis of new 
nucleosides and nucleotides analogues. 
Recently, medicinal chemistry research emphasizes the need of nucleosides and 
nucleotides analogues in high number and diversity, to be used as building blocks in the 
synthesis of new ON generations. Apart from being the genomic building blocks, 
nucleosides interact with roughly one-third of protein classes in the human genome, 
including not only polymerases but also kinases, reductases, motor proteins, membrane 
receptors and structural proteins, all targets of therapeutic importance in biological 
systems. Naturally occurring nucleosides analogues demonstrate selective activities, such 
as protein synthesis inhibitors (puromycin), glycosyl transferase inhibitors (tunicamycin), 
and methyl transferase inhibitors (sinefungin). Synthetic analogues of nucleosides have 
been the cornerstone of antiviral therapy over the past 30 years. Actually, approximatively 
50 nucleosides and nucleotide-related drugs have been pushed to the market and over 80 
nucleosides/tides are in the (pre) clinical studies for various therapeutic indications, 
including not only antivirals but also antineoplastics, antifungins  and others. However, 
some drugs such as AZT, ddI, 3TC, etc. rapidly develop drug resistance and show 
mitochondrial, bone-marrow and other toxicity. Therefore, it is essential to discover novel 
nucleoside drugs for critical medical needs. The availability of high-throughput  screening 
capabilities, together with the combinatorial synthesis of small organic molecule libraries, 
offer a unique opportunity to accelerate the discovery in these fields. At this purpose, 
recently, I’m looking for the solid phase synthesis of nucleoside and nucleotide libraries. 
Preliminary studies in this contest allowed the realization of a small library of N1-alkylated 
inosine, N1-alkylated- 2’,3’-seco-inosine and AICAR derivatives. Finally, nucleosides and 
nucleotides are also rated as the central molecules of metabolism, playing a strategic role 
as endogenous regulators of cell functions. An example is represented by  cyclic ADP-
ribose, a 18-membered cycling nucleotide. Cyclic ADP-ribose (cADPR) is an endogenous 
metabolite shown to mobilize intracellular Ca+2 in various cells, indicating that it is a 
general mediator involved in Ca+2 signalling. It is also known to mobilize intracellular Ca+2 
more actively than inositolo-1,4,5-triphosphate (IP3) by a mechanism completely 
indipendent of IP3. Since Ca+2 are regulators of diverse cell functions, e.g. muscle 
contraction, secretion of neurotransmitters, hormones and enzymes fertilization of ovocyte 
and lymphocyte activation and proliferation, the cADPR signalling pathway may become a 
valuable target for pharmaceutical intervention. The usefulness of cADPR is not only as a 
pharmacological tool, but also in the elucidation of the mechanism of cADPR action, 
labelling of binding proteins or antagonizing Ca2+ mobilization. cADPR is synthesized from 
NAD+ by ADP-ribosyl-cyclase in cells, and it is characterized by a very labile N1-glycosidic 
bond, which is rapidly hydrolized both enzimatically, by cADP-hydrolase, than non-
enzimatically, to give ADP-ribose even in a neutral aqueous solution. Therefore, stable 
analogues of cADPR that have a Ca+2 -mobilizing activity in cells similar to that of cADPR 
are urgently required. In this contest my research work have been addressed on synthesis 
of new stable analogues of cADPR, particularly N-9 ribose modified derivatives.  
Briefly, my studies in nucleoside and nucleotide analogues research have been addressed 
on such targets: 
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• Synthesis of combinatorial libraries of nucleosides, specifically inosine analogues. 
 
• Synthesis of new cIDPR (cyclic hypoxanthine-diphospho-ribose) analogues,  
designed  as novel stable mimics of cADPR, a potent Ca2+-mobilizing second  
messenger. 
 
Studies are currently in progress in order to obtain both new and largest libraries of 
nucleoside analogues and new cADPR analogues, that will be screened against a wide 
range of their respective biological assays. 
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Chapter 2 
 
“Synthesis of TFO (Triplex Forming Oligonucleotides) containing a 3’-3’ polarity 
inversion site conjugated to moieties (acridine residue) capable to stabilize  the triple 
helix complexes or to supply particular biological activities” 
 
Introduction 
 
The remarkable conformational flexibility of nucleic acids allows for the formation of a great 
variety of structures besides the canonic B-DNA duplex. Among these structures, those 
involving more than two strands have received considerable attention in the last decade[1]. 
The are two main reasons for the intense interest in such multistranded structures. First, 
there is more than circumstantial evidence for their biological role in replication, 
transcription and recombination[2]. Second, several multistranded motifs are used as the 
basis of some therapeutic approaches[3]. Nucleic acids have the potential to form not only 
double helix structures but also triple and quadruplex structures[4]. Despite a lack of direct 
evidence for the tertiary structure of nucleic acids  in vivo, the presence of H-DNA was often 
considered  to regulate gene transcription  and the sequence-specific  DNA ligands of the 
triplex forming oligonucleotides (TFOs) have been proven to target specific  mutations in 
somatic cells of adult mice after intraperitoneal injection[5]. TFOs bind specifically to duplex 
DNA and provide a strategy for site-directed modification of genomic DNA, figure 2.1. The 
recognition of double-stranded DNA by a single stranded TFO provides a technique for site-
specific genome modification in living cells. Moreover, the oligonucleotide-directed triplexes 
were extensively applied for sequence-specific modification to recognize the double-
stranded nucleic acids targets or the cleavage of nucleic acids[6]. These potential gene-
targeted therapeutic and biotechnological applications have provoked considerable interest 
in triplex formation and stability. 
 
 
 
Figure 2.1: Basic antigene concepts and corresponding applications. 
 
Fensefeld et al.[7] described the first example of the formation of triple helical nucleic acids 
structures in 1957. A decade later, transcription inhibition of Escherichia coli RNA 
polymerase by an RNA third strand was reported by Morgan and Wells[8], demonstrating a 
potential biological role  of triplex structures. Subsequently, synthetic oligonucleotides 
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designed to form triplexes have been used in a variety of applications to manipulate genes 
and gene function both in vitro and in vivo. TFOs have been used to inhibit protein binding 
to DNA, to inhibit gene expression, to inhibit DNA replication, to direct site-specific damage, 
to enhance recombination and to induce mutagenesis[9]. The process of down-regulating  
gene expression, through  triple helix formation, is referred to as the “antigene strategy”.  
Triple helix formation has also been utilized in the development of artificial nucleases, 
created by tethering a cleavage-agent to a triplex forming oligonucleotide. Binding 
characteristics of TFOs depend on their nucleotide composition. Thus, oligonucleotides 
composed of pyrimidine bases (C and T) bind through Hoogsteen hydrogen bonds and are 
oriented parallel to the purine-rich strand of the target duplex, forming  C+* G.C and T* A.T 
triplets, figure 2.2.  
 
 
 
Figure 2.2: Molecular structures of the canonical Hoogsteen and reverse Hoogsteen 
 base triplets in the known parallel and antiparallel triple helical binding motifs. 
 
TFOs composed of purine bases (G and A), or mixed purine/pyrimidine (G and T) bind in 
anti-parallel orientation through reverse Hoogsteen bonds, forming G* G.C and A* A.T or T* 
A.T triplets[10]. In certain circumstances GT-TFOs can bind in parallel orientation[11]. 
Protonation of cytosine is required to form two Hoogsteen bonds in C+* G.C triplets, so that 
binding of CT-TFOs is favoured by low pH. Triplex formation by GA and GT-TFOs is pH 
independent. Binding, in each of these motifs, can occur in physiological conditions, 
although cytosines must be modified to overcome pH dependence of CT-TFOs. Purine-rich 
tracts are frequently found in gene promoter regions and TFOs, directed to these regulatory 
sites, have been shown to selectively reduce transcription of the targeted genes, likely by 
blocking binding of transcriptional activators and/or formation of initiation complexes. 
Triplex-mediated  modulation has potential application in therapy since it can be used, for 
example, to reduce levels of proteins thought to be important in disease processes. TFOs 
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can also be useful molecular tools for studying gene expression and function. An example 
is  the down-regulating expression of the c-myc oncogene in cancer cells. c-myc is an 
attractive target for antigene agents in cancer cells because its expression drives cell 
proliferation[12]. The importance of c-myc in cancer cell growth is emphasized by the 
findings that it is frequently amplified or involved in chromosomal rearrangements and that 
its expression  is deregulated and augmented  through various mechanisms in many 
cancers. Functions of the c-myc  protein, in tandem with its obligatory binding partner Max, 
include transcriptional activation and repression. Both activities appear to promote cell 
proliferation. Recent studies demonstrated that reduced expression of inducible c-myc was 
sufficient to cause regression of hematologic tumours in mice, suggesting that this 
approach may have therapeutic potential. Several sequences, suitable for triplex formation, 
are present in the c-myc gene. Of particular interest is a highly conserved 
polypurine/polypirimidine  tract in the c-myc P2 promoter region. P2 is the major c-myc 
promoter and gives rise to 75-90% of transcripts in almost all cells, with P1 contributing 
most of the remainder. TFOs  directed to P2 sequence had transcriptional inhibitory activity 
in vitro and in cells. 
 
2.1.  DNA triple helix formation. 
 
The primary requirement for triple helix formation is a homopurine-homopyrimidine 
sequence in the target duplex. Tipically, the third strand sequence is also homopurine or 
homopyrimidine. Depending on the nature of the third strand, there are two many 
categories of triple helices: pyrimidine*purine.pyrimidine (pyr*pur.pyr) or 
purine*purine.pyrimidine (pur*pur.pyr), where * represents Hoogsteen  base pair formation 
between the third strand and the purine strand of the duplex and . denotes the Watson-
Crick base pair of the duplex. Pyr*pur.pyr triplex is less stable at low pH because the 
cytosines, on the third strand, require protonation in order to form Hoogsteen hydrogen 
bonds with the purine strand of the duplex. In contrast, pur*pur.pyr triplexes are stable at 
neutral pH. Thermal denaturation studies on pur*pur.pyr triplexes often reveal a single 
transition, suggesting the simultaneous dissociation of all three strands. In most examples 
of a  pyr*pur.pyr triplexes, a biphasic transition is observed, with the third strand  
dissociating at a lower temperature than the duplex. This suggest that a pyrimidine third 
strand may be less stable, in general, than a purine third strand. Unlike the Watson-Crick 
base-paired double helix, in which the two strands are bound antiparallel to each other, the 
third strand of a triple helix can be either parallel or antiparallel with respect to the purine 
strand  to which it is hydrogen-bonded. The polarity of the third strand in the triplex is 
dependent on the sequence as well as the base composition. A homopyrimidine  third 
strand, containing cytosine and/or thymine, binds  to the purine strand in a parallel 
orientation.  The binding of a homopurine oligonucleotide to the purine strand depends on 
the sequence. Experimental evidence has been reported for both parallel and antiparallel  
orientations of the third strand in triplexes composed solely of G*G.C triplets. But if the third 
strand contains both Gs and As, the polarity of the third strand will be antiparallel with 
respect to the purine strand, since As with anti-glycosidic bond conformations can form only 
reverse-Hoogsteen  hydrogen bonds and hence direct the oligonucleotide in an antiparallel 
orientation[13]. Hogan and co-workers[14] have been reported antigene activity of 
oligonucleotides composed of G and T bases. However, there have been only a limited 
number of physical studies on triplexes  formed by  such sequences. Helene and co-
workers[15] have demonstrated that the orientation of a GT-third strand depends on its 
sequence. Calculations indicate that a 10-mer triplex whose third strand is composed of 
equal number of G and T bases, the third strand will be antiparallel to the duplex purine 
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strand if there are three or more GpT or TpG steps; otherwise it will be parallel. According 
to the calculations of Sun and Helene, this can be explained in terms of a balance between 
the preference for the parallel orientation (Hoogsteen hydrogen bonding) in an all G-third 
strand and the better tolerance for the lack of isomorphism between G*G.C and T*A.T 
triplets in the antiparallel orientation ( reverse Hoogsteen hydrogen bonding). 
Radhakrishnan et al.[16]  have been carried out NMR studies on an intramolecular triplex 
composed of a third strand containing Gs and one T. These studies provided clear 
evidence for the distortion induced by insertion of a T*A.T triplet within a stack of G*G.C 
triplets. 
 
2.1.1. Hoogsteen base-pairing. 
In double stranded DNA, whether in A-, B-, Z-form, the complementary strands are held 
together solely through Watson-Crick (W-C) base-pairing geometry. The hydrogen bonds 
orchestrate base-pairing between dA.dT or dG.dC and maintain the geometric structure of 
regular double-helical DNA. Over 40 years ago, K.Hoogsteen discovered a novel type of 
hydrogen bonding between adenine and thymidine, termed Hoogsteen base-pairing 
geometry[17]. These  pairings involve either purines or pyrimidines interacting  with the sites 
on purine bases, that are not involved in W-C hydrogen bonding (N7 and O6 for guanine, 
N7 and N6 for adenine)[18]. Hoogsteen base pairs have quite different properties from W-C 
base pairs. The angle between  the two glycosylic bonds (ca. 80° in the A.T pair) is larger 
and the C1’-C1’ distance (8.6 Å) is smaller than in the regular geometry. In some cases, 
called reversed Hoogsteen base pairs, one base is rotated 180° with respect to the other[19], 
figure 2.2. Since the discovery  of Hoogsteen base-pairing, forms of DNA double helix 
containing both inter- as well as intra-strand Hoogsteen and reverse Hoogsteen base pairs 
have been discovered in crystal structures of undistorted B-DNA[20], DNA complexed with 
intercalating drugs[21], protein/DNA complexes[22]  and RNA[23]. The Hoogsteen base pairs 
are frequently engaged by proteins and ligands to interact with DNA. With the recent 
discovery of the formation of Hoogsteen base pairs, during DNA replication and pairing of 
double stranded DNA-helices, it is an exciting time for those interested in the biochemistry 
of specialized DNA structures[24]. 
 
2.1.2. Natural Hoogsteen-bonded triplexes. 
Naturally occurring homopurine/homopyrimidine sequences can fold into triplex 
configuration by binding a third strand of DNA or RNA in the major groove of W-C duplex 
DNA, through Hoogsteen or reverse Hoogsteen hydrogen bonds[25]. The purine strand of 
the W-C duplex engages the third strand through Hoogsteen hydrogen bonds in the major 
groove while maintaining the original duplex structure in a B-DNA like conformation. 
Triplexes offer exiciting persectives  both toward oligonucleotide-directed control of gene 
expression  and their formation in vivo as H-DNA. The latter is believed to be involved in 
diverse DNA transaction processes including DNA replication, gene transcription, 
recombination, and genome instability[26]. In H-DNA a long homopurine/homopyrimidine 
sequence donates the third strand of DNA to an adjacent compatible double helical 
acceptor. Interestingly, in silico analysis suggests that sequence capable to adopting DNA 
structures are very abundant in the human genome[27]. In contrast to other DNA secondary 
structure-forming sequences, which are typically located in the intergenic or intronic 
regions, H-DNA forming sequences are found embedded most frequently in promoters and 
exons and have been shown to be involved in regulating the expression of several disease-
linked as well as normal genes. If H-DNA structure were to occur in vivo, it is likely that their 
formation or dissociation would involve cellular proteins that specifically recognize triplex 
DNA. Recently, studies with anti-triplex DNA monoclonal antibodies have found evidence 
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for triplexes in metaphases chromosomes[27] and an inhibitory effect on cell proliferation 
when the antibodies are introduced into cells before mitosis. This lead to the hypothesis 
that triplexes and their binding proteins serve as a bridge between the mitotic fuse and 
chromosomal DNA to facilitate proper chromosome segregation.  
 
2.2.  pH and cation effects on the properties of DNA triplexes. 
 
Potential gene-targeted therapeutic and biotechnological applications have provoked 
considerable interest in triplex formation and stability. The formation pathway of a triplex is 
significantly pH dependent and fell in three groups: under acidic conditions, the triplex is 
formed by a one-step docking, under near physiological conditions, the Watson-Crick 
duplex is first structured and then accepts the Hoogsteen third strand into its major groove, 
and under basic conditions, the triplex is not formed. In general, parallel triplexes are 
expected to be more stable than anti-parallel triplexes. However, their pH dependence 
might limit their physiological stability. The pH dependent thermodynamics can be study via 
circular dicroism (CD) and UV analysis. 
 
2.2.1. Protonation effect on the triplex thermodynamic 
To evaluate the possible effect of protonation on the different base pairs and backbones, 
the pH dependent thermodynamics of the Py*Pu.Py triplex, the Py.Pu antiparallel duplex 
and the parallel Py*Pu duplex were studied under identical conditions. These data indicate 
that the thermodynamic stabilities of the Py*Pu.Py triplex and the Py*Pu duplex are clearly 
pH-dependent and are enhanced with decreasing pH, while Py.Pu duplex shows a slight 
reduction under the same conditions. This suggests that protonation has two opposite 
effects: one is to promote the stabilities of the Py*Pu.Py triplex and Py*Pu duplex, the other 
is to decrease the stability of the Py.Pu duplex. In addition, under acidic conditions free 
energy of the global triplex is much smaller than the sum of the free energies of the free 
Py.Pu duplex and free Py*Pu duplex. This suggests that a larger energy would be required 
to disrupt the H*W.C triplex compared to individually disrupting the Py.Pu duplex and Py*Pu 
duplex. Alternatively,  the triplex is a more stable complex than expected and its unfolding 
would be the one-step collapse of the global molecule  under acidic conditions. 
 
2.2.2. Ionic strenght effects on triplex stability 
The stability of a triplex can be influenced by the ionic strength and mixture of monovalent 
and divalent cations. The effect of the Na+ have been investigated[28].  Particularly, at low 
Na+ and strand concentrations, the melting temperatures of the Hoogsteen transition  are 
too small to be determined, and they are not osservable increasing only Na+ 
concentrations. Although the melting temperature of both the Hoogsteen and Watson-Crick 
transitions increase with increasing Na+ concentrations, suggesting that the stability of the 
Hoogsteen paired strand more strongly depends on the ionic strength than does that of the 
Watson-Crick paired duplex. Moreover, if the third strand dC residues in the triplex were 
uncharged at pH=7, then one would expect a positive ionic strength due to the high 
negative charge density arising from the negatively charged phosphates on the three 
strands. Such  ionic strength dependence of stability is the norm for duplexes and triplexes 
with uncharged bases, e.g. poly U*A. U. In contrast, inverse salt dependence of Tm at 
moderate ionic strengths is observed with duplexes stabilized by ionic interactions, as in the 
case of poli C+.C and poli- A+ . A+ Similarly, when the NaCl concentration increase above 
0.9M, third strand binding results destabilized. This reversal of salt dependence to 
increased shielding by the Na+, resulting in a reduced affinity of the dC residues for H+ and 
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a decrease in the electrostatic attraction between the C+-G Hoogsteen base pair and also 
the dC+ residues and the phosphodiester backbone of the duplex.  
 
2.2.3 Cation effect on the triplex thermodynamic 
The stability of the negatively charged DNA is explicitly dependent on the counterions. The 
influence of various cations, such as an alkali metal (Na+), alkali-earth metals (Mg2+, Ca2+ 
and Ba2+) and transition metals (Mn2+, Co2+, and Zn2+), have been investigated[29]. The data 
indicate that the thermodynamic stability of a triplex is much greater with divalent cations 
than with monovalent cations, and almost a 100-fold concentration of Na+ is required to 
stabilize the triplex as effectively, as Mg2+ or Mn2+ [30].  This may be related to the valence-
specific cationic stability of the triple helix structure. In the series of Mg2+ , Mn2+ , Ca2+ , and 
Ba2+ , the Watson-Crick duplex stability in the triplex increases from left to right (Mg2+ > 
Mn2+ > Ca2+ > Ba2+). This order is in good agreement with the ionic radii of the divalent 
cations (rMg2+= 0.66 Å, rMn2+= 0.80 Å, rCa2+= 0.99 Å, and rBa2+= 1.34 Å) and suggests that the 
divalent cations with a smaller radius may increase the affinity of the nucleotide alignment, 
resulting in enhancing the stability of the double helix structure. Interestingly, the order of 
the divalent cations, for stabilizing the W-C duplex in the triplex, is consistent with that for 
stabilizing the free W-C duplex, but it is different from the Hoogsteen paired strand one. 
This suggests that the interaction of divalent cations stabilize the global triplex in an order 
nearly identical to that for stabilizing the host W-C duplex, due to the large difference in free 
energy between the W-C duplex and the Hoogsteen paired strand. The influence of divalent 
cations on Py*Pu.Py triplexes shows a slight difference on the Pu*Pu.Py triplexes. Since the 
protonation at N3 of Hoogsteen cytosine residues plays a key role in stabilizing the 
Py*Pu.Py triplex structure, while the Pu*Pu.Py triplex doesn’t require this precondition, the 
interaction of divalent cations with a triplex may be very different for the two classes of 
triplexes. It has been reported that Mg2+  is crucial for the formation of the Pu*Pu.Py 
triplexes, but not for the formation of the Py*Pu.Py triplexes[31]. Another possibility may be 
due to the differences in buffer species, pH value, and base sequences. 
 
2.3.  Triplex applications  
 
The sequence specificity of triplex forming molecules and their ability to compete 
successfully with other DNA binders gives these molecules great potential as tools to alter 
gene expression. Permanent heritable genetic changes can be induced by recombination 
and mutagenesis, while gene expression can be regulated by inhibition of RNA 
transcription. In figure 2.3 are reported six key means by which TFOs can be used to 
directly alter gene expression.  In figure 2.3a is illustrated how transcriptional processes can 
be stopped by two different strategies. Both strategies are based on the binding of TFO to a 
target site and the subsequent creation of a physical block to a normal cellular process. 
Figure 2.3b shows both the use of TFOs to deliver a tethered mutagen as well as the ability 
of a TFO to cause mutagenesis within its binding site, even when not conjugated to a DNA 
reactive molecule. Figure 2.3c highlights two examples of experimental protocols in which 
TFOs have been used to promote homologous recombination between repeat sequences, 
which can be induced by TFO binding alone, and homologous recombination of a target 
genome site with a donor fragment, that is localized to its target by the TFO. 
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Figure 2.3: TFO alteration of gene expression. (a) Blocking of transcription with transcription factors or by 
interference with elongation. (b) TFO directed site – specific mutagenesis. (c) Gene correction via 
homologous recombination.  
 
2.3.1. Transcription 
Altered gene expression can be made via inhibition of transcription of extrachromosomal 
reporter genes and it seems best achieved through the binding of regulatory rather than 
coding sequence. TFO  can bind in regulatory regions and compete with the binding of 
transcription factors, thereby preventing the initiation of transcription. Studies have shown 
that TFOs can bind to their genomic target in vitro, and in cells within the chromatin 
structures[32]. In vitro studies have shown highly specific TFO binding at regulatory sites in 
physiologic conditions, in this way TFOs block transcription and/or inhibition of regulatory 
protein factors binding. Some studies show that triplex binding sequences, which are tightly 
associated with nucleosomes, cannot be targeted unless the nucleosome association is 
removed. There have also been some successes in targeting the coding region rather than 
the regulatory region of a gene, such as the block of various polymerases.  
 
2.3.2. Genome modification 
TFOs can also create permanent heritable changes in the genome. A number of studies 
have shown that TFOs are able to increase rates of site-specific mutagenesis [33] and site 
specific recombination[34]. 
 
2.3.3. Triplex-directed mutagenesis 
Both purine and appropriately modified pyrimidine TFOs have been used to direct 
mutagens to specific DNA sites. One such agent was psoralene. Psoralene-linked TFOs 
intercalate and bind covalently to duplex DNA when activated with long wavelength UVA 
irradiation increasing mutagenesis  both in vitro ( plasmid targets) and in mammalian cell 
culture lines. Wang et al. observed  that plasmide mutagenesis rates in cells were highly 
dependent upon binding affinity  and delivery concentration. TFOs with Kds in the range of 
a 
b 
c 
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10-9 M were able to induce mutagenesis, whereas those with Kds of 10-6 M were not. 
Studies with psoralene-linked TFOs also produced the first evidence that chromosomal 
sites could be targets for mutagenesis. More surprisingly is the discovery that in absence of 
psoralene, however, only purine TFOs result able to induce genomic changes (either 
mutagenesis or recombination) via the effects of third-strand binding alone. Recently 
Vasquez et al.[33] demonstrated that systematically administered TFOs could induce 
mutation at specific genomic sites in the somatic cells of adult mice (figure 2.4). 
 
 
 
Figure 2.4: Experimental protocol to detect site-specific genome modification by  
                  systematically administered TFOs in mice. 
 
In this work, a 30mer purine modified TFO containing a 3’- propanolamine group to prevent 
exonuclease-mediated degradation was injected intraperitoneally for 5 consecutive days. 
The TFO was targeted to chromosomal copies of a λsupFG1 reporter vector. After an 
additional 10 days, the mice was killed and tissues analyzed. The mice treated with the 
sequence specific TFO showed  a 5-fold elevated mutation rate in the target gene 
λsupFG1, than in the non-targeted cII gene. All tissues tested resulted have mutation, 
except the brain. This is consistent with TFOs being unable to cross the blood-brain barrier. 
 
2.3.4. Triplex-induced recombination 
Non-covalent triplexes formed by purine TFOs result active in stimulating repair and 
recombination in cell extracts, in cell culture and even in mice. Studies in human cell 
extracts and in DNA repair-deficient human cell lines have revealed the ability of non-
covalent purine motif triplexes to provoke recombination  in a manner dependent on the 
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nucleotide excision repair (NER) pathway[35]. In chromosome targeting work, two mutant 
thymidine kinase (TK) genes were integrated into a single chromosome site in mouse 
fibroblasts, followed by transfection of the cells via cationic lipids. High-affinity TFOs 
targeted against a region between the two TK-genes, stimulated recombination at a 
frequency of 6-7-fold above background and when the TFOs were microinjected into the 
nuclei of the cells, the yield increased up to 3000-fold[36]. These results suggested that 
TFOs could induce recombination at a chromosomal locus in mammalian cells, and 
highlighted the need for effective intranuclear delivery, to increase levels of targeted 
genome modification. The observation that the third strand binding can provoke DNA repair  
and stimulate recombination provides  a strategy to mediate targeted gene conversion 
using a TFO linked to a short donor DNA fragment, figure 2.3c. The donor fragment was 
homologous to the target site, except for the base pair to be corrected [37]. In this bi-
functional molecule, the TFO domain mediates site-specific binding which direct the donor 
to the desired gene. This binding is proposed to trigger, repair or sensitize the target site to 
recombination. Gamper et al.[38], using a bi-functional oligonucleotide, consisting of a 
guiding TFO domain and a strand invading homology domain, demonstrated strand 
invasion of a supercoiled plasmid DNA in an in vitro study. Interestingly, physical TFO-
linkage to the donor was unnecessary. A co-mixture of separate TFO and donor segments 
also yielded elevated gene correction frequencies. This latter result confirmes TFO ability to 
promote recombination between the target site and a third, unlinked DNA molecule, if it is 
present in high concentration. However, mechanistic question remain unanswered. Though 
pathways have been implicated in the mutagenesis and recombination effects of TFOs, the 
exact mechanism are unknown. Studies occur to establish the precise cellular processes 
that play a role in mediating these genetic changes. It is also of interest to determine which 
factors can influence the availability of genomic targets to DNA binding molecules: 
transcription levels, cell cycle phase, nucleosome binding and histone state may all play 
important roles. A major long term goal of the field is to develop TFOs as tools for the target 
modification. Efficiency, delivery  and genome availability must be reconsidered. The rate of 
mutagenesis remains at a fraction of a percent. Recently, techniques for the intracellular 
production of a single-stranded DNA molecule have been developed such as the use of 
vectors to produce TFOs intracellularly. However, disease, which require the majority of 
cells in a tissue to be corrected, may not be amenable to triplex technology. Instead, triplex 
technology is probably applicable to certain hematologic, metabolic and hepatic disease 
that requires a small percentage  of the target cells to ameliorate the phenotype of the 
disease.  
 
2.3.5. Other applications: properties of functional molecules conjugates-TFOs  
Oligonucleotides covalently linked with functional molecules have been attracting current 
interest because of their widespread biological usage. Interesting results have been 
obtained in the application of functional molecules conjugates-TFOs,  that provide new 
potential tools for altering gene function. For example, Helene et al.[39] have reported that 
oligodeoxynucleotide (ON) attached to a phenanthroline-copper chelate at the 5’- termini 
cleaves DNA by triple-stranded formation showing high specificity. Miller et al.[40] have 
shown that methylphosphonate-ONs covalently linked to psoralen and targeted single-
stranded DNA give cross-linked duplexes by cicloaddition reaction under photoirradiation.  
TFOs can be conjugated to non-specific antitumour drugs, such as  camptothecin[41] that 
normally induce massive non-specific DNA damage in cells, converting topoisomerase I 
into a cell poison by blocking the relegation step, thereby enhancing the formation of 
persistant DNA breaks responsible for cell death. Triplex-forming oligonucleotide-
camptothecin conjugates (TFO-CPT) can bind in a sequence specific manner to the major 
                                                                                                                         CHAPTER 2    Synthesis of TFO 
15 
 
groove of double helical DNA and positions the drug selectively  at the triplex site, thereby 
stimulating topoisomerase I–mediated DNA-cleavage at this site.  TFOs are also designed 
to contain a chelating agent, such as a bipyridine moiety[42]. Transition metal complexes-
containing oligonucleotides can be involved in the study of electron transfer processes, as 
well as in the development of artificial nucleases characterized by a high sequence-
specificity and efficiency. In fact, a metal centre tethered to a particular sequence  could 
enable the complex to oxidatively modify or cleave a nucleic acid target. However, drug-
conjugated TFOs can be used to enhance drug-selectivity and  to improve lower toxicity. 
Daunomycin-conjugated TFOs (dauno-TFOs) are able to down regulate  promoter activity 
and transcription of the target endogenous gene. Particularly, Myc-targeted-dauno-TFOs 
inhibits growth and induced apoptosis of prostate cancer cell constitutively expressing the 
gene, in a sequence specific and triplex mediated manner. To test the selectivity of dauno-
TFOs, they have been examined on growth of normal human fibroblasts, which express low 
levels of c-myc. Despite their ability to inhibit c-myc transcription, dauno-TFOs failed to 
inhibit growth of normal fibroblasts at concentration that inhibited growth of prostate cancer 
cells. In contrast, daunomycin inhibited equally fibroblasts and prostate cancer cells[43]. 
These data indicate that dauno-TFOs are attractive gene-targeting agents for development 
of new cancer therapeutics. 
 
2.4.  Recent improvements in antigene technology 
 
Selective artificial control of gene expression is a long-standing dream in biotechnology and 
human therapy. Oligonucleotides seem perfectly suited for this purpose because of their 
unique base-base recognition properties. The potential advantages in targeting genomic 
DNA by oligonucleotides are counterbalanced by several restrictions common to all 
oligonucleotide-based approaches (e.g. bioavailability, cell permeability and non-specific 
binding of the oligonucleotides or analogues used). Further, the triplex approach shows 
specific restrictions. Some of them are motif-dependent while others are of general nature. 
For the parallel motif, the severest restriction is the pH-sensitivity of the C+*G.C base triplet, 
which is intrinsically unstable under physiological conditions due to the low pKa of the third 
strand cytosines. Triplex stability in the antiparallel motif is markedly sequence-dependent 
due to alternative structure formation (e.g. G tetrads), of the corresponding GA or GT rich 
TFOs under physiological conditions (expecially K+ concentration). Finally there are 
common problems in both motifs. The most prominent ones are related to target 
accessibility, low overall affinity of TFOs to their target, resulting in poor competition with 
DNA binding proteins, and the restriction of the known binding motifs to 
homopurine/homopyrimidine DNA sequence tracts. 
 
2.4.1. Increasing triplex stability 
There are a few basic concepts in improving the binding of TFOs to duplex targets that 
have been successfully applied in the past few years to increase triplex stability. First, the 
introduction of positively charged amino functions on the sugar and/or base unit, designed 
to make additional binding contacts between phosphodiester residues of the target Watson-
Crick duplex besides the base-base interactions. Second, the use of conformationally 
adapted or costrained TFOs. Finally, the use of non-charged TFOs. Most recent progress 
has focused on the parallel binding motif of TFOs. 
 
2.4.2. Dual recognition 
The best explored and most promising parallel motif TFOs are those containing an 
aminoethoxy side-chain at C(2’) of the ribonucleosides units, developed by  Cuenoud and 
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collegues[44]. This amino function results protonated under physiological pH, leading to an 
increase of c.a. 3.5°C per modification at pH=7.0 Fully modified 2’-aminoethoxy TFOs (AE-
TFOs, figure 2.5) can lead to triplexes more stable than the target duplex alone. This kind of 
modification also  improve a gain in thermodynamic stability (∆G) of c.a 0,5 Kcal/mol for 
each modified unit that results in a 1000-fold enhanced association rate compared with that 
of a DNA-TFO. This is an important feature, considering the lower association kinetics for 
triplex formation than duplex formation. Further, the 2’-amino side-chain occurs in a 
gauche+ conformation and shows astonishingly low conformational mobility in the triplex[45]. 
Studies  on variations in length of the side chain indicate they do not improve binding 
efficiency.  
 
         
 
 
 
Figure 2.5: Molecular structures of TFOs with potential dual recognition properties, with 
conformationally constrained sugar analogues and with uncharged backbone structures. 
 
Another point of modification using alkylamino chains is the C(4’) of the deoxyribose unit. 
4’-amino-TFOs have been synthesized by Matsuda and co-workers[46]. They found the 
same thermal triplex stabilization than for the ethylamino side chain, by than 1°C per 
modification. Shortening or lengthening the tether between C(4’) and the amino function 
consistently reduced affinity relative to the two-carbon linker.  However, the efficiency of this 
system is not better than that of AE-TFOs. Within this context,  the pyrrolidino-pseudo-
nucleosides have been proposed. According to modelling based on X-ray data available for 
parallel motif triplexes, the furanose ring oxygen is close to a pro-R non-bridging phosphate 
oxygen of the purine duplex strand. Experiments with TFOs containing uracil or N-1-methyl-
uracil for recognizing adenine in the parallel binding motif, however, showed triplex 
destabilization, whereas those containing the base isocytosine increased triplex stability at 
neutral pH by c.a. 2°C in melting temperature (Tm) per modification. The reason for the 
different stabilization/destabilization improved by the pyrrolidino-pseudo-nucleosides is 
unclear. Another interesting consideration is that RNA-TFOs generally form more stable 
triplexes than do DNA-TFOs. NMR analysis shows that  deoxyribose units in DNA-TFOs 
don’t adopt  the same sugar pucker[47]. Thus, the overall helical conformation of DNA 
triplexes is somewhere between A and B. A recent study with 2’-deoxy- and 2’-O-methyl-
RNA-TFOs showed marked sequence-dependent differences in stability, that cannot easily 
be rationalized with known rules in conformational analysis[47]. However, a combinatorial 
method to determine conformational effects of TFOs on triplex stability was developed[48]. A 
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schematic representation of this approach is reported in figure 2.6. Within a given base 
recognition frame imposed by the target duplex, an oligonucleotide library[49], containing 
either a ribo- rU/rC or a deoxyribo-dT/dC sugar unit at each position in the chain, was 
constructed by the split and combine technique. This library was then loaded on the 
agarose-supported DNA target and fractionated via affinity chromatography in a 
temperature gradient. The fractions were then deconvoluted by mass-spectroscopy, 
combined with alkaline digestion, to determine the preferred composition and location of 
ribonucleosides within the sequences. This information needs to produce focused libraries. 
 
 
 
Figure 2.6: Schematic representation of the combinatorial approach developed for establishing a 
    structure/stability profile of TFOs with conformational variation in the backbone. 
 
Another interesting approach involves the use of TFOs containing conformationally 
constrained nucleoside units. Given the preference of RNA- over DNA-TFOs in the parallel 
binding motif, oligonucleotide analogs that are constrained in a 3’-endo conformation (RNA 
like), should be interesting. Recently a triplex containing oligopyrimidine nucleotides 
partially modified with 2’-O,4’-C-methylene nucleosides (figure 2.5), which are known as 
bridged nucleic acids (2’,4’-BNA) or locked nucleic acids (LNA)[50] was greater than that of a 
triplex containing natural 2’-deoxyribose units at physiological pH. An increase in the 
association constant, which is due to a decrease in the dissociation rate, was observed. 
Surprisingly, fully modified LNA-TFOs don’t form triplexes with DNA targets, there exist an 
optimal number of LNA-residues within a DNA-TFO that exert a stabilizing effect. Data also 
exist on triplex binding with LNA-analogue ENA[51], containing a 2’,4’- ethylene bridge. ENA 
is able to stabilize triplex formation at neutral pH roughly to the same extent as LNA and it 
is more nuclease-resistant than natural DNA and  LNA. Furthermore, fully modified ENA-
TFOs bind to their DNA target, differently from fully modified LNA-TFOs that do not . The 
reason of this phenomenon is not completely understood.  
 
2.4.3. Alternate-Strand Triple helix formation 
In the antigene strategy, proposed to control gene transcription, an oligopyrimidine-
oligopurine sequence of double helical DNA is recognized by a third-strand 
oligodeoxynucleotide that binds to the major groove of the DNA and forms a local triple 
helix (triplex). Target sequence in the antigene strategy are very restricted. Since the 
thermal stability of the triplexes is generally lower than that of the duplexes under 
physiological conditions, an oligopurine cluster with fairly long chain lengths is required for 
stable triplex formation. In addition, formation of the pyrimidine motif triplex needs 
conditions of low pH (<6), because unmodified cytosines residues, if present in the third 
strand, must be protonated to bind with guanine of the G-C duplex. Several approaches 
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have been described to overcome this limitation. If the target duplex is composed of two 
adjacent and alternating oligopurine-oligopyrimidine tracts, the duplex can form a triplex 
with a single strand ON which pairs with oligopurine tracts, recognition can be achieved by 
a single third strand, portions of which are targeted against single oligopurine tracts. Such 
an oligonucleotide zigzags along the major groove, switching from one oligopurine strand to 
another at the 5’-purine-pyrimidine-3’, or 5’-pyrimidine-purine-3’step[52]. This so called 
“alternate-strand-triplex”  or “switched triplex” can be formed in two distinct ways. By 
combining both Hoogsteen and reverse Hoogsteen motifs, the natural ONs with 
oligopurine-oligopyrimidine sequences such as 5’-oligopurine-oligopyrimidine-3’ or 5’-
oligopyrimidine-oligopurine-3’ can be used as the third strand. In the second approach, only 
one set of motifs (Hoogsteen or reverse Hoogsteen motif) is employed, namely, the 3’-and 
3’- or 5’- and 5’- ends of two ODN fragments have to be connected using a suitable linker. 
In this latter case the different possibilities for “alternate-strand-triplex” formation are shown 
in figure 2.7. When the  oligopyrimidine sequence follows the oligopurine sequence, the 3’-
3’-linked and the 5’-5’-linked ONs can form the parallel (a) and antiparallel (b) triplexes  with 
the target duplex by Hoogsteen and reverse-Hoogsteen  hydrogen bonds, respectively. On 
the other hand, when the oligopurine sequence follows the oligopyrimidine sequence, the 
5’-5’-linked and the 3’-3’-linked ONs can form the parallel (c) and antiparallel (d) triplexes 
with the target duplex by Hoogsteen and reverse-Hoogsteen  hydrogen bonds, respectively. 
Several 3’-3’ or 5’-5’ internucleoside junctions have been proposed as linkers for alternate 
strand TFOs, with the latter imparting a minor cooperativity in the binding of the two 
domains of the TFO with the target duplex.  From a chemical point of view, the 3’-3’ or 5’-5’ 
inversion can be fulfilled by a suitable linker capable of crossing the major groove and 
whose properties can be, in addition, exploited to supply the oligonucleotide with useful 
characteristics.  
 
 
 
Figure 2.7: Schematic presentation of “alternate-strand triplex” formation 
by the 3’-3’- or 5’-5’-linked ONs. 
 
For example, the 3’-3’ linker may incorporate  an intercalating agent or a major groove 
ligand in order to improve the hybridization between the probe ON and the target duplex 
and to enhance the thermal stability of the triplexes. In most recent years the synthesis of 
ONs containing a 3’-3’ inversion polarity motif (figure 2.8), able to hybridize the target 
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duplex, in parallel mode, by formation of Hoogsteen triplets[52-54] gained much attention. 
Results on the stability of these triplex structures pointed to the phosphodiester bond as a 
suitable 3’-3’ junction into TFOs.  
 
 
Figure 2.8: 3’-3’-linked ON with an intercalater at the junction point. 
 
 
Nevertheless, molecular mechanic calculation indicated that a distortion of the sugar-
phosphate backbone around the 3’-3’ phosphodiester junction occurs thus preventing the 
correct Hoogsteen hydrogen bonds formation for the nucleotide bases flanking the site of 
inversion polarity[53]. In order to balance destabilizing effects occurring in alternate strand 
triplexes, an intercalating agent near the 3’-3’ switching region of the TFO[52-54] was 
introduced.  
 
2.5.  The aim of the work 
 
The aim of this work is the conjugation of a polypyrimidinic TFO with an acridine residue in 
the proximity of the 3’-3’ inversion site, so that its intercalation may counterbalance possible 
destabilizing effects of the junction (figure 2.9). Among the possible DNA intercalator 
agents, acridine is particularly advantageous considering that: i) molecules containing an 
acridine moiety have been extensively studied as duplex and triplex DNA stabilizing agents; 
ii) acridine linked ONs have been proposed as antisense agents and as efficient TFOs;[52-54] 
iii) ONs linking acridine derivatives can induce a DNA cleavage under photoirradiation when 
combined with metal ions;[53-54] iv) a large number of acridine derivatives are commercially 
available. It is also to be noted that the only synthetic strategy so far proposed to prepare 
such ON analogues is very complex. This work  would provide an easy and convenient 
method for the synthesis of TFOs carrying a chloro-metoxyacridine residue attached to the 
N-3 of a thymidine flanking the 3’-3’ phosphodiester bond, through an alkylamino linker. 
 
 
 
 
 
 
INTERCALATOR 
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Figure 2.9: 3’-3’-linked ON 5’-(CT)4Tacridine-3’-3’-C(CT)3C. Molecular modelling. 
 
To realize it, the N-3 position reactivity of thymidine towards alkylation was considered, 
together with the reported stability of duplex and triplex DNA complexes containing 
intercalators, or other groups, attached to N-3 position of a thymidine residue[53-54]. Using 
this simpler synthetic alternative, oligonucleotides with a 3’-3’ inversion of polarity, 
containing an acridine moiety attached to the nucleotide base flanking the 3’-3’ 
phosphodiester bond, have been prepared, characterized and used to study their 
hybridization properties in the formation of stable and non canonical triple helix structures. 
These complexes have been investigated by UV melting studies and CD experiments. 
 
2.6. Chemistry 
 
This approach is based on a commercially available difunctionalized CPG support carrying 
a 2-methoxy-6-chloroacridine moiety and a primary alcoholic hydroxy function protected 
with the DMT group (1, Scheme 2.1). A suitably 3’,5’-protected thymidine 3 or 4 was linked 
to support 2, obtained by removal of DMT protecting group, through the N-3 atom of the 
base using Mitsunobu condensing conditions[55-56]  (figure 2.10), thus affording supports 5 
and 6, respectively (70% yield by DMT spectrophotometric test). Supports 5 and 6 were 
found to be stable under the chemical treatments required by the DNA chain assembly and 
cleavable, at the succinate function, in the final alkaline treatment for detachment and 
deprotection procedure. The cleavage from the support releases a thymidine base 
connected to the acridine residue through a hexylamino chain.  
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Support 5, after capping of the unreacted hydroxyl functions and successive removal of 
3’,5’-DMT groups, reacted almost quantitatively with the 5’-DMT-thymidine-3’-
phosphoramidite under standard automated procedure, giving support 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Mitsunobu mechanism 
 
 
The deprotection step of supports 5 and 8, by trityl removal, followed by an alkaline 
treatment with 0.4M solution of NaOH, furnished the expected acridine-nucleoside 7 and 
the acridine-trinucleotide 9, respectively, the latter containing the 3’-3’ phosphodiester 
junction. The structures of both released products were confirmed by 1H NMR and MS 
spectrometry. Eight coupling cycles performed on support 5, with appropriate 3’-
phosphoramidite nucleotide units, furnished TFO 10. Support 6, in which the 5’ and 3’-OH 
functions are orthogonally protected with Fmoc and DMT groups, respectively, allowed the 
sequential synthesis of different ON domains of the TFO. After the removal of 3’-DMT group 
from support 6, the elongation of the first ON domain by the formation of the 3’-3’ 
phosphodiester junction, was achieved, thus leading to 11. Then, the 5’-Fmoc group was 
removed by Et3N /pyridine treatment and the second ON domain was assembled, thus 
furnishing the TFO 12. Between the two alternative 5- or 3’-OH Fmoc protections, the 
former was chosen on the basis of preliminary experiments performed on solid supports 
carrying 5’- or 3’-Fmoc-thymidine. These had shown that complete 5’-deprotection could be 
achieved by 5% triethylamine in pyridine treatment in 1.5 hours whereas a prolonged 
reaction time was needed to quantitatively deprotect the 3’-hydroxy function. TFO 10 and 
12 were synthesized on a 1 µM scale by a DNA synthesizer. Crude oligomers, detached 
from the support as described for trinucleotide 9, were purified by HPLC on an anionic 
exchange column. The collected peaks were desalted thus furnishing more than 95% pure 
10 and 12 (by RP-HPLC) in 28 and 24 units OD260 units yields, respectively. MALDI TOF-
MS spectra of 10 and 12 were in agreement with their structures. Further, UV-VIS spectra 
of 10 and 12 confirmed the presence of the acridine moiety into the oligomers, showing a 
diagnostic absorption at λmax 424 nm.  
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Scheme 2.1: Reagents and conditions: i) TCA 3% in DCM; ii) TPP, DEAD, THF, DCM; iii) NaOH 0,1 M in 
(CH3OH-H2O 4:1 v/v); iv) coupling with thymidine; v) pyridine/Et3N (95:5 v/v, 1.5 h); vi) chain elongation with 
3’-phosphoramidite deoxynucleoside building blocks. 
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2.7.  UV and circular dichroism (CD) studies 
 
The triplexes 14 and 15 (Table 2.1) were formed by mixing equimolecular amounts of TFO 10 
and 12 respectively with the target duplex DNA 13, and successively heating at 90° C for 5 
min.  The solutions were then equilibrated for 15 h at room temperature before performing the 
analyses. The formation and stability of the triplexes 14 and 15, compared with the acridine 
devoid triplexes 16 and 17, were studied by UV thermal denaturation experiments and by CD 
in 5 mM NaH2PO4, 140 mM KCl and 5 mM MgCl2 buffer (at pH 5.5, 6.0 and 6.6). Figure 2.11 
shows melting profiles of the duplex 13 and triplexes 14-17. The Tm values are reported in 
Table 2.1. Melting curves for 14-17 showed a typical biphasic behaviour, with the first sigmoid 
attributable to the triplex dissociation, while at higher temperatures the expected pH-insensitive 
duplex to single strands transition could be observed. The UV melting data indicated for the 
acridine containing triplexes 14 and 15 a stabilization effect at all the pH values with respect to 
the corresponding acridine devoid triplexes 16 and 17. At pH 6.6 the presence of the acridine 
in the TFO led to a stabilization with ∆Tm values of 8.5 and 7.9 °C, respectively, for triplexes 
14 and 15, while at pH 5.5 slightly lower effect were observed (∆Tm 6.8 and 6.6 °C, 
respectively). 
 
∆Abs∆Abs
A B
[°C] [°C]
 
Figure 2.11: UV melting profiles (pH 6.6) (A) triplex 14 (….), triplex 16 (__) and duplex 13 (- -) (B) triplex 15 (….), 
triplex 17 (__) and duplex 13 (- -) 
 
5'-GAGAGAGAATCTCTCTC-3'
3'-CTCTCTCTTAGAGAGAG-5'
  5'-CTCTCTCTX
  5'-GAGAGAGAA
  3'-CTCTCTCTT
TCTCTCTC-3'
AGAGAGAG-5'
YCTCTCTC-5'
Triplex 14 : X = TAcr; Y = T
Triplex 15 : X = TAcr; Y = C
Triplex 16 : X = T; Y = T
Triplex 17 : X = T; Y = C
Duplex 13
 
Table 2.1: Tm values (C°)/pH for duplex 13 and triplexes 14-17 
 
Complexes pH 5.5 pH 6.0 pH 6.6 
Duplex 13 62.3 63.2 63.4 
Triplex 14 41.4 36.7 34.5 
Triplex 15 39.4 34.9 32.5 
Triplex 16 34.6 29.1 26.0 
Triplex 17 32.8 27.0 24.6 
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The Tm values of the triplex 14 resulted to be higher than those of 15 at all the tested pH and 
the same behaviour was observed for acridine devoid triplexes 16 in comparison with  17. 
These last data indicate that the substitution, into TFO, of a thymine (in 14 and 16) with a 
cytosine (in 15 and 17) at the 3’-3’ junction, induces, as expected, a destabilizing effect, likely 
due to the electrostatic repulsion between consecutive protonated cytosine. The formation of a 
triplex structure for 14-17 was confirmed by circular dichroism measurements. The 
concentration of the triplex solution was in the range 1.9-2.3x10-5 M. CD spectra of triplexes 
14-17 (pH 6.6) are reported in figure 2.12. Complexes 16 and 17, as already reported for the 
same kind of complexes showed a CD profile very similar to those observed for canonical 
Hoogsteen type triplexes, characterized by a large positive band at 280 nm and a negative 
band centred around 213 nm. Particularly the negative band is indicative of the existence of a 
triplex structure. Almost the same patterns were observed for acridine containing triplexes 14 
and 15. The CD spectra of triplexes 14 and 15 were compared with the normalized summed 
spectra of the duplex 13 and appropriate single strand TFOs (Figure 2.13). Significantly, for 14 
and 15, the diagnostic band at 213 nm results deeper if compared to the corresponding band 
in the normalized sum spectra and the 282 nm band decreases in intensity and shows a red 
shift. These data are clearly indicative of a triplex structures for the complexes 14-17. 
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Figure 2.12: (A) CD spectra at pH 6.6 of triplex 14 (___) and triplex 16 (…); (B) triplex 15 (___) and 
        triplex 17 (…). 
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Figure 2.13: (A) CD spectra at pH 6.6 of triplex 14 (___) and normalized summed spectra (…) of 
         duplex 13 and TFO 10; (B) CD spectra at pH 6.6 of triplex 15 (___) and normalized summed  
         spectra (…) of duplex 13 and TFO 12. 
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2.8.  Conclusions 
 
This research work would provide an alternative easy synthesis of ONs containing a 3’-3’-
phosphodiester linkage and bearing an acridine residue on the thymidine base flanking the 3’-
3’ junction. This synthesis was based on the preparation of a new kind of nucleoside-acridine 
solid support (5 or 6). This synthetic strategy could be an useful entry to link an intercalating 
agent near to 3’-3’ (or 5’-5’) phosphodiester linkage, thus furnishing a convenient method to 
stabilize alternate strand triple helices by minimizing the mismatching effect into the region 
between purine and pyrimidine domains. In fact, both CD and UV melting data, indicate that 
the acridine moiety, linked through a 7 atoms spacer arm to the N-3 of a thymine, does not 
hamper the formation of a triplex structure. Furthermore, the stabilization effect observed for 
triplex 14 and 15 strongly suggests an intercalation of the acridine residue into the triplex 
structure (figure 2.9). 
 
2.9.  Experimental Session 
 
2.9.1. General  Methods 
The following abbreviations were used throughout the test: triplex forming oligonucleotide 
(TFO), fluorenylmethoxycarbonyl (Fmoc), 4,4’-dimethoxytrityl (DMT), trichloracetic acid (TCA), 
dichloromethane (DCM),  triethylammonium bicarbonate (TEAB), diethylazadicarboxylate 
(DEAD), triphenylphosphine (TPP), tetrahydrofurane (THF). Acridine CPG support was 
purchased from Glen Research. Functionalization of solid supports was carried out in a short 
column (5 cm length, 1 cm i.d.) equipped with a sintered glass filter, stopcock and a cap. The 
ON were assembled with a PerSeptive Biosystems Expedite DNA synthesizer using 
phosphoramidite chemistry. HPLC analyses and purification were carried out on a Waters 
600E apparatus equipped with UV detector. UV spectra e thermal denaturation experiments 
were run with a Jasco V 530 spectrophotometer, equipped with a Jasco 505T temperature 
controller unit. CD spectra were obtained with a Jasco 715 circular dichroism 
spectrophotometer. NMR spectra were recorded with a Bruker AMX500 spectrometer. ESI 
mass spectrometric analyses were performed on a API 2000 (Applied Biosystem) machine 
used in negative mode. MALDI TOF mass spectrometric analysis wad performed on a 
PerSeptive Biosystems voyager-De Pro MALDI mass spectrometer using a picolinic/3-
hydroxy-picolinic acids mixtures as the matrix.  
 
2.9.2. General Procedures 
5’-O-fluorenylmethoxycarbonyl-3’-O-(4,4-dimethoxytriphenylmethyl)-thymidine (4) 1H-
NMR (acetone–d6) δ: 9.90 (1H, bs, N(3)-H);  8,02 (1H, s, H-6); 7.90-6.80 (21H, m’s, aromatic 
protons); 6.32, (1H, m, H-1’); 4.52 (2H, m, CH2 Fmoc residue); 4.32 (1H, m, H-3’); 4.24 (1H, t, CH 
Fmoc residue); 3.98 (3H, m, H2-5’ and H-4’); 3.81 (6H, s, OCH3 DMT); 1.92 and 1.72 (1H each, m’s, 
H2-2’); 1.65 (3H, s, CH3-5); 
Preparation of supports 5 and 6; product 7  
200 mg of commercially available support 1 (0.044 meq/g) were washed with DCM an then 
treated with 3x 2.0 mL of a DCM solution of TCA (3%, w/v) for 2 min. This treatment was 
repeated three times and the resulting support 2 was exhaustively, washed with DCM and  
then dried under reduced pressure. 207 µL (1.3 mmol) of DEAD were added to 340 mg (1.3 
mol) of triphenylphosphine (TPP) dissolved in 800 µL of THF at 0°C. After 10 min the mixture 
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was added to 200 mg of support 2 suspended with a mixture of 0.26 mmol of 5 (or 6) in 700 
µL of anhydrous DCM. After 5 hours, at room temperature, the support was exhaustively 
washed with DCM, pyridine and then treated with a solution of pyridine/acetic anhydride (2.0 
mL, 9:1 v/v) for 30 min at room temperature. Finally the support was washed with DCM, Et2O 
and dried under reduced pressure. Incorporation yields of nucleoside 3 and 4 onto 2 were in 
the range of 65-80% (0.029-0.035 meq/g), determined by quantitative DMT test performed on 
dried and weighed samples of the obtained support 5 and 6. 
The treatment of 50 mg of support 6 with 1.5 mL of solution of 0.4 M of NaOH in 
methanol/water (4:1, v/v) for 17h at room temperature followed by neutralization of the alkaline 
solution with a 2 M solution of triethylammonium acetate, furnished product 7 (0.5 mg, after RP 
HPLC purification). 
7= 1H-NMR (D2O); 8.02, 7.50, 7.48, 7.42, 7.26, 7.18, 7.06, (1H each, acridine protons and H-6 thymine; 
5.56 (1H, m, H-1’); 4.60 (1H, m, H-3’); 3.90 (3H, s, CH3-O); 3.90-3.70 (5H, overlapped signals, CH2-
NH, CH2-N(1), H-4’); 3.60 (2H, m, CH2OH); 3.48 (2H, m, H2-5’); 2.25 (2H, m, H2-2’); 1.61 (3H, s, 
CH3-5); 1.85–1.40 (7H, m’s, 3 CH2 and CH) UV-VIS (CH3OH) λmax: 265 nm and 422 nm; ESI-MS: 
m/z: 613 (M+H+). 
Oligonucleotide synthesis; products 9, 10, 12 
Symmetric oligomer elongation. 50 mg (0.0016 meq) of support 5 were used for each 
synthesis in the automated DNA synthesizer following standard phosphoramidite chemistry, 
using 45 mg/ml solution of 3’-phosphoroamidite building block in anhydrous CH3CN. 
Commercially N(4)-acetyl  protected cytidine 3’-phosphoramidite building block was used to 
avoid deamination when sodium hydroxide is used for final cleavage and deprotection. Three-
mer 9 and ON 10 were synthesized performing respectively one or eight coupling cycles with 
appropriate nucleotide unit. Coupling yields resulted always >98% (by DMT test). After 
completion of the desired ON sequence and final DMT removal, the support was treated with 
1.0 mL of 0.4 M solution of NaOH in methanol/water (4:1 v/v) for 17h at room temperature. The 
filtered solution and washings, neutralized with 5.0 mL of a solution 2 M triethylammonium 
acetate, were concentrated under reduced pressure, redissolved in water and purified by 
HPLC. Crude 9 was purified on a RP C18 column (4.6x250mm) eluted with a linear gradient of 
MeOH in TEAB buffer (pH 7.0, 0 to 10% in 50 min, flow 0.8 mL/min)), retention time 35.5 min. 
The final product (45 units OD260, from 50 mg of 5) was lyophilized and characterized by 
spectroscopic data. Crude 10 was purified an a Nucleogel SAX column (Machery-Nagel, 1000-
8/46); buffer A: 20mM KH2PO4 aq. solution, pH 7.0, containing 20% (v/v) CH3CN; buffer B: 1.0 
M KCl, 20 mM KH2PO4 aq. solution, pH 7.0, containing 20% (v/v) CH3CN; using a linear 
gradient from 0 to 100% B in 20 min; flow rate 1.0 mL/min. The collected peak at retention time 
18.8 min, desalted on Sep-Pak column (C18), furnished 28 OD260 units of pure 10.  
9= 1H-NMR (D2O); significative protons at δ: 7.95, 7.90, 7.85, 7.45, 7.40, 7.32, 7.20, 7.15, 7.02 (9H, 
partially overlapped, acridine protons and 3H-6); 6.32-6.40 (3H, m’s, 3H-1’); 1.65, 1.68, 1.70 (3H each, 
s’s, 3CH3-5) ;  31P NMR (D2O) δ: 1.55 and 1.38; UV-VIS (H2O) λmax = 265 and 422 nm. ESI-MS m/z: 
1221 (M+H)+ 1243 (M+Na)+.   
10= Maldi TOF-MS (positive mode): calculated mass 5357.03; found: 5358.83 (M+H), 5380.86 
(M+Na). 
Asymmetric oligomer elongation. 50 mg (0.0015 meq) of support 6 was used for the synthesis 
of oligomer 12 following standard phosphoramidite chemistry as described for product 10. After 
the elongation of the first ON tract, the final DMT group was removed and the resulting 5’-OH 
function capped by reaction with 1 mL of pyridine/Ac2O solution (4:1, v/v) leading to 11. The 
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removal of Fmoc protecting group was achieved by piridine/Et3N treatment (1.5h, 95:5, v/v). 
The resulting 5’-OH support was successively coupled with required 3’-phosphoramidite 
derivatives to complete the desired ON sequence, following standard automated procedure. 
Crude 12, was detached from the support, deprotected and purified as described for 10. The 
collected peak at retention time 20.5 min, after desalting furnished 24 OD260 units of pure 12. 
After HPLC purification 24 OD260 units of 12 were obtained. Maldi TOF-MS (positive mode): 
calculated mass 5342.03; found: 5343.65 (M+H), 5383.06 (M+K). 
UV thermal denaturation experiments 
The concentrations of the synthesized oligomers were determined spectrophotometrically at  
λ = 260 nm at 80 °C, using the molar extinction coefficient calculated for unstacked 
oligonucleotides using the following extinction coefficients: 11700 (G); 8800 (T) cm-1M-1. 
Aqueous solution of 5 mM NaH2PO4, 140 mM KCl and 5 mM MgCl2 (at pH 5.5, 6.0 and 6.6) 
was used for the melting experiments. Melting curves were recorded using a concentration of 
approximately 1 µM of single strand in 1 mL of the tested solution in teflon sealed quartz 
cuvettes of 1 cm optical path length. The resulting solutions were then allowed to heat at 90°C 
for 5 min, then slowly cooled and kept at 20°C for 15 h. After thermal equilibration at 20 °C UV 
absorption at λ = 260 was monitored as function of the temperature, increased at a rate of 
0.5°C/min. The melting temperatures were determined as the maximum of the first derivative 
of the absorbance vs. temperature plots. 
Circular dichroism. 
CD spectra were registered in the same buffer used for UV melting experiments at 25°C in a 
0.1 cm path length cuvette. The wavelength was varied from 200 to 340 nm at 5 nm min-1, and 
the spectra recorded with a response of 16s, at 2.0 nm bandwidth and normalized by 
subtraction of the background scan with buffer. The temperature was kept constant at 25°C 
with a thermoelectrically controlled cell holder (JASCO PTC-348). 
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Chapter 3 
 
“Synthesis and characterization of new kind ON analogues able to form stable 
monomolecular quadruple helices DNA complexes: Tetra-End-Linked Oligonucleotides 
(TEL-ON)” 
 
Introduction 
 
In 1990 Guschlbauer, Chantot and Thiele published the review article “Four-Stranded Nucleic 
Acid Structures 25 Years Later: From Guanosine Gels to Telomere DNA”[1], in which they 
highlighted the emerging importance of the G-quartet, a hydrogen-bonded ionophore[2] first 
identified in 1962 (Figure 3.1). Renewed attention to the G-quartet, in the late 1980s, was 
generated by intriguing proposals that the motif, when formed in DNA, might be biologically 
relevant[3,4]. Today, thousands of reports on some aspect of G-quartet structure or function 
have appeared, including some excellent reviews[5-10]. A G-quartet is a planar association of 
four guanines held together by eight Hoogsteen hydrogen bonds (figure 3.1); G quadruplexes 
result from the hydrophobic stacking of several quartets (figure 3.1)[4]. A cation (typically Na+ 
or K+) is located between two quartets, the first forming cation–dipole interactions with four 
guanine, the second interacts with eight guanines, reducing the repulsion of the 2x4 central 
oxygen atoms, enhancing hydrogen bond strength and stabilizing quartet stacking. 
 
 
 
 
 
 
 
 
 
Figure 3.1: G-quadruplex DNA 
 
G-quartets may have applications in areas ranging from supramolecular chemistry to 
medicinal chemistry. Several reports suggest that DNA may be used as a building block for 
novel nano-sized objects[6]. Quadruplex DNA is an excellent module for the design of devices 
for nano-technology, because of its extreme rigidity and self recognition properties. G-
quadruplexes are also likely to form higher-order structures such as synapsable DNA[8]   or G-
wires[9-10]. DNA nanodevices based on quadruplex–duplex interconversion[8] or biosensors[9], 
have been also described in literature. The self-assembly of G-rich sequences can constitute 
liquid crystals[10] and may serve as the scaffold for artificial ion channels or receptors[11-12]. 
Quadruplex-prone segments may also be found in biologically significant regions such as 
telomeres[12-16]  or oncogene promoter regions[17], and a number of proteins or small 
molecules bind to G-quadruplexes[18-19]. In this contest,  G-quadruplex DNA structures may 
provide a multitude of potential targets for drug design[20]. 
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3.1.  Structural polymorphism of G-quadruplex DNA 
 
Numerous reviews have appeared recently discussing the structural characterization and 
polymorphism of G-quadruplex DNA[9]. It is now well established that certain DNA and RNA 
sequences, possessing a preponderance of guanosine residues, can form unusual structures. 
These structures exhibit unusual mobility under gel electrophoresis conditions, protection of 
the guanosine N7 from methylation with dimethyl sulfate, a characteristic CD spectrum, a 
signature cation-dependent stability to thermal denaturation, and distinctive imino resonances 
in the 1H-NMR spectrum[1-10]. Early observations related to these structures came from the 
behaviour of guanosine nucleotides, which form gels in a cation-dependent manner. Fibre 
diffraction studies of the gels formed by guanosine-3’-monophosphate and poly(G) 
established the fundamental building block of these unusual structures, the G-tetrad, also 
called the G-quartet (figure 3.1). The G-tetrad consists of a planar arrangement of four 
guanine bases associated through a cyclic array of  Hoogsteen hydrogen bonds in which 
each guanine base both accepts and donates two hydrogen bonds. The resulting square 
planar array is unique due to the “hole” that is created in the center. The G-tetrads form four-
stranded helical structures by stacking interactions. In the case of the poly(G), the average 
distance separating the stacked G-tetrads is 3.4 Å. The tetrads are not stacked linearly, but 
adopt a right-handed helix. When one or more tetrads are stacked in this way, a cylindrical 
central cavity is produced. This cavity, lined with the guanine O-6 carbonyl oxygens, forms a 
specific binding site for metal ions. As deduced from the ability of particular metal ions to 
induce gel formation in guanosine nucleotides, the binding of metal ions follows the order 
Sr2+>K+>>Rb+~Ba2+>NH4+>Ca2+>Na+>Mg2+ ~Cs+>Li+[9]. This contrasts sharply with duplex 
DNA, in which there is only a slight preference in metal ion binding in the series 
Cs+>K+>Li+>Na+. 
 
3.1.1. Topological classification of G-Quadruplex DNA structures 
A wide array of topologies and strand stoichiometries are compatible with the stacking of G-
tetrads in helical structures. Hardin[21], expanding on the naming convention suggested by 
Cech[22], has proposed the class name G-DNA for this large class of structures; however, 
current usage appears to have settled on the class name G-quadruplex DNA. The structure 
formed from poly(G) consists of four strands, each contributing one G-residue to each G-
tetrad. In this arrangement, the four strands are parallel, and there is a four-fold symmetry 
associated with the structure. This type of intermolecular, parallel-stranded structure has been 
referred to as G-quadruplex, G-tetraplex, or simply G4-DNA. In accord with the naming 
convention of Sen and Gilbert [23], these four-stranded, parallel structures are referred to as 
G4-DNA (figure 3.2). 
Alternatively, G-quadruplex DNA may form from two separate DNA strands, each of which 
contributes two guanosine residues to each G-tetrad. These bimolecular G-quadruplex DNA 
structures have been referred to as hairpin dimers. In keeping with the naming formalism of 
Sen and Gilbert[23], this class of structures are referred to as G’2-DNA. There are a number of 
strand topologies that might be involved in the formation of G’2-DNA, but to date only four of 
these have been observed or proposed. As Bolton has noted, there are two distinct forms of 
G’2-DNA in which the loops formed by each of the two DNA strands are on opposite faces of 
the G-tetrad core[24]. In the edge form (figure 3.2), the loops connect adjacent DNA strands. A 
distinct crossover form is characterized by loops that connect strands that are diagonally 
related. A G'2-DNA topology in which the loops connecting DNA strands lie on the same face 
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of the G-tetrad stack has been proposed by Sen and Gilbert (syn-edge G’2-DNA, figure 
3.2)[25]. An alternative topology for a bimolecular G-quadruplex DNA structure is a "dog-eared" 
structure (figure 3.2). This topology requires that the DNA loops run diagonally across the 
faces of the G-quadruplex that are perpendicular to the G-tetrads. Although this topology has 
not yet been observed in G’2-DNA, a recently reported intramolecular G-quadruplex DNA has 
such a dog-eared” loop[26]. In addition to the G’2-DNA topologies mentioned above, there are 
a variety of hypothetical topologies involving alternate strand distribution (i.e. three guanines 
in each G-tetrad from one strand and the fourth guanine from a second strand) or orientation 
(i.e. three parallel strands and one antiparallel strand, this latter recently observed[16] in human 
telomere structure forming an intramolecular 3+1 G-quadruplex scaffold in K+). It is likely that 
future research may uncover examples of these alternative topologies. Just as in the case of 
the bimolecular G-quadruplex DNA structures, there are multiple topologies that are possible 
in the formation of a unimolecular, or G4'-DNA. The chair form of G4'-DNA (figure 3.2) is 
characterized by loops connecting only adjacent strands[27]. This form is similar to the 
unimolecular form of G'2-DNA proposed by Sundquist and Klug[28]. The basket form (Figure 
3.2) has one loop that crosses the G-tetrad face diagonally[27]. A strikingly different folding 
topology is that reported by Wang and Patel[26] for the Na+-stabilized NMR structure of the 
Tetrahymena telomeric repeat d(T2G4)4. This sequence adopts a fold in which adjacent 
strands are connected by an edge loop on one face of the G-tetrad stack, a second, central 
lateral loop, and a terminal “dog-eared” loop running diagonally across one of the 
perpendicular faces of the G-tetrad stack. There are a multitude of alternative G4’-DNA fold 
topologies involving combinations of crossover, edge, and dog-eared loops; only time will tell 
if these topologies are energetically accessible to certain natural or engineered DNA 
sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Different topological forms of termolecular (G4-DNA), bimolecular (G'2-DNA), 
                                       and unimolecular (G4'-DNA) G-quadruplex structures. 
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3.1.2. G-Quadruplex DNA groove widths 
 Related to the overall fold topology demonstrated by G’2-DNA and G4’-DNA are the 
glycosidic angles of the guanosine nucleotides forming the G-tetrads. In order for adjacent 
guanosines in antiparallel strands to form the hydrogen bonds necessary for G-tetrad 
formation, one of these guanosine must adopt a syn glycosidic conformation. Thus, for each 
topology listed above, there are alternative strand orientations that would result in distinct 
distribution of glycosidic conformations in the G-tetrads. For example, G’2-DNA having the 
edge topology can in principle adopt either a symmetrical form, in which the 5’-ends of the two 
strands are diagonally arranged about a common face, or an unsymmetrical form in which 
these two ends do not share any common faces. The symmetrical form requires that each G-
tetrad have alternating syn-anti-syn-anti glycosidic conformations, whereas the unsymmetrical 
form requires syn-syn-anti-anti glycosidic conformations (figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Variations in glycosidic torsional angles and their effects on groove width 
         in G-quadruplex structures. 
 
Experimentally, the symmetrical edge form is observed in the X-ray structure of 
[d(G4T4G4)]2[29]. One consequence of this variation in glycosidic conformations, is the distinct 
nature of the grooves. The parallel G4-DNA G-tetrads, in which all G’s adopt the anti 
glycosidic conformation, affords four widths of identical medium width. In cases where a 
guanosine in the syn conformation donates hydrogen bonds to a neighboring guanosine in 
the anti conformation, the groove formed between the two is extremely narrow, with a 
phosphate to phosphate distance as small as 7-9 Å[30]. In contrast, when the hydrogen 
bonding polarity between adjacent syn- and anti-guanosines is reversed, a very wide groove 
is formed[30]. An intermediate width groove results when adjacent guanosines adopt the same 
glycosidic conformation (figure 3.3)[30]. For example, in the structure of the symmetrical G’2-
DNA having the edge topology, the G-tetrads are formed from guanosines of alternating anti-
syn-anti-syn conformation, with each syn-guanosine donating hydrogen bonds to an adjacent 
anti-guanosine, and accepting hydrogen bonds from the other adjacent guanosine[29]. This 
results in a rectangular G-tetrad core with grooves of alternating wide-narrow-wide-narrow 
widths. The crossover G'2-DNA has guanosines that adopt the syn-syn-anti-anti 
conformations, which results in G-tetrads that adopt a parallelogram arrangement and the 
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formation of alternative wide, medium, narrow, medium width grooves between strands. 
Individual DNA strands in G-quadruplex structures is also a source of structural diversity, 
manifest by altered groove geometry. Both syn-anti-syn-anti and syn-syn-anti-anti G-tetrads 
typically stack upon each other such that consecutive G’s in each DNA strand adopt an 
alternating 5’-3’ syn-anti relationship. However, in G4’-DNA structures containing an odd 
number of stacked G-tetrads, unique syn-syn G-G steps are observed[29-31]. Through a 
combination of the altered base-edges and twist geometry associated with these syn-syn G-
dinucleotide steps, the narrow grooves of these particular G4’-DNA structures provide a 
unique target for ligand design[26-31]. The ability of DNA minor groove ligands to distinguish the 
variable groove width engendered by sequence has been reported[32-33]. The specific array of 
alternating groove widths in G-quadruplex DNA structures should provide a means of 
selectively targeting specific topological and conformational forms of G-quadruplex DNA. For 
example, ligands which are able to span two or more G-quadruplex grooves may be able to 
distinguish one form from another based upon the specific groove dimensions and their 
specific orientation. 
 
3.1.3. G-Quadruplex DNA metal ion binding 
As has been observed for the association of individual guanosine nucleotides, G- quadruplex 
structures are stabilized by specific metal ion interactions[34]. The central cavity formed by 
stacked G-tetrads serves as a host to a variety of cations[35]. The metal cation preference for 
G4-DNA follows the trend K+ > Ca2+ > Na+ >Mg2+ > Li+ and K+ > Rb+ > Cs+, in accord with the 
trend observed for guanosine nucleotide gel formation. In the case of K+, the stacked G-
tetrads in G-quadruplex DNA provide a bipyramidyl antiprismatic coordination geometry 
(figure 3.4a), with each of eight carbonyl oxygens interacting equally with the cation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Metal ion coordination geometry. a) K+; b) Na+. 
 
In the crystal structure of [d(G4T4G4)]2, a region of weak electron density was found between 
planes of stacked G-tetrads and this was assigned to bound K+[36]. In the high resolution 
crystal structure of [d(TG4T)]4, two G4-DNA structures stack coaxially upon each other, 
forming an extended cylindrical central cavity[36]. Sodium ions are located between G-tetrad 
planes in the center of this cavity (figure 3.4b), but stack out of phase with the G-tetrad 
repeats, so as to bind in the terminal G-tetrad planes[36].  The selectivity of G-quadruplex DNA 
for K+ versus Na+ ion has been studied by Feigon and co-workers using 1H-NMR and the G'2-
DNA formed by d(G3T4G3), as a model system[37]. In this system, the G'2-DNA binds two K+ 
or Na+ ions, corresponding to one metal ion sandwiched between each pair of G-tetrads. 
a b 
                                                                                                                          CHAPTER 3   Synthesis of TEL-ON 
 34
Using competition NMR experiments, Feigon and co-workers determined that there is only a 
modest difference in free energy of 1.7 kcal/mole, favoring the binding of K+ versus Na+ 
ions[37]. They suggest that this modest free energy difference is a result of the contributions of 
the relative free energies of hydration, which favors K+ binding. The effect of various cations 
on the kinetics of G-quadruplex DNA formation and the conformational polymorphism of G-
quadruplex DNA has also been studied. Although original observations by Sen and Gilbert[38] 
indicated that K+ prevented the formation of G4-DNA from DNA oligonucleotides containing 
multiple runs of G’s, this appears to be a kinetic, rather than thermodynamic phenomenon. G-
quadruplex DNA structures can be trapped in metastable states in the presence of K+ ions, 
which stabilize and inhibit the interconversion of G-quadruplex DNA structures. Thomas[39], 
Bolton[27] , and Hardin[40] have shown that the specific complexation of K+ by G-quadruplex 
DNA leads to a preference for the formation of G4-DNA structures under high K+ 
concentrations. Low K+ concentrations, or higher Na+/K+ ratios, favour G4’-DNA structures. 
Whether a linear or a folded structure is formed is dependent on the exact sequence and 
number of repeats per strand, cations have a strong influence on their relative stabilities. It 
has been found that potassium ions preferably stabilize linear, four-stranded parallel 
quadruplexes whereas sodium ions stabilize folded forms. Cations have profound effects on 
loop geometry in G4’-DNA structures[27]. DNA oligonucleotides, with four runs of –GG- 
separated by two to four bases, can form chair G4’-DNA structures, but only in the presence 
of K+[27]. When the -GG- runs are separated by four residues, a basket G4’-DNA structure can 
form in either Na+ or Na+/K+[27] . Sequences with runs of three or four G’s separated by two to 
four bases can form basket G4’-DNA structures in the absence of K+[27]. The presence of a 
purine in the loop can block both K+ binding and formation of the chair G4’-DNA structure. 
Modelling indicates that the requirement for K+ ion for chair formation is due to the ability of 
this ion to interact with the terminal G-tetrad and residues in the adjacent loop[27]. In addition 
to these cation-induced changes in G-quadruplex DNA topology, there is evidence for K+-ion 
facilitated formation of G-quadruplex DNA structures from duplex DNA precursors[34]. 
Increasing K+ causes an increased cooperativity of G4-DNA thermal dissociation, despite the 
increased stabilization of G4-DNA at these higher K+ concentrations. Structural transitions of 
G-quadruplex DNA, induced by changes in univalent cation concentrations (i.e. K+ and Na+), 
may play an important role in DNA replication, organization, and function[39-40]. The transient 
changes in K+ concentration during the cell cycle may drive structural transitions in G-rich 
DNA. Low basal K+ concentrations (ca. 110 mM[41] ) are thought to stabilize the G4’-DNA 
structures that may form from single-stranded G-rich sequences at the ends of the telomeres. 
As the cell cycle proceeds, K+ concentrations increase (ca. 130mM[42] ) and this temporal 
elevation in K+ concentration initially favours the formation of G'2-DNA structures, which may 
facilitate the alignment of chromosomal pairing in preparation for homologous recombination 
events. Further elevation in K+ concentration subsequently promotes the formation of G4-
DNA structures that may be involved in the process of meiotic (or mitotic) telomere 
association[16]. An alternative view is that altered K+/Na+ ratios in cancer cells may result in 
altered G-quadruplex DNA structure and function. A number of reports have documented 
altered K+/Na+ ratios in tumour cells, although the magnitude and trend of change appear to 
be tumour type specific[43]. These cancer cell-specific K+/Na+ ratios may effect conformational 
changes in G-quadruplex structures, resulting in altered transcription of particular genes and 
altered telomere function and maintenance.  
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3.2.  Other Tetrads 
 
In addition to the arrangement of four guanine bases, depicted in figure 3.1, there has been a 
variety of alternative tetrad arrangements of DNA bases observed or proposed in G-
quadruplex structures. The inosine base also can adopt a tetrad structure, as has been 
observed in the gel formed by poly(I)[44]. Examples of stable assemblies containing 
combinations of stacked G•C•G•C[45], G•T•G•T[46] and A•T•A•T tetrads are reported in the 
literature. Others have also demonstrated that a T•T•T•T tetrad can be can be accommodated 
when sandwiched between adjacent G-tetrads, although when placed at the ends of G-stacks 
the T-tetrads are largely disordered[47]. T-tetrad are less stable than G-counterpart, its 
geometry is stabilized through only four inter-strand hydrogen bonding  that involve the O6 
and N1 of each T-residue. The stability of A tetrads also appears to be context-dependent. 
Two possible geometries are envisaged in which the A-tetrad is stabilised through a putative 
interstrand hydrogen bonding between the 6-NH2 group and the N7, or 6-NH2 group and 
N1[48].  
 
3.3.  Biological relevance of G-quadruplex DNA 
 
One of the strongest arguments in favour of the biological relevance of G-quadruplex DNA 
comes from the multitude of proteins that have been shown to bind these DNA structures. 
Moreover, many of these proteins bind only specific topological forms of G-quadruplex DNA. 
G-quadruplex forming elements can be found in important regions of human genome[1-9] in the 
telomeres, in the immunoglobulin switch regions, in the promoter regions of c-myc and other 
oncogenes, in the retinoblastoma susceptibility gene and upstream of the insulin gene. In 
principle, gene expression regulation can be obtained by modulation of a specific DNA 
binding protein, as a transcription factor, and directly intervening on the promoter of the 
recognized gene. Selectively interfering with these recognition processes, by exploiting small 
organic molecules specifically binding GROs (G-rich oligonucleotides), as the ones present in 
promoters of c-myc or K-ras oncogenes, which favour quadruplex formation, is a new and 
challenging therapeutic frontier. In this context, an interesting study on the promoter of c-myc 
oncogene recently appeared in the literature, which shows the direct evidence of in vivo 
existence of G-quadruplex structures[8]. DNA quadruplex structures are also thought to be 
involved, in vivo, in the inhibition of telomerase, a nucleoprotein devoted to maintain the 
length of chromosomes. The single stranded overhang of 5’-TTAGGG-3’ repeats in the 
human telomere has been proposed to fold into an intramolecular G-quadruplex, and ionic 
conditions that stabilize G-quadruplexes inhibit telomerase. One approach to inhibit 
telomerase is to block the enzyme–substrate interaction. Whereas single-stranded DNA is a 
telomerase substrate, G-quadruplex DNA is not. Folding of telomeric DNA into G-quartet 
structures seems to influence the extent of telomere elongation in vitro and might therefore 
act as a negative regulator of elongation in vivo. A particularly appealing pharmacological 
approach is therefore based on the possibility to inhibit telomerase activity in tumour cells, 
where it results over-expressed, and to promote, as a consequence, their apoptosis by 
exploiting suitable drugs able to stabilize quadruplex structures in telomeres. Additional 
interest for quadruplex structures arises from the fact that they constitute the main scaffold of 
aptamers[13], i.e. oligonucleotide-based molecules able to specifically interact with a given 
protein, thus modulating its function. Short DNA or RNA fragments are able to specifically 
bind proteins, as for example thrombin or HIV-integrase: therefore, these molecules cannot 
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be considered only as mere passive carriers of gene information, but as biomolecules directly 
involved in a complex series of cellular processes as well. On these grounds, synthetic GROs 
can represent a new class of pharmacologically interesting molecules, characterized by a 
high selectivity of action. 
 
3.4.  G-quadruplex ligands: molecular recognition 
 
The wide array of G-quadruplex topologies, groove widths, loop conformations, and 
alternative DNA base-associations observed to date is probably just a small sampling of the 
structural diversity exemplified by G-quadruplex DNA. The unique features of G-quadruplex 
DNA: the association of up to four separate DNA strands, the hydrophobic stacking of large, 
planar hydrogen bonded DNA base quartets, and the specific interactions with metal ions, 
provide the basis for building up these diverse structures. Once formed, the G-tetrads of G-
quadruplex DNA, can provide an "assembly floor" for the creation of unusual DNA base 
associations. The potential existence of G-quadruplex DNA in vivo opens up new vistas for 
the targeting of DNA sequences by molecular recognition of these structurally diverse DNA 
motifs. The structural uniqueness of the G-quadruplex can only aid in the realization of this 
ultimate goal in DNA sequence recognition. As shown in figure 3.5 and table 3.1, there are 
different ways in which molecules can interact with G-quadruplexes: by face recognition, edge 
recognition, loop recognition, or by simultaneous binding to the surface of the G-quartet and 
an adjacent loop or groove.  
 
 
Table 3.1: Molecular recognition of G-quadruplexes  
a) face recognition through stacking: 
• nucleobase triads and tetrads 
• aromatic molecules/telomerase inhibitors 
 
b) edge recognition through hydrogen bonding: 
• hydrogen bonding of other nucleobases 
• protein recognition: edge interaction with amino acids 
• water-nucleobase interactions 
 
c) loop recognition through hydrogen bonding and electrostatic interactions: 
• protein interactions: electrostatic phosphate -ammonium interactions 
• small molecules and water 
 
d) groove recognition through hydrogen bonding and electrostatic 
interactions 
• water interactions with the hydration spine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Schematic representation showing 
some of the ways that other molecules 
recognize a bimolecular G-quadruplex. 
 • side-chain interactions with stacked aromatic molecules 
 
 
Within the context of nucleic acids, there are two major ways for adjacent nucleobases to 
recognize a G-quartet: either by stacking on its surface or by hydrogen bonding to an 
exposed edge. Molecular recognition of the G-Quartet Edges Hydrogen-bond donor (N2-H 
and C8-H) and acceptor (N3) atoms on the exposed edges of the G-quartet are also 
molecular recognition sites. These sites, which are located along the floor of a groove running 
the length of the G-quadruplex, can bind water, ions, amino acid side chains, and other 
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nucleobases. Furthermore, neighboring loops in bimolecular and unimolecular G-
quadruplexes are also molecular recognition sites, particularly for proteins and small 
molecules. 
 
3.4.1. Molecular Recognition of G-Quadruplexes by Proteins 
DNA and RNA oligonucleotides called aptamers have been selected by in vitro selection to 
bind molecular targets[49]. These targets are often proteins. One well-known aptamer is the 
thrombin binding aptamer (TBA), a DNA 15 mer that inhibits clotting. Crystallographic[50] and 
NMR[51] spectroscopic studies have shown that TBA forms a unimolecular G-quadruplex with 
two G-quartets and three loops. The structure and biological activity of TBA are K+-
dependent. NMR spectroscopic, calorimetric, and ESI-MS studies have shown, however, that 
TBA is even more stable with divalent Pb2+, Sr2+, and Ba2+ ions[52]. Related DNA aptamers are 
inhibitors of human HIV integrase with IC50 values in the nm region[53] and adopt a 
unimolecular G-quadruplex similar to TBA[54]. An intermolecular G-quadruplex aptamer that 
bound the V3 loop of HIV reverse transcriptase was formed by a 17-mer phosphorothioate 
oligonucleotide[55]. Like many G-quadruplexes, this phosphorothioate aptamer was extremely 
stable and had a dissociation half-life of 60 days. Many other protein-binding aptamers have 
been proposed to form G-quadruplexes as part of their bioactive structure[56]. Although many 
proteins, including aptamers, oncogenic factors[57], antibodies[58], and telomeric proteins[10], all 
bind G-quadruplexes, there are few molecular details known about quadruplex–protein 
interactions. The crystal structure of TBA bound to thrombin showed some ion pairs between 
the phosphate groups in the loops of the aptamer and Lys and Arg side chains[59]. A crystal 
structure of the telomeric protein of Oxytricha nova complexed to d[G4T4G4]4 is particularly 
valuable. As in the DNA solution structures, the bimolecular quadruplex in this complex has 
diagonal loops. Most of the DNA–protein contacts take place with these loops, rather than 
with the quadruplex core. However, the major DNA–protein interactions include: 1) 
electrostatic interactions, wherein the surface formed by three symmetry-related proteins 
provides a deep, electropositive cavity to hold the folded DNA; 2) van der Waals interactions, 
such as where the aromatic rings of Tyr142and Phe141 pack against the G-4 sugar; 3) water 
mediated hydrogen bonds, wherein one of the T4 loops forms an extensive network of water-
mediated hydrogen bonds with the protein; 4) nucleobase– peptide packing interactions, 
wherein the T6 residue of the other loop contacts the protein using both van der Waals and H-
bond interactions. This T6 nucleobase packs between a Leu side chain and the polarized 
Asp437–Gly438 peptide bond, while simultaneously hydrogen bonding with atoms of the 
protein side chain and main chain. In both cases where crystal structures are available, for 
the Oxytricha and for the thrombin systems[59], there are few direct interactions between the 
protein and the G-quadruplex core. Instead, the G-quadruplex seems to function as a scaffold 
on which loops are displayed for molecular recognition. Certainly, the crystal structure of the 
unimolecular G-quadruplex formed from the human telomeric sequence d(TTAGGG) 
suggests that the extended loops provide ideal protein-binding sites. In time, as more 
structural information becomes available, we should learn if a preference to bind loops is 
general for G-quadruplex protein interactions[57].  
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3.4.2. G-Quadruplex Aptamers : Recognition by Small Molecules 
Small molecules can also generate DNA and RNA aptamers, and G-quartets often appear as 
part of the aptamer structure[60]. Porphyrins and G-quartets have similar surface areas, and 
many biophysical and biochemical studies have demonstrated stacking interactions between 
porphyrins and G-quadruplexes[61]. Sen and co-workers also identified DNA aptamers able to 
catalyze  reactions[62]. Some DNA–hemin complexes had enhanced peroxidase activity 
relative to the heme cofactor alone. They concluded that the folded DNA activates the bound 
heme[62]. A G-quadruplex, with a heme intercalated between G-quartets was proposed to 
explain the enhanced peroxidase activity of the aptamers. These studies underscore the 
potential of DNA to function as a catalyst, in addition to its information storage role. By using 
in vitro selection, Isalen et al. discovered Zn2+ finger peptides that bind G-quadruplexes[63]. 
High affinity peptides (Ka=25 nM) containing three helices bound the human telomeric 
sequence d(GGTTAG). These Zn2+ fingers were G-quadruplex-specific; duplex DNA with the 
same sequence was not bound. The Zn2+fingers contained high amounts of certain amino 
acids, and the authors speculated that Glu/Asp side chains might form hydrogen bond with 
the N2-amino groups of the guanosine, while His groups could stack on the G-quartet.  
 
3.4.3. Small Molecules that Stabilize DNA G-Quadruplexes: Telomerase Inhibitors  
Telomerase inhibition depends on shifting the equilibrium between the single-strand and 
quadruplex towards the folded form. One strategy is to stabilize the G-quadruplex form by 
binding high-affinity small molecules. A number of reviews describe well how drug design and 
screening efforts have identified compounds that bind G-quadruplexes and inhibit telomerase. 
As shown by the structural formulas 1–10 (figure 3.6), most telomerase inhibitors are aromatic 
compounds with electron-deficient rings suited for stacking with the electron rich G-quartet. 
Ethidium bromide (1), a well-known duplex intercalator, binds DNA quadruplexes[64], but its 
surface area doesn't quite cover a G-quartet, and it was reasoned that larger aromatic 
compounds would be better inhibitors. The first report of a small molecule, anthraquinone 
derivative 2, that binds G-quadruplex DNA and inhibits telomerase came in 1997[65]. Since 
then, hundreds of telomerase inhibitors have appeared. There is debate about how the 
aromatic inhibitors interact with G-quadruplex DNA. Some suggest that they intercalate 
between G-quartets, while others argue that the compounds end-stack on terminal G-
quartets. The few known quadruplex–ligand structures, obtained from NMR spectroscopic[66], 
fiber diffraction[67], and single-crystal X-ray crystallographic analysis[67] indicate that 
telomerase inhibitors end-stack rather than intercalate. In their recent X-ray study of 
interactions between G-quadruplex and daunomycin (3) Clark et al. noted that intercalation of 
drugs between G-quartet layers should be energetically more costly than end stacking, as 
intercalation requires unstacking of the tetrad and unwinding of the helix. In addition, end 
stacking of aromatic drugs, as opposed to intercalation, would allow stabilizing cations to 
remain coordinated within the G-quadruplex core. Structure-based design and activity-based 
screening have both identified telomerase inhibitors. For example, Shafer and co-workers 
used computer modelling to screen “virtual” libraries for compounds that might interact with G-
quadruplexes. These efforts identified a carbocyanine dye that binds bimolecular G-
quadruplexes[69]. Molecular modeling studies suggested that addition of a properly positioned 
third side chain to an existing acridine drug 4 (to give 8) would increase the affinity of the G-
quadruplex.  
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Figure 3.6: High – affinity small molecules binding G-quadruplex. 
 
They reasoned that additional contacts between the side chains and grooves would further 
stabilize the folded DNA, and thus lead to more telomerase inhibition. A comparison of the 
properties of acridines 4 and 8 showed that attachment of this third side chain improved the 
drug's affinity to bind with the G-quadruplex, it's quadruplex–duplex selectivity, and it's 
telomerase inhibitory activity. In another modeling approach, Fedorov, Hurley, and coworkers 
designed and synthesized the quadruplex interactive compound PIPER (6), which was a 
potent telomerase inhibitor[70]. The slow NMR exchange between DNA bound and free PIPER 
(6), along with ligand–DNA NOE interactions, allowed determination of the drug's location 
when bound to G-quadruplex DNA. The conclusion was that PIPER (6) end-stacked over a 
terminal G-quartet. Promising telomerase inhibitors have also come from combinatorial 
screening strategies. The research groups of Mergny and HQlRne used a FRET-based assay 
to identify triazine compounds, such as 9, that induce a DNA oligonucleotide to fold into a G-
quadruplex[71]. Some of these triazines were inhibitors of human telomerase at nanomolar 
concentrations. Such combinatorial screens can lead to active compounds that might not 
have been considered in structure based design. Finally, the most potent and selective 
telomerase inhibitor, telomestatin (10), is a natural product isolated from Streptomyces 
anulatus during an activity screen[72]. NMR and modeling studies indicate that telomestatin 
stacks on a G-quartet, which again suggests that telomerase inhibition derives from an ability 
to stabilize the G-quadruplex form of telomeric DNA[73].  
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3.5.  Guanosine self-assembly in materials science, biosensor design, and 
nanotechnology 
 
Quadruplexes show also promise as components for nanowires, ion channels, and building 
blocks for directing the assembly of nanoscale components into sophisticated structures.  
 
3.5.1. DNA Nanostructures: G-Wires, Frayed Wires, and Synapses 
Fiber diffraction studies on crystalline GMP and poly-(guanylic acid) had shown that these 
compounds self-assemble into rods of stacked G-quartets[74]In the mid-1990s, the research 
groups of both Henderson and Sheardy further established that G-rich DNA formed 
nanometer assemblies[75]. They showed by using gel electrophoresis that d(G4T2G4), in the 
presence of K+ and Mg2+ ions formed high molecular weight assemblies that were well 
resolved from the smaller G-quadruplex [d(G4T2G4)]4. The polymers were extraordinarily 
stable; heating at 80°C or dissolving in 8M urea did not denature them. Marsh and Henderson 
coined the term “G-wires” to describe the continuous, parallel-stranded DNA superstructures 
formed when the 5’-end of one DNA-duplex with G-G pairs associates with the 3’-end of a 
similar duplex[76]. Marsh and Henderson proposed that G-wires could be useful in 
nanotechnology, nano-electronics and biosensor development.  
 
3.5.2. Toward Synthetic Ion Channels 
G-quadruplexes can organize themselves to build transmembrane ion channels. NMR studies 
have shown that base pairs in DNA G-quadruplexes open slowly and G-quadruplex 
dissociation is often quite slow, taking days or weeks. These results suggest that ions move 
without disruption of the G-quartet, thus making the G-quadruplex analogous to an ion 
channel.   
 
3.5.3. Formation of Biosensors and Nanomachines with G-Quadruplex DNA 
While DNA aptamers have potential as therapeutics and diagnostics, they also have 
applications in bioanalytical chemistry. Small molecules and proteins can be separated by 
using G-quadruplex DNA as stationary phases in chromatography or electrophoresis. DNA 
aptamers featuring an intramolecular G-quadruplex served as the stationary phase for the 
separation of the isomeric dipeptides Trp–Arg and Arg–Trp[77]. DNA G-quadruplex aptamers 
labeled with fluorescent dyes have also served as a prototype for biosensors[78]. In particular, 
FRET has been used to study the secondary structure of G-rich DNA oligonucleotides[79]. 
FRET is a distance-dependent method for detecting conformational changes over distances 
of 10–100Å. FRET has also been used to monitor the formation of molecular “nanomotors” 
from single-stranded DNA[80]. Li and Tan used FRET to monitor in real time the 
conformational switching between a double-stranded duplex and a folded G-quadruplex 
caused an extension and shrinking motion[81]. In 1975 Aviram and Ratner proposed that 
organic molecules could conduct charge[82]. Today, with the miniaturization of semiconductor 
components, the potential of molecular electronics is even clearer[83]. Recent experiments 
with DNA suggest that biomolecular self-organization is a viable strategy for electron 
transport[84]. Guanine derivatives are attractive candidates for electron transport. Guanine has 
the lowest oxidation potential of the nucleobases and it forms a variety of ordered structures. 
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3.6.  Future direction 
 
Three decades after its identification in 5’-GMP gels, the G-quartet really gained visibility 
because of the biological implications of G-quadruplex DNA. Consequently, structural 
characterization of nucleic acid G-quadruplexes has accelerated over the past decade. 
In 1992 the Protein Data Bank showed just two entries for G-quadruplexes. Ten years later, 
there are more than 35 deposited G-quadruplex structures, including 9 crystal structures. This 
data provides a wealth of information about the interactions that drive self-assembly of G-rich 
nucleic acids. More structures of G-quadruplex–protein and quadruplex–ligand complexes are 
needed in the future; indeed, the first three examples were published in the last three 
years[85]. Detailed information about protein and ligand complexes with G-quadruplexes will 
help us to better understand G-quadruplex molecular recognition and further enhance drug 
design. DNA quadruplex structures are very appealing from a pharmacological point of view, 
both as scaffolds of oligonucleotides (ONs) able to specifically inhibit proteins (aptamers) and 
in vivo, as targets in antitumour therapies. However, the pharmacological use of natural  ON 
in vivo experiments is dramatically limited by factors concerning their stabilization, 
administration and bioavailability. In order to overcome these drawbacks, recently many 
research efforts  have been devoted to the design and synthesis of ONs containing suitable 
chemical modifications, for example at 3’- or 5’-ends, in the backbones  and  others,  in order 
to improve better applications in biomedicine and biochemisty. 
In this contest, my effort has been addressed to synthesize and study of a class of ON 
analogues forming quadruplex structures with potential biological properties. These studies 
would be a part of a more general and promising investigations aimed at using ON analogues 
as drugs able to selectively interfere with the normal functions of nucleic acids and specific 
cellular proteins, thus inducing a specific control of the gene expression. Potential 
applications not only as therapeutic aptamers, but also as chromatography supports, and 
molecular electronic devices may be promising and aim the synthesis and the structural 
studies of this new class of ON analogues, that I wish to propose. 
 
3.7.  The aim of the work 
 
The potential of quadruplex DNA as targets for therapeutic intervention and as therapeutics is 
certain, and require, for its realization, more detailed structural informations about  G-
quadruplex selective targeting.  Up to today, many of the studies have used ONs that may 
form multiple structures making it difficult to ascertain which quadruplex structure type, or 
types, were involved in the interaction examined. The use of ONs that form a known, single 
quadruplex structure will allow the interactions to be better characterized and may also 
indicate that the binding affinities are stronger than those deduced from results on the ONs 
that adopt multiple structures.  In order to better understand G-quadruplex molecular 
recognition and further enhance drug design, simpler models of biologically relevant tetrads 
needed, in order  to obtain high resolution data on drug-DNA interactions. Tetramolecular 
quadruplexes (also called G4-DNA) have been used at this purpose. First, these structures 
show simpler configuration. Second, the conformation of the stem of these quadruplex is very 
close to the central core of intramolecular parallel quadruplexes found for human telomeric 
repeats or other motifs. Third, several tetramolecular quadruplexes strongly interact with the 
HIV gp120 protein, and act as specific inhibitors of infections in vitro[86]. Unfortunately, the in 
vivo formation of intermolecular quadruplexes is very slow, requiring high ONs concentration. 
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These unfavourable kinetic and thermodynamic parameters could be disadvantageous in 
view of their potential therapeutic use. Starting from these observations, the first goal of my 
research work, in this contest, was the synthesis of a new modified ON (TEL-ON, 1, Scheme 
3.1) capable of forming the monomolecular parallel G-quadruplex I, which thermal stability 
has been proved to be significantly higher than that observed for its tetramolecular 
counterpart [d(TG4T)]4[87]. 
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Scheme 3.1: i: two couplings with 6a; ii: ODN synthesis with 3’ or 5’-phosphoramidites; iii: detachment and 
deprotection with NH4OH conc. 32% (7 h,55 °C); iv: HPLC purification and annealing. 
 
The main structural feature of this molecule is the presence of four ON strands whose 3’-ends 
are attached to a non-nucleotidic tetra-end-linker. The synthesis of the symmetric tetra-
branched linker was carried out on polymeric support. This branched structure bears four 
primary alcoholic functions prone to ON chain assembly (for example  TGGGT o TGGGXT, 
where X is a variable base). By choosing appropriate alcoholic protecting groups of the linker 
structure and the ON chain assembly procedure, TEL-ONs having predetermined strand 
orientation (parallel, antiparallel or both, 1-4) or containing modified bases, were obtained[88]. 
Moreover, quadruplex complexes, containing less stable quartets such as T- tetrads[89], were  
synthesized. Modulating the length and nature of linker was also performed in order both to 
generate quadruplexes of higher stability and to hinder the folding of the linker around the 
whole quadruplex structure, thus forcing the predetermination of quadruplex strands polarity 
upon the basis of the relative orientation of the ON strands into the TEL-ON molecules. 
Furthermore, the construction of new and stable monomolecular quadruplexes possessing 
unusual strand orientation could expand their employment in both the study and control of 
important biological processes as well as in DNA-based nanotechnologies. Several studies 
have investigated the effect of loops on quadruplex stability and typology. With regard to 
nucleotidic loops, the base composition, the length, and the orientation of the phosphodiester 
linkage have influenced quadruplex typology. Non-nucleotidic loops have also been 
investigated. In this case both the kinetics of the quadruplex formation and the complex 
stabilities were found to be affected by the nature of the linker. Tetra-End-Linked linker seems 
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to provide favourable kinetic and thermodynamic parameters. Preliminary studies confirm that 
TEL-ON are more stable than the corresponding tetramolecular counterpart. Briefly, my 
research work in quadruplex-DNA  was employed and  addressed on the synthesis and 
characterization of a new kind ON analogues able to form stable monomolecular quadruple 
helices DNA complexes (TEL-ON). Studies on the length of tetra-end-linked linker on the 
orientation of the ON strands aimed  at of obtaining  stable quadruplex structures and studies 
on quadruplex complexes, containing less stable quartets such as T-tetrads, have been also 
performed and reported. 
 
3.8 .  Synthesis and characterization of a new kind ON analogues able to form    
        stable monomolecular quadruple helices DNA complexes (TEL-ON) 
 
The first goal of my research on TEL-ON was the chemical synthesis and the structural 
characterization of TEL-[d(TG4T)]4, which represents the first example of a new class of ONs 
forming quadruplex. The sequence of the chains was chosen mainly because d(TG4T) forms 
a stable tetramolecular helix, already well characterized by thermodynamic measurement as 
well as NMR, X-ray crystallography and CD spectra[85]. This quadruplex possesses a fourfold 
symmetry with all strands parallel to each other and all nucleotides in an anti conformation. 
CD and NMR spectroscopies have been used to investigate the solution structure of TEL-
[d(TG4T)]4 in the presence of potassium or sodium ions in comparison with the natural 
counterpart [d(TG4T)]4.  
Synthesis and Purification of TEL-ON (I). The synthetic strategy employed starts from the 
commercially available Controlled Pore Glass (CPG) support 5 and the phosphoramidite 
derivative of the di-functional linker 6a. On support 5 (0.048 meq/g), performing two coupling 
cycles with 6a by an automatic DNA synthesizer, support 7 was obtained, that bears four 
symmetrical protected primary alcoholic functions, prone to ON-chain assembly (0.085 meq/g 
of OH functions, by DMT spectrophotometric test). ON chains were assembled on 7 utilizing 
3’-phosphoramidite nucleotide units, thus obtaining the polymer bound ON 8 (coupling yields 
>98% per cycle). The presence of a β-sulfone phosphodiester function in the linker connecting 
the TEL-ON to the solid support allows the release of the phosphomonoester group via a β-
elimination under alkaline treatment (conc. NH4OH, 7 h, 55° C), affording the TEL-ON 1. 
Crude 1 was purified by HPLC on an anionic exchange column and the collected peaks were 
desalted on a RP18 column thus furnishing 1 (>95% pure, by HPLC and PAGE). In a typical 
synthetic cycle, starting from 100 mg (0.0085 meq) of support 5 135 OD260 units yield of pure 
1 were obtained. The structure of 1 was confirmed by 1H NMR data and by ESI mass 
spectrometry, which showed pattern peaks indicating a molecular weight at 8762.6 a.m.u. 
(calcd. 8763.7) (Scheme 4.1).  
CD and NMR studies of I and d(TG4T). In order to demonstrate that 1 can adopt a G-
quadruplex structure I and, in case, to estimate its stability, circular dichroism (CD) studies 
and CD thermal denaturation experiments were performed, in comparison with the 
tetramolecular G-quadruplex [d(TG4T)]4. CD spectra were registered at 20° C at quadruplex 
concentrations in the range 4.0–4.5·10-5M in K+ or Na+ buffers. Particularly, TEL-ON I and 
[d(TG4T)]4 showed almost identical CD profiles in both saline conditions (figure 3.7, columns 
A, B), characterized by a positive and a negative Cotton effect at 264 and 249 nm, 
respectively, diagnostic of a G-quadruplex structure involving four parallel strands. CD 
thermal denaturation experiments (figure 3.7, column C) were performed monitoring the CD 
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values (mdeg) at 264 nm in the range 20–90°C with 1°C/min heating rate. In K+ buffer both I 
and [d(TG4T)]4 G-quadruplexes undergo irrelevant CD264 variation up to 90°C, thus not 
showing the typical descendant sigmoidal curves indicative of a melting process. On the other 
hand, in Na+ buffer, the increase of temperature leads to a significant reduction of CD264 
values for both complexes, thus indicating the fusion to occur. The complex [d(TG4T)]4, 
showed a defined sigmoidal curve with a derivatizable Tm value (56°C at 4.5·10-5M 
concentration). In the case of I the melting curves registered at concentrations 1.0 · 10-5, 2.0· 
10-5 and 4.5 · 10-5M did not show well-defined changes of convexity up to 90°C, thus 
suggesting that only partial fusions occur. Furthermore, it is noteworthy that the melting curve 
profiles of I are not concentration dependent thus indicating that the complex is mainly 
present as a monomolecular species. The whole of data suggests that I, in Na+ buffer, is 
characterized by a higher stability than its tetramolecular counterpart [d(TG4T)]4, most likely 
due to the favourable entropy of the monomolecular complex. 1H NMR studies (500 MHz) on 
both complexes confirmed the data obtained by CD. Spectra were recorded in Na+ and K+ 
buffers at 25, 65 and 85°C using pulse field gradient WATERGATE for H2O suppression. The 
spectrum of I, in Na+ buffer at 25°C (figure 3.8A), shows the presence of four singlets in the 
range 10.5–12.0 ppm, two of them partially overlapping, confidently assigned to exchange 
protected imino protons involved in Hoogsteen N(1)H/O(6) hydrogen bonds of G-quartets also 
on the basis of the comparison with the corresponding region of the spectrum of [d(TG4T)]4 
(figure 3.8B), which displays a very similar peak profile. Even if a detailed 1H-NMR study has 
not been yet accomplished, it is not unreasonable at this stage to hypothesize that I is 
characterized by a quadruplex structure containing four G-quartets with a pseudo fourfold 
symmetry, so that the imino protons of the four oligonucleotide chains resonate as they were 
magnetically equivalent. NMR spectra in Na+ buffer at higher temperatures indicate that the 
above structure of I is preserved at least up to 85°C, whereas the tetramolecular complex 
[d(TG4T)]4 is destroyed at this temperature, as indicated by the disappearance of the imino 
protons signals. The 1H-NMR spectra in K+ buffer, for both complexes, displayed quite similar 
signal patterns. However, it was not possible to observe any quenching of the imino protons 
up to 85°C also for [d(TG4T)]4. Even though TEL-[d(TG4T)]4 is not the first monomolecular 
parallel quadruplex ever investigated, nevertheless, thanks to its unique structural features, it 
can be regarded as the prototype of a new class of quadruplex forming ONs, potentially 
useful for a number of interesting applications, considering the increasing number of 
ascertained or supposed biological roles in which quadruplex structures are involved. As a 
matter of fact, monomolecular quadruple helices formed by TEL-ONs are provided with more 
favourable thermodynamic and kinetic parameters than their tetramolecular counterparts. 
Therefore, TEL-ONs with suitable sequences and predetermined strand orientations could be 
used as aptamers or decoys with improved properties.  
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Figure 3.7: CD and CD melting spectra of I-IV and d[(TG4T)]4 in K+ buffer (left column), in Na+ buffer (middle 
column) at 25 °C (solid line) and 90 °C (dotted line). CD265 melting profiles (right column) in K+ (solid line) and 
Na+ (dotted line). 
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Figure 3.8: 1H NMR (500 MHz) spectra of I-IV and [d(TG4T)]4 in Na+ and K+ buffers. The spectra were  
   registered in H2O/D2O, (9:1, v/v) solution at 0.5 mM of quadruplex at 25 and 85 °C. The aromatic and  
   imino proton regions of the spectra are reported. 
 
Starting from these perspectives, the syntheses of several parallel and/or antiparallel 
stranded TEL-ONs, also containing such types of unusual tetrads, have been performed. Two 
synthetic strategies have been used to obtain d(TG4T) ON strands which were linked with 
their 3’ or 5’-ends to each of the four arms of the linker. The first approach allowed the 
synthesis of the TEL-ONs containing the four ON strands with a parallel orientation (1, 2 
Scheme 3.1), while the latter synthetic pathway led to the synthesis of TEL-ONs each 
containing antiparallel ON pairs (3, 4, Scheme 3.2). CD, CD melting, NMR spectroscopy, and 
molecular modeling have been used to investigate the solution structures of the resulting 
TEL-quadruplexes I-IV formed in the presence of sodium or potassium ions. 
Synthesis and Purification of TEL-ONs 1-4. In the synthesis of the TEL-ONs 1-4  two 
hydroxyl functionalized solid supports (5 and 10) and the bifunctional linkers 6a,6b have been 
used. The synthesis of 1 was just above described. 2 has been obtained following the same 
protocol employed for 1 (Scheme 3.1). 2 differs from 1 only in ON chain orientation, which 
synthesis require 5’- phosphoramidite nucleotides as building blocks. In both syntheses 
coupling yields were higher than 98% per cycle.  As a further step of this work we synthesized 
the TEL-ONs 3 and 4 (Scheme 3.2). In 3 a pair of strands was linked to the primary linker 
branch A through the 5’-ends whereas the second pair is linked to the primary branch B 
through the 3’-ends. Instead 4 is characterized by both branches (A and B) carrying two 
strands linked through opposite ends. For the preparation of 3 and 4, we adopted two 
A, (Na+, 25°) IV
III
II
I
[d(TG4T)]4 
B, (Na+, 85°) IV
III
II
I
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I
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I
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                                                                                                                          CHAPTER 3   Synthesis of TEL-ON 
 47
synthetic strategies both based upon bi-functional linker 6b in which the two alcoholic 
functions, thanks to the orthogonal protection with Fmoc and DMT groups, allowed the 
sequential synthesis of the ON chains with opposite polarity. 10 was used as solid support 
since, when 5 was used, we observed the release of ON material from the support during the 
Fmoc deprotection step, due to the concomitant β -elimination at the sulfone group.  
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Scheme 3.2:  i: coupling with linker 6;  ii: DMT removal and coupling with linker 6; iii: ON synthesis with 3'-
phosphoramidites; iv: Fmoc removal and coupling with linker 6a; v:ON synthesis with 5'-phosphoramidites; vi: 
detachment and deprotection with NH4OH conc. 32% (7 h, 55°C) and HPLC purification; vii: Fmoc removal and 
ON synthesis with 5'-phosphoramidites 
 
Therefore, we prepared the hydroxyl-functionalized support 10 bearing an ester function, 
stable under Fmoc deprotection conditions but cleavable by ammonia treatment, to release 
the assembled TEL-ON. Support 10 (0.18-0.20 mequiv/g of OH groups), prepared by reacting 
a carboxyl-functionalized Tentagel resin (0.28 mequiv/g of COOH groups) with 1,3-
dihydroxypropane in the presence of MSNT and NMI, was used in two synthetic pathways 
leading to the TEL-ONs 3 and 4. Support 10, by reaction with the phosphoramidite linker 6b 
yielded the asymmetrical protected bifunctional support 11 (0.17 mequiv/g by DMT test) 
which, after removal of DMT protection from the branch B and successive reaction with linker 
6a furnished the three-functionalized support 12. Six coupling cycles with 3’-phosphoramidite 
units, performed as described for 7, and a final capping step of the 5’-OH ON ends, gave 13. 
Then the 5’-Fmoc group was removed from the branch A by piperidine treatment, and the 
successive coupling with 6a yielded 14. On 14 the second ON domain was assembled using 
5’-phosphoramidite units, thus obtaining polymer bound TEL-ON 15. The synthetic pathway to 
obtain 4 started with reaction of 10 with 6a and subsequently 6b as described above, thus 
obtaining the tetra-branched support 16 (0.28 mequiv/g by DMT). The removal of DMT 
groups, followed by ON synthesis with 3’-phosphoramidite units, allowed the assembly of the 
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first pair of ON chains. After Fmoc deprotection, the remaining ON pair having opposite 
polarity was then assembled using 5’-phosphoramidite units, thus obtaining 17. Detachment 
from the solid support and complete deprotection of the TEL-ONs 3 and 4 were achieved 
treating supports 15 and 17 with concentrated NH4OH, as described for 1 and 2. Analyses 
and purifications of crude products 1-4 were carried out by HPLC using an RP18 column. The 
purity of the products was checked by PAGE, and the structures were confirmed by 1H NMR 
and MALDI-MS data. The quadruple helices were obtained by dissolving the samples 1-4 in 
Na+ or K+ buffers and by the annealing procedure to ensure the correct formation of 
quadruplex structures.  
Native Gel Electrophoresis. The purity of the products 1-4 and the molecularity of the 
complexes obtained were investigated by performing a non-denaturing polyacrylamide gel 
electrophoresis (figure 3.9) in comparison to the tetramolecular quadruplex [d(TG4T)]4. The 
samples (300 µM quadruplex) were annealed in Na+ buffer, and the electrophoretic analysis 
was carried out using a 20% polyacrylamide gel in TBE buffer. TEL-quadruplexes I-IV and 
d[(TG4T)]4 migrated as single bands demonstrating quite similar mobilities. This result, 
besides indicating the purities of I-IV, strongly suggests that they form monomeric species at 
this concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: I-IV non denaturing gel analysis. 
 
CD and CD Thermal Analysis on Quadruplexes I-IV. To investigate whether TEL-ONs 2-4 
adopt quadruplex structures and, if such is the case, determine their nature and stability, CD 
studies, including CD thermal denaturation experiments, were carried out and compared with 
those already reported for 1 and their tetramolecular counterpart [d(TG4T)]4. The ON 
samples were analyzed in Na+ or K+ buffers after the annealing procedure. CD spectra (figure 
3.7) were performed at 25 and 90 °C at a quadruplex concentration of 1.0 10-5 and 5.0 10-5M. 
TEL-ONs 1, 2 and [d(TG4T)]4 showed almost identical CD profiles in K+ buffer at 25 °C, 
characterized by positive and negative bands centered around 264 and 244 nm, respectively, 
which are indicative of a parallel stranded G-quadruplex structure. Upon the basis of these 
findings, it is reasonable to hypothesize that the 2, bearing the tetra-end-linker at the 5’-end of 
quadruplex, adopts the parallel G-quadruplex structure II. The data also suggest that 3 and 4 
adopt parallel G-quadruplex structures which, considering the mutual antiparallel orientation 
of the ON pairs, can be explained only by hypothesizing that a considerable folding of the 
linker around the whole G-quadruplex takes place. The parallel structures adopted by 3 and 4 
were substantiated by molecular modeling studies (see below) that clearly indicate that these 
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conformations are obtainable and stable as a result of the linker arrangement as shown in 
figure 3.10 and schematically depicted in IIIa and IVa (Scheme 3.3).  
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Scheme 3.3: Quadruplexes III and IV from bunch-ONs 3 and 4 after annealing 
                           procedure in K+ on Na+ buffer. 
 
CD spectra of 1-3 and [d(TG4T)]4 in Na+ buffer at 25 °C match those observed in K+ showing 
positive and negative bands at 262 and 244 nm, respectively, whereas in the CD profile of 4 
in Na+ buffer a slight shift of the positive and negative bands at 259 and 239 nm, respectively, 
takes place. Furthermore, in the latter the presence of a new lower positive band centered at 
289 nm is observable. These data indicate that even in Na+ buffer, possessing a lower 
stabilizing effect on G-quadruplex structures when compared to K+ buffer, the TEL-ON 1-3 are 
structured in parallel quadruplexes. For 4 in Na+ buffer the coexistence of two or more 
conformational species could be a hypothesis , among which the parallel (main) IVa and the 
antiparallel (minor) IVb,c structures are present, considering that most antiparallel G-
quadruplexes are characterized by a positive band centered at 290-295 nm and a negative 
band centered around 265 nm. CD spectra of 1-4 and [d(TG4T)]4 at 90 °C for both buffers are 
reported in figure 3.7. The data in K+ buffer confirm that the parallel G-quadruplex structures 
are completely retained in the complexes I and II while a detectable destructuration can be 
observed for complexes III and IV. CD spectra in Na+ at 90 °C suggest that complexes I-III 
retain, to some extent the characteristic parallel G-quadruplex profile, while complex IV and 
[d(TG4T)]4 are completely unstructured to random coils. CD thermal denaturation-
renaturation experiments were performed monitoring the CD value (mdeg) at 265 nm in the 
range 25-90 °C with 1 °C/min temperature scan rate. CD melting curves in K+ buffer for 
quadruplexes I, II and d[(TG4T)]4 underwent irrelevant or low CD265 variations up to 90 °C 
while a relatively high CD265 variation was shown by the complexes III and IV. The melting 
profiles of the complexes I-IV and [d(TG4T)]4 in Na+ showed higher CD265 variation with 
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respect to the corresponding values registered in K+; however, only for the [d(TG4T)]4 
complex was a typical and derivatizable sigmoidal curve (Tm=59°C) registered. These data 
indicate that the melting process for the complexes I-III in Na+ is not complete at 90 °C, while 
a complete melting of IV can be observed in Na+ at this temperature. However, considering 
the shape of the apparent sigmoidal curve and the possible polymorphism of IV, we could not 
determine its melting temperature in both buffers. We also registered the CD265 thermal 
renaturation curves for all complexes in the range 90-25 °C. For the tetramolecular 
[d(TG4T)]4 complex, as expected, a very slow renaturation process and a high hysteresis 
phenomenon was indicated by the profile of the renaturation curve at 1 °C/min scan rate. The 
renaturation curves of I and II showed relatively low hysteresis at the same temperature scan 
rate. The fast reformation of the complexes I and II was also confirmed by the CD spectrum 
profiles registered at the end of the renaturation processes (data not shown). In the case of 
complexes III and IV the renaturation curves showed high hysteresis associated with low 
restructuration levels. 
1H NMR Studies on Quadruplexes I-IV and [d(TG4T)]4. 
1H NMR studies on quadruplexes I-IV were performed, after annealing, in the same buffers 
used for CD measurements. The spectrum of I and II, recorded in Na+ buffer at 25 °C (Figure 
3.8A), showed the presence of four singlets in the range 10.9-11.8ppm, two of them partially 
overlapped, attributable to exchange protected imino protons involved in Hoogsteen N(1)/O(6) 
hydrogen bonds of G-quartets. These signals were almost superimposable with those 
observed in the spectrum of the [d(TG4T)]4 complex already characterized by NMR data. The 
1H NMR spectra recorded in Na+ buffer at 85°C (Figure 3.8B) indicated that I is completely 
stable at least up to 85 °C. II is partially preserved (only two imino proton signals are still 
detectable at this temperature), whereas the tetramolecular complex [d(TG4T)]4 is completely 
unstructured as indicated by the disappearance of all the imino proton signals. Upon the basis 
of these data, it appears that quadruplex II in Na+ buffer is more stable than the 
tetramolecular counterpart, yet it is less stable than quadruplex I. The 1H-NMR spectra of I, II, 
and [d(TG4T)]4 recorded in K+ buffer displayed quite similar signal patterns; however, it was 
not possible to observe any quenching of the imino proton signals up to 85 °C (Figure 3.8D). 
This observation is in accordance with reported data about the capability of K+ cations to form 
more stable quadruplex structures in comparison with those observed in Na+ buffer. As 
expected, 1H-NMR spectra of III indicated that this compound is more structured in K+ than in 
Na+ buffer. In K+ buffer it was possible to detect the four imino proton signals up to 85°C 
(Figure 3.8C and 3.8D), whereas in Na+ the spectrum showed large imino proton signals at 25 
°C (Figure 3.8A) which almost disappeared at 85 °C (Figure 3.8B). The 1H-NMR spectra of IV 
at 25 °C showed very large and overlapped imino proton signals both in Na+ (Figure 3.8A) 
and K+ buffers (Figure 3.8C). The increase of temperature for 1H-NMR spectra of IV led to the 
sharpening of all imino proton signals both in Na+ and K+ buffers. In K+ buffer at least three 
imino proton signals are clearly detectable even at 85 °C (Figure 3.8D), whereas in Na+ buffer 
all imino proton signals are completely lost since 65 °C (data not shown). These data, which 
are consistent with UV and CD experiments, indicate that both complexes III and IV result in 
less stable quadruplex structures than I and II. Furthermore, III results more stable than IV 
especially in K+ buffer. 
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Molecular Modeling. To explore the capability of TEL-ONs 3 and 4 of adopting the parallel 
quadruplex structure IIIa and IVa, respectively, a modeling study was performed. 
The minimized structures obtained are shown in figure 3.10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Molecular models of quadruplex structures IIIa and IVa; A: front view, B top view. 
              The tetrabranched linker is in red. 
 
Inspection of these structures reveals that in both IIIa and IVa, the tetra-end-linker is able to 
span the distance between the 5’- and 3’-ends of the strands assembled in parallel 
quadruplex structure. It can be noted that the orientation of the linker with respect to the 
helical axis is different in IIIa and IVa quadruplexes. For both the complexes the inter-atomic 
distances between the linker atoms and the quadruplex groove hydrogen bonding sites 
suggest the possibility of favorable non-bonded interactions. Although the integrity of the G-
tetrads is maintained after energy minimization for both complexes, a detailed analysis of the 
H-bonds scheme inside the G-tetrads reveals some differences between the quadruplexes. In 
particular, in IIIa, each G-tetrad shows the same hydrogen bond scheme with an optimum 
distance and angle between donor and acceptor atoms, resulting in strong hydrogen bonds. 
Indeed in IVa there is a change of hydrogen-bond distances and angles between adjacent 
quartets, and, on average, two hydrogen bonds for each G-tetrad are lost. Furthermore, the 
degree of coplanarity between the G residues in each G-tetrad is greater in IIIa than in IVa. It 
is important to point out that the perturbation of each G-tetrad directly affects the stacking 
energy of the neighboring G-tetrads. In summary, the TEL-ON 3 can form a parallel 
quadruplex structure IIIa without causing any distortion in the G-tetrad region, whereas in the 
TEL-ON 4, which forms the quadruplex IVa, a major readjustment of the G-tetrads occurs. 
A B
A B
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These findings appear consistent with the experimental CD and NMR data revealing the 
formation of a more stable quadruplex III in comparison to IV.  
The results described in this paper confirm the potential of TEL-ONs as a new class of ON 
analogues prone to adopt stable intramolecular quadruplex structures. In each case the Tm 
values are higher in potassium- than in sodium-containing buffer. It is noteworthy that, 
irrespective of the ends by which the four strands are attached to the tetra-end-linker, the CD 
spectra of the obtained complexes are typical of parallel quadruplex structures, displaying 
positive maxima centered at 264 nm, in contrast to maxima at 295 nm observed for 
antiparallel structures. The only exception concerns the CD spectrum of 4 in Na+ buffer, in 
which a positive shoulder at 295 nm is present, indicating that a mixture of parallel and 
antiparallel forms could exist (quadruplex IVa-c). The whole of data, including molecular 
modelling calculations, suggest that (i) the tetra-end- linker used in the present study is long 
and flexible enough to allow the organization of the ON strands into a parallel quadruplex 
structure and (ii) that, at least in the presence of potassium ions, this form is favored over the 
antiparallel one, even if it is at the cost of a major readjustment of G-tetrads, which is the case 
of IVa. To confirm these conclusions and in order to obtain TEL-quadruplexes with suitable 
sequences and predetermined strand orientations useful as aptamers, decoy and molecular 
probes, TEL-ONs characterized by shorter branched spacers have been performed., in which 
shortness branches could be able into force the  predetermination of quadruplex strands 
polarity. 
 
EXPERIMENTAL SESSION  
 
General Methods  
Chemicals and solvents were purchased from Fluka-Sigma-Aldrich. Reagents and 
phosphoramidites for DNA syntheses were purchased from Glen Research. ON syntheses 
were performed on a PerSeptive Biosystems Expedite. HPLC analyses and purifications were 
performed by a JASCO PU2089 pumps equipped with UV detector 2075 Plus using a Merck 
Hibar (5 µm, 250-10) column. CPG support 5 and linkers 6a,b were purchased from Glen 
Research. Tentagel carboxy resin, used as starting material for preparation of solid support 
10, was purchased from Novabiochem. Preparation of 10 was carried out in a short column 
(10 cm length, 1 cm i.d.) equipped with a sintered glass filter, a stopcock and a cap. The ONs 
were assembled by a PerSeptive Biosystems Expedite DNA synthesizer using 
phosphoramidite chemistry. UV spectra were run with a Jasco V 530 spectrophotometer. CD 
spectra and thermal denaturation experiments were obtained with a Jasco 715 circular 
dichroism spectrophotometer equipped with a JASCO 505T temperature controller unit. NMR 
spectra were recorded on a Varian Unity Inova 500 MHz spectrometer. MALDI-TOF mass 
spectrometric analyses were performed on a PerSeptive Biosystems voyager-De Pro MALDI 
mass spectrometer using a picolinic/3-hydroxypicolinic acids mixture as the matrix. The ON 
concentration was determined spectrophotometrically at 260 nm and 90 °C, using the molar 
extinction coefficient 57800 cm-1 M-1 calculated for the unstacked oligonucleotide by the 
nearest neighbor mode. 
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General Procedures 
Synthesis and Purification of TEL-ONs 1 and 2. 50 mg of support 5 (0.048 mequiv/g) was 
used for each synthesis in the automated DNA synthesizer following standard 
phosphoramidite chemistry, using 45 mg/mL of solution of phosphoramidite 6a (two coupling 
cycles) and 3’- or 5’-phosphoramidite nucleotide building block (six cycles) in anhydrous 
CH3CN, thus obtaining the polymer bound ON 8 and 9, respectively. The coupling efficiency 
with nucleotide units was consistently higher than 98% (by DMT spectrophotometric 
measurements). The solid support 8 (or 9) was then treated with 25% aq ammonia solution 
for 7 h at 55 °C. The filtered solution and washings were concentrated under reduced 
pressure and purified by HPLC on a RP18 column eluted with a linear gradient CH3CN in 
TEAB buffer (pH 7.0, from 0 to 100% in 60 min, flow 1.0 mL/min), retention time 26.1 and 
27.0 min for 1 and 2, respectively. The collected peaks furnished pure 1 and 2 (72 and 77 
OD260 units, respectively) which, after lyophilization, were characterized by spectroscopic 
data. TEL-ON 2: MALDI TOF-MS (negative mode): calculated mass (8763.7); found: 8762.6. 
Preparation of Support 10. 500 mg of Tentagel carboxyl resin (0.28 mequiv/g of COOH) 
suspended in CH2Cl2 were left dihydroxypropane (0.56 mmol, 0.36 mL), N-methylimidazole 
(NMI, 0.56 mmol, 0.40 mL) and mesitilensulphonylnitrotriazole (MSNT 0.056 mmol, 1.48 g) 
and the mixture was shaken for 36 h at room temperature. The obtained hydroxyl support 10 
was exhaustively washed with CH2Cl2 and then dried under reduced pressure. The amount of 
hydroxyl groups, determined by DMT measurements after the successive coupling step with 
3’-phosphoramidite nucleotide units, resulted to be in the range 0.18-0.20 mequiv/g. 
Synthesis and Purification of TEL-ONs 3 and 4. 50 mg of support 10 (0.18 mequiv/g) 
reacted, in the automated DNA synthesizer, with phosphoramidite 6b (45 mg/mL in CH3CN) 
following standard phosphoramidite chemistry at 15-µmol scale, yielded support 11 (0.17 
mequiv/g of DMT groups). After removal of the DMT group by DCA/standard treatment, the 
second coupling cycle was performed in the same manner using phosphoramidite 6a, thus 
obtaining support 12 (0.30 mequiv/g of DMT groups). 12 was then subjected to six coupling 
cycles using 3’-phosphoramidite nucleotide building blocks (45 mg/mL in CH3CN, 15-µmol 
scale), followed by final DMT removal and 5’-OH capping with Ac2O, to yield ON-
functionalized support 13. The removal of Fmoc groups was achieved by treatment with 
piperidine/DMF solution (2:8 v/v, 30 min RT). The resulting support was then reacted with 
phosphoramidite 6a, thus obtaining 14 (0.27 mequiv/g of DMT groups). On branches A of 14 
the second ON domain was assembled, performing six coupling cycles with the 5’-
phosphoroamidite nucleotide building block as described for support 12, yielding the polymer 
bound ON 15. For the synthesis of 4, support 10 (50 mg) was functionalized with 6a and then 
6b, as described before, yielding the tetrabranched support 16 (0.28 mequiv/g of DMT 
groups). After removal of the DMT protecting groups, the first two ON chains were 
assembled, using 3’-phosphoramidite nucleotide building blocks. After capping of the terminal 
5’-OH functions by Ac2O treatment, the Fmoc groups were removed as previously described, 
and the successive two ON chains were assembled using 5’-phosphoroamidite nucleotide 
building blocks, thus obtaining the polymer bound ON 17. TEL-ONs were detached from the 
supports 15 and 17, deprotected, and purified as described for 1 and 2, thus obtaining 3 and 
4 (retention time 25.8 and 25.2 min, respectively). After lyophilization, the final pure products 
3 and 4 (68 and 62 OD260 units, respectively) were characterized by spectroscopic data. TEL-
ON 3: MALDI TOF-MS (negative mode): calculated mass (8821.7); found: 8820.5. TEL-ON 4: 
MALDI TOF-MS (negative mode): calculated mass (8821.7); found: 8820.2 
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Preparation of Quadruple Helices (Annealing). Quadruplexes I-IV were formed by 
dissolving the TEL-ONs 1-4, in the appropriate buffer and annealed by heating to 90 °C for 20 
min followed by slow cooling to room temperature. The solutions were equilibrated at 10 °C 
for 24 h before performing the experiments. The buffers used were 10 mM Na2HPO4, 70 mM 
NaCl, 0.2 mM EDTA (Na+ buffer) or 10 mM K2HPO4 70 mM KCl, and 0.2 mM EDTA (K+ 
buffer). 
Native Gel Electrophoreses. Native gel electrophoreses were run on 20% nondenaturing 
polyacrylamide gels in 0.6x TBE buffer, pH 7.0, with 50 mM NaCl. ON solutions, with a final 
concentration of 300 µM in quadruplex, were prepared in 50 mM Tris-borate pH 7.0, 80 mM 
NaCl, 1 mM spermine, and 3 mM MgCl2 and annealed as above-described. At 2 µL of the 
ODN solution (300 µM in quadruplex) was then added 1 µL of 30% glycerol and the mixture 
charged on gel. The gels were run at room temperature at constant voltage (100 V) for 2.5 h. 
The bands were visualized by UV shadowing. 
CD Experiments. CD spectra of the quadruplexes were registered on a Jasco 715 circular 
dichroism spectrophotometer in a 0.1 cm path length cuvette at 25 and 90 °C at 1.0 x10-5 and 
5.0 x10-5M quadruplex concentrations. The wavelength was varied from 220 to 320 nm at 5 
nm min-1. The spectra were recorded with a response of 16 s, at 2.0 nm bandwidth and 
normalized by subtraction of the background scan with buffer. CD thermal denaturation-
renaturation experiments were performed monitoring the CD value (mdeg) at 264 nm in the 
range 25-90 °C with 1 °C/min heating rate. 
1H NMR Experiments. 1H NMR data were collected on a Varian Unity INOVA 500 
spectrometer equipped with a broadband inverse probe with z-field gradient and processed 
using Varian VNMR software package. 1D-NMR spectra were acquired as 16,384 data points 
with a recycle delay of 1.0 s at temperatures in the range 25-85 °C. Data sets were zero filled 
to 32,768 points prior to Fourier transformation and apodized with a shifted sine bell squared 
window function. Pulsed-field gradient WATERGATE sequence was used for H2O 
suppression. All NMR samples I-IV were prepared in H2O/ 
D2O (9:1, v/v) at 0.5 mM of quadruplex concentration with a final salt concentration of 100 mM 
KCl and 10 mM K2HPO4 or 100 mM NaCl and 10 mM Na2HPO4 for K+ or Na+ buffer, 
respectively. 
Molecular Modeling. The conformational features of the quadruplexes III and IV have been 
explored by means of molecular modeling study. All the calculations were performed on a 
personal computer running the HyperChem 7.5 suite of programs. The AMBER force field 
based on AMBER 99 parameter set was used. The initial coordinates for the starting model of 
[d(TGGGGT)]4 quadruplex were taken from the NMR solution structure of the 
[d(TTGGGGT)]4 quadruplex (Protein Data Bank entry number 139D), choosing randomly one 
of the four available structures. The initial [d(TGGGGT)]4 quadruplex models were built by 
deletion of the 5’-end tymidine residue in each of the four TTGGGGT strands. The complete 
structures of III and IV were then built using the HyperChem 7.5 building tool. Partial charges 
for each of the tetra-end-linker atoms were assigned using the Gasteiger-Marsili algorithm 
implemented in the QSAR module of HyperChem suite. The resulting coordinates of tetra-
end-linker’s atoms were energy minimized in a vacuum, keeping all DNA coordinates frozen 
(500 cycles of the steepest descent method). Three sodium ions were manually positioned in 
the central channel, equidistant from adjacent G-tetrads to allow octahedral coordination with 
G carbonyl oxygen O6 atoms. The two complexes were neutralized by addition of further 26 
sodium ions placed in the most negative positions of the systems. Each quadruplex was then 
solvated by a periodic TIP3P water box (5833 water molecules), which extended to a distance 
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of 10 Å from each atom. The minimal distance between water and system atoms was set to 
2.3 Å. The whole systems were initially subjected to energy minimization followed by 50 ps of 
molecular dynamics at 300 K, and then the systems were slowly cooled at 10°K. The obtained 
structures were further minimized using 1000 cycles of the steepest descent method followed 
by conjugate gradient method until convergence to a rms gradient of 0.1 kcal mol-1 Å-1. 
 
3.9 .  Studies on the length of tetra-end-linked linker on the orientation of the ON    
        strands aimed  at of obtaining  stable quadruplex structures 
 
In the attempt to obtain monomolecular quadruplexes having predetermined strands polarity, 
the synthesis of two new tetra-branched linker moieties characterized by the shortening of the 
primary or both primary and secondary TEL branches (sl-TEL or ss-TEL, Scheme 3.4), was 
performed. To test if the sl-TEL and ss-TEL moieties were still able to allow the formation of 
stable quadruplex structures, synthesis of  sl-1 and ss-1 via the above reported solid-phase 
procedure using the CPG support and the branching bi-functional linkers 6a and 6c  were 
performed. ls-TEL-d(TGGGGT)4 (ls-1) was not synthesized because its primary branch is 
long enough to span the distance between the quadruplex edges, thus allowing the loss of 
strands polarity predetermination. 
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Scheme 3.4: i: two couplings with 6a ,6c; ii: ODN synthesis with 3’ or 5’-phosphoramidites; iii: detachment and 
deprotection with NH4OH conc. 32% (7 h,55 °C); iv: HPLC purification and annealing. 
 
1H-NMR and CD studies. In order to assess if sl-1 and ss-1 could still fold into the 
quadruplex structures sl-I and ss-I, respectively, and if such were the case, to estimate their 
stabilities, we performed 1H-NMR (at 25, 65, and 85°C using pulse field gradient 
WATERGATE sequences for H2O suppression) and CD studies. Comparison of 1H-NMR 
stacked spectra of sl-I and ss-I (figure 3.11) showed that both adopted parallel quadruplex 
structures in presence of K+ ions.  
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Figure 3.11: 1H NMR (500 MHz) spectra of sl-I and ssI and [d(TG4T)]4 in K+ buffers. The spectra were 
registered in H2O/D2O, (9:1, v/v) solution at 0.5 mM of quadruplex at 25,65 and 85 °C. The aromatic and imino 
proton regions of the spectra are reported. 
 
 
However, it appeared that the presence of the ss-TEL moiety  lead to the lowering of the 
thermal stability of ss-I, and to the partial loss of the magnetic equivalence between the imino 
protons in each G-tetrad. On the other hand sl-I, characterized by the presence of the sl-TEL 
moiety, appeared to be very stable up to 85°C. Furthermore, in the case of sl-I no loss of 
imino protons magnetic equivalence was observed. Finally, the CD spectra and the CD 
melting curves were well in agreement with the NMR data (figure 3.12). Upon the basis of 
these findings, the sl-TEL seems to be very promising for the achieving of monomolecular 
multistranded quadruplex structures characterized by both high thermal stability and 
predeterminable strands orientation. CD studies suggest that the shortening of the branches 
could enhance the folding of the quadruplex: i) ss-I appears more folded (higher mdeg value 
at 264nm) than sl-I, followed by I (overlayer spectra, samples prepared in the same 
concentration and ionic strength conditions); ii) the melting process for all complexes in study 
is not complete at 90°C; iii) thermal renaturation curves have been registered for al the 
complexes in the range 20-95°C.  Data indicate that sl-I such as I (figure 3.12C and 3.12B, 
respectively) showed relatively low hysteresis at 1°C/min scan rate. 
 
 
 
 
 
 
 
 
 
 
 
sl-1 ss-1 
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Figure 3.12: A) Overlayer CD spectra of I (Ill) sl-I and ss-I at 25°C. CD melting (solid line) and refolding (dotted 
line) for each one Ill (B), sl-I (C) and ss-I (D)in the range 25-90°C at 1°C/min heating rate. 
 
The fast reformation of the complex ss-I (figure 3.12D) and the absence of  hysteresis in its 
case suggest that ss-I could be a good candidate to realize studies on nanomotors. 
Furthermore, CD studies on the refolding rate of I, sl-I and ss-I, have been made (data not 
shown). ss-I refolding is complete in just 15 min (the shortest time to register melting and 
refolding curves in 25-95°C range by CD instrument), while I and sl-I are not completely 
refolded in the same conditions. The syntheses of the antiparallel sl-TEL-d(TGGGGT)4 (sl-III 
and sl-IV) and also ss-TEL-d(TGGGGT)4 (ss-III and ss-IV) have been performed. These 
structural features may be able at hinder the folding of the linker around the whole quadruplex 
structure thus forcing the predetermination of quadruplex strands polarity upon the basis of 
the relative orientation of the ON strands into the TEL-ON molecules. CD and NMR data on 
these new synthesized TEL-ON analogues are currently acquiring.  
 
EXPERIMENTAL SESSION 
 
General Procedures 
The sl-I and  ss-I; sl-III and ss-III; sl-IV and ss-IV syntheses (scheme 3.5) were performed 
using the same protocols employed for the corresponding analogues above reported (I,III,IV). 
The only difference is in TEL-supports synthesis. CD and NMR studies were performed using 
the same procedures for the 1-4 analogues above reported. 
ISS 
Ill 
ISl A B 
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D 
B
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Synthesis of sl- and ss-TEL-ON- I (sl-I and ss-I). 50 mg of support 5 (0.048 mequiv/g) was 
used for each synthesis in the automated DNA synthesizer following standard 
phosphoramidite chemistry, using 45 mg/mL of solution of each phosphoramidite: 6a (for the 
first coupling cycle) and 6c (for the second coupling cycle); or two coupling cycles with 45 
mg/mL of solution of phosphoramidite 6c, to obtain two different length tetra-branched 
supports sl-7 and ss-7, respectively.  The followed couplings with  3’- phosphoramidite 
nucleotide building block (six cycles) in anhydrous CH3CN led the polymer bound sl-ON 8 and 
ss-ON 8, respectively. The coupling efficiency with nucleotide units was consistently higher 
than 98% (by DMT spectrophotometric measurements). The solid support sl-8 (or ss-8) was 
then treated with 25% aq ammonia solution for 7 h at 55 °C. The filtered solution and 
washings were concentrated under reduced pressure and purified by HPLC on a RP18 
column eluted with a linear gradient CH3CN in TEAB buffer (pH 7.0, from 0 to 100% in 60 
min, flow 1.0 mL/min), retention time 25.5 and 24.9 min for sl-1 and ss-1, respectively. The 
collected peaks furnished pure sl-1 and ss-1 (90 and 95 OD260 units, respectively) which, 
after lyophilization, were characterized by spectroscopic data. sl-TEL-ON1: MALDI TOF-MS 
(negative mode): calculated mass (8320.26); found: 8319.6; ss-TEL-ON 1(negative mode): 
calculated mass (8061.7); found: 8062.6 
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Scheme 3.5: i: coupling with linker 6;  ii DMT removal and coupling with linker 6; iii: ON synthesis with 3'-
phosphoramidites; iv: Fmoc removal and coupling with linker 6a; v: ON synthesis with 5'-phosphoramidites; vi: 
detachment and deprotection with  NH4OH conc. 32% (7 h, 55°C) and HPLC purification; vii: Fmoc removal and 
ON synthesis with 5'-phosphoramidites.  
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Synthesis and Purification of sl-3 and ss-3 TEL-ONs. For the syntheses of sl-3 and ss-3, 
50 mg of support 10 (0.18 mequiv/g) in each case were reacted, in the automated DNA 
synthesizer, with phosphoramidite 6d (45 mg/mL in CH3CN) following standard 
phosphoramidite chemistry at 15-µmol scale, yielded support s-11 (0.17 mequiv/g of DMT 
groups). After removal of the DMT group by DCA/standard treatment, the second coupling 
cycle was performed in the same manner using phosphoramidite 6a or 6c, respectively to 
obtain support sl-12 or ss-12, respectively (0.30 mequiv/g of DMT groups). These latters 
were then subjected to six coupling cycles using 3’-phosphoramidite nucleotide building 
blocks (45 mg/mL in CH3CN, 15-µmol scale), followed by final DMT removal and 5’-OH 
capping with Ac2O, to yield ON-functionalized supports sl-13 from sl-12  and ss-13 from ss-
12. The removal of Fmoc groups was achieved by treatment with piperidine/DMF solution (2:8 
v/v, 30 min RT). The resulting support was then reacted with phosphoramidite 6a or 6c 
respectively, thus obtaining sl-14 and ss-14 (0.27 mequiv/g of DMT groups). On these latters, 
the second ON domain was assembled, performing six coupling cycles with the 5’-
phosphoroamidite nucleotide building block as described for support 12, yielding the polymer 
bound sl-ON 15 and ss-ON 15. 
Synthesis and Purification of sl-4 and ss-4 TEL-ONs. Support 10 (50 mg) was 
functionalized with 6c and then 6b, and/or 6c followed by 6d, yielding the tetra-branched 
supports  sl-16 and/or ss-16, respectively (0.28 mequiv/g of DMT groups). After removal of 
the DMT protecting groups, the first two ON chains were assembled, using 3’-
phosphoramidite nucleotide building blocks. After capping of the terminal 5’-OH functions by 
Ac2O treatment, the Fmoc groups were removed as previously described, and the successive 
two ON chains were assembled using 5’-phosphoroamidite nucleotide building blocks, thus 
obtaining the polymer bound sl-ON 17 and/or ss-ON 17. 
TEL-ONs were detached from the supports sl- and ss-15 and sl- and ss-17, deprotected, and 
purified as described for 3 and 4, thus obtaining sl- and ss-3 and sl- and ss-4 (retention time 
25.3 and 24.5 min , respectively for sl- and ss-3; 24.7 and 24.2 min, respectively for sl- and 
ss-4). After lyophilization, the final pure products sl- and ss-3 (75 and 78 OD260 units, 
respectively)  and sl- and ss-4 (65 and 80 OD260 units, respectively)  were characterized by 
spectroscopic data. sl-TEL-ON 3: MALDI TOF-MS (negative mode): calculated mass 
(8320.26); found: 8320.5.  ss-TEL-ON 3: MALDI TOF-MS (negative mode): calculated mass 
(8061.7); found: 8062.6. sl-TEL-ODN 4: MALDI TOF-MS (negative mode): calculated mass 
(8320.26); found: 8319.2 ss-TEL-ODN 4: MALDI TOF-MS (negative mode): calculated mass 
(8061.7); found: 8062.6.  
Synthesis of 6c. 0.34g (3.6mmol) of 1,2,3-propantriol dried by repeated coevaporations with 
anhydrous pyridine and then dissolved in 8mL of the same solvent, were reacted with 2.5g 
(7.2mmol) of 4,4’-dimethoxytrytilchloride at R.T. for 12h. The reaction was quenced by 
addition of water and the resulting mixture, taken to dryness and redissolved in benzene, was 
purified on a silica gel column giving 1.63 g (2.34 mmol, 65% yield) of 1,3- bis-(O-DMT)-
propantriol, in mixture with the full protected derivative. The bis-tritylated compound was 
dissolved in dry CH2Cl2 (5mL) and N,N-diisopropylethylamine was added (0.860 mL, 4.6 
mmol) followed by 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.48 mL, 2.76 mmol). 
The mixture was stirred for 1h at R.T. then diluited with ethyl acetate (50mL) and washed with 
saturated sodium chloride solution(25mLx4).The organic phase was dried over sodium 
sulphate and evaporated to an oil in the presence of toluene(10mL). The product was purified 
by short column chromatography on Kieselghel 60H (10g) eluting with CH2Cl2/ethyl 
acetate/2,6-lutidine 50:50:2. The product was dried to give a white powder (90%yields).  
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6c 1H-NMR (400 MHz) ppm (acetone, d6) 1.05 (d, 12H, CHCH3), 2.97 (m, 2H, CHCH3), 3.52 (d, 4H, 
CH2ODMT), 3.82 (s, 12H, OCH3), 3.87 (m, 1H, CHOP), 4.05 (s, 2H, CH2CN), 6.82-7.55 (m,26H, 
aromatic protons).ESI-MS calculated m/z:882.11,(C53H59N2O8P),found:883.40(M + H)+ 
Synthesis of 6d. 0.34 g (3.6 mmol) of 1,2,3-propantriol dissolved in 8mL of pyridine, were 
reacted with 0.325 g (0.9 mmol) of 4,4’-dimethoxytrytilchloride at R.T.for 12h to afford after 
purification the monotrityl derivative as main product (0.343 g, 0.8 mmol, 80%).This latter was 
protected at the remaining primary hydroxyl group by reaction with 
fluorenylmethoxycarbonylchloride (Fmoc-Cl 232 mg, 0.9 eq) in anhydrous CH2Cl2. 
Phosphoramidite derivative was prepared as just described for obtaining 6c.  
6d 1H-NMR (400 MHz) ppm (acetone, d6): 1.05 (d, 12H, CHCH3), 2.97 (m, 2H, CHCH3), 3.52 (d, 2H, 
CH2ODMT), 3.82 (s, 6H, 4OCH3), 4.05 (s, 2H, CH2CN),  4.14 (m, 1H, CHOP), 4.31(d, 2H, 
CH2OFmoc), 4.46 (t, 1H, CH-fluorenyl), 4.78 (d, 2H, CH2-fluorenyl),  6.80-7.65 (m, 21H, aromatic 
protons). ESI-MS calculated m/z: 802.34, (C47H51 N2O8P), found: 803.80 (M + H)+. 
 
3.10 Studies on quadruplex complexes, containing less stable quartets such as  
T-tetrads 
 
In order to extend TEL-ON approach in the study of quadruplex complexes containing less 
stable quartets, T-tetrads have aroused interest since methyl groups of T residues could give 
rise to hydrophobic contacts into G-quadruplex grooves potentially useful for improving the 
interaction between quadruplex-based aptamers and their target molecules. Even though the 
presence of a T-tetrad in quadruplex structures could be an attractive topic, particularly in the 
aptamer research area, it shows a main drawback due to the minor stability of a T-tetrad (only 
four hydrogen bonds and a smaller surface for stacking interactions in comparison with a G-
tetrad, figure 3.13) that could decrease the stability of the overall complex. Since TEL-ON 
analogue is provided with more favourable thermodynamic properties than its tetramolecular 
counterpart, it is reasonable to suppose that the destabilization of a quadruplex structure due 
to the presence of a T-tetrad could be counterbalanced by the improvement caused by the 
tetra-banched spacer. In order to verify this hypothesis, the synthesis of the [d(TG2TG2C)]4-
bunch (1T) (Scheme 3.6) has been performed, whose base sequence matches that of the ON 
3T forming the tetramolecular quadruplex structure IIIT in which a T-tetrad was observed for 
the first time[90].  
 
Figure 3.13: Hydrogen bonds involved in G and T tetrads 
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The resulting IT was investigated by circular dichroism (CD), CD thermal denaturation 
experiments, 1H, and nuclear Overhauser effect spectroscopy (NOESY) nuclear magnetic 
resonance (NMR) experiments. Further, studies on the TEL-[d(CG2TG2T)]4 (2T) and its 
corresponding natural ON 4T, have been carried out, in which, in respect to 1T, the C and T 
end bases are mutually exchanged, with the aim to explore the capability of the tetrabranched 
linker to stabilize other sequences potentially prone to form quadruplex structures containing 
a T-tetrad. 
Synthesis and Purification of Quadruplexes IT–IVT. The syntheses of TEL-ONs 1T and 2T 
(Scheme 3.6) have been performed using the above reported solid-phase procedure, which 
uses the hydroxyl functionalized  CPG support 5 and the bifunctional linker 6a to prepare 
support 7 bearing a symmetrical tetrabranched linker with four protected primary alcoholic 
functions, prone to ON chain assembly. Support 7 was used to synthesize the TEL-ONs 1T 
and 2T, each characterized by having the four ON strands linked to the spacer through the 3’- 
or 5’-end, respectively. The ON chains were assembled by an automatic DNA synthesizer 
using 3’- or 5’-phosphoramidite nucleotide building blocks, thus obtaining the polymer bound 
TEL-ONs 10 and 11 respectively. 
Supports 10 and 11 treated with conc. NH4OH (7 h, 55°C), afforded crude TEL-ONs 1T and 
2T, which after high performance liquid chromatography (HPLC) purification and annealing 
procedure furnished the quadruplexes IT and IIT, respectively. The natural ONs 3T and 4T, 
precursors of the tetramolecular quadruplexes IIIT and IVT, respectively, have been prepared 
using a standard automatic DNA synthetic procedure followed by HPLC purification. The 
purity of the products was checked by polyacrylamide gel electrophoresis (PAGE) and the 
structures confirmed by 1H-NMR and matrix-assisted laser desorption ionization–mass 
spectroscopy (MALDI-MS) data. The quadruple helices IT –IVT were obtained dissolving the 
samples 1T –4T in K+ buffers (110 mM K+) and annealing to assure the correct formation of 
quadruplex structures. 
CD Experiments. To investigate whether TEL-ONs 1T and 2T adopt the quadruplex 
structures IT and IIT, and to determine their nature and stability in comparison with the 
tetramolecular complexes IIIT and IVT, CD studies, including CD thermal denaturation 
experiments were carried out after the annealing procedure. CD spectra (Figure 3.14) were 
performed at 25°C at a quadruplex concentration of 2.0  10-5 M in K+ buffer. TEL-ONs 1T, 2T, 
as well as natural ON 3T, showed very similar CD profiles characterized by positive bands at 
266, 264, and 262 nm, respectively, and negative bands at 246, 240, and 238 nm, 
respectively (figure 3.14 A and 3.14C), which are indicative of parallel stranded G-quadruplex 
structures (IT, II T, and III T). However, the CD spectrum of 4T showed a different profile 
characterized by the presence of two positive bands at 262 and 289 nm and a negative band 
at 239 nm (figure 3.14C).To further investigate the unexpected CD profile showed by 4T, we 
registered CD spectra in the range 5–80°C (melting process) and 80–5°C (fast annealing 
process) at 1°C/min scan rate (figure 3.15A and 3.15B, respectively). In each process, the CD 
values of the positive bands at 262 and 289 nm varied in a non constant ratio. These data 
suggest that the two positive bands can be attributed to different complexes. Considering that 
the majority of publications have reported that most antiparallel G-quadruplexes are 
characterized by a positive band centred at 290–295 nm and a negative band centred around 
265 nm, it is reasonable to hypothesize that 4T leads to a mixture of quadruplex species 
probably containing parallel (IVTa) and antiparallel complexes (IVTb, IVTc). 
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                Scheme 3.6: i: two couplings with 6a; ii: ON synthesis with 3' or 5'-phosphoramidites; 
 iii: detachment and deprotection with NH4OH conc. 32% (7 h, 55°C); iv: HPLC purifi- 
 cation and annealing. 
 
CD Thermal Analysis and CD thermal denaturation experiments were performed in K+ buffer 
monitoring the CD value (mdeg) at 265 nm in the range 5–80°C with 1°C/min heating rate. 
The melting curve of IT (figure 3.14B) did not show a well-defined change of convexity up to 
80°C; however, a drastic reduction of the CD265 value was observed in the range 60–80°C. 
The contrary is true in the melting profile of the tetramolecular complex IIIT (figure 3.14D), 
since 15–20°C, a significant reduction of the CD265 value, and two detectable changes of 
convexity were observed. These data suggest that the helix–coil transition point for complex IT 
is at a higher temperature and is more cooperative than that of the corresponding 
tetramolecular complex IIIT.  
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Figure 3.14: CD spectra at 5°C and melting profiles of quadruplexes I–II (solid line) and III–IV 
               (dotted line) in K+ buffer. 
 
 
The melting curve of IIT was shown to be very similar to that of IVT (figure 3.14D), both being 
characterized by the reduction of CD265 values up to 55–60°C followed by a point of inflection 
and the complete melting at 80°C, even if a shift toward higher temperature is clearly 
noticeable for the CD profile of IIT. The whole of the CD melting data suggests that TEL-ONs 
IT and IIT are more stable than their natural counterparts IIIT and IVT, respectively, although a 
quantitative determination of the relative thermal stability was not performed yet, due to the 
very slow kinetics of quadruplex denaturation process and considering that, in the case of IIT 
and IVT, the latter could be a mixture of different complexes.  
1H-NMR Studies on Quadruplexes IT–IVT. Temperature-dependent one-dimensional spectra 
(25, 45, 65, and 75°C) and NOESY spectra (25°C) were recorded in H2O/D2O (9:1, v/v) in K+ 
buffer using pulse field gradient WATERGATE for H2O suppression. 
1H-NMR spectrum of complex IT at 25°C (figure 3.16A) showed the presence of four well-
resolved signals between 11.1 and 11.6 ppm attributable to exchange protected imino protons 
involved in Hoogsteen N(1)H/O(6) hydrogen bonds of G-quartets also on the basis of the 
comparison with the corresponding region of the spectrum of IIIT (figure 3.16C) that forms a 
stable parallel stranded quadruplex already characterized by NMR data. 
                                                                                                                          CHAPTER 3   Synthesis of TEL-ON 
 64
 
 
Figure 3.15: CD spectra of IV. (A) Melting process 5–80°C; (B) fast annealing process 80–5°C, 
              at 1°C/min scan rate. 
 
In IT, the broad signal centred around 9.8 ppm is attributable to H-bonded GNH2 protons, 
while the weak signal at 9.2 ppm is attributable to T4NH imino protons involved in N(3)H/O(4) 
hydrogen bonds, thus confirming the formation of a T-tetrad comprised between the G3 and 
G5 tetrad planes. 1H-NMR spectra at higher temperatures indicated that the quadruplex IT is 
preserved at least up to 65°C, whereas the tetramolecular counterpart IIIT is almost 
completely destructurated at this temperature, as indicated by the disappearance of the imino 
proton signals (figure 3.16C). Assignment of all aromatic and imino proton signals of IT was 
carried out by mean of a NOESY spectrum (25°C; 300 ms mixing time) and comparison of 
NOEs with those of IIIT reported by Patel and Hosur[97] (data not shown). The pattern of 
H8/H6–H10–H8/H6 NOE connectivities for IT resulted almost completely superimposable to 
that reported for the corresponding tetramolecular quadruplex IIIT, with the exceptions of 
G6H8 signal, upfield shifted from 7.75 to 7.66 ppm, and of C7H6 signal downfield shifted from 
7.53 to 7.63 ppm. Further, the presence of strong interstrand T4NH—T4CH3 and intrastrand 
T4CH3—G5NH NOEs confirms that IT adopts a T tetrad containing parallel stranded 
quadruplex structure. The absence of significative chemical shift drifts for aromatic and imino 
proton signals of IT and IIIT demonstrates that the ‘‘TEL’’ linker is capable to stabilize the 
parallel quadruplex structure of IT without any substantial influence on quadruplex 
topology.1H-NMR spectrum of compound IIT recorded at 25°C (figure 3.16B) supports the CD 
data about the aptitude of IIT to form a parallel quadruplex structure. In fact, the low field 
region of 1H-NMR spectrum of IIT shows the presence of three strong and two weak partially 
overlapped signals attributable to exchange protected imino protons of G-quartets. Recording 
1H-NMR spectra of IIT at higher temperatures, with 10°C increasing steps, the sharpening and 
the reduction of intensity of all imino proton signals were observed, followed by their complete 
disappearance at 75°C. Differently from IT, no T-tetrad imino signals were observed in the 1H-
NMR spectra of II. The low field region of 1H-NMR spectrum of IVT recorded at 25°C (figure 
3.16D) is characterized by the presence of several H-bonded imino signals. The number of 
imino signals revealed that more than one quadruplex structure must be present in solution. 
At higher temperatures, with 10°C increasing steps, the disappearance of some signals and 
the sharpening of the residual ones were observed. Particularly, five major imino signals were 
detected at 65°C, four of which closely matched those observed for the parallel-stranded 
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quadruplex IIT at the same temperature. This observation supports the hypothesis that 4 folds 
into more than one quadruplex structures. Considering that CD spectra of IVT showed a 
positive shoulder band at 289 nm, it is reasonable to hypothesize that 4T in K+ buffer could 
fold into a mixture of quadruplex structures, one of which could be of the antiparallel type. If 
this were the case, it would be the first occurrence of a tetramolecular antiparallel quadruplex 
structure. 
 
 
 
Figure 3.16: Aromatic and imino proton region of 500-MHz 1H-NMR spectra of IT–IVT (A–D, 
                 respectively) in 100 mM K+ buffer. 
 
The syntheses and investigations of two TEL-ONs, 1T and 2T, characterized by ON 
sequences potentially able to form T-tetrad containing quadruplexes, have been presented. 
TEL-ON 1T is based on the sequence TG2TG2C, whose natural counterpart represents, to 
my knowledge, the first example of an experimentally detected T-tetrad. Collected data from 
NMR and CD melting experiments clearly indicate that the presence of the tetra-branched 
linker in 1T not only does not hamper the formation of a T-tetrad, but also provides a higher 
thermal stability to the complex. The capacity of the tetra-branched linker to stabilize a T-
tetrad containing quadruplex structure might be particularly interesting in the research area of 
quadruplex based aptamers. In fact, the presence of a T-tetrad, thanks to the methyl groups 
located on the groove surface, could make achievable new hydrophobic interactions capable 
of improving both the affinity and specificity of a given aptamer toward their target molecule.  
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EXPERIMENTAL SESSION 
 
General Procedures 
Synthesis and Purification of TEL-ON  1T and 2 T 
See above, “ Synthesis and Purification of TEL-ON  1 and 2 ”  
The purity of the products was confirmed by HPLC analysis on a HYPERSIL 100-C18 column 
eluted with a linear gradient CH3CN in triethylammonium bicarbonate (TEAB) buffer (pH 7.0, 
from 0 to 100% in 60 min, flow 1.0 mL/min), with a result higher than 98% 
(retention time 13.5 and 14.2 min for 1T and 2T, respectively). The desalifications furnished 
pure 1T and 2T (68 and 73 OD260 units, respectively) which, after lyophilization, were 
characterized by spectroscopic data. 
TEL-ON 1T: MALDI-TOF-MS (negative mode) calculated mass: 9070.8; found: 9069.5  TEL-
ON 2T: MALDI-TOF-MS (negative mode) calculated mass: 9070.8; found: 9069.6 
Preparation of Quadruple Helices(Annealing).  Quadruplexes IT –IVT were formed by 
dissolving the TEL-ONs 1T –4T, in 10 mM K2HPO4 100 mM KCl, 0.2 mM EDTA (K+ buffer) and 
annealed by heating to 90°C for 20 min followed by slow cooling to room temperature. The 
solutions were equilibrated at 5°C for 24 h before performing the experiments. 
CD Experiments CD spectra of the quadruplexes were registered on a Jasco 715 circular 
dichroism spectrophotometer in a 0.1-cm pathlength cuvette at 20°C. The wavelength was 
varied from 220 to 320 nm at 5 nm min-1. The spectra were recorded with a response of 16 s, 
at 2.0 nm bandwidth, and normalized by subtraction of the background scan with buffer. CD 
thermal denaturation experiments were performed monitoring the CD value (mdeg) at 265 nm 
in the range 5–80°C with 1°C/min heating rate. The CD melting experiments were registered 
at 2.0  10-5M concentration. 
1H-NMR Experiments NMR data were obtained either on a Varian Unity-INOVA 700 MHz or 
a Varian Unity-INOVA 500 MHz spectrometer equipped with a broad-band inverse probe with 
a z-field gradient, and processed using Varian VNMR software package. NMR samples of I–
IV were prepared in H2O/D2O 9:1 at a concentration of single strand of approximately 1.3 
mM with a final salt concentration of 100 mM KCl and 
10 mM K2HPO4. One-dimensional (1D) NMR spectra (500MHz) were acquired as 16,384 data 
points with a recycle delay of 1.0 s at temperatures in the range 25–75°C. Data sets were 
zero filled to 32,768 points and apodized with a squared shifted sine-bell window function. A 
300-ms two-dimensional (2D) NOESY spectrum (700 MHz) was acquired at 25°C as a matrix 
of 512 - 2048 complex points. Relaxation delay was kept to 1.0 s and a squared shifted sine-
bell window function was applied in both dimensions prior to Fourier transformation. A pulsed-
field gradient WATERGATE sequence was used for H2O suppression in both 1D and 2D 
spectra. 
 
3.11.  Final Conclusions 
 
The results, described in this work, confirm the potential of the TEL-ONs, as a new class of 
ON analogues prone to form intramolecular quadruplex structures, to be more stable than the 
corresponding tetramolecular counterparts also when a less stable T-tetrad is present in the 
complex. So the ‘‘TEL’’ approach to the DNA quadruplex can be considered a useful tool for 
their in vivo applications, furnishing complexes characterized by high stability and predictable 
structure even at low ON concentrations. The high stability of TEL-structures could be 
extended to the complexes containing DNA-PNA hybrid strands, to investigate the formation 
                                                                                                                          CHAPTER 3   Synthesis of TEL-ON 
 67
of PNA guanine quartets, not observed so far. Furthermore, parallel monomolecular TEL-
quadruplexes could be used as models in structural studies, being capable to select the 
formation of only one type of complex, that in some cases is not achievable for tetramolecular 
complexes. Finally, TEL-ONs show promising properties in terms of rapid kinetic of 
riassociation so they could be very useful to realize and study nanomotors. 
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Chapter 4 
 
“Synthesis of combinatorial libraries of nucleosides, specifically inosine 
analogues” 
 
Introduction 
 
Nucleoside research has historically been an area of keen interest for small molecole drug 
discovery due predominately to the medicinal value and biological importance of these 
molecules. Apart from being the genomic building blocks, nucleosides interact with 
roughly one-third of the protein classes in the human genome, including polymerases, 
kinases, reductases, motor proteins, membrane receptors, and structural proteins, all 
targets of biological importance.  
The binding motifs of these nucleosides are associated with a broad array of targets of 
therapeutic importance in biological systems. It was early recognized that, introducing 
diversity into the carbohydrate or the base subunits of nucleosides, represents promising 
strategies to identify specific receptor ligands, enzyme inhibitors, or nucleoside function 
modifiers. Nucleoside analogues, showing very complex and interesting structures, have 
been isolated from t-RNA (5-methylcytidine, 3’-methyluridine), marine organism and 
several other microbiological forms. Naturally occurring nucleosides analogues 
demonstrate selective activities, such as protein synthesis inhibitors (puromycin), glycosyl 
transferase inhibitors (tunicamycin), methyl transferase inhibitors (sinefungin) and 
antibiotic activity (coformicine A and adenomicine). The discovery that some nucleoside 
analogues can possess biological activities has been a significant breakthrough especially 
in antiviral and anticancer chemotherapy. In this regard, the isolation from natural 
sources, but especially synthetic work have lead to the discovery of a large variety of new 
analogues. After decades of drug discovery and development effort from hundreds of 
academic laboratories and pharmaceutical companies, approximately 50-nucleoside- and 
nucleotide-related drugs, have been approved by the US Food and Drug Administration, 
and pushed to the market, and over 80 nucleosides/nucleotides are in the (pre) clinical 
studies for various therapeutic indications, including antiviral[1] , anticancer[2] , antibiotic[3] 
and antifungal[4] .  
In the search for antiviral nucleoside analogues, structural modifications of the 
heterocyclic bases and/or modifications on the sugar moiety of natural nucleosides, can 
be attempted. In the latter, the main modifications involved changes in the (2-deoxy)-D-
ribofuranose moiety like, inversion of hydroxyl group configurations, their 
substitution/functionalisation by various synthetic groups, or cleavage of the sugar ring 
leading to acyclic nucleosides. Other structural modifications have also been attempted 
such as replacement by a methylene group or a sulfur atom of the endocyclic oxygen, 
transposition of the latter and/or additional insertion of a second heteroatom in the sugar 
moiety. Currently, nucleoside analogues are prominent drugs in the management of 
several viral infections. The nucleoside analogues at present formally approved for the 
treatment of viral infections are shown in figure 4.1 Acyclovir is an important antiviral in 
hepatitis C (HCV) treatment, while Lamivudine (3’-thiocytidine, 3TC) is a nucleoside 
analogue used for treatment of hepatitis B virus (HBV), the 5-iodouridine is employed in 
Herpes Simplex infections (HSV). Furthermore, it must be considered that the most 
commonly used anti-HIV drugs are nucleoside analogues,  including Zidovudine (AZT, 
azidothymidine), Hivid (ddC, zalcitabine), Zerit (d4T, stavudine) and some others, all 
possessing high activity in antiretroviral therapies[4]. They mimic natural nucleosides and 
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target a unique, but complex viral polymerase that is essential for viral replication. Some 
nucleosides show also antiproliferative properties, for example  arabinosylcytidine and 5-
azacytidine are both utilized in the treatment of leukaemia, while 5-fluorouracil (5-FU) is 
employed in breast tumour. 
 
 
Figure 4.1: Nucleoside analogues currently used in antiviral therapy. 
 
For salvage to be efficient, mediated transport of nucleosides and nucleobases across the 
plasma membrane has to occur. Then metabolic activation of nucleosides and 
nucleobases takes place, modulating their pharmacological action. The biochemical 
mechanism can be of various type, but in most cases the 5’-phosphorilation of the sugar 
moiety is the first step. The nucleoside 5’-phosphate is then converted into a triphosphate 
derivative that inhibits, in different way, the replication of DNA or RNA. However, some 
drugs such as AZT, ddI, 3TC etc. rapidly develop drug resistance and show mitochondrial, 
bone-marrow and other toxicity. The increasing resistance of pathogens, the often severe 
side effects of nucleosides in chemotherapy, and the lack of selective ligands for 
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adenosine receptor subclasses, despite extensive medicinal chemistry research, 
emphasizes the need for nucleoside analogues in high number and diversity. In addition, 
the availability of high-throughput screening capabilities, together with the combinatorial 
synthesis of small organic molecule libraries, offers a unique opportunity to accelerate the 
discovery of novel pharmaceutical targets and leads, especially, with biologically 
priviledged scaffolds, such as nucleosides in hand.  
 
4.1.  Nucleoside analogues  
 
The design of selective, specific and non-toxic antiviral, but also anticancer agents, has 
presented extraordinary challenges compared with the design of other antimicrobial 
agents. This is primarily because, in contrast to bacteria and parasites that are equipped 
with their own metabolic machinery for reproduction and growth, viruses rely on the host 
cellular machinery for replication and propagation. Consequently, there are few virus-
specific molecular targets that are amenable to antiviral intervention. In addition, drug 
resistance to antiviral agents is a major problem as many viruses mutate rapidly under the 
selective pressure of the antiviral therapy. In recent times, however, and largely owing to 
the AIDS epidemic and advances in molecular virology, the structure and function of a few 
virus-specific molecular targets such as proteases and helicases have been revealed. 
Furthermore, in the past decade , a repertoire of discovery tools in terms of structure and 
mechanism–based drug design, such as delucidations on nucleoside analogues uptake 
and export, their activaction, mechanism of action and mitochondrial toxicity, have 
provided novel strategies for the design of antiviral agents against new molecular targets. 
In this regard different sites of diversity on both purine- and pyrimidine-nucleoside 
scaffolds have been introduced, schematically represented in figure 4.2, bearing a myriad 
of functional groups. Generally, nucleosides analogues can be catalogued in “Base-
modified” and “Sugar-modified” nucleoside analogues.  
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Nucleoside, nucleotide modifications 
 
Notwithstanding these advances, progress in the discovery of new antiviral therapeutics 
has remained slow, and current antiviral chemotherapy  is heavily dependent on a 
“cocktail” of antiviral agents. New antiviral agents, with unique mechanisms of action, are 
urgently needed, given the propensity of viruses to mutate rapidly under the selective 
pressure of chemotherapy. In the last years, the combinatorial chemistry has emerged as 
very efficient tool to produce a large number of new molecules differing in punctiform 
manner around a core structure of active compounds. Solid phase combinatorial 
strategies have been mainly used in the nucleoside field. 
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4.2.  Nucleoside analogue uptake 
 
The intracellular concentration of nucleosides and nucleobases is of great importance for 
the success of antiviral and anticancer therapies and,  to some extent, it is the result of 
the metabolic background of the specific cell line used for infection studies, its particular 
suit of enzymes and transporters. Transporter-mediated pathways are involved in either 
the uptake or the efflux of nucleoside and  nucleobase derivatives. From a biochemical 
point of view, four different types of transport processes for nucleoside-related drugs are 
involved: 1) equilibrative uniport; 2) substrate exchange; 3) concentrative Na+ - or H+-
dependent uptake and finally 4) substrate export through primary ATP-dependent active 
efflux pump. These mechanisms are mainly related to the following set of transporter 
families: Concentrative Nucleoside Transporter (CNT), Equilibrative Nucleoside 
Transporter (ENT), Organic Anion Transporter (OAT) and Organic Cation Transporter 
(OCT), Peptide Transporter (PEPT) and Multidrug Resistance Protein (MRP)[5] . The 
scheme in figure 4.3 shows an idealistic  epithelial cell expressing all known nucleoside-
based antiviral drug transporters, emphasizing their location, eitheir apical or basolateral, 
which ensure, when necessary, vectorial flux of substrates across the epithelium. 
Although information regarding the plasma membrane domains, in which they are 
inserted, has recently became available, the location for some specific transporters, such 
as Multidrug Resistance Proteins (MRP8) is still in doubt and so they are shown at the 
lateral side of the cell.  
 
Figure 4.3: Major transporters implicated in the uptake and efflux of nucleoside-derived 
                 drugs used in antiviral therapy. A model of an idealized polarized epithelial cell, with the  
                 apical and basolateral membrane domains. 
 
Equilibrative uniport works down the substrate concentration gradient and thus, it is in 
principle a reversible mechanism that responds only to the transmembrane substrate 
gradient tending to equilibrate it. This would be the case for the basolateral Equilibrative 
Nucleoside Transporter (ENT) carriers. The working model for an exchanger, particularly 
an obligatory exchanger, implies that efficient translocation of the substrate occurs only if 
both molecules are bound at both sides of the membrane to allow substrate exchange. An 
example of this mechanism depicted in figure 4.3 is that the Organic Anion Transporter, 
also located at the basolateral plasma membrane, which exchanges an extracellular 
organic anion with a dicarboxylic acid, such as alphaketoglutarate. This process may be 
thermodynamically favourable, due to the ability of certain cells to concentrate 
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dicarboxylates thanks to a complementary transporter, such as SDCT2 (also show in 
Figure 4.3), which allows the cell to concentrate alpha-ketoglutarate in a Na+-dependent 
manner. The latter is an example of the fourth mechanism of transport processes listed 
above. Coupling with Na+ also occurs for other transporters, such as Concentrative 
Nucleosides Transporters (CNTs), implicated in the uptake of natural nucleosides, 
whereas H+-dependent uptake is involved into Peptide Transporters (PEPTs). These two 
basic mechanisms of concentrative transport, Na+- and H+-dependent, require tight 
coupling with carriers responsible for the immediate recovery of the ionic transmembrane 
gradients, the Na+, K+-ATPase and the Na+/H+ exchanger. In contrast to these secondary 
and tertiary active transport mechanism, ATP-dependent primary export pumps, 
responsible for antiviral drug efflux, have recently been identified. This would be the case 
of the Multidrug Resistance Protein isoforms (MRPs), shown in figure 4.3, which mediates 
efflux, also in an energy-dependent manner, against substrate concentration, thanks to a 
direct coupling with ATP hydrolysis. The hypothesis that transporters belonging to the 
same gene family are responsible for the uptake of structurally related compounds is 
valid, at least for those responsible for uptake processes other than export pumps such as 
MRPs. Nevertheless, structurally related molecules can often be substrates of completely 
unrelated carrier proteins. However, when natural substrates are modified for 
pharmacological purposes, the spectrum of transporter proteins able to recognize them  
may vary. 
 
4.3.  Nucleoside analogue activaction 
 
Phosphorylation is required for mutagenesis and nucleotide metabolism interference. 
Nucleosides are phosphorylated by intracellular kinases to their active fraudulent 
nucleoside triphosphate (TP) analogue form, which compete with the natural dNTP for 
incorporation into the elongating proviral DNA. Since all current nucleoside-TP analogues 
lack a 3’-hydroxyl group, incorporation results in chain termination. The fact that a specific 
nucleoside-TP analogue competes with its natural nucleotide each time, and also it 
appears in the active site near the reverse-transcribing viral RNA chain, produces multiple 
opportunities for their blockade during a single round of reverse transcription. The long 
intracellular half-life of many nucleoside-TP analogues can result in a significant post-
antibiotic effect[6]. Factors that influence their efficacy and dose frequency include the 
drug concentration versus time profile in plasma (pharmacokinetics), the efficiency of 
cellular uptake of the nucleoside analogues, levels of phosphorylation  to their 
correspondent TP- derivatives, and their inhibition costant (Ki) with the target (viral DNA-
polymerases, reverse transcriptase, respectively in DNA and RNA viruses).   
  
4.4.  Mechanism of action of nucleoside analogues  
 
Although all orally available drugs target the viral polymerase, nucleoside analogues have 
different mechanisms of action on the viral genome replication machinery. Several drugs 
such as adefovir, entecavir and amdoxovir inhibit the priming of reverse transcription, a 
unique enzymic reaction that results in the synthesis of a short DNA primer covalently 
attached to a conserved tyrosine residue of the viral polymerase. Other compounds inhibit 
the elongation of viral minus-strand DNA, such as lamivudine, emtricitabine and 
elvucitabine. The mechanism of action of clevudine involves a weak effect on the priming 
reaction but a stronger inhibitory activity on plus-strand DNA synthesis. The mechanism of 
action of telbivudine has not been described so far. Based on these distinct modes of 
action, one may speculate that the combination of drugs targeting different steps of viral  
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genome replication may lead to an additive or synergic effect[7]. Therefore, the evaluation 
of the combination of drugs such asemtricitabine and clevudine, which are under clinical 
investigation, is relevant for the future development of combination therapy. Nucleoside 
analogues are also an emerging field of novel anticancer drugs, that is revolutionizing 
cancer therapy. In addition to inhibiting DNA replication by one or more mechanisms, 
these compounds may produce effects subsequent to their incorporation into the DNA; for 
example, premature DNA chain termination, structural lesions in the DNA product, and 
effects on transcription of modified DNA. Since charged nucleotides were believed 
normally do not enter the cells and considered ineffective as drugs, nucleosides have 
proved critical as therapeutic agents. Nucleosides and their analogues are precursors, 
that are intracellularly phosphorylated (‘activated’) into nucleotides (dNTPs), and act to 
inhibit or are incorporated by DNA polymerases in vivo (figure 4.4).  
 
 
 
 
 
Figure 4.4: The intracellular formation of nucleotide triphosphate for araC and gemcitabine 
              (gemC), as well as, their incorporation into new DNA. 
 
 
Some two of these nucleoside analogues are currently used in chemotherapy or are in 
clinical trials or development. Examples include arabinofuranosylcytosine (araC)[8] and 5-
FU (the first for the treatment of non-solid tumors like leukemia, while the latter involved in 
breast tumour treatment),  and 2’,2’-difluorodeoxycytosine (gemcitabine)[9] (for treatment 
of various non-solid and solid tumours, figure 4.5). Promising applications of nucleotides 
analogues in antiviral and anticancer therapy are currently evaluated. 
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Figure 4.5: Nucleoside structures highlighting the differences on the groups on 
    the 2’-carbon of the ribose-ring. A. Naturally occurring nucleosides  dCTP and  
    rCTP, and B. sugar-modified nucleoside analogues, araC, 2’FdC and gemcitabine.  
 
4.5.  Mitochondrial toxicity of nucleoside analogues [6] 
 
Generally, the mechanism of action of nucleoside analogues is based upon the 
intracellular phosphorylation to their 5’-triphosphate form which can interact with virus-
specific polymerases, acting as a competitive inhibitor or an alternate substrate for these 
target enzymes, usually preventing further viral nucleic acid chain elongation. Long-term  
toxicities associated with nucleosides phosphorylation may be related to over-activation of 
this process. Elevated cell activation results in high nucleic acid synthesis and an up-
regulation of kinases that phosphorylate nucleosides. Most of the clinical manifestations, 
resemble mitochondrial disease, and histological evidence, demonstrates abnormal 
mitochondria (mt) and/or mtDNA depletion in affected tissues. Studies show that 
nucleoside tri-phosphates competitively inhibit mtDNA polymerase gamma in vitro, the 
sole enzyme responsible for the base excision repair of oxidative damage to mitochondrial 
DNA. This in turn may decrease the number of mitochondrial respiratory chain proteins, 
inhibit aerobic respiration, induce oxidative stress, increase mutation in mtDNA, and result 
in mitochondrial and/or tissue failure, evidenced by the toxic accumulation of non-
esterified fatty acids, dicarboxylic acids and free radical damage. 
 
4.6.  Nucleotide analogues 
 
Since the discovery that monophosphorylated forms of nucleosides can be carried in cells 
by the Multidrug Resistance Proteins (MRP), and known that, monophosphorylated (MP) 
derivatives show smallest drug-induced cytotoxicity,  AZT MP (Schuetz et al. 1999), d4T 
MP (Reid et al., 2003) and 5-FU MP(Guo et al., 2003) have been synthesized and 
evaluated in MRP uptake, in their activities and  toxicities. Adefovir dipivoxil (ADV), the 
first prototype nucleotide analogue, has been approved recently for HBV therapy[10] . ADV 
seems relatively non-toxic upon longer-term use, overcome viral resistance to 
chemotherapy, and prevent viral replication rebound following cessation of therapy. 
Towards this objective, there is genuine optimism  that selected nucleotide analogues 
could become front-line agents to be used in combination with nucleosides and other 
agents in antiviral therapy producing improved pharmacological effects. Furthermore, 
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nucleotide analogues can be useful tools in investigating the DNA polymerase 
mechanism. Considering the irreplaceable role of DNA polymerases in numerous 
important molecular biological core technologies, future potentials for biotechnological 
applications could be envisaged for nucleotide analogues. However, all these promising 
applications are limited by the broad tissue distribution of MRP proteins, including 
endothelia, most epithelia, smooth muscle and immune system cells (Adachi et al.,2002). 
However, the list of tissues and/or cell types is increasing, although there is discrepancy 
between the detection of the mRNA and the corresponding protein. Unfortunately, 
although the pharmacology of these transporter proteins is being studied, there is little 
information about the regulation of MRP activity, with the exception of the evidence that 
specific isoforms can be over-expressed in particular tumours. 
 
4.7.  Solid-phase synthesis of nucleoside analogues 
 
A variety of different modified nucleosides derivatives, above reported, were synthesized 
by the classical approaches in solution, which is expensive and time consuming. 
Combinatorial synthesis of large diverse libraries and high-throughput screening 
technologies have recently emerged as powerful drug discovery paradigms. Various solid-
phase[11] , solution-phase[11], liquid phase[12], and third-phase combinatorial approaches 
have been successfully utilized for the generation of different oligomeric  and small 
molecule libraries for a wide range of biological screenings. Unfortunately, these power 
technologies, especially parallel solid-phase combinatorial strategies[13], have not been 
applied to the nucleoside chemistry for small molecule drug discovery yet although di/tri-
and oligonucleotides[14] were synthesized on solid support, and the modified solid 
supports have been used as acylating agent to acylate nucleosides derivatives[15]. Several 
key considerations had to be taken into account in order to develop a strategy for the 
combinatorial solid-phase synthesis of nucleosides analogues in high number and short 
period of time, to explore wide biological activities: i) most applicable linkers do not meet 
the general requirements for the solid phase synthesis of nucleoside libraries: stable 
enough under the required reaction conditions during synthesis, and labile enough to be 
cleaved easily from solid support without affecting nucleoside products; ii) limited 
positions on nucleoside can be attached on solid support; iii) limited types of reactions can 
be utilized and limited number of sites can be utilized and limited number of sites can be 
combinatorialized on the nucleoside skeletons, which prevent the generation of large 
diverse nucleoside libraries; iv) it is more difficult to get high quality and purity nucleoside 
libraries without purification compared to other small molecule libraries. Only in the most 
recent years, a variety of solid phase combinatorial strategies have been reported for the 
preparation of nucleoside and small oligonucleotide analogues libraries. In these 
approaches both the chemical stability and the position of the linkage with the polymeric 
support, play an important role in the selection of the chemical treatments allowing the 
nucleobase or sugar-phosphate modifications. For example, a solid support binding 
uridine or thymidine nucleosides by the acid labile 5′-O-trityl linkage has been used to 
prepare libraries of N-4-alkylated cytidine derivatives[16]. Another recently reported 
nucleoside functionalized support uses an alkaline labile 5′-O-succinyl linkage to bind the 
6-chloro-2-nitro inosine derivative to produce a set of N-6- or N-2 alkylated adenosine 
derivatives[17].  Also the 2′,3′-acetal linkage has been used to bind purine and pyrimidine 
nucleosides to a solid support which has employed  to introduce chemical diversities both 
on the base (C-6 of purine and C-4 of pyrimidine) and on the 5′-ribose position[18]. In 
another approach, a pyrimidine or purine nucleoside is anchored to the polymeric support 
by the N-3 or N-1 base position, respectively, through a N-alkyl-β-thioether function[19-21], 
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which results stable to both the acidic and basic conditions. The above supports have 
been used to prepare 2′, 3′-ribose modified nucleoside or nucleotide analogues. 
Furthermore, CPG support loading 5′-DMT-nucleosides by the classical 3′-succinyl 
linkage[22-23] or by a 3′ acyloxyaryl phosphate linker[24], have been successful exploited to 
prepare very large nucleic-acid-bases (NABTM) libraries of nucleosidic 5′-phosphoramidate 
derivatives, and nucleic acid fragments to be tested in their antiviral activity[25]. 
 
4.8.  The aim of the work 
 
Although hundreds of purine and pyrimidine nucleosides were synthesized for a variety of 
biological and biomedical studies only a handful of N1-alkylated-inosine derivatives and 
the corresponding 2’,3’- seco-nucleosides were reported. 
To thoroughly explore the biological and biomedical properties of these analogues, the 
design and synthesis of these derivatives were performed by combinatorializing the N1-
(2,4-dinitro)-phenyl derivatized position with a variety of amino building blocks, obtaining a 
first small library of N1-alkylated inosine and AICAR derivatives. 
Moreover, the supports bearing N1-alkylated inosine and AICAR derivatives, furnished, by 
a solid phase cleavage of the 2’, 3’ ribose bond, a set of new N1-alkylated-2’,3’-
secoinosine derivatives and AICAR derivative ones, in high yields. 
 
4.9.  Chemistry 
  
In an effort to enlarge the nucleoside chemical reactivity on the solid phase, and thus the 
number of obtainable structurally diverse analogues, the synthesis and exploitation of the 
new acid labile nucleoside functionalized supports 4 and 5, which bind the N-1-
dinitrophenyl-inosine derivatives 2 or 3 through the ribose 5′-position, is reported. These 
supports have been employed in the solid phase synthesis of the N-1 substituted inosine 
8a-e, 9a-e, the related 2′, 3′-seconucleoside derivatives 11a-e and the AICAR derivatives 
14 and 15. The solid phase strategy, here proposed, is based on our previous studies on 
the C-2 reactivity of N-1-dinitrophenyl-2′-deoxy-inosine towards N-nucleophiles[26-27], to 
obtain N-1 substituted inosine and AICAR derivatives. The reported reaction mechanism 
(figure 4.6) indicates that, when a strong electron-withdrawing group, such as the 2,4-
dinitrophenyl (DNP), nitro group[28] (NO2) or arylsulfonyl[29] one (ArS) is attached to the N-1 
atom of the hypoxanthine ring, the C-2 carbon become electrophilic enough to react with 
amino nucleophiles (R-NH2), leading to N1 substituted inosine derivative, by a fast opening 
and re-closure of the six terms purine cycle. It is to be noted that, as a consequence of the 
purine rearrangement, the endocyclic N-1 atom is substituted by the nitrogen atom of the 
nucleophilic reactant. This purine reactivity has been also exploited by others to introduce 
a modified base into oligonucleotides[30]. 
 
 
 
 
 
 
 
 
Figure 4.6: The nitrogen of nucleofile substitutes the purine N-1 nitrogen. 
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To exploit this reaction in a solid phase strategy to obtain a small library of N-1 alkyl 
inosine derivatives, we bound the 1-(2,4-dinitrophenyl)-2′,3′-O-isopropylideneinosine 2, or 
the corresponding unprotected inosine derivative 3 to the commercially available 
polystyrenemonomethoxytrityl chloride (MMTCl) resin by 5′-O-trityl ether linkage 
(iii,Scheme 4.1). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.1: Acid labile N-1-(2,4-dinitrophenyl)-nucleoside functionalized supports 4 and 5  
 
 
Inosine derivative 2 was synthesized by the reaction of the commercially available 2′,3′-O-
isopropilidene inosine (1) with 2,4-dinitrochlorobenzene (DNClB), essentially as previously 
described[31](i, Scheme 4.1). The 2′,3′-deprotected-inosine-derivative 3, was obtained 
treating 2  with aqueous formic acid  (5 h, r.t., 90 % yield, Scheme 4.1, ii). The reaction of 
the MMTCl polystyrene resin (1.3 meq/g) with 2 or 3 (2 equiv.) in anhydrous pyridine at 
room temperature and in presence of 4-(N,N-dimethylamino)-pyridine (DMAP), afforded 
the support 4 or 5 respectively, in almost quantitative yields (iii, Scheme 4.1). The 
structure and the loading of the supports 4 and 5 were confirmed analyzing, by NMR and 
quantitative UV experiments, the released inosine derivatives 2 and 3, respectively, by 
treatment with 2% TFA in DCM (8 min r.t.).  
Support 4 and 5 were then reacted with several N-nucleophiles (R2-NH2, Table 4.1 entry a-
e) to give supports 6a-e and 7a-e, respectively (scheme 4.2). In a typical reaction, 100 mg 
(0.13 mmol) of support 4 (or 5), swollen in DMF, was left in contact with the R2-NH2 
nucleophile (5.0 mmol) in 1.5 mL of DMF under shaking (8 h, at 50 °C). After washings 
with DMF and MeOH, the support was dried under reduced pressure and the reaction yield 
was evaluated detaching the nucleoside material from a weighted amount of resin. The 
reaction of 4 or 5 with ethylenediamine (Table 4.1, entry f) furnished, as expected, the 
supports 12 and 13 bearing 2′-3′-isopropilidene-AICAR and AICAR, respectively, in almost 
quantitative yields. The structure of the support 6, 7, 12, and 13 were ascertained 
analyzing and purifying by HPLC, 1H NMR and MS analyses the corresponding detached 
crude materials 8, 9, 14, and 15. The product yields and the 1H NMR data are reported in 
Table 4.1.  
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Table 4.1: Reactions of the support 2 Products 4, 6, and 8. N.T: not tested 
a Starting from resin 2. b 400 MHz, (CD3OD) significative protons at ppm. cStarting from resin 3. 
 
 
 
The second goal of this research work was aimed to combining the set of the base 
modified nucleoside (support 7) with a ribose modification (scheme 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.2: i: 2 or 3 (1.5 eq) in pyridine (1.5 mL/250 mg of resin), DMAP (0.05eq.), 24 h r.t; ii: R-NH2/DMF 
(1:1,w/w), 8 h 50 °C; iii: TFA 5% solution in DCM; iv: EDA/DMF (1:1, w/w) 8 h 50 °C; v: NaIO4 (50 eq.) in 
DMF/H2O (1:1,v/v), 12 h, 60 °C; resin washings and treatment with NaBH4 (20 eq.) in EtOH, 2 h, r.t. 
 
As indicative example, the well known C2′-C3′ bond oxidative cleavage of the ribose 
moiety by reaction with metaperiodate followed by the reduction of the di-aldehyde 
derivative which leads to 2′,3′-seconucleosides[32], was examined. In a typical reaction the 
support 7a-e (100 mg, 0.13 mmol) was left in contact with a solution of NaIO4 (1.3 mmol) 
in DMF/H2O (1.5 mL, 1:1,v/v) and shaken for 12 h at 60 °C. The resulting support, after 
washings with DMF and EtOH, was treated with NaBH4 (2.6 mmol) in 1.5 mL of EtOH and 
shaken for 2.0 h at r.t. After washings, the resin 10a-e was dried under reduced pressure 
and analyzed by detachment of the nucleoside material by TFA treatment. HPLC analyses 
indicated that the 2′,3′-secoinosine derivatives 11a-e were obtained in 75-85% yield. The 
structures of 11a-e were confirmed by 1H-NMR (Table 4.1) and MS analyses. The above 
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oxidative cleavage performed in EtOH/H2O (at several ratios and temperatures) afforded 
the seconucleosides in lower reaction yields most probably due to the scanty swelling of 
the polystyrene matrix in these solvents mixtures. 
 
4.10.  Conclusions 
 
In conclusion, the synthesis of new N-1-dinitrophenyl-inosine based solid supports (4 and 
5) in which the nucleoside are anchored to a MMT-polystyrene resin by the 5′ position, was 
performed. The supports 4 and 5, reacting at C-2 position of the purine base with R-NH2 
nucleophiles, were converted in the N-1 alkylated inosine supports (6 and 7) and AICAR 
derivatives supports (12 and 13) in very high yields. The detachment of the nucleosidic 
material, from the above supports, furnished small libraries of N-1 alkylated inosine (8a-e 
and 9a-e) and AICAR derivatives (14-15), having the ribose moiety both protected and 
unprotected at the 2′,3′-hydroxyl functions, in high purities (90-98%). In a further solid-
phase reaction, the set of the N-1 alkylated inosine of the supports 7a-e  were combined 
with the cleavage of the 2′,3′-ribose bond. These reactions furnished the new group of 
solid supports 10a-e bearing base modified acyclo-nucleosides. Supports 10a-e released, 
under acidic conditions, N-1 alkylated-2′,3′-secoinosine derivatives 11a-e in good purity 
(75-85 %). It reasonable to suppose that  the supports 6, 7, 10, 12 and 13, bearing a 
nucleoside derivative can be fruitfully utilized in a combinatorial manner to introduce a 
number of further derivatizations/conjugations both on the 1-(hydroxyalkyl) function and/or 
on the ribose or seco-ribose moieties. Briefly, this research work reports the parallel solid-
phase combinatorial approach for the rapid synthesis of new N1-alkylated inosine and N1-
alkylated-2’,3’-secoinosine derivative libraries. MMT-Cl polystyrene resin was confirmed to 
be an efficient solid support for nucleoside library synthesis. Hydroxyl groups at the 5’-
position were preferentially involved into attach the nucleoside scaffold onto the MMT-Cl 
polystyrene resin. The DNP group is an excellent leaving group for various nucleophilic 
substitutions on the inosine base to synthesize high quality nucleoside libraries. The 
method seems good also to prepare a N1-alkylated-2’,3’-secoinosine collection. All these 
new inosine derivatives, with various modifications at N1-position and at 2’,3’-bond of the 
sugar moiety, will be screened against a wide range of biological assays. Further studies 
are currently in progress in this direction to obtain new and largest libraries of nucleoside 
analogues. 
 
4.11.  Experimental Session 
 
4.11.1 General Methods 
NMR spectra were recorded at 400 MHz, and the chemical shifts were expressed relative 
to the added trimethylsilane.  Libraries were analyzed on a HPLC-UV system Jasco 
PU2089PLUS/UV2075PLUS. A  C18 column from Thermo was used for compound 
purification.The mass spectra at m/z 100-1000 were acquired using electrospray 
ionization with both positive and negative ion detections, by API2000 (Applied Biosystem). 
UV spectra were recorded at 220-400 nm by a Jasco V530, and the compound purity was 
monitored based on the UV absorbency at 246-248nm, 267-270nm, 249-250nm, 
respectively for N1-alkylated-inosine, AICAR derivatives,  and N1-alkylated-2’,3’-
secoinosine.  
MMT-Cl polystyrene resin was purchased from Novabiochem. Other starting materials , 
building blocks, and reagents were purchased from Aldrich and other companies and 
used directly. The following abbreviations were used throughout the text: DMF = N,N-
dimethylformammide, Py = pyridine, MeOH= methanol, EtOH=ethanol, DNP = 2,4-
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dinitrophenyl, K2CO3 = potassium carbonate, MMT-Cl= 4-methoxytrityl chloride 
polystyrene resin, DMAP= 4,4’-dimethylaminopyridine, NaIO4 = sodium m-periodate, 
NaBH4 = Sodium borohydride,  s’s = singlets, d’s = doublets, m’s = multiplets, q’s = 
quartets 
 
4.11.2. General Procedures 
N1-(2,4-dinitrophenyl)-2’,3’-O-isopropylideneinosine (compound 2). A mixture of 1 (1 
g, 2.6 mmol), 2,4-dinitrochlorobenzene (1.87g, 8.1 mmol) and K2CO3 ( 897 mg, 6.5 mmol) 
was stirred in anhydrous DMF (16 mL) at 80 °C for 2.5 h. After cooling, the mixture was 
filtered and the solid was washed with CHCl3. The filtrate and washings, evaporated to 
dryness under reduced pressure, were purified on a silica gel column eluted with 
increasing amount of CH3OH in CHCl3 (from 0 to 5%) to give 1.208 g of 2 (as 1: 1 mixture 
of atropoisomers at N-1-phenyl bond) as pale yellow amorphous solid (98% yield). 
1H-NMR (400 MHz) ppm (CDCl3) 1.30 (s, 3H, CH3), 1.45 (s, 3H, CH3), 3.65-4.0 (m, 2H, 2*5’-H), 
4.5 (m, 1H, 4’-H), 5.10 (m, 1H, 3’-H), 5.30 (m, 1H, 2’-H), 6.00 (m, 1H, 1’-H), 7.70 (m, 1H, orto-
H), 8.10 (m, 2H, H-8, H-2), 8.70 (m, 1H, meta-H), 9.00 (m, 1H, meta-H); ESI-MS calculated m/z: 
474.11, (C19H18N6O9), found: 513.50(M + H)+. 
N1-(2,4-dinitrophenyl)-inosine (compound 3). A solution of 2 ( 500 mg, 1.05 mmol) in 
aqueous HCO2H (60%, 14 mL) was stirred at 50°C for 2 h. After the solvent was 
evaporated under reduced pressure and the residue, dissolved in H2O and purified on a 
C-18 silica gel column eluted with increasing amount of CH3OH in H2O (from 0 to 10%) to 
give 451 mg, 99% of 3. 
1H-NMR (400 MHz) ppm (CD3OD) 3.72-3.95 (m, 2H, 2*5’-H), 3.9 (m, 1H, 4’-H), 4.15 (m, 1H, 
3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’H), 6.10 (m, 1H, 1’-H), 8.00 (m, 1H, orto-H), 8.50 
(m, 2H, H-8, H-2), 8.76 (m, 1H, meta-H), 9.06 (m, 1H, meta-H); ESI-MS calculated m/z: 434.08 
(C16H14N6O9), found: 435,32 (M + H)+. 
Support 4. A suspension of  MMT-Cl  resin (500 mg, 0.65 mmol; Novabiochem, loading 
capacity 1.3 mmol/g), N1-(2,4-dinitrophenyl)-2’,3’-O-isopropylideneinosine, 2 (370mg, 
0.78mmol, 1.2eq), DMAP (6 mg, 0.05 mmol) in 1.5 mL of anhydrous pyridine was shaken 
at room temperature for 24h. The resin was filtered and washed sequentially with pyridine-
DMF (1:1 v/v, three times) and then with dichloromethane (three times). The thus obtained 
resin was dried under vacuum  for 1h.   
Functionalization. 1,0 mL of TFA(2% in dichloromethane) was added to 20mg of weight 
resin. The reaction mixture was shaken for 8 min, then the solution was filtered into a vial. 
The resin was washed with  MeOH, and filtered in the same vial. The solvents were 
evaporated in vacuo, to evaluate the loading efficiency 85%(1.21mmol/g) based on 
starting calculated loading  capacity of the resin (1.3 mmol/g). 
Support 5. A suspension of  MMT-Cl  resin (1g, 1.3 mmol; Novabiochem, loading capacity 
1.3 mmol/g), N1-(2,4-dinitrophenyl)-inosine, 3 (676 mg, 1.56 mmol), DMAP (12 mg, 0.1 
mmol) in 1.5 mL of anhydrous pyridine was shaken at room temperature for 24h. The resin 
was filtered and washed sequentially with pyridine-DMF (1:1 v/v, three times) and then 
with dichloromethane (three times). The thus obtained resin was dried under vacuum  for 
1h. Loading efficiency 78% (1.01mmol/g). 
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Synthesis of N1-alkylated-inosina library 
 
Support 6a-f. Approximately 80 mg (0.1mmol) of starting resin 4 was dispensed in 6 
reaction wells using a dispensed spatula and funnel. To each well of resin were added 
100µL of anhydrous DMF and 0,5mL (1M) of the (a-e) appropriate amine (see Table 1) in 
DMF. The reaction mixtures were shaken for 4h at 50°C, then filtered and washed with 
DMF (three times), MeOH-DMF (1:1 v/v, four times), MeOH (three times), MeOH-
dichloromethane (1:1 v/v, four times), and finally with dichloromethane (two times). The 
resultant resins 6a-f were dried under nitrogen. 
Cleavage. Compounds 8a-e and 14. To the dried resin in each well was added 2ml of 
TFA (2% in dichloromethane). The reaction mixtures were shaken for 8 min, then the 
solution were filtered into a pre-labeled and pre-weighted vials. The resins were washed 
with  MeOH, and filtered in the same corresponding vials. To the combined filtrates was 
added toluene. The solvents were evaporated under vacuum  to provide compounds 8a-e. 
The reaction of 4 with ethylenediamine (Table 1, entry f) furnished, as expected, the 
support 12, bearing the 2’,3’-isopropilidene-AICAR which corresponding detached form 14 
was obtained in almost quantitative yields. 
8a= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 0.98 (t, 3H, CH3 of R2-
moiety ), 1.36 (s, 3H, CH3), 1.6 (s, 3H, CH3), 1.40-1.76 (m, 4H, CH2 of R2-moiety), 3.66-3.80 (m, 
2H, 2*5’-H), 4.12 (t, 2H, CH2N), 4.32-4.39 (m, 1H, 4’-H), 5.00 (dd, 1H, 3’-H), 5.26 (dd, 1H, 2’-H), 
6.02 (d, 1H, 1’-H), 8.36-8.41 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 364.17, 
(C17H24N4O5),found: 364.35 (M + H)+. 
8b= 92% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.36 (s, 3H, CH3), 1.6 (s, 
3H, CH3), 1.94- 2.04 (m, 2H, CH2), 3.66-3.80 (m, 2H, 2*5’-H), 3.82 (t, 2H, CH2O), 4.19 (t, 2H, 
CH2N), 4.32-4.39 (m, 1H, 4’-H), 5.00 (dd, 1H, 3’-H), 5.26 (dd, 1H, 2’-H), 6.01 (d, 1H, 1’-H), 8.26-
8.41 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 352.11, (C15H20N4O6), found: 353.28,(M + H)+. 
8c= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.36 (s, 3H, CH3), 1.6 (s, 
3H, CH3), 1.94- 2.04 (m, 2H, CH2), 3.60 (t, 2H, CH2O), 3.66-3.80 (m, 2H, 2*5’-H), 4.20 (t, 2H, 
CH2N), 4.32-4.39 (m, 1H, 4’-H), 5.00 (dd, 1H, 3’-H), 5.26 (dd, 1H, 2’-H), 6.02 (d, 1H, 1’-H), 8.32-
8.41 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 366.15, (C16H22N4O6), found:367.32 (M + H)+. 
8d= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.37 (s, 3H, CH3), 1.40-
1.49 (m, 2H, CH2), 1.42- 1,81 (m, 9H, CH3, CH2), 3.56 (t, 2H, CH2O), 3.67-3.80 (m, 2H, 2*5’-H), 
4.12 (t, 2H, CH2N), 4.33-4.39 (m, 1H, 4’-H), 5.00 (dd, 1H, 3’-H), 5.26 (dd, 1H, 2’-H), 6.02 (d, 1H, 
1’-H), 8.35-8.40 (s, 2H, H-8, H-2). ESI-MS calculated m/z: 394.19, (C18H26N4O6), found: 395.44 
(M + H)+. 
8e= 92% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.37 (s, 3H, CH3), 1.60 
(s, 3H, CH3), 3.67-3.80 (m, 2H, 2*5’-H), 3.92 (m, 1H, CHN), 3.98 (d, 4H, CH2O), 4.35 (m, 1H, 4’-
H), 5.28 (dd, 1H, 2’-H), 6.00 (d, 1H, 1’-H), 8.32-8.38 (s, 2H, H-8, H-2). ESI-MS calculated m/z: 
382.15, (C16H22N4O7 ), found: 382.32 (M + H)+. 
14= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.37 (s, 3H, CH3), 1.60 
(s, 3H, CH3), 3.67-3.80 (m, 2H, 2*5’-H), 4.35 (m, 1H, 4’-H), 5.28 (dd, 1H, 2’-H), 5.66 (d, 1H, 1’-
H), 8.04 (s, 1H, H-8). ESI-MS calculated m/z: 298.13, (C12H18N4O5), found: 299.23 (M + H)+. 
Support 7a-f. Approximately 150 mg (0.15mmol) of starting resin 5 was dispensed in 6 
reaction wells. To each well of resin were added 100µL of anhydrous DMF and 0,5mL 
(1M) of the appropriate amine (see Table 1) in DMF. The reaction mixtures were shaken 
for 4h at 50°C, then filtered and washed with DMF (three times), MeOH-DMF (1:1 v/v, four 
times), MeOH (three times), MeOH-dichloromethane (1:1 v/v, four times), and finally with 
dichloromethane (two times). The resultant resins 7a-f were dried under nitrogen. An half 
of each one resin (7a-f) was dispensed in other 6 reaction wells and cleavaged. The 
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remaining ones were stored as starting material for synthesis of the N1-alkylated-2’,3’-
secoinosine library.  
Cleavage. Compounds 9a-e and 15. To the dried resin in each well was added 2ml of 
TFA (2% in dichloromethane). The reaction mixtures were shaken for 8 min, then the 
solution were filtered into a pre-labeled and pre-weighted vials. The resins were washed 
with  MeOH, and filtered in the same corresponding vials. To the combined filtrates was 
added toluene. The solvents were evaporated under vacuum  to provide compounds 9a-e. 
The reaction of 5 with ethylenediamine (Table 1, entry f) furnished, as expected, the 
support 13 bearing the AICAR  compound, which corresponding detached form 15 was 
obtained in almost quantitative yields. 
9a= 98% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD) 0.98 (t, 3H, CH3 of R2-
moiety ), 1.40-1.76 (m, 4H, CH2 of R2-moiety), 3.72-3.95 (m, 2H, 2*5’-H), 4.12 (t, 2H, CH2N), 
4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’H), 6.02 (m, 1H, 1’-H), 8.36-8.41 (m, 
2H, H-8, H-2). ESI-MS calculated m/z: 324.15, (C14H20N4O5),found: 325.35 (M + H)+. 
9b= 95% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  3.72-3.95 (m, 2H, 2*5’-
H), 3.82 (t, 2H, CH2O), 4.19 (t, 2H, CH2N),  4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 
1H, 2’H), 6.01 (m, 1H, 1’-H), 8.26-8.42 (m, 2H, H-8, H-2). ESI-MS calculated 312.11, 
(C12H16N4O6), found: 313.28, (M + H)+. 
9c= 96% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  1.98 (q, 2H, CH2), 3.60 
(t, 2H, CH2O), 3.72-3.95 (m, 2H, 2*5’-H), 4.20 (t, 2H, CH2N),  4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 
4’-H), 4.60-4.70 (m, 1H, 2’H), 6.02 (m, 1H, 1’-H), 8.32-8.41 (m, 2H, H-8, H-2). ESI-MS calculated 
m/z: 326.12, (C13H18N4O6), found:327.20 (M + H)+. 
9d= 98% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  1.42-181 (m, 6H, CH2), 
3.56 (t, 2H, CH2O), 3.72-3.95 (m, 2H, 2*5’-H), 4.12 (t, 2H, CH2N),  4.15 (m, 1H, 3’-H), 4.35 (m, 
1H, 4’-H), 4.60-4.70 (m, 1H, 2’H), 6.02 (m, 1H, 1’-H), 8.35-8.40 (m, 2H, H-8, H-2). ESI-MS 
calculated m/z: 354.15, (C15H22N4O6), found: 355.45, (M + H)+. 
9e= 90% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  3.92 (m, 1H, CHN), 
3.98 (d, 4H, CH2O), 3.72-3.95 (m, 2H, 2*5’-H), 4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 
(m, 1H, 2’H), 6.00 (m, 1H, 1’-H), 8.32-8.38 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 342.12,( 
C13H18N4O7), found: 342.30, (M + H)+. 
15= 98% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)   3.72-3.95 (m, 2H, 
2*5’-H), 4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’H), 5.66 (m, 1H, 1’-H), 8.04 
(m, 2H, H-8). ESI-MS calculated m/z:258.10, (C9H14N4O5), found: 259.30 (M + H)+. 
 
Synthesis of N1-alkylated-2’,3’-secoinosine derivative library 
 
Support 10a-e. The resins 7a-e (75mg of each one, 0.075mmol)were treated with a 
solution of NaIO4 ( 168mg,0.75mmol)) in DMF/H20 (1,5 mL, 1:1 v/v), and shaken for 12h at 
60°C.The resulting supports after washings with DMF and EtOH, were left in contact with a 
solution of NaBH4 ( 60mg, 1.5 eq) in 1,5mL of EtOH/ H20 for 2h at room temperature. After 
washings with EtOH, the obtained supports 10a-e were dried under reduced pressure and 
analyzed detaching the nucleoside material by TFA treatment.  
Cleavage. Compounds 11a-e. To the dried resin in each well was added 2ml of TFA (2% 
in dichloromethane). The reaction mixtures were shaken for 8 min, then the solution were 
filtered into a pre-labeled and pre-weighted vials. The resins were washed with  MeOH, 
and filtered in the same corresponding vials. To the combined filtrates was added toluene. 
The solvents were evaporated under vacuum  to provide compounds 11a-e. 
11a= 85% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 0.96 (t, 3H, CH3), 
1.38-1.75 (m, 4H, CH2), 3.20 (m, 1H, 4’-H), 3.90 (m, 4H, 2*5’-H, 2*3’-H), 4.00 (t, 2H, CH2N), 
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4.22 (d, 2H, 2’H), 6.04 (t, 1H, 1’-H), 8.26-8.30 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 326.16, 
(C14H22N4O5), found: 349.05 (M + Na)+.  
11b= 85% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD)  3.20 (m, 1H, 4’-H), 
3.83 ( t, 2H, CH2O), 3.90 (m, 4H, 2*5’-H, 2*3’-H), 4.20 (t, 2H, CH2N), 4.40 (d, 2H, 2’H), 6.04 (t, 
1H, 1’-H), 8.24-8.28 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 326.16, (C14H22N4O5), found: 
349.05 (M + Na)+.  
11c= 84% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 1.98 (m, 2H, CH2), 
3.20 (m, 1H, 4’-H), 3.60 ( t, 2H, CH2O), 3.90 (m, 4H, 2*5’-H, 2*3’-H), 4.21 (t, 2H, CH2N), 4.40 (d, 
2H, 2’H), 6.03 (t, 1H, 1’-H), 8.26-8.31 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 326.16, 
(C14H22N4O5), found: 349.05 (M + Na)+.  
11d= 82% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 1.43-1.79 (m, 6H, 
CH2), 3.20 (m, 1H, 4’-H), 3.55 ( t, 2H, CH2O), 3.90 (m, 4H, 2*5’-H, 2*3’-H), 4.11 (t, 2H, CH2N), 
4.40 (d, 2H, 2’H), 6.03 (t, 1H, 1’-H), 8.25-8.28 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 326.16, 
(C14H22N4O5), found: 349.05 (M + Na)+.  
11e= 75% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 3.20 (m, 1H, 4’-H), 
3.90 (m, 4H, 2*5’-H, 2*3’-H), 3.95 (q, 1H, CHN), 4.02 ( d, 4H, CH2O), 4.40 (d, 2H, 2’H), 6.05 (t, 
1H, 1’-H), 8.29-8.04 (m, 2H, H-8, H-2). ESI-MS calculated m/z: 326.16, (C14H22N4O5), found: 
349.05 (M + Na)+.  
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Chapter 5 
 
“Synthesis of a new series of cIDPR (cyclic hypoxanthine-diphospho-ribose) 
analogues, designed as novel stable mimics of cADPR a potent Ca2+-mobilizing 
second messenger” 
 
Introduction 
 
Cyclic ADP-ribose (cADPR) was discovered in 1987 when Lee and co-workers[1]  
examined various metabolites for their abilities to induce calcium release in sea urchin egg 
homogenates. Observing pyridine nucleotide levels fluctuated markedly after fertilization, 
they tested NAD+ released almost as much calcium as IP3, but there was a time lag of 1-4 
min. Since NAD+ itself does not induce calcium release, the delayed response was later 
shown to reflect the time for its enzymatic conversion to a novel metabolite, which was 
isolated by HPLC in quantities sufficient  for structural determination. Using NMR and 
mass spectroscopy, Lee and co-workers[1]   suggested that this metabolite is a cyclic 
compound with the adenine ring of the NAD+  molecule forming a N-glycosidic linkage 
between the N6-amino group of the adenine with the anomeric carbon of the terminal 
ribosyl unit by displacing the nicotinamide group (figure 5.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Lee’s first proposed structure of cADPR. 
 
cADPR has the characteristic 18-membered cycling structure consisting of an adenine, 
two (N1- and N9-) riboses, and a pyrophosphate, in which the two primary hydroxyl groups 
of the riboses are linked by a pyrophosphate unit. Under neutral conditions, cADPR is in a 
zwitterionic form  with a positive charge around  the N(1)-C(6)-N6 moiety (pKa=8.3), 
making the molecule extremely unstable. The charged adenine moiety attached to the 
anomeric carbon of the N1-ribose can be a  very efficient leaving group. Since the 
metabolite is a cyclic compound and can be hydrolyzed to ADP-ribose (ADPR), the name 
cyclic-ADP-ribose was assigned to this compound with the proposed gross structure as 
shown in figure 5.1. The absolute stereochemistry of the linkage between the adenine and 
the terminal ribose (α or β-linkage) was left unassigned. Cyclic ADP-ribose has been 
shown to mobilize intracellular Ca2+ in various cells, such as sea urchin eggs, pancreatic 
β-cells, smooth muscles, cardiac muscles, T-lymphocytes, and cerebellar neurons, 
indicating that it is a general mediator involved in Ca2+ signalling[2]. Indeed, ADP-ribosyl-
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cyclase activities are present in many mammalian and invertebrate tissues, suggesting 
that cADPR may function widely as a calcium mobilizing agent. Since cADPR is a newly 
identified metabolite, it is appropriate  to group all the cADPR synthesizing enzymes 
together in a new family of ADP-ribosyl cyclases. ADP-ribosyl ciclase  cyclizes NAD to 
produce cyclic ADP-ribose (cADPR) and releases nicotinamide in the process. It is an 
ubiquitous enzyme widely present in animal cells, and has been identified in Euglena, a 
protozoan. The first cyclase purified was from Aplysia ovotestis. It is a soluble protein of 
approximately 30 KDa. Sequence comparison reveals that CD38, a lymphocyte antigen, is 
a mammalian homolog. CD38 is a transmembrane glycoprotein of approximately 45 KDa.  
Additionally, both CD38 and the Aplysia cyclase use NADP as a substrate and catalyze 
the exchange of the nicotinamide group with nicotinic acid, producing nicotinic acid 
adenine dinucleotide phosphate (NAADP). In addition to the Aplysia cyclase and CD38, 
CD157 (BST1), another antigene, is also a homolog . The three proteins share 25-30% 
sequence identity and there is also a perfect alignment of the cysteines of the homologs. 
However, CD38 and CD157 have very similar catalytic properties, possessing both cADPR 
synthesizing and hydrolizing activities, while the other two members, the Aplysia and 
Euglena cyclases, lack the hydrolase activity. The dominant enzymatic product of CD38 
and CD157 from NAD is thus ADP-ribose, with cADPR being only a minor component 
(figure 5.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Mechanism of CD38 activity. 
 
 
The overall reaction is similar to classical NADases. Aplysia and Euglena cyclases, are 
clearly different from NADase as they produce cADPR instead of ADP-ribose. However, 
ADP-ribosyl cyclase can be easily distinguished from other NADases and the cyclases can 
be operationally classified. In contrast to cyclase, cADPR hydrolases are also widely 
distributed along mammalian tissues, where they hydrolize cADPR at the N-1 ribosyl 
linkage to give the inactive ADPR.  Biological as well as chemical cADPR instability 
(discussed below), limits studies of its physiological role. Therefore, stable analogues of 
cADPR that have similar Ca+2-mobilizing activity to that cADPR are required. 
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5.1.  Cyclic-ADP-Ribose: a new way to control calcium 
 
Cyclic adenosine diphosphate ribose (cADPR) is a novel Ca2+-releasing second 
messenger candidate. As a natural occurring metabolite of nicotinamide adenine 
dinucleotide (NAD+), it mobilizes calcium by a mechanism completely independent of the 
IP3 receptor[3]. When a second class of intracellular calcium release channels, the 
ryanodine receptor, was found in sea urchin eggs[4], the possibility that cADPR was an 
endogenous regulator  of ryanodine receptors arose. Ryanodine receptors were first 
characterized as the major calcium release channel of muscle sarcoplasmic reticulum and 
share substantial similarities with IP3 receptors in that they are both transmembrane 
proteins with large cytoplasmatic domains and a quatrefoil arrangement of four identical 
subunits[5]. A key property of ryanodine receptors, first recognized from studies on isolated 
sarcoplasmatic reticulum and then confirmed by channel isolation and reconstitution in 
artificial bilayers, is that they can be opened by calcium, that is, they can mediate calcium-
induced calcium-release (CICR)[5]. Ryanodine receptors are widespread in many cell types 
and have been incorporated in many models to explain the spatial and temporal 
complexity of cellular calcium signals, which can be oscillatory and can propagate as 
regenerative planar or spiral waves[6]. On the basis of cross-desensitization studies and 
experiments with known ryanodine receptor antagonist ( ryanodine, ruthenium red and 
procaine), cADPR was shown to release calcium via this ryanodine-sensitive CICR 
mechanism  in the sea urchin eggs, suggesting that cADPR is an endogenous regulator of 
CICR through a ryanodine receptor rather than through an IP3 receptor[4]. This hypothesis 
has been supported by the demonstration that cADPR at nanomolar concentrations, but 
not IP3, mimics caffeine (a ryanodine receptor activator) in inducing oscillations  in a 
calcium dependent ion current known to reflect intracellular calcium oscillations in rat 
dorsal root ganglion cells[7]. Although cADPR has been shown to have calcium mobilizing 
activity in a number of cell types, including sea urchin eggs, pituitary cells and dorsal root 
ganglion cells, it has not been clear whether cADPR functions as a second messenger for 
extracellular stimuli. Rather, cADPR could be a factor for CICR, simply enhancing the 
sensitivity of its receptor to calcium; this notion would be consistent with the fact that 
calcium and cADPR potentiate the effects of each other and that cADPR itself is present in 
many mammalian cell types under resting conditions. However, the major advance in 
identifying cADPR as a new calcium-mobilizing second messenger has come from  the 
finding that glucose induces a rise in cADPR concentrations in pancreatic β-cells, and 
moreover cADPR stimulates insulin secretion from permeabilized β-cells[8]. Furthermore, 
cADPR seems to release calcium from β-cell microsomes via a ryanodine-sensitive 
mechanism, consisted with the proposed mechanism for this agent’s actions in regulating 
CICR. Although many agents have been suggested as important intracellular mediators of 
nutrient-induced insulin secretion, cADPR is particularly attractive because a role for this 
molecule in stimulus-secretion coupling in the β-cell can explain the mechanisms of a 
class of diabetogenic drugs, the β-cytotoxins such as streptozotocin. These agents deplete 
intracellular NAD+, the precursor of cADPR. 
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5.2.  ADP-rybosil cyclase 
 
ADP-rybosil cyclase is a dimer, in which each monomer was a bean-shaped molecule 
consisting of two domains separated by a central cleft[9]. The two monomers associated  
with each other in a head-to-head fashion forming a donout-like molecule with a central 
cavity, as shown by chemical cross-linking and dynamic laser scattering. The tentative 
assignment of the bound nicotinamide is shown in yellow in the figure 5.3A. The binding 
site was in a pocket at the central cleft of the monomer and was very close to the central 
cavity of the dimer. Nicotinamide was bound to each monomer. The binding pocket of the 
monomer colored dark blue was not visible, because it was on the other side of the 
monomer. The cyclase has a stretch of six amino acids (TLEDTL) that are highly 
conserved with CD38. This conserved region formed part of the binding pocket  and is 
shown in orange in figure 5.3A. Figure 5.3B shows the three amino acids in the binding 
pocket that were closest to the placement of the bound nicotinamide (yellow) and 
appeared to complex the bound substrate.  
 
 
 
Figure 5.3: Molecular modelling of site active of ADPribosylcyclase. 
 
These three residues were Trp140 (2.8A°), Glu98 (3.5A°) and Asn107 (3.1A°). The 
conserved sequence is shown as orange sticks, and Glu 98 is part of this sequence. 
Trp140, although not in the conserved region, is nevertheless conserved among two 
species of the cyclase and three species of CD38. Asn107, on the other hand, is not a 
conserved residue. If these amino acids are indeed responsible for substrate binding, their 
alteration by site-direct mutagenesis should result in reduction or elimination of the 
enzymatic activities of the cyclase. Data indicates that the enzyme activity has an 
exquisitely specific requirement for both the charge and size of the chain at the 98 
position, and any alteration would result in decrease in activity. Of the three amino acids 
that complex the nicotinamide, Trp140 is the most critical to the cyclase activity. It is 
closest to the bound nicotinamide, and its conversion to glycine resulted in a 4,648-fold 
decrease in activity. Asn107 is the least critical; only a 2-fold decrease in activity was 
measured for the mutant N107G. Asp99 is next to Glu98 and is similarly charged. It is also 
in the highly conserved sequence, TLEDTL. Neverthless its conversion to glycine 
produced much less pronounced effect on the cyclase activity, only a 10-fold decrease. 
These results indicate that the effect of the site-direct mutagenesis is residue specific and 
that Trp140 is the most critical residue for the cyclase activity. To search for the catalytic 
residues, other amino acids that make-up the binding pocket were mutagenized. The 
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results indicate that Glu179 and also Trp77 are most likely the catalytic residues.The 
critical importance of Glu179 was further shown by substituting it with various other 
residues. All substitutions resulted in inactivation of the enzyme. X-ray crystallography 
shows that both Trp77 and Trp140 line the rim of the binding pocket, one on each side. 
Particularly, Trp140 is in close proximity to the bound nicotinamide, suggesting that it is 
important in positioning the substrate, while Trp77 may serve a similar function in 
positioning the substrate NAD+ through hydrophobic interaction. Another important 
function that the two tryptophan residues may serve is to curtail the access of water to the 
catalytic site through the hydrofobicity of their side chains. Inaccessibility of water to the 
active site would ensure that the nucleophilic attack of the oxocarbenium intermediate by 
the 1-nitrogen of the adenine is the dominant reaction, leading to the cyclization of NAD+ to 
produce cADPR. Access of water to the active site, on other hand, would lead to the 
formation of ADP-ribose through hydrolysis, which is the dominant reaction catalyzed by 
CD38. Figure 5.3C shows a stereo view of the active site. The van der Waals contact 
surface of the site is shown with the three most critical amino acids, Trp140, Trp77, and 
Glu179, rendered as space filling models. The active site is in a pocket with Glu179 deep 
inside the pocket, one on each side. The carboxyl oxygen atoms of Glu179 and the 
carbonyl oxygen atom of Trp77, which are likely to participate directly in catalysis, are 
shown in red. The bound nicotinamide is shown in yellow. The aromatic ring of Trp140 is 
close to, and appears to position, the bound nicotinamide, presumably through 
hydrophobic interaction. Another notable structural feature of the active site is its close 
proximity to the central cavity formed by the two monomer cyclase molecules. The size of 
the central cavity is similar to the dimension of a molecule of cADPR. This suggests the 
possibility that the central cavity may serve as a channel, through which the product of 
catalysis, cADPR, can pass.  
5.3.  CD38 
 
The crystal structure of CD38 has not been determined. However, it is possible to model 
the structure of its extra-membrane domain using the crystal coordinates of the Aplysia 
cyclase because of the sequence homology between the proteins. The resulting energy-
minimized structure reveals that the two extra pairs of cysteines, Cys119 and Cys201 are 
close enough to form a disulfide bond[10]. More importantly, it also reveals that the residues 
in CD38, Glu226, Trp125 and Trp189, corresponding to the critical amino acids of the 
cyclase are all clustered in a pocket near the middle of the molecule, very similar to the 
active site pocket of Aplysia cyclase. This is remarkable considering that these residues 
spread over a third of the sequence of the molecule. Mutagenizing Glu226 to even highly 
conserved residues, such as aspartate, results in complete loss of all enzymatic 
activities[11]. Another critical residue is Glu146[12]. It is part of the conserved sequence. 
Glu146 is located directly across from the catalytic residue, Glu 226. This is not situated as 
deep inside the active site pocket as Glu 226 and is closer to the position of the 
coordinating tryptophane, Trp189, which is at the rim of the pocket. The distance between 
Glu226 and Glu146 is about 8A°. Homology modelling is used to assess the structural 
changes at the active site caused by the mutations. Replacement of Glu146 with alanine 
greatly increases the cyclase activity and depressess the hydrolase activity. The side 
chain of alanine is smaller than glutamate. The distance between Ala146 and Glu226 is 
thus larger, at 9.8A°, making the opening of the active site pocket slightly wider. The net 
effect of these changes likely allows the substrate to bind deeper into the pocket. Glu146 
substitution with amino acids that  increase hydrophobicity, greatly enhances cyclase 
activity. For example, substituting Glu146 of CD38 with phenylalanine (E146F) enhances 
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the cyclase activity as much as the E146A mutant. The main difference between the two 
mutants is that E146F has higher hydrolase activity than E146A.The size of the side chain 
of the phenylalanine is larger than glutamine and the distance between Phe146 and 
Glu226 in now closer  at 7.5Å. The substitution is likely to reduce access to the catalytic 
residue[13]. CD38 have also provided strong experimental support that it may function as 
such a novel transporter of cADPR. It is shown that when resealed right-side-out red cell 
ghosts that contain ecto-CD38 are incubated with NAD, active transport of cADPR occurs, 
generating a concentration gradient of the product 10-80 fold higher inside than outside[14]. 
Inhibition of the enzymatic activity of cADPR by mercaptoethanol blocks the process. 
Similar active transport of the enzymatic products is seen with purified CD38 reconstituted 
into liposomes. That CD38 is a transporter capable of active translocation of its enzymatic 
products across membranes provides a novel explanation of how a surface antigen with its 
catalytic domain on the outside of the cells can participate in intracellular Ca2+ signalling. 
 
5.4.  Stability of cADPR 
 
cADPR is characterized by a very labile N1-glycosidic bond, which is rapidly hydrolized 
both enzimatically, by cADP-hydrolase[15], than non-enzimatically, to give ADP-ribose even 
in a neutral aqueous solution[16]. It is slowly hydrolyzed to ADPR at room temperature 
under slightly acidic conditions with a half-life of about 10 days. At 37°C, the half-life for 
spontaneous hydrolysis is about 24h. The pH titration curve of cADPR revealed that it has 
a pKa of 8.2 and ε=3200 at 290  nm. The absence of a pKa at pH=4.0, corresponding to 
the pKa of the amino group of ADPR or AMP, indicates that cADPR, like N1-P-rib-ATP 
forms an imino base rather than an amino base[17]. It is well documented that N1-alkylated 
adenosine derivatives undergo the Dimroth rearrangement in base to give the N6-
derivatives[18],(figure 5.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4:  Base-catalyzed transformation of N1-P-rib-ATP to N6-P-rib-ATP. 
 
Numerous mechanistic studies, including 15N-isotope labelling, have shown that this 
rearrangement  proceeds through adenine ring opening without cleavage of the N1-alkyl 
bond. Indeed Ames[19] has observed that N1-P-rib-ATP, an open ring analogue of cADPR, 
underwent such a rearrangement at pH 10. On the other hand, it is interesting to note that 
cADPR is very stable in base and does not undergo the Dimroth rearrangement at pH 10. 
The pyrophosphate bond in cADPR is also moderately resistant to alkaline hydrolysis, but 
can be cleaved to N1-P-rib-AMP with potassium t-butoxide in dimethyl sulfoxide[20](figure 
5.5).  
 
 
N
N N
N
NH
O
OHOH
HH
OPO
O-
O
P
O-
O
OP-O
O-
O
O
OHOH
H
OP-O
O-
O
H
pH 10 N
N N
N
NH
O
OHOH
HH
OPO
O-
O
P
O-
O
OP-O
O-
O
O
OHOH
H
OP-O
O-
O
H
                                                                                              CHAPTER 5   Synthesis of cIDPR analogues 
 92
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Base –catalyzed cleavage of cADPR. 
 
The pyrophosphate linkage in cADPR is resistant to the action of pyrophosphatases in 
contrast to ADPR, which is readily attacked by these enzymes[21]. Biological as well as 
chemical instability of cADPR limits studies of its physiological role. Therefore, stable 
analogues of cADPR that have a Ca2+ mobilizing activity in cells similar to that of cADPR 
are urgently required. 
 
5.5.  Synthesis of cADPR analogues 
 
cADPR analogues can be used in investigating the mechanism of cADPR-mediated Ca2+ 
signalling pathways. Agonists or antagonists of cADPR are also expected to be lead 
structures for the development of drugs, since cADPR has been shown to play important 
physiological roles, such us insulin release from β-cells[8]. Therefore the synthesis of 
cADPR analogues has been extensively investigated. At least, cADPR analogues have 
been synthesized predominantly by enzymatic and chemoenzymatic methods using ADP-
ribosyl-cyclase-catalyzed cyclization under mild neutral conditions. By this method, cADPR 
analogues modified in the purine ring and the N9-ribose moieties have been prepared from 
the corresponding β-nicotinamide-di-nucleotide-type precursors[22]. Although evaluation of 
these analogues has identified biologically useful ones, the analogues obtained by these 
methods are limited due to the substrate specificity of the ADP-ribosyl-cyclase. Then, 
previous studies of enzimatically and chemoenzimatically synthesized cADPR analogues 
have disclosed the structure-activity relationship (SAR) for the N9-ribose and adenine 
moieties[23], at least to some extent. Nevertheless, the SAR of the N1-ribose moiety 
remained virtually unknown, since N1-ribose-modified analogues are difficult to access by 
the chemoenzymatic and enzymatic route. In the enzymatic and chemoenzymatic 
synthesis, preparation of sugar-modified NAD-type precursors is crucial. Furthermore, 
even if these sugar-modified NAD analogues are provided, the cyclase may still not 
catalyze their desired cyclization. Therefore, a chemical synthetic method is essential for 
providing these N1-ribose-modified analogues to clarify the SAR and also to develop 
compounds of further biological importance. In recent years, on other hand, methods for 
the chemical synthesis of cADPR analogues have been extensively studied, and useful 
cADPR analogues, which could not be prepared by the enzymatic and chemoenzymatic 
methods, have been synthesized. In the synthesis of cADPR and its analogues, 
construction of the large 18-membered ring structure is the key step, and different 
methods have been developed. 
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5.5.1.  Enzymatic synthesis of cADPR derivatives 
There are three types of enzyme systems known for the conversion of NAD+ into cADPR 
(cyclase) or ADPR (NADase) and the hydrolysis of cADPR to ADPR (hydrolase): 
1. A membrane-bound NAD+ glycohydrolase (NADase) was purified to homogeneity 
from canine spleen microsomes, which contained three enzyme activities.The ratio 
of NADase:cyclase:hydrolase activities for this enzyme was found to be 100:2:30[24].  
2. The human and rodent CD38 antigen also possess cyclase and  hydrolase 
activities. An ectoenzyme was purified to homogeneity from solubilized human 
erythrocyte  membranes and exhibited a similar ratio of enzyme activities (100:1:10) 
[25]. 
3. In contrast, the enzyme derived from the invertebrate, Aplysia Californica is  very 
rich in cyclase activity and has little NADase and hydrolase activities[26].  
This enzyme, namely  ADP-ribosyl cyclase, and is now commercially available from Sigma 
in a highly purified state, and has been widely used for the laboratory preparation of 
cADPR and its analogues. The crystal structure of the cyclase was reported in 1996[27]. 
This enzyme has been also cloned in the methylothrophic yeast, Pichia pastoris that 
expressed high levels of this enzyme[28]. Using high biomass fermentation up to 300 
milligram per liter of cyclase was achieved. SDS-PAGE analysis revealed that the 
heterologous protein comprised 90-95% of the total protein secreted extracellularly. The 
properties of the recombinant enzyme compared favourably  to those of the native 
enzyme. The yeast expression system can produce gram quantities of this cyclase. Hence 
the supply of the enzyme for synthetic applications is no longer a problem. The ADP-
ribosyl cyclase of Aplysia Californica converts β-NAD+ analogues into three different types 
of products depending on the structural features of substrates. In all cases, α-NAD+ 
derivatives are not cyclized or hydrolyzed by this enzyme (figure 5.6). 
Cyclization at N-1: The ADP-ribosyl cyclase efficiently converts β-NAD+ into cADPR(1)  in 
over 90% yield because this enzyme has little NADase and hydrolase activities. In a 
similar manner, it transforms NADP+ into the corresponding cADPRP(2), 3’-NADP+ into 3’-
cADPRP(3) and 2’,3’ cyclic NADP+ into 2’,3’-cADPRP(4)[29]. cADPRP stimulates calcium 
release two times more effectively than cADPR, but by a mechanism distinct from both 
cADPR and IP3. The other two analogues are inactive in inducing calcium release. The 
occurrence of cADPRP in mammalian tissues was also demonstrated[29]. Due to the wide 
distribution of NADP+ in mammalian systems and its unique calcium releasing property, 
several papers on the role of cADPRP in the regulation of Ca2+ homeostasis and its 
characterization have been reported[30]. The 2’-deoxy, 3’-deoxy and 3’-O-methyl 
derivatives of NAD+ were convertedby ciclase into their respective cADPR derivatives[31]. 
2’-deoxy-cADPR(5) is similar to cADPR in inducing Ca2+ release, whereas 3’-deoxy-
cADPR(6) is 100-fold less potent. However, 3’-O-methyl-cADPR(7) inhibited the cADPR-
induced Ca2+ release in a dose-dependent manner. This suggested that the 3’ hydroxy-, 
but not the 2’-hydroxy group was essential for the calcium releasing activity. Cyclic 
aristeromycin diphosphate ribose (cArisDPR, 8), the first carbocyclic analogue of cADPR, 
was prepared via the cyclization of NArisD+[32].  Interestingly, while retaining a similar 
calcium release profile to that of cADPR, cArisDPR showed higher stability towards 
enzymatic hydrolysis. All the above results indicated that the cyclase can tolerate 
substantial changes around the ribosyl moiety of the adenosine portion of the NAD+  
derivatives. As the cyclase enzyme can accommodate large substituens at the 8-position 
of the adenine ring of NAD+ analogues, a series of 8-substitued cADPR analogues were 
prepared. Among these, 8-amino-cADPR(9), was the strongest antagonist of cADPR, 
whereas 8-Br-(10) and 8-azido-cADPR(11) were less potent as antagonists, and 8-
piperidyl-cADPR(12)  was inactive[33]. 
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Figure 5.6: cADPR analogues cyclized at the N-1 position. 
 
The triphosphate analogues of cADPR (cATPR, 13) was formed via the cyclization of 5’-
triphosphopyridine nucleotide (5’-TPN)[34]. cATPR was about 20 times more potent in 
inducing Ca2+ release and was more resistant than cADPR to hydrolysis by NAD-
glycohydrolase. More importantly, cATPR and cADPR modulate the Ca2+ release via the 
same mechanism. These properties enabled cATPR to be used as a suitable molecular 
probe for the study of cADPR binding proteins. The cyclization of nicotinamide cytosine 
dinucleotide using the Aplysia cyclase was attempted, also, but no cyclized product was 
detected, which suggested that a bicyclic ring system may be required for cyclization. This 
assumption led to deployment of 3,N4-ethenocytosine ring system as a mimic of the 
adenine ring of NAD+. Indeed, this nicotinamide-3,N4-ethenocytosine diphosphate 
analogues was converted into a new cyclic nucleotide, cyclic etheno-CDP-ribose (cε-
CDPR,14) in 92% yield[35]. This result poignantly reflected the importance of substrate 
structure in dictating product formation. Although cε-CDPR was found to be inactive in 
inducing Ca2+ release, it is the first cADPR analogue with a modified purine ring. Comparing 
the structural features of the 3,N4-ethenocytosine ring  versus that of the adenine ring, it is 
worth nothing that the cyclization site of cε-CDPR (N-1) corresponded to the N-9 position of 
adenine ring. This means the direction of cyclization of NAD+  analogues could occur not 
only from N-9 to N-1 but also possibly from N-1 to N-9 for the generation of unique cADPR 
analogues. cADPR analogues modified  at N-7, such as 7-deaza-cADPR(15) and 7-deaza-
8-bromo-cADPR(16)[36] were also prepared via cyclization of the corresponding NAD+ 
analogues. The former was a partial agonist  whereas the latter was an antagonist of 
cADPR. However, both were resistant to chemical and enzymatic hydrolyses and 
possessed the important feature of membrane permeability.  
Cyclization at N-7: The cyclase of Aplysia Californica catalyzed an alternative mode of 
cyclization of nicotinamide guanine dinucleotide (NGD+) and nicotinamide hypoxanthine  
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dinucleotide (NHD+) to form cyclic GDP-ribose (cGDPR, 17) and cyclic HDP-ribose 
(cHDPR,18), respectively (figure 5.7)[37].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: cADPR analogues cyclized at N-7. 
 
In these cyclic nucleotides, the newly formed glycosyl bonds were shown to be attached 
onto the N-7 nitrogen of the purine rings and not to the N-1 position of the guanine ring as 
previously proposed[38]. The cyclase also catalyzed the transformation of nicotinamide -
1,N6-etheno-adenine dinucleotide into a novel cyclic nucleotide (cε-ADPR,19) whose N-
glycosil bond was attached onto the N-1 position of the 1,N6-etheno-adenine nucleus 
corresponding to the N-7 position of the adenine ring[39]. While all of the three N-7 cyclized 
cADPR analogues were much less active than cADPR in inducing calcium release in the rat 
microsomal system, their novel ring structures were more stable than cADPR towards heat 
and NADase hydrolysis. Furthermore, their unique fluorescent properties provide 
investigators with a useful tool for monitoring the cyclase reaction especially in crude 
homogenates[40].The cyclization of NGD+  to cGDPR may be used as a continuous 
spectrofluorimetric assay of cyclase activity. This assay method has several advantages. 
NGD+ is cyclized to cGDPR in yield higher than that of NAD+  to cADPR, the fluorescent 
cromophore is formed only upon cyclization offering low background and high sensitivity, 
the assay is continuous and is adaptable to spectrophotometric or fluorimetric detection. 
 
5.5.2. Non-enzymatic syntheses of cADPR analogues 
Since the discovery of cADPR, much attention has been paid to its synthesis by non-
enzymatic methods. The goal of the non-enzymatic methods was not only to verify the 
structure of cADPR, but also to prepare stable cADPR analogues or analogues that were 
not possible to prepare by the enzymatic method (figure 5.8).  
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Figure 5.8: NAD+ analogues not cyclized  by ADP-ribosyl cyclase 
 
Until now, two strategies have been developed  for the synthesis of cADPR and its 
analogues: 
 
Biomimetic synthesis of cADPR. Since de novo synthesis of cADPR would require 
extensive chemoselective protection and deprotection of functional groups, Yamada et al. 
[41] developed a biomimetic cyclization of α- and β-NAD+. It was discovered that by reacting 
β-NAD+ with NaBr and triethylamine in dry DMSO at 70°C, cADPR was obtained in 28% 
yield (figure 5.9).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Biomimetic cyclization of β-NAD+. 
 
Lower yields were obtained using other halide salts. It is noteworthy that this 
intramolecular cyclization was completely stereoselective as cADPR was obtained as the 
sole isomer and it proceeded via a common oxo-carbenium ion intermediate (figure 5.10a). 
To determine the versatility of this cyclization reaction, a series of NAD+ analogues were 
treated  under  the same reaction conditions. In most cases biomimetic rote gives similar 
product profiles to that of enzymatic method, but higher yields are generally obtained by 
the latter method. 2’-deoxy-cADPR, cε-CDPR and cATPR were obtained via N-1-
cyclization, whereas cGDPR(17) and cHDPR(18) were obtained via N-7 cyclization (figure 
5.10b). However, one exception was when nicotinamide- N6-etheno-adenine dinucleotide 
(ε-NAD+) was subjected to the condition of biomimetic synthesis, no formation of cε-ADPR 
was detected. Instead, a new cyclic nucleotide (9- cε-ADPR)was obtained[39] and its 
structure was assigned as a cyclic product in which the newly formed glycosyl bond was 
attached to N-9 instead of N-1 position. It was about two times more potent than cADPR in 
inducing Ca+2 release and its unique fluorescence behaviour, provides investigators with a 
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useful probe for the study of cADPR-binding proteins. This is the first time that it is 
possible to observe that the enzymatic and biomimetic methods proceeded via different 
reaction pathways to give different cyclization products, thereby, demonstrating the 
uselfuness of the biomimetic method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Mechanism of biomimetic cyclization of α and β-NAD+ via  
    a) N-1cyclization; b) N-7cyclization. 
 
Total synthesis of cADPR analogues via intramolecular condensation reaction 
This method was first used by Zhang and coworkers to prepare cADPR in order to confirm 
its structure. The key intermediate N1-P-rib-AMP was prepared  by a chemoenzymatic 
method. Its cyclization to cADPR in the presence of EDC was attempted but was not 
successful, due to the low cyclization yield (<1%). Later, several hydrolysis-resistant 
carbocyclic analogues of N1-P-rib-AMP were prepared. The ring closure was attempted 
but failed. Later successful cyclization of analogues of N1-P-rib-AMP, using a modified 
method of Shuto et al.[42], was achieved. It was surmised that the intramolecular cyclization 
would depend on the conformations of the nucleotides. Nucleotides could exist as the anty 
and syn conformers (figure 5.11). In the syn conformer, the two phosphate groups are 
close to each other, which should facilitate the intramolecular condensation reaction. 
Unfortunately, it is well known that the anti conformation predominates in most natural 
nucleotides, which may be the reason for the unsuccessfull cyclization of N1-P-rib-AMP. 
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By introducing a bulky group at the 8-position of purine nucleosides, the conformation of 
nucleotides may be restricted to the syn form due to the steric interaction between the 
bulky group and the ribose moiety. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Possible nucleoside conformations. 
 
Based on this assumption, Shuto et al.[43] synthesized compound (20), an 8-bromo 
substituted analogue of N1-P-rib-IMP, which was cyclized to afford (21). After removal of 
the 8-bromo substituent  and the protecting groups, the cADPR analogue (22) was 
obtained (figure 5.12). This constituted the first cADPR analogue synthesized by a total 
synthetic approach, and provided a general method for the preparation of stable cADPR 
analogues. However, the overall yield was low (23%). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: The first total synthesis of a cADPR analogue. 
 
 
5.6.  Chemical cyclization strategies for new cADPR analogues synthesis 
 
Chemical synthesis of cADPR and its analogues also show limitation due to the regio- and 
stereo-selective formation of N1-glycosilic bond and to the intramolecular cyclization 
involving the pyrophosphate bond realization. The difficulty of forming such an 
intramolecular pyrophosphate linkage, which prevented the completion of the synthesis of 
target cADPR analogues, has also been experienced of other groups. Thus, the 
development of an efficient condensation method for forming the intramolecular 
pyrophosphate linkage was needed. Matsuda and co-workers proposed a new synthetic 
plan to obtain cIDPcR (22), in which formation of the intramolecular pyrophosphate linkage 
was completed using AgNO3 or I2/3MS as promoter and 5’-phenylthiophosphate-N1-P-
carbaribose-inosine (23, figure 5.13) as substrate for cyclizing[44].  
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Figure 5.13: Phenylthiophosphate-type substrate. 
 
Adopting Matsuda’s condensation procedure, in Piccialli’s laboratories has been 
synthesized a new cIDPR analogue (24, figure 5.14), characterized by the presence of 
carbaribosyl and butyl moieties at N-1 and N-9 of hypoxanthine, respectively[45].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: N1, N9-ribose modified cIDPR. 
 
This compound was the first example of a new class of molecules characterized by a 
linear chain at N-9, designed to investigate the role  of the N-9 attached ribosyl moiety in 
the mechanism of Ca+2 intracellular modulation. Then, the synthesis of a new cIDPR 
analogue (25) having a penthyl chain at N-1 of an inosine unit, has been realized[46]. In this 
latter case an alternative intramolecular condensation reaction was performed to cyclize a 
and b (figure 5.15), respectively the emiprotected and unprotected linear bisphosphate 
precursors of 25. In the former method a, dissolved in pyridine, was added over 15h to I2, 
dissolved in the same solvent, in the presence of molecular sieves (3A°), to furnish  the 
cyclic product 25 (60% isolated yield). In the latter, the intramolecular condensation 
reaction of the two phosphate groups of b was performed by addition of a slight excess of 
EDC in MPD and allowing  the mixture to stand at 50°C for 60 h. The desired cyclic 
product 25 was obtained in 80% yield after HPLC purification. The surprisingly and 
unprecedent high cyclization yields observed using EDC as a condensing agent of the two 
phosphomonoester functions of the linear precursor b, indicates this reaction as an 
efficient and easy method to obtain large rings characterized by a high conformational 
mobility. Previous computational studies followed using SOFTWARE INSIGHT II 2000, 
and as forcing drive the CVFF, minimized with the conjugated alghorithm, RMS derivative 
0.001; DINAMIC: EQUILIBRATION 4000 STEPS, STEPS 4000, History 100, at 323°K and 
using MPD as solvent with  a dielectric constant of 32, suggested that the N1-penthyl 
cIDPR derivative adopts a conformation in which the phosphates distance is 12.10 Å, a 
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smallest value if we consider  cIDPR. This latter strategy will considerably facilitate the 
preparation of further cADPR analogues as it is both fast and economical.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Intramolecular condensation strategies. 
 
5.7.  Structural cADPR analogues for SAR elucidation 
 
Intensive studies of cADPR have been made and needed because of its biological 
importance not only as  pharmacological tool, but also in the elucidation of SAR, of 
mechanism of cADPR action and labelling of binding proteins. Since cADPR is rapidly 
hydrolized, many non-hydrolyzable mimics of cADPR, which retained a similar calcium 
release profile to that of cADPR are reported.  Numerous structural modifications of 
cADPR described include the replacement of the adenine portion with a deaza-ring 
system[47], the modification or deletion of either one of the ribose units, as well as 
combinations of the above structural features. Additional structural modification of cADPR 
includes the pyrophosphate moiety. Cyclic adenosine triphosphate ribose was more potent 
in inducing Ca2+ release as compared to cADPR[34]. Since the N1-ribosyl moiety and the 6-
amino group in cADPR are not critical structural factors for retaining the biological activity, 
cyclic IDP-ribose analogues  have been synthesized. Shuto and co-workers first described 
the chemical synthesis of cyclic IDP-carbocyclic-ribose (cIDP-carbaribose)[43]. cIDPR 
analogues were found to retain  the cADPR activities to induce Ca2+ release in T-cells[48]. 
N1 and/or N9 glycosyl-substituted cyclic IDP-ribose derivatives were previously reported in 
our laboratory, the N1-pentyl cyclic inosine diphosphate ribose and the N1-carbocyclic, 
N9-butyl analogue (24, 25). These compounds were designed to investigate the role of the 
N-1 and N-9 attached ribosyl moiety in the mechanism of Ca2+ intracellular modulation. 
Preliminary tests  to evaluate  their biological effects on SK-N-BE cells of a human 
neuroblastome system, have been performed. [Ca2+]i releasing activity was observed only 
when compound 25 the N1-penthyl analogue was added, while compound 24 didn’t show 
activity both in the same and higher concentrations. Other 3’-modified cIDPR derivatives 
were also synthesized, their biological response suggested that the 3’-OH was essential 
for the calcium releasing activity. 
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5.8.  The aim of the work 
 
To further collect more informations on southern N-9 ribose role (more precisely hydroxyl 
groups and/or cycle rigidity occurrence) into Ca2+ release activity of cyclic IDP-ribose 
derivatives, the synthesis of N-9 acyclic sugar derivatives have been recently performed. 
Many different bond scissions of the furanosyl endocyclic frame can be chemoselectively 
accomplished to produce a variety of acyclic derivatives.    
The oxidative cleavage of 2’, 3’-cis-diol portion of inosine with NaIO4[49], followed by 
reduction with NaBH4, and the selective cleavage of the C1’-O4’ bond in the ribose ring 
with DIBAL-H[50] have been performed, to obtain 2’,3’-seco- and N9-ribityl-cADPR 
analogues, respectively (Figure 5.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: New synthesized cIDPR derivatives. 
 
I wish to report here the synthesis of new cIDPR analogues (I, II, III, IV), which are 
expected to be resistant to both enzymatic and chemical hydrolysis as are similar N-1-
alkylated analogues, and possessing respectively: 
• I a hydroxypenthyl chain at N-9 and a carbaribose at N-1 of the hypoxantine base;  
• II differs from I for the presence of a penthyl chain at N-1 position of the 
hypoxanthine base; 
• III a polihydroxylate ether strand at N-9 and a carbaribose at N-1 of the hypoxantine    
base;  
• IV differs from III at N-1 position of the hypoxanthine base, where the carbaribose 
moiety is substituted by a penthyl chain. 
 
 
 
 
 
 
N
N N
N
O
PO
OH
O
PO
O-
O
O
OHOH
HH
O
N
N N
N
O
PO
OH
OH
HH
O
OH
OH
HOHO
HH
HH
OPO
O-
O
I
N
N N
N
O
PO
OH
OH
HH
O
OH
PO
O-
O
O
OHOH
HH
O
II
N
N N
N
O
PO
OH
O
PO
O-
O
OH
OHOH
HH
O
III IV
                                                                                              CHAPTER 5   Synthesis of cIDPR analogues 
 102
5.9.  Chemistry 
 
The new compounds (I;II;III;IV) have been synthesized from the inosine base, differently 
opened at N9-ribose, and alternatively substituted at N1 position with a carbaribose  or a 
penthanol unit. The key steps for the synthesis of these analogues  involve ribose opening 
strategy, substitution at N1-position of inosine and intramolecular cyclization of 
corresponding bisphosphate, following Piccialli’s method. The syntheses of compounds I; 
II and III; IV are summarized in Scheme 5.1 and 5.2, respectively. 
 
I and II compounds: 
The synthetic strategy adopted for I and II is shown in Scheme 5.1. The 2’,3’-O-
isopropylidene-inosine 1 was allowed to react with DIBAL-H in anhydrous THF[50]. 
In this way the sugar moiety was reduced to afford the corresponding 1-D-ribitylinosine 
derivative 2. Acetylation of the hydroxyl functions of 2 gave derivative 3. N-1 nitroinosine 
derivative 4 was prepared according to the procedure proposed by Vilarrasa and co-
workers  by treatment of 3 with ammonium nitrate and trifluoroacetic anhydride (TFAA) in 
dichloromethane[51] Derivatives 6a and 6b have been obtained by reaction of 4 with 5a and 
5b, respectively, in DMF. Removal of the acetyl protecting groups from 6a and 6b by 
treatment with K2CO3 in MeOH, yielded 7a and 7b, respectively. The 
bis(phenylthio)phosphoryl groups were introduced on the primary hydroxyl functions by 
treatment of 7a and 7b with S,S-diphenyl-phosphorodithioate (cyclohexylammonium salt) 
in the presence of 2,4,6-triisopropylbenzenesulphonylchloride (TPSCl) and tetrazole in 
pyridine[52] to give the protected bisphosphate derivative 8a and 8b as the main product 
together with the triphosphate derivatives in a 8:2 ratio. After HPLC (RP-C18) purification, 
8a and 8b were treated with silver acetate (AgAc) for complete removal of protecting 
groups of both phosphate residues[52]. The deprotected bisphosphate derivative 9a and 9b 
were further purified by HPLC (RP-C18) before cyclization, which was performed as 
previously described, to obtain 10a and 10b (55 % yield after purification). Finally, these 
latters were deprotected at 2’,3’-hydroxyl groups by treatment with formic acid, which 
afforded the target compounds I and II, respectively from 10a and 10b  (15 % overall yield 
starting from 1), whose structures were confirmed by 1H and and MS data.   
 
III and IV compounds: 
The synthetic strategy adopted to obtain compounds III and IV is reported in Scheme 5.2. 
The inosine 1’, in anhydrous pyridine, was treated with dimethoxytrytilchloride (DMT-Cl) to 
afford 5’-(O-DMT)-inosine (2’), as main product. 1-chloro-2,4-dinitrobenzene and 
anhydrous K2CO3 were added to a solution of 2’ in dry DMF to afford the N1-(2,4-dinitro)-
phenyl derivative 3’. This intermediate was rapidly transformed in 4’a or 4’b using  a or b 
(10 equiv in DMF, 80 °C), respectively. Then the oxidative cleavage of 2’,3’-cis-diol portion 
of inosine with NaIO4, followed by reduction of aldehydic groups with NaBH4[49] was 
performed and afforded  compound 5’a and 5’b. The unprotected 2’,3’-seco-nucleosides 
5’a and 5’b were treated with acetic anhydride to lead fully protected compound 6’a and 
6’b in high yields. These latters were treated with 2% trifluoracetic acid (TFA) in DCM to 
remove  the dimethoxytrytil  groups (7’a and 7’b). The unprotected hydroxyl groups were 
converted into corresponding bis-(phenylthio)-phosphoryl derivatives (8’a and 8’b) treating 
7’a and 7’b with S,S-diphenyl-phosphorodithioate (cyclohexylammonium salt) in the 
presence of 2,4,6-triisopropylbenzenesulphonylchloride (TPSCl in pyridine). After 
purification, 8’a and 8’b were treated with silver acetate (AgAc) for complete removal of 
protecting groups from both phosphate residues (9’a and 9’b).  
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Scheme 5.1: Synthetic scheme followed to obtain compounds I and II 
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The deprotected bisphosphate derivative 9’a and 9’b were further purified by HPLC (RP-
C18) before cyclization, which was performed with EDC/NMP, to obtain 10’a  and 10’b (50 
% yield after purification). Finally, these latters were deprotected at hydroxyl groups by 
treatment with anhydrous K2CO3 to remove the 2’, 3’-acetyl groups, common at both 10’a  
and 10’b, followed by HCOOH 60%(aq) treatment, only for 10’a. The target compounds III 
and IV were obtained respectively from 10’a and 10’b (36 % overall yield starting from 1), 
and their structures were confirmed by 1H NMR and MS data.   
 
5.10.  Conclusions  
 
The above compounds were designed to investigate the role that N-1 and N-9 attached 
ribosyl moieties play in the mechanism of intracellular Ca2+ modulation. The structure of 
these compounds were confirmed by UV, 1H-NMR and MS, and they will be tested in their 
Ca2+-mobilizing activity. The evaluated mobilizing effect of these newly synthesized 
compounds  would be effective in understanding the SAR and it will provide a greater 
demonstrating of the southern ribose role in the ligand-receptor recognition, both about the 
importance of hydroxyl groups presence and ribose cycle rigidity need. These results 
could lead to novel therapeutic agents. 
 
5.11.  Experimental Session 
 
5.11.1. General Methods 
 
1H and 13C NMR spectra were recorded in CDCl3 on a Bruker WM 500 spectrometer. 
Residual proton and carbon signals of the solvent (CDCl3 δ= 7.24 and 77.5; CD3OD δ = 
3.30 and 77.5; D2O δ = 4.60) were used as internal references. 1H NMR signals were 
assigned to the pertinent nuclei through two-dimensional 1H-1H and 1H-13C COSY 
experiments. Mass spectra were registered by an API-2000 of Applied Biosystem 
instruments. General reagents and solvents were purchased from Sigma-Aldrich-Fluka. 
UV measurements were carried out on a Jasco V-530 UV spectrophotometer. HPLC 
purifications were performed on a Nucleosil C18 column (Macherey Nagel, 250/10, 7 µm). 
The following abbreviations were used throughout the text: NH4NO3 = ammonium nitrate, 
TPSCl = 2,4,6-triisopropylbenzenesulphonylchloride, EDC = 1-[3-(dimethylamino)propy]-3-
ethylcarbodiimide hydrochloride, MPD = N-methylpyrrolidone, DMF = N,N-
dimethylformammide, CH2Cl2 = dichloromethane, Py = pyridine, TEAB = triethylammonium 
bicarbonate, DNP = 2,4-dinitrophenyl, NaIO4 = sodium m-periodate, NaBH4 = Sodium 
borohydride, DIBAL-H = diisobutylaluminiumhydride, THF = tetrahydrofurane, K2CO3 = 
potassium carbonate,  EtOH=ethanol, DMT-Cl= dimethoxytrytilchloride, R.T.= room 
temperature, s’s = singlets, d’s = doublets, m’s = multiplets, q’s = quartets. 
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Scheme 5.2: Synthetic scheme followed to obtain compounds III and IV 
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5.11.2. General Procedures  
 
Synthesis of compounds I and II 
 
9-(2’,3’-O-isopropylidene -D-ribityl)-hypoxanthine (compound 2). To a stirred 
suspension of nucleoside 1 (617 mg, 2 mmol) in anhydrous THF (30 mL) at room 
temperature was added DIBAL-H (1.0 mL of 1.0M solution in toluene, 10mmol) dropwise 
under argon atmosphere. After being stirred at 25°C for 24h, the reaction mixture was 
quenched with saturated 10% aqueous AcOH at 0°C and then evaporated in vacuo. The 
residue was purified by column chromatography on silica gel (CHCl3/MeOH 9:1-8:2), to 
afford pure 2 in 70% yield (416mg) as a colorless solid. 
UV (MeOH) λmax 249nm. 1H NMR δH (400MHz: DMSO-d6) 1.19 and 1.42 (s,each 3H, 
isopropylidene), 3.41 (d,1H, 5’H), 3.61-3.64 (m, 2H, 4’H and 5’H), 4.10 (dd,1H, 3’H), 4.21 (dd,1H, 
1’H), 4.49 (ddd,1H, 2’H), 4.53 (dd,1H, 1’H), 4.64(t, 1H, 5’OH), 5.12(d, 1H, 4’OH), 8.02 (s, 2H, H2 
and H8), 12.26 (s, 1H, N1H). ESI-MS calculated m/z: 310.11, (C13H18N4O5), found: 311.50(M + 
H)+. 
4’,5’-bis-O-acetyl-9-(2’,3’-O-isopropylidene -D-ribityl)-hypoxanthine (3) 
2 (416 mg, 1.4 mmol) was treated with 10 mL of Ac2O/pyridine solution (6:4, v/v). After 2 h 
at room temperature the dried mixture was dissolved in CHCl3 and washed with water. The 
dried organic layer gave 566mg of 3 as white solid (95% yield). 
1H NMR δH (400MHz: CHCl3-d1) 1.19-1.42 (s, each 3H, isopropylidene), 3.67 (s, 6H, acetyl), 3.86 
(dd,1H, 1’H), 3.9 (ddd,1H, 2’H), 4.40 (d,2H, 5’H), 4.47 (dd,1H, 3’H), 4.87 (m, 1H, 4’H), 8.02 (s, 
2H, H2 and H8).ESI-MS calculated m/z:426.14,(C17H22N4O9), found:427.30 (M+H)+. 
4’,5’-bis-O-acetyl-9-(2’,3’-O-isopropylidene -D-ribityl)-N1-nitro-hypoxanthine (4) 
Trifluoroacetic anhydride (350 µL, 5.2 mmol) was added to a suspension of finely 
powdered NH4NO3 (208 mg, 2.6 mmol) in anhydrous CH2Cl2 (5 mL) at 0°C. The mixture 
was vigorously stirred at room temperature until the solid was dissolved (ca.1h) and then 
cooled again. Follow the addition of the nucleoside (1.3 mmol, 566 mg) in 3mL CH2Cl2  at -
20°C for 60min.  The reaction was monitored by TLC and quenched adding cold 
phosphate buffer. The organic layer dried and then filtered through a pad of silica gel (98:2 
CH2Cl2- MeOH), afforded the pure N1-nitro-derivative 4 as a yellow oil (337mg, 55%yield). 
1H NMR δH (400MHz: CHCl3-d1) 1.19-1.42 (s, each 3H, isopropylidene), 3.67 (s, 6H, acetyl), 3.86 
(dd,1H, 1’H), 3.9 (ddd,1H, 2’H), 4.40 (d,2H, 5’H), 4.47 (dd,1H, 3’H), 4.87 (m, 1H, 4’H), 7.8-8.2 (s, 
2H, H2 and H8). ESI-MS calculated m/z: 471.16, (C17H21N5O11), found: 472.30(M + H)+. 
4’,5’-bis-O-acetyl-9-(2’,3’-O-isopropylidene-D-ribityl)-N1carbaribosehypoxanthi-ne 
(6a) A solution of 4 (168 mg, 0.35 mmol) in dry DMF (1.0 mL) was treated with 5a (163 
mg, 0.89 mmol) at 80 °C for 2 h under stirring. The resulting solution, dried under reduced 
pressure, was purified on silica gel column eluted with increasing amount of CH3OH in 
CHCl3. The fractions eluted with 12% CH3OH furnished 177 mg of 6a as white amorphous 
solid (85% yield), which could not be induced to crystallize. 
1H NMR δH (400MHz: CHCl3-d1) 1.42-1.61 (s, each 6H, isopropylidene), 1.69 (dd, 2H, 6’’H), 1.91 
(dd, 1H, 4’’H), 3.49 (d, 2H, 5’’H), 3.67 (s, 6H, acetyl), 3.86 (dd,1H, 1’H), 3.87 (dd, 1H, 3’’H), 3.9 
(ddd,1H, 2’H), 3.95 (m, 1H, 1’’H),  4.43(d,2H, 5’H), 4.40 (dd,1H, 3’H), 4.50 (dd, 1H, 2’’H), 4.87 
(m, 1H, 4’H), 7.8-8.2 (s, 2H, H2 and H8). ESI-MS calculated m/z: 596.23, (C26H36N4O12), found: 
597.30(M + H)+. 
4’,5’-bis-O-acetyl-9-(2’,3’-O-isopropylidene-D-ribityl)-N1-(5-hydroxypenthyl)-hy- 
poxanthine (6b) A solution of 4 (168 mg, 0.35 mmol) in dry DMF (1.0 mL) was treated 
with 5b (90 mg, 0.89 mmol) at 80 °C for 2 h under stirring. The resulting solution, dried 
under reduced pressure, was purified on silica gel column eluted with increasing amount 
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of CH3OH in CHCl3. The fractions eluted with 15% CH3OH furnished 143 mg of 6b as 
white amorphous solid (85% yield), which could not be induced to crystallize. 
6b 1H NMR δH (400MHz: CH3OH-d3) 1.41 (s, 3H, isopropylidene), 1.3-1.55 (m, 6H, 2’’H, 3’’H, 
4’’H), 2.01 (s, 6H, acetyl) 2.95(t, 1H, 1’’H),  3.49 (d, 2H, 5’’H), 3.86 (dd,1H, 1’H), 3.9 (ddd,1H, 
2’H), 4.32 (d, 2H, 5’H), 4.47 (dd,1H, 3’H), 4.87 (m, 1H, 4’H), 7.97-8.02 (s, 2H, H2 and H8). ESI-
MS calculated m/z: 480.22, (C22H32N4O8), found: 481.44(M + H)+. 
Products 7a and 7b. Compounds 6a and 6b were treated each one with anhydrous 
K2CO3 in dry MeOH to remove acetyl groups in high yields, affording 7a and 7b, 
respectively.  
7a 1H NMR δH (400MHz: CHCl3-d1) 1.42-1.61 (s, each 6H, isopropylidene), 1.69 (dd, 2H, 6’’H), 
1.91 (dd, 1H, 4’’H), 3.49 (d, 2H, 5’’H), 3.62(m, 1H, 4’H), 3.68 (d, 2H, 5’H), 3.86 (dd,1H, 1’H), 
3.87 (dd, 1H, 3’’H), 3.9 (ddd,1H, 2’H), 3.95 (m, 1H, 1’’H),  3.96 (dd,1H, 3’H), 4.50 (dd, 1H, 
2’’H), 7.8-8.2 (s, 2H, H2 and H8). ESI-MS calculated m/z: 480.23, (C22H32N4O8), found: 
481.30(M + H)+. 
7b 1H NMR δH (400MHz: CH3OH-d3) 1.41(s, 3H, isopropylidene), 1.3-1.55 (m, 6H, 2’’H, 3’’H, 
4’’H), 2.95 (t, 1H, 1’’H),  3.49 (d, 2H, 5’’H), 3.62(m, 1H, 4’H), 3.68 (d, 2H, 5’H), 3.86(dd,1H, 
1’H), 3.9 (ddd,1H, 2’H), 3.96 (dd,1H, 3’H), 7.97-8.02 (s, 2H, H2 and H8). ESI-MS calculated m/z: 
396.15, (C18H28N4O6), found: 397.44(M + H)+. 
Products 8a and 8b. PSS (126 mg, 0.33 mmol) was co-evaporated with dry pyridine 
(3x2mL) and dissolved in dry Py (2 mL). TPSCl was added (252 mg, 0.66 mmol) and the 
mixture was stirred at R.T. for 1h.Two solution were prepared, to which one compound 7a 
(143 mg, 0.30 mmol, 1eq) and 7b (118 mg, 0.30 mmol) were separately added. After 
stirring for 22 h at R.T. the mixtures were diluited with  CHCl3 (10mL) and then water 
(10mL) was added. The organic layers were dried on Na2SO4 , evaporated to dryness and 
co-evaporated with toluene. The residues were chromatographed on silica gel with (95:5) 
CHCl3- MeOH, to afford 8a from 7a and 8b from 7b, respectively in high yields.  
8a 1H NMR δH (400MHz: CHCl3-d1) 1.42-1.61 (s, each 6H, isopropylidene), 1.69 (dd, 2H, 6’’H), 
1.91 (dd, 1H, 4’’H), 3.49 (d, 2H, 5’’H), 3.62 (m, 1H, 4’H), 3.68 (d, 2H, 5’H), 3.86 (dd,1H, 1’H), 
3.87 (dd, 1H, 3’’H), 3.9 (ddd,1H, 2’H), 3.95-3.96 (2H, m, 1’’H,  dd, 3’H), 4.50 (dd, 1H, 2’’H), 
7.04-7.20 ( m, 20H, PhS), 7.8-8.2 (s, 2H, H2 and H8). ESI-MS calculated m/z: 1008.24, 
(C46H50N4O10P2S4), found: 1009.40(M + H)+. 
8b 1H NMR δH (400MHz: CHCl3-d1) 1.41 (s, 3H, isopropylidene), 1.3-1.55 (m, 6H, 2’’H, 3’’H, 
4’’H), 2.95 (t, 1H, 1’’H),  3.55 (d, 2H, 5’’H), 3.62 (m, 1H, 4’H), 3.75 (d, 2H, 5’H), 3.86 (dd,1H, 
1’H), 3.9 (ddd,1H, 2’H), 3.96 (dd,1H, 3’H), 7.0-7.2 (m, 20H, PhS), 7.97-8.02 (s, 2H, H2 and H8). 
ESI-MS calculated m/z: 924.22, (C42H46N4O8P2S4), found: 925.54(M + H)+. 
Products 9a and 9b. One step removal of all four phenylthio-groups, from each 8a and 
8b,  was carried out at R.T. for 16h using 32 equiv. of silver acetate (AgAc) in 10mL of 
pyridine-water (2:1 v/v). After the deblocking reaction was completed, the excess of AgAc 
was converted in the less soluble silver chloride, adding NaCl, until solution saturation. 
Insoluble silver sulfide and silver chloride were separated off by centrifugation. The 
surnatant was collected, desalted  and purified on RP-C18 HPLC to afford 9a and 9b from 
8a and 8b, respectively (90%yield). 
9a 1H NMR δH (400MHz: CH3OH-d3) 1.42-1.61 (s, each 6H, isopropylidene), 1.69 (dd, 2H, 6’’H), 
1.91 (dd, 1H, 4’’H), 3.49 (d, 2H, 5’’H), 3.62 (m, 1H, 4’H), 3.68 (d, 2H, 5’H), 3.86 (dd,1H, 1’H), 
3.87 (dd, 1H, 3’’H), 3.9 (ddd,1H, 2’H), 3.95 (m, 1H, 1’’H),  3.96 (dd,1H, 3’H), 4.50 (dd, 1H, 
2’’H), 7.8-8.2 (s, 2H, H2 and H8). ESI-MS calculated m/z: 640.14, (C22H34N4O14P2), found: 
641.37(M + H)+. 
9b 1H NMR δH (400MHz: CH3OH-d3) 1.30-1.55 (m, 6H, 2’’H ,3’’H, 4’’H), 1.42-1.61 (s, 3H, 
isopropylidene), 1.69 (dd, 2H, 6’’H), 2.96 (m, 1H, 1’’H),  3.49 (d, 2H, 5’’H), 3.62 (m, 1H, 4’H), 
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3.68 (d, 2H, 5’H), 3.86 (dd,1H, 1’H), 3.9 (ddd,1H, 2’H), 3.96 (dd,1H, 3’H), 7.8-8.2 (s, 2H, H2 and 
H8). ESI-MS calculated m/z: 556.24, (C18H30N4O12P2), found: 557.38(M + H)+. 
Products 10a and 10b. To each solution of 9a (169 mg, 0.26 mmol) and 9b (144 mg, 0.26 
mmol)  in MDP (0.5 mL), EDC (273 mg, 1.43 mmol) was added and the mixture stirred at 
room temperature for 60 h. Then the mixture was evaporated under reduced pressure and 
the residue was dissolved in 2 mL of TEAB buffer (0.1 M, pH 7.0). The solution was 
purified and desalted by a C18 reversed phase HPLC column, to give 133mg of 10a and 
116mg 10b as bis-triethylammonium salt (80% yield). Spectroscopic data are identical to 
product 9a and 9b.   
Compounds I and II.  A solution of each 10a and 10b  in aqueous HCO2H (60%, 2.0 mL) 
was stirred at room temperature for 3.5 h. After the solvent was evaporated under reduced 
pressure and the residue, dissolved in H2O, was purified by a RP-C18 HPLC column, 
eluted with a linear gradient (from 0 to 40% in 80 min) of CH3CN in TEAB buffer (0.1 M, pH 
7.0), flow 1.0 mL/min. The fractions with retention time of 22.4 min and 23.0 min were 
evaporated under reduced pressure and excess of TEAB was coevaporated with MeOH. 
The residue was freeze-dried to give 116 mg of compound I and  102mg of II as 
triethylammonium salt, as white amorphous solid (85% yield). 
I from 10a 1H NMR δH (400MHz: CH3OH-d3) 1.67 (m, 1H, 4’’H), 1.69 (dd, 2H, 6’’H), 3.30 (dd, 
1H, 2’’H), 3.33 (ddd,1H, 2’H), 3.37 (dd,1H, 3’H), 3.38 (m, 1H, 4’H), 3.49(d, 2H, 5’’H), 3.68(d, 
2H, 5’H), 3.69 (m, 1H, 1’’H),  3.88 (dd,1H, 1’H), 3.94 (dd, 1H, 2’’H), 7.8-8.2 (s, 2H, H2 and H8). 
ESI-MS calculated m/z: 557.14, (C16H25N4O13P2), found: 558.37(M + H)+. 
II from 10b 1H NMR δH (400MHz: CH3OH-d3) 1.30-1.55 (m, 6H, 2’’H ,3’’H, 4’’H), 1.69 (dd, 2H, 
6’’H), 2.96 (m, 1H, 1’’H),  3.49 (d, 2H, 5’’H), 3.62 (m, 1H, 4’H), 3.68 (d, 2H, 5’H), 3.86 (dd,1H, 
1’H), 3.9 (ddd,1H, 2’H), 3.96 (dd,1H, 3’H), 7.8-8.2 (s, 2H, H2 and H8). ESI-MS calculated m/z: 
499.02, (C15H26N4O11P2), found: 500.15(M + H)+. 
 
Synthesis of compounds III and IV 
 
5’-(O-dimethoxytrytil)-inosine (compound 2’). To a stirred solution of nucleoside 1’ 
(308 mg, 1 mmol) in anhydrous Py (5mL) at room temperature DMT-Cl (170 mg, 0.5 
mmol) was added. After being stirred at 25°C for 2.5 h, the reaction mixture was 
quenched with MeOH and then evaporated in vacuo. The residue was purified by column 
chromatography on silica gel, to afford pure 2’ (CHCl3/MeOH/Pyr 9:1:0.5) in 90% yield 
(513 mg) as a yellow solid. 1H NMR δH (400MHz: Acetone-d6) 3.50 (d, 2H, 5’H), 3.65 (dd,1H, 
3’H), 3.7 (m,1H, 2’H), 4.15 (m, 1H, 4’H), 6.03 (d, 2H, 1’H), 7.1-7.6 (m, 13H, trytil),  7.97-8.02 (s, 
2H, H2 and H8), ESI-MS calculated m/z: 570.11, (C31H30N4O7), found: 571.34(M + H)+. 
5’-(O-dimethoxytrytil)- N1-(2,4-dinitrophenyl)-inosine (compound 3’) 
A mixture of 2’ (513 mg, 0.9 mmol), 1-chloro-2,4-dinitrobenzene (272 mg, 1.2 mmol) and 
K2CO3 (147 mg, 0.95 mmol) was stirred in anhydrous DMF (5 mL) at 80 °C for 2.5 h. After 
cooling, the mixture was filtered and the solid was washed with CHCl3. The filtrate and 
washings, evaporated to dryness under reduced pressure, were purified on a silica gel 
column eluted with increasing amount of CH3OH in CHCl3 (from 0 to 5%) to give 649 mg 
of 4’ (as 1: 1 mixture of atropoisomers at N-1-phenyl bond) as pale yellow amorphous 
solid (98% yield).1H NMR δH (400MHz: Acetone-d6) 3.43 (s, 6H, -OCH3), 3.50 (d, 2H, 5’H), 
3.65 (t, 1H, 3’H), 3.7 (m, 1H, 2’H), 4.15 (m, 1H, 4’H), 6.03 (d, 2H, 1’H), 7.1-7.6 (m, 13H, trityl), 
7.97-8.12 (s, 2H, H2 and H8), 8.2-9.1 (m, 3H, DNP). ESI-MS calculated m/z: 736.21, 
(C37H32N6O11), found: 737.42(M + H)+. 
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N1-carbaribose-5’, 5’’-bis-(O-DMT)-inosine (compound 5’a) 
A solution of 4’ (324mg, 0.44 mmol) in dry DMF (2.5 mL) was treated with a (196 mg, 1.1 
mmol) at 80 °C for 6 h under stirring. The resulting solution, dried under reduced 
pressure, was purified on silica gel column eluted with increasing amount of CH3OH in 
CHCl3. The fractions eluted with 12% CH3OH furnished 390 mg of 5’a as white 
amorphous solid (85% yield) which could not be induced to crystallize. 
1H NMR δH (400MHz: Acetone-d6) 1.4-1.6 (s, 6H, isopropylidene), 1.7 (dd, 2H, 6’’H),  2.15 (m, 
1H, 4’’H),  3.33 (d, 2H, 5’’H), 3.43 (s, 6H, OCH3), 4.15 (m, 1H, 4’H), 3.50 (d, 2H, 5’H), 3.87 (t, 
1H, 3’’H), 3.93 (m, 1H, 1’’H), 3.63 (t, 1H, 3’H), 4.50 (m, 1H, 2’’H), 3.7 (m, 1H, 2’H), 6.03 (d, 2H, 
1’H), 7.1-7.6 (m, 26H, trytil), 7.97-8.12 (s, 2H, H2 and H8). ESI-MS calculated m/z: 1043.47, 
(C61H62N4O12), found: 1044.53(M + H)+. 
N1-(5’’-ODMT)-penthyl- 5’-(ODMT)-inosine (compound 5’b) 
A solution of 4’ (324 mg, 0.44 mmol) in dry DMF (2.5 mL) was treated with b (110 mg, 1.1 
mmol) at 80 °C for 6 h under stirring. The resulting solution, dried under reduced 
pressure, was purified on silica gel column eluted with increasing amount of CH3OH in 
CHCl3. The fractions eluted with 15% CH3OH furnished 390 mg of 5’b as white 
amorphous solid (85% yield) which could not be induced to crystallize. 
1H NMR δH (400MHz: Acetone-d6): 1.3-1.6 (m, 6H, 2’’H, 3’’H, 4’’H), 2.96 (t, 2H, 1’’H), 4.15 (m, 
1H, 4’H), 3.37 (t, 2H, 5’’H),  3.50 (d, 2H, 5’H), 3.65 (dd, 2H, 3’H), 3.7 (m, 2H, 2’H), 6.03 (t, 1H, 
1’H), 7.1-7.6 (m, 26H, trytil), 7.97-8.12 (s, 2H, H2 and H8). ESI-MS calculated m/z: 944.20, 
(C56H56N4O10), found: 945.31 (M + H)+. 
N1-(5”ODMT)-alkyl-5’-(O-DMT)- 2’,3’- seco-inosine (compounds 6’a and 6’b) 
To a stirred solution of each one 5’a (390 mg, 0.37 mmol) and 5’b (353 mg, 0.37 mmol) in 
EtOH/H20 (2.5 mL, 1:1 v/v), NaIO4 ( 119 mg, 0.55 mmol) was added and shaken for 2h at 
50°C. At the resulting mixture a solution of NaBH4 in EtOH ( 0.9mM, 6 mg, 0.5eq)  was 
added dropwise at 0°C and then shaken  for 2h at room temperature. The resulting mixture 
was concentrated  under reduced pressure and rapidly filtered on silica gel to afford 
compound 6’a and 6’b (CHCl3/MeOH/Pyr 8:2:0.5) in 95% yields  as a yellow oil. 
7’a = 1H NMR δH (400MHz: Acetone-d6) 1.4-1.6(s, 6H, isopropylidene), 1.7(dd, 2H, 6’’H),  2.15 
(m, 1H, 4’’H),  3.25 (m, 1H, 4’H), 3.33 (d, 2H, 5’’H), 3.43(s, 6H, OCH3), 3.50 (d, 2H, 5’H), 3.87(t, 
1H, 3’’H), 3.93 (m, 1H, 1’’H), 3.66 (d, 1H, 3’H), 4.50 (m, 1H, 2’’H), 4.14 (m, 1H, 2’H), 5.13 (d, 
2H, 1’H), 7.1-7.6(m, 26H, trytil), 7.97-8.12 (s, 2H, H2 and H8).ESI-MS calculated m/z: 1045.11, 
(C61H64N4O12), found: 1046 (M + H)+. 
7’b= 1H NMR δH (400MHz: Acetone-d6): 1.3-1.6 (m, 6H, 2’’H, 3’’H, 4’’H), 2.96 (t, 2H, 1’’H), 
4.15 (m, 1H, 4’H), 3.37 (t, 2H, 5’’H),  3.50 (d, 2H, 5’H), 3.65 (dd, 2H, 3’H), 3.7 (m, 2H, 2’H), 
6.03 (t, 1H, 1’H), 7.1-7.6(m, 26H, trytil),  7.97-8.12(s, 2H, H2 and H8). ESI-MS calculated m/z: 
944.20, (C56H58N4O10), found: 945.31 (M + H)+. 
N1-(5”ODMT)-alkyl-5’-(O-DMT)-2’,3’-(bis-O-acetyl)-seco-inosine (compound 6’a and 
6’b) 
5’a (367 mg, 0.35 mmol) and 5’b (332 mg, 0.35 mmol)  were treated separately with 5 mL 
of Ac2O/pyridine solution (6:4, v/v). After 2 h, at R.T., the stirred mixture was diluited with 
MeOH, dried   under reduced pressure and  coevaporated with toluene (10mLx5 times), to 
give 6’a and  6’b as yellow solid (99% yield). 
 N1-alkyl-2’,3’-(bis-O-acetyl)- seco-inosine (compound 7’a and 7’b) 
Dimethoxytrityl group was removed from 6’a and  6’b using a solution 2% TFA in DCM. 
The mixture was kept for 20 min, evaporated to dryness in vacuo, and coevaporated with 
pyridine. The residue was chromatographed on silica gel with increasing amount of MeOH 
in CHCl3, affording 7’a and 7’b as a white foam.  
7’a= 1H NMR δH (400MHz: Acetone-d6): 1.4-1.6 (s, 6H, isopropylidene), 1.7 (dd, 2H, 6’’H),  2.01 
(s, 6H, 2’,3’-OCOCH3), 2.15 (m, 1H, 4’’H), 3.49 (d, 2H, 5’’H), 3.52 (m, 1H, 4’H), 3.66 (d, 2H, 
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5’H), 3.87 (t, 1H, 3’’H), 3.93 (m, 1H, 1’’H), 4.21 (t, 1H, 3’H), 4.50 (m, 1H, 2’’H), 4.67 (m, 1H, 
2’H), 5.64 (d, 2H, 1’H), 7.97-8.12 (s, 2H, H2 and H8). ESI-MS calculated m/z: 524.52, 
(C23H32N4O10), found: 525.76 (M + H)+. 
7’b= 1H NMR δH (400MHz: Acetone-d6):  1.3-1.6 (m, 6H, 2”H, 3”H, 4”H), 2.01 (s, 6H, 
2’OCOCH3), 2.96 (t, 2H, 1”H), 3.52 (m, 1H, 4’H and 5”H), 3.66 (d, 2H, 5’H), 4.21 (d, 1H, 3’H), 
4.69 (d, 1H, 2’H), 5.64 (t, 2H, 1’H), 7.97-8.12 (s, 2H, H2 and H8).  ESI-MS calculated m/z: 440.19, 
(C19H28N4O8), found: 441.35(M + H)+. 
Products 8’a and 8’b. For procedure see above (analogue products 8a and 8b). 
8’a 1H NMR δH (400MHz: Acetone-d6) 1.4-1.6 (s, 6H, isopropylidene), 1.7 (dd, 2H, 6’’H),  1.9 
(m, 1H, 4’’H),  2.01(s, 6H, 2’,3’-OCOCH3), 3.52-3.6 (m, 3H, 4’H and 5’’H), 3.71 (d, 2H, 5’H), 
3.87 (t, 1H, 3’’H), 3.93 (m, 1H, 1’’H), 4.21 (d, 1H, 3’H), 4.50 (m, 1H, 2’’H), 4.69 (d, 1H, 2’H), 
5.64 (t, 2H, 1’H), 7.04-7.2 (m, 20H, PhS), 7.97-8.12 (s, 2H, H2 and H8). ESI-MS calculated m/z: 
1052.17, (C47H50N4O12 P2S4), found: 1053.15(M + H)+. 
8’b 1H NMR δH (400MHz: Acetone-d6): 1.3-1.55 (m, 6H, 2’’H, 3’’H, 4’’H), 2.01 ( s, 6H, acetyl), 
2.96 (t, 2H, 1’’H), 3.01 (m, 1H, 4’H), 3.60 (t, 2H, 5’’H),  3.73 (d, 2H, 5’H), 4.21 (d, 2H, 3’H), 4.69 
(d, 2H, 2’H), 5.64 (t, 1H, 1’H), 7.04-7.2 (m, 20H, PhS), 7.97-8.12 ( s, 2H, H2 and H8). ESI-MS 
calculated m/z: 968.70, (C43H46N4O10P2 S4), found: 969.90 (M + H)+. 
Products 9’a and 9’b. For procedure see above (analogue products 9a and 9b). 
9’a 1H NMR δH (400MHz: Acetone-d6) 1.4-1.6 (s, 6H, isopropylidene), 1.7 (dd, 2H, 6’’H),  1.9 
(m, 1H, 4’’H),  2.01 (s, 6H, 2’,3’-OCOCH3), 3.52 (m, 3H, 4’H and 5’’H), 3.68 (d, 2H, 5’H), 3.73 
(m, 1H, 1’’H), 3.87 (t, 1H, 3’’H), 4.21 (d, 1H, 3’H), 4.50 (m, 1H, 2’’H), 4.69 (d, 1H, 2’H), 5.64 (t, 
2H, 1’H), 7.97-8.12 (s, 2H, H2 and H8). ESI-MS calculated m/z: 684.14, (C23H34N4O16P2), found: 
685.48(M + H)+. 
9’b 1H NMR δH (400MHz: Acetone-d6): 1.3-1.55 (m, 6H, 2’’H, 3’’H, 4’’H), 2.01 ( s, 6H, acetyl), 
2.96 (t, 2H, 1’’H), 3.01 (m, 1H, 4’H), 3.58 (t, 2H, 5’’H),  3.71 (d, 2H, 5’H), 4.21 (d, 2H, 3’H), 4.69 
(d, 2H, 2’H), 5.64 (t, 1H, 1’H), 7.97-8.12 ( s, 2H, H2 and H8). ESI-MS calculated m/z: 600.10, 
(C19H30N4O14P2), found: 601.16 (M + H)+. 
Products 10’a and 10’b. For procedure see above (analogue products 9a and 9b). 
Spectroscopic data are identical to product 9’a and 9’b.   
Compound III and IV . A solution of each 10’a and 10’b in anhydrous K2CO3 and dry 
MeOH was stirred at R.T for 10’. 10’a requires also the removal step of isopropylidene 
group, that was performed adding HCO2H (60%, 2.0 mL) and stirring at room temperature 
for 3.5 h. After the solvent was evaporated under reduced pressure and the residue, 
dissolved in H2O, was purified by a RP-C18 HPLC column, eluted with a linear gradient 
(from 0 to 40% in 80 min) of CH3CN in TEAB buffer (0.1 M, pH 7.0) flow 2.0 mL/min. The 
fractions with retention time of 20.2 min and 21.5 min were evaporated under reduced 
pressure and excess of TEAB was coevaporated with H2O. Each residue was freeze-
dried to give 140 mg of compound III and 128 mg of  IV as triethylammonium salt as white 
amorphous solid (85% yield). 
III from 10’a 1H NMR δH (400MHz: Acetone-d6): 1.7(dd, 2H, 6’’H),  1.9 (m, 1H, 4’’H), 3.01 (m, 
1H, 4’H) 3.49 (d, 2H, 5’’H), 3.66 (d, 2H, 5’H), 3.31 (t, 1H, 3’’H), 3.66 (d, 1H, 3’H), 3.70 (m, 1H, 
1’’H), 3.94 (m, 1H, 2’’H), 4.14 (d, 1H, 2’H), 5.13 (t, 2H, 1’H), 7.97-8.12 (s, 2H, H2 and H8). ESI-
MS calculated m/z: 543.10, (C16H25N4O13P2), found: 544.36(M + H)+. 
IV from 10’b 1H NMR δH (400MHz: Acetone-d6): 1.3-1.55 (m, 6H, 2’’H, 3’’H, 4’’H), 2.96 (t, 2H, 
1’’H), 3.01 (m, 1H, 4’H), 3.53 (t, 2H, 5’’H) 3.66 (d, 4H, 3’H and 5’H), 4.14 (d, 2H, 2’H), 5.13 (t, 
1H, 1’H), 7.97-8.12( s, 2H, H2 and H8). ESI-MS calculated m/z: 499.10, (C15H25N4O11P2), found: 
500.16(M + H)+. 
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Synthesis of 33-Linked Pyrimidine Oligonucleotides Containing an Acridine
Moiety for Alternate Strand Triple Helix Formation
Jussara Amato,[a] Aldo Galeone,[a] Giorgia Oliviero,[a] Luciano Mayol,*[b]
Gennaro Piccialli,[a] and Michela Varra[b]
Keywords: Acridine / Circular dichroism / Helical structures / Oligonucleotides / Triplex
Oligonucleotides with a 3−3 inversion of polarity, con-
taining an acridine moiety attached to the nucleotide base
flanking the 3−3 phosphodiester bond, have been syn-
thesised, characterised and used to form alternate-strand
Introduction
Oligodeoxynucleotides (ODNs) can bind the major
groove of double-stranded DNA oligopurine tracts to form
local triple helices by sequence-specific hydrogen bonding.[1]
Pyrimidine-rich, triplex-forming oligonucleotides (TFOs)
target, in a parallel orientation, homopurine strands in a
duplex DNA by Hoogsteen-type triplets (T·AT and
C·GC), while purine-rich TFOs can bind, in an anti-
parallel orientation, the purine strand of a duplex DNA by
reverse Hoogsteen-type base triplets (G·GC and A·AT).
To extend the range of applicability of this gene-control
strategy,[2] which is otherwise confined to the rare presence
of a long — at least 1617 bases — homopurine sequence
on the target gene, it is possible to form triplex structures
in which the duplex is composed of two adjacent and alter-
nating oligopurine-oligopyrimidine tracts. In this approach,
called ‘‘alternate strand triple helix formation’’ ODNs hav-
ing a 33 or 55 internucleoside junction simul-
taneously hybridise the adjacent purine tracts by switching
strand at the junction between the oligopurine and the olig-
opyrimidine domains of the duplex.[3] Several 33 and
55 internucleoside junctions have been proposed as link-
ers for alternate strand TFOs,[411] with the latter imparting
a minor cooperativity in the binding of the two domains of
the TFO with the target duplex.[5]
In the last few years we have focused our attention on
the synthesis of ODNs containing a 33 inversion po-
[a] Facolta` di Scienze Biotecnologiche, Dipartimento di Chimica
delle Sostanze Naturali, Universita` di Napoli Federico II,
Via D. Montesano 49, 80131 Napoli, Italy
Fax: (internat.)  39-081-678552
E-mail: mayoll@unina.it
[b] Facolta` di Farmacia, Dipartimento di Chimica delle Sostanze
Naturali, Universita` di Napoli Federico II,
Via D. Montesano 49, 80131 Napoli, Italy
Eur. J. Org. Chem. 2004, 23312336 DOI: 10.1002/ejoc.200300803  2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 2331
triple helix complexes. These have been investigated by UV
melting studies and CD experiments.
( Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim,
Germany, 2004)
larity motif, which is able to hybridize the target duplex, in
parallel mode, by formation of Hoogsteen triplets.[1215]
Our results on the stability of these triplex structures
pointed to the phosphodiester bond as a suitable 33
junction into TFOs.[1214,16]
Nevertheless, molecular-mechanics calculations indicated
that a distortion of the sugar-phosphate backbone around
the 33 phosphodiester junction occurs, thus preventing
the correct Hoogsteen-hydrogen-bond formation for the nu-
cleotide bases flanking the site of inversion polarity.[17] In
order to balance the destabilizing effects occurring in alter-
nate strand triplexes, several research groups have intro-
duced an intercalating agent near the 33 switching re-
gion of the TFO.[1820] Among the possible DNA intercal-
ating agents, acridine is particularly advantageous consider-
ing that: i) molecules containing an acridine moiety have
been extensively studied as duplex and triplex DNA stabil-
izing agents; ii) acridine-linked ODNs have been proposed
as antisense agents and as efficient TFOs;[2123] iii) ODNs
linking acridine derivatives can induce a DNA cleavage un-
der photoirradiation when combined with metal ions;[24,25]
and iv) a large number of acridine derivatives are commer-
cially available.
We report here an easy and convenient method for the
synthesis of TFOs carrying a chloro-methoxyacridine resi-
due attached to the N-3 atom of a thymidine flanking the
33 phosphodiester bond, through an alkylamino linker.
We chose the N-3 position of thymidine on the basis of
its inherent reactivity towards alkylation and the reported
stability of duplex and triplex DNA complexes containing
intercalators, or other groups, attached to the N-3 position
of a thymidine residue.[26,27]
Results and Discussion
Our approach is based on a commercially available di-
functionalised CPG support carrying a 2-methoxy-6-chlo-
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Scheme 1. Reagents and conditions: i) TCA 3% in DCM; ii) TPP, DEAD, THF, DCM; iii) NaOH 0.1  in CH3OH/H2O (4:1 v/v); iv)
coupling with thymidine; v) pyridine/NEt3 (95:5 v/v, 1.5 h); vi) chain elongation with 3-phosphoramidite deoxynucleoside building blocks
roacridine moiety and a primary alcoholic hydroxy function
protected with the acid-labile DMT group (1, Scheme 1).
A suitably 3,5-protected thymidine 3 or 4 was linked to
support 2, obtained by removal of the DMT protecting
group, through the N-3 atom of the base under Mitsunobu
condensation conditions,[28,29] thus affording supports 5
and 6, respectively (70% yield by DMT spectrophotometric
test). Supports 5 and 6 were found to be stable under the
 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.eurjoc.org Eur. J. Org. Chem. 2004, 233123362332
chemical treatments required by the DNA chain as-
sembly[30] and cleavable, at the succinate function, in the
final alkaline treatment for detachment and deprotection
procedure. The cleavage from the support releases a thymid-
ine base connected to the acridine residue through a hexyla-
mino chain. Support 5, after capping of the unchanged
hydroxy functions and successive removal of the 3,5-DMT
groups, reacted almost quantitatively with the 5-DMT-thy-
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midine-3-phosphoramidite in a standard automated pro-
cedure, giving support 8. The detritylation of supports 5
and 8, followed by alkaline treatment with a 0.4  solution
of NaOH, furnished the expected acridine-nucleoside 7 and
the acridine-trinucleotide 9, respectively, the latter contain-
ing the 33 phosphodiester junction. The structures of
both released products were confirmed by 1H NMR spec-
troscopy and mass spectrometry. Eight coupling cycles per-
formed on support 5, with appropriate 3-phosphoramidite
nucleotide units, furnished TFO 10. Support 6, in which the
5- and 3-OH functions are orthogonally protected with
Fmoc and DMT groups, respectively, allowed the sequen-
tial synthesis of different ODN domains of the TFO. After
the removal of the 3-DMT group from support 6, the
elongation of the first ODN domain by the formation of
the 33 phosphodiester junction was achieved, thus lead-
ing to 11. Then, the 5-Fmoc group was removed by pyri-
dine/NEt3 treatment and the second ODN domain was as-
sembled, thus furnishing the TFO 12. Between the two
alternative 5- or 3-OH Fmoc protections, the former was
chosen on the basis of preliminary experiments performed
on solid supports carrying 5- or 3-Fmoc-thymidine. These
have shown that complete 5-deprotection could be
achieved by treatment with 5% triethylamine in pyridine in
1.5 hours, whereas a prolonged reaction time was needed to
quantitatively deprotect the 3-hydroxy function. TFOs 10
and 12 were synthesised on a 1 µ scale by a DNA syn-
thesiser. The crude oligomers, detached from the support as
described for trinucleotide 9, were purified by HPLC on an
anionic exchange column. The collected peaks were de-
salted, thus furnishing 10 and 12 with greater than 95%
purity (by RP-HPLC) in 28 and 24 OD260 units yields,
respectively. The MALDI TOF-MS spectra of 10 and 12
were in agreement with their structures. Furthermore, the
UV/Vis spectra of 10 and 12 confirmed the presence of the
acridine moiety in the oligomers, showing a diagnostic ab-
sorption at λmax  424 nm.
UV and Circular Dichroism (CD) Studies
The triplexes 14 and 15 (Table 1) were formed by mixing
equimolar amounts of TFO 10 and 12, respectively, with
Figure 1. UV melting profiles (pH 6.6): A triplex 14 (····), triplex 16 () and duplex 13 ( ); B triplex 15 (····), triplex 17 () and
duplex 13 ( ).
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the target duplex DNA 13, and heating at 90 °C for 5 min.
The solutions were then equilibrated for 15 h at room tem-
perature before performing the analyses. The formation and
stability of the triplexes 14 and 15, compared with the acri-
dine-devoid triplexes 16 and 17, were studied by UV ther-
mal denaturation experiments and by CD in 5 m
NaH2PO4, 140 m KCl and 5 m MgCl2 buffer (at pH 5.5,
6.0 and 6.6). Figure 1 shows the melting profiles of the du-
plex 13 and triplexes 1417. The Tm values are reported
in Table 1.
Table 1. Tm values (C°)/pH for duplex 13 and triplexes 1417
The melting curves for 1417 show a typical biphasic
behaviour, with the first sigmoid attributable to the triplex
dissociation, while at higher temperatures the expected pH-
insensitive duplex-to-single-strands transition can be ob-
served. The UV melting data for the acridine-containing
triplexes 14 and 15 indicate a stabilisation effect at all the
pH values with respect to the corresponding acridine-de-
void triplexes 16 and 17. At pH 6.6 the presence of the
acridine in the TFO led to a stabilisation, with ∆Tm values
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of 8.5 and 7.9 °C, respectively, for triplexes 14 and 15, while
at pH 5.5 a slightly smaller effect was observed (∆Tm 6.8
and 6.6 °C, respectively). The Tm values of the triplex 14
were higher than those of 15 at all the tested pH’s and the
same behaviour was observed for acridine-devoid triplexes
16 and 17. These latter data indicate that the substitution
of a thymine (in 14 and 16) for a cytosine (in 15 and 17) at
the 33 junction in TFO induces, as expected, a destabil-
izing effect, probably due to the electrostatic repulsion be-
tween consecutive protonated cytosines.
The formation of a triplex structure for 1417 was con-
firmed by circular dichroism measurements. The concen-
tration of the triplex solution was in the range 1.92.3 
105 . The CD spectra of triplexes 1417 (pH 6.6) are
reported in Figure 2. Complexes 16 and 17, as already re-
ported for the same kind of complexes,[16,17,31] show a CD
profile very similar to those observed for canonical Hoogs-
teen-type triplexes, characterised by a large positive band at
280 nm and a negative band centred around 213 nm.[12,15]
The negative band, in particular, is indicative of the exist-
ence of a triplex structure.[32] Almost the same patterns
were observed for acridine-containing triplexes 14 and 15.
The CD spectra of triplexes 14 and 15 were compared with
the normalised summed spectra of the duplex 13 and ap-
propriate single-strand TFOs (Figure 3). Significantly, for
Figure 2. A: CD spectra at pH 6.6 of triplex 14 () and triplex 16 (···); B: triplex 15 () and triplex 17 (···)
Figure 3. A: CD spectra at pH 6.6 of triplex 14 () and normalised summed spectra (···) of duplex 13 and TFO 10; B: CD spectra at
pH 6.6 of triplex 15 () and normalised summed spectra (···) of duplex 13 and TFO 12
 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.eurjoc.org Eur. J. Org. Chem. 2004, 233123362334
14 and 15, the diagnostic band at 213 nm is deeper than the
corresponding band in the normalised sum spectra, and the
282 nm band decreases in intensity and shows a red shift.
These data are clearly indicative of a triplex structures for
complexes 1417.
Conclusion
In this paper we report the easy synthesis of ODNs con-
taining a 33-phosphodiester linkage and bearing an
acridine residue on the thymidine base flanking the 33
junction. This synthesis was based on the preparation of a
new kind of nucleoside-acridine solid support (5 or 6). In
our opinion this synthetic strategy could be a useful entry
to link an intercalating agent near to a 33 (or 55)
phosphodiester linkage, thus furnishing a convenient
method to stabilize alternate strand triple helices by minim-
izing the mismatching effect into the region between purine
and pyrimidine domains. Both CD and UV melting data
indicate that the acridine moiety, linked through a seven-
atom spacer arm to the N-3 of a thymine, does not hamper
the formation of a triplex structure. Furthermore, the stabil-
isation effect observed for triplexes 14 and 15 strongly sug-
gests an intercalation of the acridine residue into the trip-
lex structure.
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Experimental Section
General Remarks: The following abbreviations are used throughout
the paper: triplex forming oligonucleotide (TFO), fluorenylme-
thoxycarbonyl (Fmoc), 4,4-dimethoxytrityl (DMT), trichloracetic
acid (TCA), dichloromethane (DCM), triethylammonium hydrogen
carbonate (TEAB), diethyl azadicarboxylate (DEAD), tri-
phenylphosphane (TPP), tetrahydrofuran (THF).
The acridine CPG support was purchased from Glen Research.
Functionalisation of solid supports was carried out in a short col-
umn (5 cm length, 1 cm i.d.) equipped with a sintered-glass filter,
stopcock and a cap. The ODNs were assembled with a PerSeptive
Biosystems Expedite DNA synthesiser using standard phos-
phoramidite chemistry. HPLC analyses and purification were car-
ried out on a Waters 600E apparatus equipped with a UV detector.
UV spectra and thermal denaturation experiments were run with a
Jasco V 530 spectrophotometer, equipped with a Jasco 505T tem-
perature controller unit. CD spectra were obtained with a Jasco 715
circular dichroism spectrophotometer. NMR spectra were recorded
with a Bruker AMX500 spectrometer. ESI mass spectrometric
analyses were performed on a API 2000 (Applied Biosystem) ma-
chine used in negative mode. MALDI TOF mass spectrometric
analysis wad performed on a PerSeptive Biosystems voyager-De
Pro MALDI mass spectrometer using picolinic/3-hydroxypicolinic
acid mixtures as the matrix.
3-O-(4,4-Dimethoxytriphenylmethyl)-5-O-fluorenylmeth-
oxycarbonylthymidine (4): 1H NMR ([D6]acetone): δ  9.90 [br. s,
1 H, N(3)-H], 8.02 (s, 1 H, H-6), 7.906.80 (m, 21 H’s, aromatic
protons), 6.32 (m, 1 H, H-1), 4.52 (m, 2 H, CH2 Fmoc residue),
4.32 (m, 1 H, H-3), 4.24 (t, 1 H, CH Fmoc residue), 3.98 (m, 3 H,
H2-5 and H-4), 3.81 (s, 6 H, OCH3 DMT), 1.92 and 1.72 (m, 1
H each, H2-2), 1.65 (s, 3 H, CH3-5) ppm.
Preparation of Supports 5 and 6, and Product 7: Commercially avail-
able support 1 (200 mg; 0.044 mequiv./g) was washed with DCM
and then treated with 3  2.0 mL of a DCM solution of TCA (3%,
w/v) for 2 min. This treatment was repeated three times and the
resulting support 2 was exhaustively washed with DCM and then
dried under reduced pressure.
DEAD (207 µL, 1.3 mmol) was added to a solution of tri-
phenylphosphane (TPP; 340 mg, 1.3 mol) dissolved in 800 µL of
THF at 0 °C. After 10 min this mixture was added to 200 mg of
support 2 suspended with a mixture of 0.26 mmol of 5 (or 6) in
700 µL of anhydrous DCM. After 5 hours at room temperature the
support was exhaustively washed with DCM, pyridine and then
treated with a solution of pyridine/acetic anhydride (2.0 mL, 9:1 v/
v) for 30 min at room temperature. Finally, the support was washed
with DCM and Et2O, and dried under reduced pressure. Incorpor-
ation yields of nucleoside 3 and 4 onto 2 were in the range of
6580% (0.0290.035 mequiv./g), as determined by a quantitative
DMT test performed on dried and weighed samples of the obtained
supports 5 and 6.
Treatment of 50 mg of support 6 with 1.5 mL of a 0.4  solution of
NaOH in methanol/water (4:1, v/v) for 17 h at room temperature,
followed by neutralisation of the alkaline solution with a 2  solu-
tion of triethylammonium acetate, furnished product 7 (0.5 mg,
after RP HPLC purification).
7: 1H NMR (D2O): δ  8.02, 7.50, 7.48, 7.42, 7.26, 7.18, 7.06 (1
H each, acridine protons and H-6 thymine), 5.56 (m, 1 H, H-1),
4.60 (m, 1 H, H-3), 3.90 (s, 3 H, CH3-O), 3.903.70 [m’s, 5 H,
overlapped signals, CH2-NH, CH2-N(1), H-4], 3.60 (m, 2 H,
CH2OH), 3.48 (m, 2 H, H2-5), 2.25 (m, 2 H, H2-2), 1.61 (s, 3 H,
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CH3-5), 1.851.40 (m’s, 7 H, 3 CH2 and CH) ppm. UV/Vis
(CH3OH): λmax  265 and 422 nm. ESI-MS: m/z  613 [MH].
Oligonucleotide Synthesis. Products 9, 10 and 12. Symmetric Olig-
omer Elongation: Support 5 (50 mg, 0.0016 mequiv.) was used for
each synthesis in the automated DNA synthesiser following stand-
ard phosphoramidite chemistry, with a 45 mg/mL solution of 3-
phosphoroamidite building block in anhydrous CH3CN. A com-
mercially available N(4)-acetyl-protected cytidine 3-phosphoram-
idite building block was used to avoid deamination when sodium
hydroxide was used for final cleavage and deprotection. Three-mer
9 and ODN 10 were synthesised by performing one or eight coup-
ling cycles, respectively, with the appropriate nucleotide unit. The
coupling yields were always better than 98% (by DMT test). After
completion of the desired ODN sequence and final DMT removal,
the support was treated with 1.0 mL of a 0.4  solution of NaOH
in methanol/water (4:1, v/v) for 17 h at room temperature. The fil-
tered solution and washings, neutralised with 5.0 mL of a 2  solu-
tion of triethylammonium acetate, were concentrated under re-
duced pressure, redissolved in water and purified by HPLC.
Crude 9 was purified on an RP C18 column (4.6 250 mm), eluting
with a linear gradient of MeOH in TEAB buffer (pH 7.0, 0 to 10%
in 50 min, flow 0.8 mL/min); retention time 35.5 min. The final
product (45 units OD260 from 50 mg of 5) was lyophilized and
characterised.
9: 1H NMR (D2O): δ  7.95, 7.90, 7.85, 7.45, 7.40, 7.32, 7.20,
7.15, 7.02 (9 H, partially overlapped, acridine protons and 3H-6),
6.326.40 (m’s, 3 H, 3 H-1), 1.65, 1.68, 1.70 (s’s, 3 H each, 3 CH3-
5) ppm. 31P NMR (D2O): δ  1.55, 1.38 ppm. UV/Vis (H2O):
λmax  265, 422 nm. ESI-MS: m/z  1221 [M  H], 1243 [M
 Na].
Crude 10 was purified an a Nucleogel SAX column (Macherey-
Nagel, 1000-8/46); buffer A: 20 m aqueous KH2PO4 solution, pH
7.0, containing 20% (v/v) CH3CN; buffer B: 1.0  KCl, 20 m
aqueous KH2PO4 solution, pH 7.0, containing 20% (v/v) CH3CN;
using a linear gradient from 0 to 100% B in 20 min; flow rate
1.0 mL/min. The collected peak at retention time 18.8 min, desalted
on a Sep-Pak column (C18), furnished 28 OD260 units of pure 10.
Maldi TOF-MS (positive mode): calculated mass 5357.03; found
5358.83 [M  H], 5380.86 [M  Na].
Asymmetric Oligomer Elongation: Support 6 (50 mg, 0.0015
mequiv.) was used for the synthesis of oligomer 12 following stand-
ard phosphoramidite chemistry as described for product 10. After
the elongation of the first ODN tract, the final DMT group was
removed and the resulting 5-OH function capped by reaction with
1 mL of pyridine/Ac2O solution (4:1, v/v) leading to 11. Removal
of the Fmoc protecting group was achieved by pyridine/NEt3 treat-
ment (1.5 h, 95:5, v/v). The resulting 5-OH support was success-
ively coupled with the required 3-phosphoramidite derivatives to
complete the desired ODN sequence, following a standard auto-
mated procedure. Crude 12 was detached from the support, depro-
tected and purified as described for 10. The collected peak at reten-
tion time 20.5 min, after desalting, furnished 24 OD260 units of
pure 12.
After HPLC purification 24 OD260 units of 12 were obtained.
Maldi TOF-MS (positive mode): calculated mass 5342.03; found
5343.65 [M  H], 5383.06 [M  K].
UV Thermal Denaturation Experiments: The concentrations of the
synthesised oligomers were determined spectrophotometrically at
λ  260 nm and 80 °C, using the molar-extinction coefficient calcu-
lated for unstacked oligonucleotides from the following extinction
coefficients: 11700 (G); 8800 (T) cm1 1. An aqueous solution
of 5 m NaH2PO4, 140 m KCl and 5 m MgCl2 (at pH 5.5, 6.0
J. Amato, A. Galeone, G. Oliviero, L. Mayol, G. Piccialli, M. VarraFULL PAPER
and 6.6) was used for the melting experiments. Melting curves were
recorded using a concentration of approximately 1 µ of single
strand in 1 mL of the tested solution in TeflonR-sealed quartz cu-
vettes of 1-cm optical path-length. The resulting solutions were
then heated at 90 °C for 5 min, then slowly cooled and kept at 20
°C for 15 h. After thermal equilibration at 20 °C the UV absorption
at λ 260 nm was monitored as function of the temperature, which
was increased at a rate of 0.5 °C/min. The melting temperatures
were determined as the maximum of the first derivative of the ab-
sorbance vs. temperature plots.
Circular Dichroism: CD spectra were registered in the same buffer
as used for UV melting experiments at 25 °C in a 0.1 cm path-
length cuvette. The wavelength was varied from 200 to 340 nm at
5 nm/min, and the spectra recorded with a response of 16 s, at
2.0 nm bandwidth and normalised by subtraction of the back-
ground scan with buffer. The temperature was kept constant at 25
°C with a thermoelectrically controlled cell holder (JASCO PTC-
348).
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SYNTHESIS OF A NEW N-9 RIBITYL ANALOGUE OF CYCLIC
INOSINE DIPHOSPHATE RIBOSE (cIDPR) AS A MIMIC OF
CYCLIC ADP RIBOSE (cADPR)
Giorgia Oliviero, Jussara Amato, Michela Varra, Gennaro Piccialli, and
Luciano Mayol 5 Dipartimento di Chimica delle Sostanze Naturali, Universita` di Napoli
Federico II, Napoli, Italy
5 A new analogue of cyclic inosine diphosphate ribose (cIDPR), in which the N-1 and N-9 ribosyl
moieties were substituted by a carbocyclic moiety and a hydroxyl-alkyl chain, has been synthesized and
characterized.
Keywords Cyclic ADP Ribose (cADPR), cIDPR, IP3
INTRODUCTION
Many cel lular functions are modulated by the concentration of intracel lular
calcium ions.[1] Two major mechanisms of calcium mobilization are known that
utilize calcium stored in cytoplasmic compartments for signal ling. The release of
Ca2+ is triggered by the interaction of the second messenger, inositol 1,4,5-
triphosphate (IP3), with its receptor, a ligand-activated calcium-selective channel. A
second class of intracel lular calcium-releasing channels is the ryanodine receptor.[2]
Although the physiological activator of this receptor is unknown, it can be activated
by Ca2+, causing the so cal led Ca2+-induced Ca2+ release (CICR). Recent research
establishes that, in addition to inositol triphosphate, the internal calcium stores can
be mobilized by new messenger molecules via cyclic ADP-ribose (cADPR,
Figure 1). cADPR that serves as a second messenger to activate the ryanodine
receptors of the sarcoplasmic reticulum and to mobilize intracel lular Ca2+ in many
cel l types in different species covering protozoa, plants, animals, and human.[3]
However, the mechanisms mediating the effect of cADPR remain unknown. Since
Ca2+ ions are regulators of several cel l functions, muscle contraction, secretion
of neurotransmitters, hormones and enzymes, fertilization of ovocytes, and
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lymphocyte activation and proliferation, the cADPR signaling pathway may
become a valuable target for pharmaceutical intervention.
cADPR is characterized by a very labile N-1 glycosidic bond which is rapidly
hydrolyzed both enzymatical ly, by cADP hydrolase, and non-enzymatical ly, to
give ADP-ribose even in neutral aqueous solution. This biological and chemical
instability deeply hinders further studies on cADPR aimed at elucidating its
physiological role, particularly as far as regulation of Ca2+mobilization in the cel ls is
concerned. Hence, stable yet active cADPR analogues are of great interest in this
field.[4]
In our laboratories we have previously synthesized two analogues of cADPR
(A and B, Figure 1).[5,6] These compounds, which display a carboribosyl and a
butyl moiety at N-1 and N-9 of a hypoxantine base, respectively, are designed to
investigate the role of a ribosyl moiety in the mechanism of Ca2+ intracel lular
modulation. We wish to report here the synthesis of a new cIDPR analogue (C,
Figure 1) having a three-hydroxylated butyl chain at the N-9 of the hypoxanthine
base and a carboribosyl moiety at the N-1 position, which is expected to be
resistant to both enzymatic and chemical hydrolysis as are the similar N-1
alkylated analogues.
The synthetic strategy adopted for C is shown in Scheme 1. The 2’,3’-O-
isopropylidene-inosine 1 was al lowed to react with DIBAL-H in anhydrous THF. In
this way the sugar moiety was reduced to afford the corresponding 1-D-ribitylinosine
derivative 2. Acetylation of the hydroxyl functions of 2 gave derivative 3. N-1
FIGURE 1
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nitroinosine derivative 4 was prepared according to the procedure proposed by
Vilarrasa and coworkers[7] by treatment of 3 with ammonium nitrate and tri-
fluoroacetic anhydride (TFAA) in dichloromethane. Derivative 6 could be ob-
tained by reaction of 4 with 5 in DMF as previously described.[5] Removal of the
acetyl protecting groups of 6 by treatment with K2CO3 in MeOH yielded 7. The
bis(phenylthio)phosphoryl groups were introduced on the primary hydroxyl
functions by treatment of 7 with S,S-diphenyl-phosphorodithioate (cyclohexylam-
monium salt) in the presence of 2,4,6-triisopropylbenzenesulphonylchloride
(TPSCl) and tetrazole in pyridine to give the protected bisphosphate derivative
8 as the main product together with the triphosphate derivative in a 8:2 ratio. After
HPLC (RP18) purification, 8 was treated with silver acetate (Ag Ac) for complete
removal of protecting groups of both phosphate residues. The deprotected
bisphosphate derivative 9 was further purified by HPLC (RP18) before cyclization,
which was performed as previously described,[6] to obtain 10 (50% yield after
purification). Final ly, 10 was deprotected at phosphate residues by treatment with
acetic acid, which afforded the target compound C (10% overal l yield starting from
1) whose structure was confirmed by 1H and 31P NMR and MS data.
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SCHEME 1 Reagents and conditions: a) DIBAL-H, THF; b) Ac2O, pyridine, r.t.; c) NH4NO3, TFA, CH2Cl2,
0C; d) 5, DMF, r.t.; 8 h; e) K2CO3, CH3OH, r.t.;15 min; f) S,S-diphenylphosphorodithioate, TPSCl, pyridine, N2,
r.t.; 8 h; g) AcAg, pyridine/H2O; h) EDC, NMP, r.t.; 60 h; i) aq. CH3CO2H, r.t.; 3.5 h.
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UNUSUAL MONOMOLECULAR DNA QUADRUPLEX STRUCTURES
USING BUNCH-OLIGONUCLEOTIDES
Giorgia Oliviero, Jussara Amato, Nicola Borbone, Aldo Galeone, Michela Varra,
Gennaro Piccialli, and Luciano Mayol 5 Dipartimento di Chimica delle Sostanze
Naturali, Universita` di Napoli Federico II, Napoli, Italy
5 The chemical synthesis of several G-rich bunch-oligonucleotides and the structural characterization
of the corresponding monomolecular G-quadruplexes (I -- IV) have been reported. The synthetic method
allow the achievement of monomolecular DNA quadruplex structures having unusual and
predeterminable oligodeoxyribonucleotide (ODN) strand orientation.
Keywords G-Quadruplex, Bunch-ODN, Solid-Phase Synthesis
INTRODUCTION
DNA quadruple helices based on G-quartets (G-quadruplexes) have aroused
widespread interest not only for their substantiated presence in many biological ly
important regions of the genome but also because such structures form the scaffold
of several aptamers provided with useful biological properties.[1 -- 6] G-quadruplexes
can be classified on the basis of the number of self-associating strands one, two, or
four strand and are further distinguished by the orientation of the strands to each
others (paral lel or antiparal lel).[7]
The monomolecular complexes, largely involved in biomolecular events are,
almost exclusively, of antiparal lel type, showing a higher stability than bi- or
tetramolecular counterparts. On the contrary, tetramolecular complexes, whose
formation is characterized by unfavorable kinetic and thermodynamic parameters,
show the four strands in a paral lel orientation. General ly, only the quadruplexes
having an adequate stability are suitable for structural investigations.
In this frame the achievement of stable quadruplex models, having prede-
terminable strand orientation or less stable quartets could be useful for biological
and structural studies. The intermolecular formation of paral lel structures in vitro is
very slow and may require high ODN concentrations. These unfavorable kinetic
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SCHEME 1 General synthetic procedure for the functionalization of the solid supports 2 and 3 with the bunch-
spacers 1a or 1b.
SCHEME 2 Synthetic procedure for the quadruplexes I -- IV.
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and thermodynamic parameters could be disadvantageous in view of their potential
therapeutic use.
We recently synthesized a new class of ODNs analogues, which we cal led
bunch-ODNs,[8] capable to form very stable monomolecular G-quadruplex
structures. The structural feature of these analogues is the presence of four ODN
strands whose 3’-ends are linked together by a tetra-branched spacer (bunch-
spacer). Our solid-phase synthetic strategies uses a commercial ly available
bifunctional linker (1a--b, Scheme 1) having symmetrical or orthogonal protected
alcoholic functions. As solid support we employed the commercial ly available
CPG-resin 2 or a suitable functionalizated carboxy-TentaGel-resin 3 which al low
the release of the bunch-ODNs by mild basic treatment. Using a tailored synthetic
pathway (Scheme 2), which uses nucleotides 3’ or 5’ phosphoramidite building
blocks, the bunch-quadruplexes d[(TGGGGT)]4 I--IV having a predetermined
strands orientation, were obtained.
The correct structure of the bunch-ODNs was ascertained by 1H NMR and
MALDI data. Furthermore, the structure and the stability of the G-quadruplexes
(I--IV) were investigated by CD thermal denaturation and 1H NMR experiments
at variable temperature. Preliminary results indicate that al l bunch-ODNs are
capable to adopt a G-quadruplex structure and that the bunch-spacer leads to a
more stable complex (I) when linked to 3’-ODN ends.
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Abstract: The solid phase syntheses of the bunch oligonucleotides 1 and 2 based on the sequences
of the natural oligodeoxynucleotides (ODNs) d(TG2TG2C) (3) and d(CG2TG2T) (4), respectively,
attached to a non-nucleotidic tetrabranched linker, are reported. Bunch-ODNs 1 and 2 were shown
to form more stable monomolecular parallel G-quadruplexes I and II when compared with their tet-
ramolecular counterparts [d(TG2TG2C)]4 (III) and [d(CG2TG2T)]4 (IV), respectively. The struc-
ture and stability of all the synthesized complexes have been investigated by circular dichroism
(CD), CD thermal denaturation experiments, and 1H-NMR (nuclear magnetic resonance) experi-
ments at variable temperatures. Particularly, the spectroscopic data conﬁrmed that 1 adopts a T-
tetrad containing parallel-stranded quadruplex structure I as in the tetramolecular complex III.
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INTRODUCTION
Quadruplex structures are the main topic of a very
large number of reports dealing with their chemistry,
molecular biology, and recently, pharmacologic impli-
cations.1 These structures are likely to form in G-rich
sequences and are characterized by a stacked arrange-
ment of several GGGG planar tetrads in which each
G interacts with the adjacent one via two hydrogen
bonds and behaves both as acceptor and donor of
what is known as a Hoogsteen base pair.
Although G-rich sequences occur very frequently
in the human genome2,3 and the formation of G-quad-
ruplexes in vitro is well established, direct evidence
for their existence in vivo is just beginning to ap-
pear.4–6 In contrast, many reports have shown the pres-
ence of G-quadruplexes in several biologically active
oligodeoxynucleotides (ODNs) known as aptamers.7,8
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In spite of their common features in the sequences
(the need of several G-tracts), G-quadruplex structures
so far described showed an unexpected structural vari-
ability. In fact, quadruplex structures can differ in the
stoichiometry of strands, their relative orientation, the
glycosidic torsion angle of each G residue, the nature
of the coordinating cation, and both the sequence and
size of spacer stretches separating guanine tracts. The
occurrence of participation of both natural and modi-
ﬁed nonguanine nucleotides in tetrad formation further
increased the variety of quadruplex structures. As a
matter of fact, several unusual tetrad such as A-tet-
rads,9–11 T-tetrads,12,13 C-tetrads,14 mixed tetrads (for
a recent example, see Ref. 15), and modiﬁed bases
containing tetrads16,17 have been described.
Among these, T-tetrads (Figure 1) have aroused
our interest since methyl groups of T residues could
give rise to hydrophobic contacts into G-quadruplex
grooves potentially useful for improving the interac-
tion between quadruplex-based aptamers and their
target molecules.
Even though the presence of a T-tetrad in quadru-
plex structures could be an attractive topic, particularly
in the aptamer research area, it shows a main drawback
due to the minor stability of a T-tetrad (only four
hydrogen bonds and a smaller surface for stacking
interactions in comparison with a G-tetrad) that could
decrease the stability of the overall complex. Recently,
our group has carried out the synthesis and structural
characterization of a bunch-ODN able to form a mono-
molecular parallel quadruplex structure—namely,
bunch-[d(TG4T)]4, in which 3
0-ends are linked together
by a tetrabranched spacer.18 Since this ODN analogue
is provided with more favorable thermodynamic prop-
erties than its tetramolecular counterpart, we reasoned
that the destabilization of a quadruplex structure due to
the presence of a T-tetrad could be counterbalanced by
the improvement caused by the bunchy spacer.
In order to verify this hypothesis, we report here-
in the synthesis of the [d(TG2TG2C)]4-bunch (1)
(Scheme 1) whose base sequence matches that of the
ODN 3 forming the tetramolecular quadruplex struc-
ture III in which a T-tetrad was observed for the ﬁrst
time.12 The resulting bunch-quadruplex I was investi-
gated by circular dichroism (CD), CD thermal dena-
turation experiments, 1H, and nuclear Overhauser
effect spectroscopy (NOESY) nuclear magnetic reso-
nance (NMR) experiments. Further, we report our
studies on the bunch-[d(CG2TG2T)]4 (2) and its cor-
responding natural ODN 4, in which, in respect to 1,
the C and T end bases are mutually exchanged, with
the aim to explore the capability of the tetrabranched
linker to stabilize other sequences potentially prone
to form quadruplex structures containing a T-tetrad.
RESULTS AND DISCUSSION
Synthesis and Puriﬁcation of
Quadruplexes I–IV
The syntheses of bunch-ODNs 1 and 2 (Scheme 1)
have been performed using the recently reported
solid-phase procedure,18 which uses the hydroxyl-
functionalized Controlled Pore Glass (CPG) support
5 and the bifunctional linker 6 to prepare support 7
bearing a symmetrical tetrabranched linker with four
protected primary alcoholic functions, prone to ODN-
chain assembly. Support 7 was used to synthesize the
bunch-ODNs 1 and 2, each characterized by having
the four ODN strands linked to the spacer through the
30- or 50-end, respectively. The ODN chains were
assembled by an automatic DNA synthesizer using
30- or 50-phosphoramidite nucleotide building blocks,
thus obtaining the polymer bound bunch-ODNs 8 and
9 respectively. Supports 8 and 9 treated with conc.
NH4OH (7 h, 558C), afforded crude bunch-ODNs 1
and 2, which after high performance liquid chroma-
tography (HPLC) puriﬁcation and annealing proce-
dure furnished the quadruplexes I and II, respec-
tively. The natural ODNs 3 and 4, precursors of the
tetramolecular quadruplexes III and IV, respectively,
have been prepared using a standard automatic DNA
synthetic procedure followed by HPLC puriﬁcation.
The purity of the products was checked by polyacry-
lamide gel electrophoresis (PAGE) and the structures
conﬁrmed by 1H-NMR and matrix-assisted laser
desorption ionization–mass spectroscopy (MALDI-
MS) data. The quadruple helices I–IV were obtained
dissolving the samples 1–4 in Kþ buffers and anneal-
ing to assure the correct formation of quadruplex
structures.
CD Experiments
To investigate whether bunch-ODNs 1 and 2 adopt
the quadruplex structures I and II, and to determineFIGURE 1 G-tetrad and T-tetrad; dR: 20-deoxyribose.
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their nature and stability in comparison with the tetra-
molecular complexes III and IV, we carried out CD
studies, including CD thermal denaturation experi-
ments after the annealing procedure. CD spectra
(Figure 2) were performed at 258C at a quadruplex
concentration of 2.0  105M in Kþ buffer. Bunch-
ODNs 1, 2, as well as natural ODN 3, showed very
similar CD proﬁles characterized by positive bands at
SCHEME 1 (i) two couplings with 2; (ii) ODN synthesis with 30- or 50-phosphoramidites; (iii) detach-
ment and deprotection with NH4OH conc. 32% (7 h, 558C); (iv) HPLC puriﬁcation and annealing.
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266, 264, and 262 nm, respectively, and negative bands
at 246, 240, and 238 nm, respectively (Figure 2A,C),
which are indicative of parallel stranded G-quadru-
plex structures18,19–22 (I, II, and III). However, the
CD spectrum of 4 showed a different proﬁle charac-
terized by the presence of two positive bands at 262
and 289 nm and a negative band at 239 nm (Figure
2C). To further investigate the unexpected CD proﬁle
showed by 4, we registered CD spectra in the range
5–808C (melting process) and 80–58C (fast annealing
process) at 18C/min scan rate (Figure 3A and 3B,
respectively). In each process, the CD values of the
positive bands at 262 and 289 nm varied in a nonconst-
ant ratio. These data suggest that the two positive
bands can be attributed to different complexes. Consid-
ering that the majority of publications have reported
that most antiparallel G-quadruplexes are characterized
by a positive band centred at 290–295 nm and a nega-
tive band centred around 265 nm,19–22 it is reasonable
to hypothesize that 4 leads to a mixture of quadruplex
species probably containing parallel (IVa) and antipar-
allel complexes (IVb, IVc).
FIGURE 3 CD spectra of IV. (A) Melting process 5–808C; (B) fast annealing process 80–58C,
at 18C/min scan rate.
FIGURE 2 CD spectra at 58C and melting proﬁles of quadruplexes I–II (solid line) and III–IV
(dotted line) in Kþ buffer.
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CD Thermal Analysis
CD thermal denaturation experiments were per-
formed in Kþ buffer monitoring the CD value (mdeg)
at 265 nm in the range 5–808C with 18C/min heating
rate. The melting curve of I (Figure 2B) did not show a
well-deﬁned change of convexity up to 808C; however,
a drastic reduction of the CD265 value was observed in
the range 60–808C. The contrary is true in the melting
proﬁle of the tetramolecular complex III (Figure 2B),
since 15–208C, a signiﬁcant reduction of the CD265
value, and two detectable changes of convexity were
observed. These data suggest that the helix–coil transi-
tion point for complex I is at a higher temperature and
is more cooperative than that of the corresponding tet-
ramolecular complex III. The melting curve of II was
shown to be very similar to that of IV (Figure 2D),
both being characterized by the reduction of CD265
values up to 55–608C followed by a point of inﬂection
and the complete melting at 808C, even if a shift
toward higher temperature is clearly noticeable for the
CD proﬁle of II. The whole of the CD melting data
suggests that bunch-ODNs I and II are more stable
than their natural counterparts III and IV, respectively,
although a quantitative determination of the relative
thermal stability was not performed yet, due to the very
slow kinetics of quadruplex denaturation process and
considering that, in the case of II and IV, the latter
could be a mixture of different complexes.
1H-NMR Studies on Quadruplexes I–IV
Temperature-dependent one-dimensional spectra (25,
45, 65, and 758C) and NOESY spectra (258C) were
recorded in H2O/D2O (9:1, v/v) in K
þ buffer using
pulse ﬁeld gradient WATERGATE for H2O suppres-
sion.23
1H-NMR spectrum of complex I at 258C (Figure 4A)
showed the presence of four well-resolved signals
between 11.1 and 11.6 ppm attributable to exchange-
protected imino protons involved in Hoogsteen N(1)H/
O(6) hydrogen bonds of G-quartets24,25 also on the
basis of the comparison with the corresponding region
of the spectrum of III that forms a stable parallel-
stranded quadruplex already characterized by NMR
data.12 In I, the broad signal centred around 9.8 ppm is
attributable to H-bonded GNH2 protons, while the
weak signal at 9.2 ppm is attributable to T4NH imino
protons involved in N(3)H/O(4) hydrogen bonds, thus
conﬁrming the formation of a T-tetrad comprised
between the G3 and G5 tetrad planes.
1H-NMR spec-
tra at higher temperatures indicated that the quadru-
plex I is preserved at least up to 658C, whereas the
tetramolecular counterpart III is almost completely
destructurated at this temperature, as indicated by the
disappearance of the imino proton signals (Figure 4C).
Assignment of all aromatic and imino proton signals of
I was carried out by mean of a NOESY spectrum
(258C; 300 ms mixing time) and comparison of NOEs
FIGURE 4 Aromatic and imino proton region of 500-MHz 1H-NMR spectra of I–IV (A–D,
respectively) in 100 mM Kþ buffer.
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with those of III reported by Patel and Hosur12 (data
not shown). The pattern of H8/H6–H10–H8/H6 NOE
connectivities for I resulted almost completely super-
imposable to that reported for the corresponding tetra-
molecular quadruplex III, with the exceptions of G6H8
signal, upﬁeld shifted from 7.75 to 7.66 ppm, and of
C7H6 signal downﬁeld shifted from 7.53 to 7.63 ppm.
Further, the presence of strong interstrand T4NH—
T4CH3 and intrastrand T4CH3—G5NH NOEs conﬁrms
that I adopts a T tetrad containing parallel stranded
quadruplex structure. The absence of signiﬁcative
chemical shift drifts for aromatic and imino proton sig-
nals of I and III demonstrates that the ‘‘bunch’’ linker
is capable to stabilize the parallel quadruplex structure
of I without any substantial inﬂuence on quadruplex
topology.
1H-NMR spectrum of compound II recorded at
258C (Figure 2B) supports the CD data about the apti-
tude of II to form a parallel quadruplex structure. In
fact, the low ﬁeld region of 1H-NMR spectrum of II
shows the presence of three strong and two weak par-
tially overlapped signals attributable to exchange pro-
tected imino protons of G-quartets. Recording 1H-
NMR spectra of II at higher temperatures, with 108C
increasing steps, the sharpening and the reduction of
intensity of all imino proton signals were observed,
followed by their complete disappearance at 758C.
Differently from I, no T-tetrad imino signals were
observed in the 1H-NMR spectra of II. The low ﬁeld
region of 1H-NMR spectrum of IV recorded at 258C
(Figure 2D) is characterized by the presence of sev-
eral H-bonded imino signals. The number of imino
signals revealed that more than one quadruplex struc-
ture must be present in solution. At higher tempera-
tures, with 108C increasing steps, the disappearance
of some signals and the sharpening of the residual
ones were observed. Particularly, ﬁve major imino
signals were detected at 658C, four of which closely
matched those observed for the parallel-stranded
quadruplex II at the same temperature. This observa-
tion supports the hypothesis that 4 folds into more
than one quadruplex structures. Considering that
CD spectra of IV showed a positive shoulder band at
289 nm, it is reasonable to hypothesize that 4 in Kþ
buffer could fold into a mixture of quadruplex struc-
tures, one of which could be of the antiparallel type.
If this were the case, it would be the ﬁrst occurrence
of a tetramolecular antiparallel quadruplex structure.
CONCLUSIONS
In this article, we present the syntheses and investiga-
tions of two bunch-ODNs, 1 and 2, characterized by
ODN sequences potentially able to form T-tetrad con-
taining quadruplexes. Bunch-ODN 1 is based on the
sequence TG2TG2C, whose natural counterpart repre-
sents, to our knowledge, the ﬁrst example of an experi-
mentally detected T-tetrad. Collected data from NMR
and CD melting experiments clearly indicate that the
presence of the tetrabranched linker in 1 not only does
not hamper the formation of a T-tetrad, but also pro-
vides a higher thermal stability to the complex. The
capacity of the tetrabranched linker to stabilize a T-tet-
rad containing quadruplex structure might be particu-
larly interesting in the research area of quadruplex-
based aptamers. In fact, the presence of a T-tetrad,
thanks to the methyl groups located on the groove
surface, could make achievable new hydrophobic
interactions capable of improving both the afﬁnity
and speciﬁcity of a given aptamer toward their target
molecule.
The results described in this article conﬁrm the
potential of the bunch-ODNs, as a new class of ODN
analogues prone to form intramolecular quadruplex
structures, to be more stable than the corresponding
tetramolecular counterparts when a less stable T-tet-
rad is present in the complex. So the ‘‘bunch’’ ap-
proach to the DNA quadruplex can be considered a
useful tool for their in vivo applications, furnishing
complexes characterized by high stability and pre-
dictable structure even at low ODN concentrations.
Furthermore, parallel monomolecular bunch-quadru-
plexes could be used as models in structural studies,
being capable to select the formation of only one type
of complex, that in some cases is not achievable for
tetramolecular complexes.
EXPERIMENTAL
Reagents and Equipment
Chemicals and solvents were purchased from Fluka-Sigma-
Aldrich. Reagents and phosphoramidites for DNA synthe-
ses were purchased from Glen Research. The ODN were
assembled with a PerSeptive Biosystems Expedite DNA
synthesizer using phosphoramidite chemistry. HPLC analy-
ses and puriﬁcations were performed by a JASCO PU2089
pump system equipped with an ultraviolet (UV) detector
2075 Plus. A Nucleogel SAX (Macherey-Nagel 1000-8/46)
and a RP-18 (Thermo, HYPERSIL, 100-C18, 250  4.6,
5 mm) columns were used for the puriﬁcations. CPG support
5 and phosphoramidite linker 6 were purchased from Glen
Research. UV spectra were run by a Jasco V 530 spectro-
photometer. CD spectra and thermal denaturation experi-
ments were obtained with a Jasco 715 circular dichroism
spectrophotometer equipped with a Jasco 505T temperature
controller unit. NMR spectra were recorded with Varian
Unity-INOVA 500- and 700-MHz spectrometers. MALDI-
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TOF (time of ﬂight) mass spectrometric analysis was
performed on a PerSeptive Biosystems voyager-De Pro
MALDI mass spectrometer using a picolinic/3-hydroxy-
picolinic acids mixture as the matrix. The concentration of
the ODNs was determined spectrophotometrically at  ¼
260 nm and at 908C, using the molar extinction coefﬁcient
calculated for the unstacked oligonucleotide using the fol-
lowing extinction coefﬁcient " ¼ 64100 cm1 M1, calcu-
lated by the nearest neighbor mode.26
Synthesis and Puriﬁcation of
Bunch-Oligonucleotides 1 and 2
Fifty milligrams of support 5 (0.18 meq/g) reacted with
phosphoramidite 6 (45 mg/mL in CH3CN) following two
coupling cycles of standard phosphoramidite chemistry
on a 15-mmol scale, yielded support 7 [0.17 meq/g of 4,
40-dimethoxytrityl (DMT) groups]. After removal of the
DMT protecting groups, the ODN chains were assembled,
using 30 or 50-phosphoramidite nucleotide building blocks
(45 mg/mL in CH3CN, 15-mmol scale) to give the polymer
bound ODNs 8 and 9, respectively. The solid support 8 (or
9) was then treated with 25% aqueous ammonia solution
for 7 h at 558C. The ﬁltered solutions and washings were
concentrated under reduced pressure and puriﬁed by HPLC
on a Nucleogel SAX column eluted with a linear gradient
of the following buffers. Buffer A: 20 mM KH2PO4 aque-
ous solution pH ¼ 7 containing 20% CH3CN; buffer B: 1M
KCl, 20 mM KH2PO4 aqueous solution pH ¼ 7.0 contain-
ing 20% CH3CN; linear gradient from 0 to 100% B in 30
min, ﬂow rate 1 mL/min. The collected products with reten-
tion times 23.0 and 20.1 min for 1 and 2, respectively, were
desalted by gel ﬁltration on a Sephadex G25 column eluted
with H2O/ethanol (9:1, v/v). The purity of the products was
conﬁrmed by HPLC analysis on a HYPERSIL 100-C18 col-
umn eluted with a linear gradient CH3CN in triethylammo-
nium bicarbonate (TEAB) buffer (pH 7.0, from 0 to 100%
in 60 min, ﬂow 1.0 mL/min), with a result higher than 98%
(retention time 13.5 and 14.2 min for 1 and 2, respectively).
The desaliﬁcations furnished pure 1 and 2 (68 and 73
OD260 units, respectively) which, after lyophilization, were
characterized by spectroscopic data.
 Bunch-ODN 1: MALDI-TOF-MS (negative mode)
calculated mass: 9070.8; found: 9069.5.
 Bunch-ODN 2: MALDI-TOF-MS (negative mode)
calculated mass: 9070.8; found: 9069.6.
Preparation of Quadruple Helices
(Annealing)
Quadruplexes I–IV were formed by dissolving the bunch-
ODNs 1–4, in 10 mM K2HPO4 100 mM KCl, 0.2 mM
EDTA (Kþ buffer) and annealed by heating to 908C for 20
min followed by slow cooling to room temperature. The
solutions were equilibrated at 58C for 24 h before perform-
ing the experiments.
CD Experiments
CD spectra of the quadruplexes were registered on a Jasco
715 circular dichroism spectrophotometer in a 0.1-cm path-
length cuvette at 208C. The wavelength was varied from
220 to 320 nm at 5 nm min1. The spectra were recorded
with a response of 16 s, at 2.0 nm bandwidth, and normal-
ized by subtraction of the background scan with buffer. CD
thermal denaturation experiments were performed monitor-
ing the CD value (mdeg) at 265 nm in the range 5–808C
with 18C/min heating rate. The CD melting experiments
were registered at 2.0  105M concentration.
1H-NMR Experiments
NMR data were obtained either on a Varian Unity-INOVA
700 MHz or a Varian Unity-INOVA 500 MHz spectrometer
equipped with a broad-band inverse probe with a z-ﬁeld
gradient, and processed using Varian VNMR software
package. NMR samples of I–IV were prepared in H2O/D2O
9:1 at a concentration of single strand of approximately 1.3
mM with a ﬁnal salt concentration of 100 mM KCl and
10 mM K2HPO4. One-dimensional (1D) NMR spectra (500
MHz) were acquired as 16,384 data points with a recycle
delay of 1.0 s at temperatures in the range 25–758C. Data
sets were zero ﬁlled to 32,768 points and apodized with a
squared shifted sine-bell window function. A 300-ms two-
dimensional (2D) NOESY spectrum (700 MHz) was
acquired at 258C as a matrix of 512  2048 complex points.
Relaxation delay was kept to 1.0 s and a squared shifted
sine-bell window function was applied in both dimensions
prior to Fourier transformation. A pulsed-ﬁeld gradient
WATERGATE sequence23 was used for H2O suppression
in both 1D and 2D spectra.
REFERENCES
1. Davis, J. T. Angew Chem Int Ed 2004, 43, 668–698.
2. Huppert, J. L.; Balasubramanian, S. Nucleic Acids Res
2005, 33, 2908–2916.
3. Todd, A. K.; Johnston, M.; Neidle, S. Nucleic Acids
Res 2005, 33, 2901–2907.
4. Schafﬁtzel, C.; Berger, I.; Postberg, J.; Hanes, J.; Lipps,
H. J.; Plueckthun, A. Proc Natl Acad Sci USA 2001,
98, 8572–8577.
5. Chang, C. C.; Kuo, I. C.; Ling, I. F.; Chen, C. T.; Chen,
H. C.; Lou, P. J.; Lin, J. J.; Chang, T. C. Anal Chem
2004, 76, 4490–4494.
6. Duquette, M. L.; Handa, P.; Vincent, J. A.; Taylor,
A. F.; Maizels, N. Genes Dev 2004, 18, 1618–1629.
7. Baldrich, E.; O’Sullivan, C. K. Anal Biochem 2005,
341, 194–197.
8. Chou, S. H.; Chin, K. H.; Wang, A. H. J. Trends Bio-
chem Sci 2005, 30, 231–234.
9. Patel, P. K.; Koti, A. S. R.; Hosur, R. V. Nucleic Acids
Res 1999, 27, 3836–3843.
10. Gavathiotis, E.; Searle, M. S. Org Biomol Chem 2003,
1, 1650–1656.
200 Oliviero et al.
Biopolymers DOI 10.1002/bip
11. Searle, M. S.; Williams, H. E. L.; Gallagher, C. T.;
Grant, R. J.; Stevens, M. F. G. Org Biomol Chem 2004,
2, 810–812.
12. Patel, P. K; Hosur, R. V. Nucleic Acids Res 1999, 27,
2457–2464.
13. Caceres, C.; Wright, G.; Gouyette, C.; Parkinson, G.;
Subirana, J. A. Nucleic Acids Res 2004, 32, 1097–1102.
14. Patel, P. K.; Bhavesh, N. S.; Hosur, R. V. NMR Bio-
chem Biophys Res Comm 2000, 270, 967–971.
15. For a recent example see: Webba da Silva, M. Bio-
chemistry 2005, 44, 3754–3764.
16. Chen, J.; Zhang, L. R.; Min, J. M.; Zhang, L. H.
Nucleic Acids Res 2002, 30, 3005–3014.
17. Virgilio, A.; Esposito, V.; Randazzo, A.; Mayol, L.;
Galeone, A. Bioorg Med Chem 2005, 13, 1037–1044.
18. Oliviero, G.; Borbone, N.; Galeone, A.; Varra, M.;
Piccialli, G.; Mayol, L. Tetrahedron Lett 2004, 45,
4869–4872.
19. Petraccone, L.; Erra, E.; Esposito, V.; Randazzo, A.;
Mayol, L.; Nasti, L.; Barone, G.; Giancola, C. Bio-
chemistry 2004, 43, 4877–4884.
20. Jin, R.; Gaffney, B. L.; Wang, C.; Jones, R. A.; Bresla-
uer, K. J. Proc Natl Acad Sci USA 1992, 89, 8832–
8836.
21. Dapic´, V.; Abdomerovic´, V.; Marrington, R.; Pederby,
J.; Rodger, A.; Trent, J. O.; Bates, P. Nucleic Acids Res
2003, 31, 2097–2170.
22. Lu, M.; Guo, Q.; Kallenbach, N. R. Biochemistry 1993,
32, 598–601.
23. Piotto, M.; Saudek, V.; Sklenar, V. J. Biomol NMR
1992, 2, 661–665.
24. Feigon, J.; Koshlap, K. M.; Smith, F. W. Methods
Enzymol 1995, 261, 225–255.
25. Feigon, J. Encyclopedia of Nuclear Magnetic Reso-
nance; JohnWiley & Sons: West Sussex, 1996; pp 1726–
1731.
26. Breslauer, K. J.; Frank, R.; Blo¨cker, H.; Marky, L. A.
Proc Natl Acad Sci USA 1986, 83, 3746–3750.
Reviewing Editor: Kenneth Breslauer
DNA Quadruplexes Containing T-Tetrads 201
Biopolymers DOI 10.1002/bip
Synthesis and Characterization of Monomolecular DNA G-Quadruplexes Formed
by Tetra-End-Linked Oligonucleotides
Giorgia Oliviero,† Jussara Amato,† Nicola Borbone,† Aldo Galeone,† Luigi Petraccone,‡ Michela Varra,†
Gennaro Piccialli,*,† and Luciano Mayol†
Dipartimento di Chimica delle Sostanze Naturali, Universita` degli Studi di Napoli “Federico II”, Via D. Montesano 49,
I-80131 Napoli, Italy, and Dipartimento di Chimica, Universita` degli Studi di Napoli “Federico II”, Via Cintia,
I-80126 Napoli, Italy. Received January 17, 2006; Revised Manuscript Received May 18, 2006
Guanine-rich DNA sequences are widely dispersed in the eukaryotic genome and are abundant in regions with
relevant biological significance. They can form quadruplex structures stabilized by guanine quartets. These structures
differ for number and strand polarity, loop composition, and conformation. We report here the syntheses and the
structural studies of a set of interconnected d(TG4T) fragments which are tethered, with different orientations, to
a tetra-end-linker in an attempt to force the formation of specific four-stranded DNA quadruplex structures. Two
synthetic strategies have been used to obtain oligodeoxyribonucleotide (ODN) strands linked with their 3′- or
5′-ends to each of the four arms of the linker. The first approach allowed the synthesis of tetra-end-linked ODN
(TEL-ODN) containing the four ODN strands with a parallel orientation, while the latter synthetic pathway led
to the synthesis of TEL-ODNs each containing antiparallel ODN pairs. The influence of the linker at 3′- or
5′-ODN, on the quadruplex typology and stability, in the presence of sodium or potassium ions, has been investigated
by circular dichroism (CD), CD thermal denaturation, 1H NMR experiments at variable temperature, and molecular
modeling. All synthesized TEL-ODNs formed parallel G-quadruplex structures. Particularly, the TEL-ODN
containing all parallel ODN tracts formed very stable parallel G-quadruplex complexes, whereas the TEL-ODNs
containing antiparallel ODN pairs led to relatively less stable parallel G-quadruplexes. The molecular modeling
data suggested that the above antiparallel TEL-ODNs can adopt parallel G-quadruplex structures thanks to a
considerable folding of the tetra-end-linker around the whole quadruplex scaffold.
INTRODUCTION
DNA quadruple helices (quadruplexes) based on guanine (G)1
quartets have recently emerged as biologically important
structures (1-4). G-rich sequences, which are found primarily
in telomeric region at 3′-end of chromosomes, are able to fold
into G-quadruplex structures. It has been suggested that qua-
druplex formation could inhibit the telomere maintenance
provided by telomerase activity thus affecting the lifespan of
the cells of a number of cancer types characterized by a high
level of telomerase expression (5-8). Furthermore, studies on
the oncogene c-MYC, involved in a number of malignancies,
have demonstrated the existence of G-quadruplex structures in
vivo which can be considered useful targets to repress c-MYC
transcription (9-11). G-quadruplex structures are present in the
scaffold of several aptamers provided with useful biological
properties (12-16), as well as within the insulin gene-linked
polymorphic region of the human insulin gene, in vivo, where
they may play a role in the expression of the insulin gene (17).
G-quadruplexes, have been also put forth as DNA structures
capable of transferring electrons through the G-quadruplex
ð-stack and forming nanowires for molecular nanoelectronics
(18-20). Within this framework, a number of studies have been
undertaken to investigate the DNA G-quadruplexes and, par-
ticularly, to define the factors that can stabilize them as well as
proposing synthetic ODN analogues capable of forming novel
quadruplex typologies.
G-quadruplexes can be classified based upon the number of
strands involved in the structure, their relative orientation and
the glycosidic conformation of guanosine residues (anti or syn).
The stability of G-quadruplexes mainly depends on the number
of G-tetrad planes, the molecularity of the complex, and the
nature of cations which accommodate themselves in the central
channel of the quadruplex lowering the energy of the complex
(1-3). Normally, the molecularity of the complex induces well
defined patterns in the relative ODN strand orientation. The
monomolecular complexes largely involved in biomolecular
events (1-4) are prevalently of antiparallel type even if
examples of parallel monomolecular complexes have been
discovered (21-24). Tetramolecular complexes, which have
recently displayed interesting biological properties (25-27),
always show the four strands in a parallel orientation. However,
the development of therapeutic applications for such ODN
complexes has been so far prevented by their unfavorable kinetic
and thermodynamic parameters. It is a fact that the in vitro
formation of a tetramolecular quadruplex is very slow and may
require high ODN and salt concentrations (28). On the contrary,
monomolecular quadruplexes are mostly characterized by high
stability and fast kinetic formation (1-3). On these bases, the
construction of new and stable monomolecular quadruplexes
possessing unusual strand orientation could expand their
employment in both the study and control of important
biological processes as well as in DNA-based nanotechnologies.
Several studies have investigated the effect of loops on
quadruplex stability and typology (29-35). With regard to
* Corresponding author. E-mail: picciall@unina.it. Voice: +39-
081-678541. Fax: +39-081-678552.
† Dipartimento di Chimica delle Sostanze Naturali.
‡ Dipartimento di Chimica.
1 Abbreviations: ODN, oligodeoxyribonucleotide; TEL, tetra-end-
linked; CD, circular dichroism; G, guanine; Fmoc, fluorenylmethoxy-
carbonyl; DMT, 4,4′-dimethoxytrityl; NMI, 1-methylimidazole; MSNT,
1-(2-mesitylenesulfonyl)-3-nitro-1H-1,2,4-triazole; DCA, dichloracetic
acid; TEAB, triethylammonium bicarbonate; CPG, controlled pore glass;
TBE, Tris-borate electrophoresis.
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nucleotidic loops, the base composition, the length, and the
orientation of the phosphodiester linkage have already been
examined (29-34). In addition, mono- or bimolecular quadru-
plexes formed by circular ODNs have been shown to display
noteworthy thermal and enzymatic degradation stability (35).
In another reported approach aimed at studying the effect of
the connecting loops on the stability and typology of the
monomolecular quadruplexes, non nucleotidic linkers have been
inserted between d(GGG) tracts into a single ODN strand (30).
In this case both the kinetics of the quadruplex formation and
the complex stabilities were found to be affected by the nature
of the linker.
Starting from these observations, we recently proposed the
synthesis of a new modified ODN (TEL-ODN, 1, Scheme 1)
capable of forming the monomolecular parallel G-quadruplex
I (Scheme 1) whose thermal stability has been proved to be
significantly higher than that observed for its tetramolecular
counterpart [d(TG4T)]4 (36). The main structural feature of this
molecule is the presence of four ODN strands whose 3′-ends
are attached to a non nucleotidic tetra-end-linker. Furthermore,
TEL-ODNs were also shown to be a useful tool to study
quadruplexes containing less stable quartets such as T-tetrad
(37).
We wish to report here our study on the influence of the tetra-
end-linker placement on the typology and stability of this kind
of quadruplexes. Two synthetic strategies have been used to
obtain d(TG4T) ODN strands which were linked with their 3′
or 5′-ends to each of the four arms of the linker. The first
approach allowed the synthesis of the TEL-ODNs containing
the four ODN strands with a parallel orientation (1, 2, Scheme
1) while the latter synthetic pathway led to the synthesis of TEL-
ODNs each containing antiparallel ODN pairs (3, 4, Scheme
2). CD, CD melting, NMR spectroscopy, and molecular
modeling have been used to investigate the solution structures
of the resulting TEL-quadruplexes I-IV (Schemes 1 and 3)
formed in the presence of sodium or potassium ions.
EXPERIMENTAL PROCEDURES
Reagents and Equipment. Chemicals and solvents were
purchased from Fluka-Sigma-Aldrich. Reagents and phosphor-
amidites for DNA syntheses were purchased from Glen Re-
search. ODN syntheses were performed on a PerSeptive Biosys-
tems Expedite. HPLC analyses and purifications were performed
by a JASCO PU2089 pumps equipped with UV detector 2075
Plus using a Merck Hibar (5 ím, 250-10) column. CPG support
5 and linkers 6a,b were purchased from Glen Research. Tentagel
carboxy resin, used as starting material for preparation of solid
support 10, was purchased from Novabiochem. Preparation of
10 was carried out in a short column (10 cm length, 1 cm i.d.)
equipped with a sintered glass filter, a stopcock and a cap. The
ODNs were assembled by a PerSeptive Biosystems Expedite
DNA synthesizer using phosphoramidite chemistry. UV spectra
were run with a Jasco V 530 spectrophotometer. CD spectra
and thermal denaturation experiments were obtained with a Jasco
715 circular dichroism spectrophotometer equipped with a
JASCO 505T temperature controller unit. NMR spectra were
recorded on a Varian Unity Inova 500 MHz spectrometer.
MALDI-TOF mass spectrometric analyses were performed on
a PerSeptive Biosystems voyager-De Pro MALDI mass spec-
trometer using a picolinic/3-hydroxypicolinic acids mixture as
the matrix. The ODN concentration was determined spectro-
photometrically at ì ) 260 nm and 90 °C, using the molar
extinction coefficient  ) 57800 cm-1 M-1 calculated for the
unstacked oligonucleotide by the nearest neighbor mode (38).
Synthesis and Purification of TEL-ODNs 1 and 2. 50 mg
of support 5 (0.048 mequiv/g) was used for each synthesis in
the automated DNA synthesizer following standard phosphor-
amidite chemistry, using 45 mg/mL of solution of phosphor-
amidite 6a (two coupling cycles) and 3′- or 5′-phosphoramidite
nucleotide building block (six cycles) in anhydrous CH3CN,
thus obtaining the polymer bound ODN 8 and 9, respectively.
The coupling efficiency with nucleotide units was consistently
Scheme 1. Synthetic Procedures for Quadruplexes I and IIa
a i: two couplings with 6a; ii: ODN synthesis with 3′ or 5′-phosphoramidites; iii: detachment and deprotection with NH4OH concd 32% (7 h,
55 °C); iv: HPLC purification and annealing.
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higher than 98% (by DMT spectrophotometric measurements).
The solid support 8 (or 9) was then treated with 25% aq
ammonia solution for 7 h at 55 °C. The filtered solution and
washings were concentrated under reduced pressure and puri-
fied by HPLC on a RP18 column eluted with a linear gradient
CH3CN in TEAB buffer (pH 7.0, from 0 to 100% in 60 min,
flow 1.0 mL/min), retention time 26.1 and 27.0 min for 1 and
2, respectively. The collected peaks furnished pure 1 and 2 (72
and 77 OD260 units, respectively) which, after lyophilization,
were characterized by spectroscopic data.
TEL-ODN 2: MALDI TOF-MS (negative mode): calculated
mass (8763.7); found: 8762.6.
Preparation of Support 10. 500 mg of Tentagel carboxy
resin (0.28 mequiv/g of COOH) suspended in CH2Cl2 were left
Scheme 2. Synthetic Procedures for Quadruplexes III and IVa
a i: coupling with linker 6; ii: DMT removal and coupling with linker 6; iii: ODN synthesis with 3′-phosphoramidites; iv: Fmoc removal and
coupling with linker 6a; v: ODN synthesis with 5′-phosphoramidites; vi: detachment and deprotection with NH4OH concd 32% (7 h, 55 °C) and
HPLC purification; vii: Fmoc removal and ODN synthesis with 5′-phosphoramidites;
Scheme 3. Quadruplexes III and IV from TEL-ODNs 3 and 4 after the Annealing Procedure in K+ or Na+ Buffer
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in contact with a CH2Cl2 solution (7.0 mL) containing 1,3-
dihydroxypropane (0.56 mmol, 0.36 mL), NMI (0.56 mmol, 0.40
mL) and MSNT (0.056 mmol, 1.48 g) and the mixture was
shaken for 36 h at room temperature. The obtained hydroxy-
support 10 was exhaustively washed with CH2Cl2 and then dried
under reduced pressure. The amount of hydroxyl groups,
determined by DMT measurements after the successive coupling
step with 3′-phosphoramidite nucleotide units, resulted to be in
the range 0.18-0.20 mequiv/g.
Synthesis and Purification of TEL-ODNs 3 and 4. 50 mg
of support 10 (0.18 mequiv/g) reacted, in the automated
DNA synthesizer, with phosphoramidite 6b (45 mg/mL in
CH3CN) following standard phosphoramidite chemistry at
15-ímol scale, yielded support 11 (0.17 mequiv/g of DMT
groups). After removal of the DMT group by DCA/standard
treatment, the second coupling cycle was performed in the
same manner using phosphoramidite 6a, thus obtaining sup-
port 12 (0.30 mequiv/g of DMT groups). 12 was then sub-
jected to six coupling cycles using 3′-phosphoramidite nucleo-
tide building blocks (45 mg/mL in CH3CN, 15-ímol scale),
followed by final DMT removal and 5′-OH capping with
Ac2O, to yield ODN-functionalized support 13. The removal
of Fmoc groups was achieved by treatment with piperidine/
DMF solution (2:8 v/v, 30 min RT). The resulting support
was then reacted with phosphoramidite 6a, thus obtaining
14 (0.27 mequiv/g of DMT groups). On branches A of 14 the
second ODN domain was assembled, performing six coupling
cycles with the 5′-phosphoroamidite nucleotide building block
as described for support 12, yielding the polymer bound
ODN 15.
For the synthesis of 4, support 10 (50 mg) was functionalized
with 6a and then 6b, as described before, yielding the tetra-
branched support 16 (0.28 mequiv/g of DMT groups). After
removal of the DMT protecting groups, the first two ODN
chains were assembled, using 3′-phosphoramidite nucleotide
building blocks. After capping of the terminal 5′-OH functions
by Ac2O treatment, the Fmoc groups were removed as previ-
ously described, and the successive two ODN chains were
assembled using 5′-phosphoroamidite nucleotide building blocks,
thus obtaining the polymer bound ODN 17.
TEL-ODNs were detached from the supports 15 and 17,
deprotected, and purified as described for 1 and 2, thus obtaining
3 and 4 (retention time 25.8 and 25.2 min, respectively). After
lyophilization, the final pure products 3 and 4 (68 and 62 OD260
units, respectively) were characterized by spectroscopic data.
TEL-ODN 3: MALDI TOF-MS (negative mode): calculated
mass (8821.7); found: 8820.5.
TEL-ODN 4: MALDI TOF-MS (negative mode): calculated
mass (8821.7); found: 8820.2
Preparation of Quadruple Helices (Annealing). Quadru-
plexes I-IV were formed by dissolving the TEL-ODNs 1-4,
in the appropriate buffer and annealed by heating to 90 °C for
20 min followed by slow cooling to room temperature. The
solutions were equilibrated at 10 °C for 24 h before performing
the experiments. The buffers used were 10 mM Na2HPO4, 70
mM NaCl, 0.2 mM EDTA (Na+ buffer) or 10 mM K2HPO4 70
mM KCl, and 0.2 mM EDTA (K+ buffer).
Native Gel Electrophoreses. Native gel electrophoreses were
run on 20% nondenaturing polyacrylamide gels in 0.6x TBE
buffer, pH 7.0, with 50 mM NaCl. ODN solutions, with a final
concentration of 300 íM in quadruplex, were prepared in 50
mM Tris-borate pH 7.0, 80 mM NaCl, 1 mM spermine, and 3
mM MgCl2 and annealed as above-described. At 2 íL of the
ODN solution (300 íM in quadruplex) was then added 1 íL of
30% glycerol and the mixture charged on gel. The gels were
run at room temperature at constant voltage (100 V) for 2.5 h.
The bands were visualized by UV shadowing.
CD Experiments. CD spectra of the quadruplexes were
registered on a Jasco 715 circular dichroism spectrophotometer
in a 0.1 cm path length cuvette at 25 and 90 °C at 1.0  10-5
and 5.0  10-5 M quadruplex concentrations. The wavelength
was varied from 220 to 320 nm at 5 nm min-1. The spectra
were recorded with a response of 16 s, at 2.0 nm bandwidth
and normalized by subtraction of the background scan with
buffer. CD thermal denaturation-renaturation experiments were
performed monitoring the CD value (mdeg) at 264 nm in the
range 25-90 °C with 1 °C/min heating rate.
1H NMR Experiments. 1H NMR data were collected on a
Varian Unity INOVA 500 spectrometer equipped with a broad-
band inverse probe with z-field gradient and processed using
Varian VNMR software package. 1D NMR spectra were
acquired as 16384 data points with a recycle delay of 1.0 s at
temperatures in the range 25-85 °C. Data sets were zero filled
to 32768 points prior to Fourier transformation and apodized
with a shifted sinebell squared window function. Pulsed-field
gradient WATERGATE (39) sequence was used for H2O
suppression. All NMR samples I-IV were prepared in H2O/
D2O (9:1, v/v) at 0.5 mM of quadruplex concentration with a
final salt concentration of 100 mM KCl and 10 mM K2HPO4
or 100 mM NaCl and 10 mM Na2HPO4 for K+ or Na+ buffer,
respectively.
Molecular Modeling. The conformational features of the
quadruplexes III and IV have been explored by means of
molecular modeling study. All the calculations were performed
on a personal computer running the HyperChem 7.5 suite of
programs. The AMBER force field based on AMBER 99
parameter set was used (40). The initial coordinates for the
starting model of [d(TGGGGT)]4 quadruplex were taken from
the NMR solution structure of the [d(TTGGGGT)]4 quadruplex
(Protein Data Bank entry number 139D), choosing randomly
one of the four available structures. The initial [d(TGGGGT)]4
quadruplex models were built by deletion of the 5′-end tymidine
residue in each of the four TTGGGGT strands. The complete
structures of III and IV were then built using the HyperChem
7.5 building tool. Partial charges for each of the tetra-end-linker
atoms were assigned using the Gasteiger-Marsili algorithm (41)
implemented in the QSAR module of HyperChem suite. The
resulting coordinates of tetra-end-linker’s atoms were energy-
minimized in a vacuum, keeping all DNA coordinates frozen
(500 cycles of the steepest descent method). Three sodium ions
were manually positioned in the central channel, equidistant
from adjacent G-tetrads to allow octahedral coordination with
G carbonyl oxygen O6 atoms. The two complexes were
neutralized by addition of further 26 sodium ions placed in the
most negative positions of the systems. Each quadruplex was
then solvated by a periodic TIP3P water box (5833 water
molecules) (42), which extended to a distance of 10 Å from
each atom. The minimal distance between water and system
atoms was set to 2.3 Å. The whole systems were initially
subjected to energy minimization followed by 50 ps of molecular
dynamics at 300 K, and then the systems were slowly cooled
at 10 K. The obtained structures were further minimized using
1000 cycles of the steepest descent method followed by
conjugate gradient method until convergence to a rms gradient
of 0.1 kcal mol-1 Å-1.
RESULTS AND DISCUSSION
Synthesis and Purification of TEL-ODNs 1-4. In the
synthesis of the TEL-ODNs 1-4 we used two hydroxy-
functionalized solid supports (5 and 10) and the bifunctional
linkers 6a,b. Support 5 (0.048 mequiv/g), by way of two
coupling cycles with 6a by an automatic DNA synthesizer, was
turned into support 7 bearing a symmetrical tetra-end-linker with
four protected primary alcoholic functions prone to ODN-chain
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assembly (0.085 mequiv/g of OH functions, by DMT spectro-
photometric test). Support 7 was used to synthesize the TEL-
ODNs 1 and 2 in which the four ODN strands were attached to
the tetra-end-linker by the same end (3′- and 5′-end, respec-
tively). ODN chains were assembled on 7 by using 3′- or 5′-
phosphoramidite nucleotide building blocks, thus obtaining the
polymer bound TEL-ODNs 8 and 9, respectively. In both
syntheses coupling yields were higher than 98% per cycle, thus
reducing the amounts of TEL-ODNs having one or more
truncated chains. The presence of a â-sulfone phosphodiester
function connecting the linker to the solid support, allows the
release of the TEL-ODN via a â-elimination under basic
treatment. In this way supports 8 and 9, treated with concentrated
NH4OH (7 h, 55 °C), afforded crude TEL-ODNs 1 and 2, which
after HPLC purification and the annealing procedure, furnished
the quadruplex I and II, respectively.
As a further step of this work we synthesized the TEL-ODNs
3 and 4 (Scheme 2). In 3 a pair of strands was linked to the
primary linker branch A through the 5′-ends whereas the second
pair is linked to the primary branch B through the 3′-ends.
Instead 4 is characterized by both branches (A and B) carrying
two strands linked through opposite ends. For the preparation
of 3 and 4, we adopted two synthetic strategies both based upon
bifunctional linker 6b in which the two alcoholic functions,
thanks to the orthogonal protection with Fmoc and DMT groups,
allowed the sequential synthesis of the ODN chains with
opposite polarity. 10 was used as solid support since, when 5
was used, we observed the release of ODN material from the
support during the Fmoc deprotection step, due to the concomi-
tant â-elimination at the sulfone group. Therefore, we prepared
the hydroxy-functionalized support 10 bearing an ester function,
stable under Fmoc deprotection conditions but cleavable by
ammonia treatment, to release the assembled TEL-ODN.
Support 10 (0.18-0.20 mequiv/g of OH groups), prepared by
reacting a carboxy-functionalized Tentagel resin (0.28 mequiv/g
of COOH groups) with 1,3-dihydroxypropane in the presence
of MSNT and NMI (43), was used in two synthetic pathways
leading to the TEL-ODNs 3 and 4. Support 10, by reaction with
the phosphoramidite linker 6b yielded the asymmetrical pro-
tected bifunctional support 11 (0.17 mequiv/g by DMT test)
which, after removal of DMT protection from the branch B and
successive reaction with linker 6a furnished the three-function-
alized support 12. Six coupling cycles with 3′-phosphoramidite
units, performed as described for 7, and a final capping step of
the 5′-OH ODN ends, gave 13. Then the 5′-Fmoc group was
removed from the branch A by piperidine treatment, and the
successive coupling with 6a yielded 14. On 14 the second ODN
domain was assembled using 5′-phosphoramidite units, thus
obtaining polymer bound TEL-ODN 15. The synthetic path-
way to obtain 4 started with reaction of 10 with 6a and
subsequently 6b as described above, thus obtaining the tetra-
branched support 16 (0.28 mequiv/g by DMT). The removal of
DMT groups, followed by ODN synthesis with 3′-phosphor-
amidite units, allowed the assembly of the first pair of ODN
chains. After Fmoc deprotection, the remaining ODN pair
having opposite polarity was then assembled using 5′-phos-
phoramidite units, thus obtaining 17. Detachment from the solid
support and complete deprotection of the TEL-ODNs 3 and 4
were achieved treating supports 15 and 17 with concentrated
NH4OH as described for 1 and 2. Analyses and purifications of
crude products 1-4 were carried out by HPLC using an RP18
column. The purity of the products was checked by PAGE, and
the structures were confirmed by 1H NMR and MALDI-MS
data. The quadruple helices were obtained by dissolving the
samples 1-4 in Na+ or K+ buffers and by the annealing
procedure to ensure the correct formation of quadruplex
structures.
Native Gel Electrophoresis. The purity of the products 1-4
and the molecularity of the complexes obtained were investi-
gated by performing a nondenaturing polyacrylamide gel
electrophoresis (Figure 1) in comparison to the tetramolecular
quadruplex [d(TG4T)]4. The samples (300 íM quadruplex) were
annealed in Na+ buffer, and the electrophoretic analysis was
carried out using a 20% polyacrylamide gel in TBE buffer. TEL-
quadruplexes I-IV and d[(TG4T)]4 migrated as single bands
demonstrating quite similar mobilities. This result, besides
indicating the purities of I-IV, strongly suggests that they form
monomeric species at this concentration.
CD and CD Thermal Analysis. To investigate whether TEL-
ODNs 2-4 adopt quadruplex structures and, if such is the case,
determine their nature and stability, we carried out CD studies,
including CD thermal denaturation experiments, which were
compared with those already reported for 1 (36) and their
tetramolecular counterpart [d(TG4T)]4 (27, 38). The ODN
samples were analyzed in Na+ or K+ buffers after the annealing
procedure. CD spectra (Figure 2) were performed at 25 and 90
°C at a quadruplex concentration of 1.0  10-5 and 5.0  10-5
M. TEL-ODNs 1, 2 and [d(TG4T)]4 showed almost identical
CD profiles in K+ buffer at 25 °C, characterized by positive
and negative bands centered around 264 and 244 nm, respec-
tively, which are indicative of a parallel stranded G-quadruplex
structure (36, 44-47). Upon the basis of these findings, it is
reasonable to hypothesize that the TEL-ODN 2, bearing the
tetra-end-linker at the 5′-end of quadruplex, adopts the parallel
G-quadruplex structure II. The data also suggest that 3 and 4
adopt parallel G-quadruplex structures which, considering the
mutual antiparallel orientation of the ODN pairs, can be
explained only by hypothesizing that a considerable folding of
the linker around the whole G-quadruplex takes place. The
parallel structures adopted by 3 and 4 were substantiated by
molecular modeling studies (see below) that clearly indicate that
these conformations are obtainable and stable as a result of the
linker arrangement as shown in Figure 4 and schematically
depicted in IIIa and IVa (Scheme 3).
CD spectra of 1-3 and [d(TG4T)]4 in Na+ buffer at 25 °C
match those observed in K+ showing positive and negative
bands at 262 and 244 nm, respectively, whereas in the CD
profile of 4 in Na+ buffer a slight shift of the positive and
negative bands at 259 and 239 nm, respectively, takes place.
Furthermore, in the latter the presence of a new lower positive
band centered at 289 nm is observable. These data indicate that
even in Na+ buffer, possessing a lower stabilizing effect on
G-quadruplex structures when compared to K+ buffer (3, 48),
the TEL-ODN 1-3 are structured in parallel quadruplexes. For
4 in Na+ buffer we hypothesize the coexistence of two or more
conformational species, among which the parallel (main) IVa
and the antiparallel (minor) IVb,c structures are present,
considering that most antiparallel G-quadruplexes are character-
ized by a positive band centered at 290-295 nm and a negative
Figure 1. Nondenaturing gel analysis of I-IV and [d(TG4T)]4 (20%
polyacrylamide), Tris-borate (TBE), pH 7.0. The samples were annealed
in Na+ buffer. The bands were visualized by UV shadowing.
Monomolecular Tetra-End-Linked DNA G-Quadruplexes Bioconjugate Chem., Vol. 17, No. 4, 2006 893
band centered around 265 nm (44-47). CD spectra of 1-4 and
[d(TG4T)]4 at 90 °C for both buffers are reported in Figure 2.
The data in K+ buffer confirm that the parallel G-quadruplex
structures are completely retained in the complexes I and II
while a detectable destructuration can be observed for complexes
III and IV. CD spectra in Na+ at 90 °C suggest that complexes
I-III retain, to some extent the characteristic parallel G-qua-
druplex profile, while complex IV and [d(TG4T)]4 are com-
pletely unstructured to random coils.
CD thermal denaturation-renaturation experiments were
performed monitoring the CD value (mdeg) at 265 nm in the
range 25-90 °C with 1 °C/min temperature scan rate. CD
melting curves in K+ buffer for quadruplexes I, II and
d[(TG4T)]4 underwent irrelevant or low CD265 variations up to
90 °C while a relatively high CD265 variation was shown by
the complexes III and IV. The melting profiles of the complexes
I-IV and [d(TG4T)]4 in Na+ showed higher CD265 variation
with respect to the corresponding values registered in K+;
Figure 2. CD and CD melting spectra of I-IV and d[(TG4T)]4 in K+ buffer (left column), in Na+ buffer (middle column) at 25 °C (solid line) and
90 °C (dotted line). CD265 melting profiles (right column) in K+ (solid line) and Na+ (dotted line).
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however, only for the [d(TG4T)]4 complex was a typical and
derivatizable sigmoidal curve (Tm ) 59 °C) registered. These
data indicate that the melting process for the complexes I-III
in Na+ is not complete at 90 °C, while a complete melting of
IV can be observed in Na+ at this temperature. However,
considering the shape of the apparent sigmoidal curve and the
possible polymorphism of IV, we could not determine its
melting temperature in both buffers. We also registered the
CD265 thermal renaturation curves for all complexes in the range
90-25 °C. For the tetramolecular [d(TG4T)]4 complex, as
expected, a very slow renaturation process and a high hysteresis
phenomenon was indicated by the profile of the renaturation
curve at 1 °C/min scan rate. The renaturation curves of I and
II showed relatively low hysteresis at the same temperature scan
rate. The fast reformation of the complexes I and II was also
confirmed by the CD spectrum profiles registered at the end of
the renaturation processes (data not shown). In the case of
complexes III and IV the renaturation curves showed high
hysteresis associated with low restructuration levels.
1H NMR Studies on Quadruplexes I-IV and [d(TG4T)]4.
1H NMR studies on quadruplexes I-IV were performed, after
annealing, in the same buffers used for CD measurements. The
spectrum of I and II, recorded in Na+ buffer at 25 °C (Fig-
ure 3A), showed the presence of four singlets in the range
10.9-11.8, two of them partially overlapped, attributable to
exchange protected imino protons involved in Hoogsteen
N(1)/O(6) hydrogen bonds of G-quartets (45, 48, 49). These
signals were almost superimposable with those observed in the
spectrum of the [d(TG4T)]4 complex already characterized by
NMR data (50). The 1H NMR spectra recorded in Na+ buffer
at 85 °C (Figure 3B) indicated that I is completely stable at
least up to 85 °C. II is partially preserved (only two imino proton
signals are still detectable at this temperature), whereas the
tetramolecular complex [d(TG4T)]4 is completely unstructured
as indicated by the disappearance of all the imino proton signals.
Upon the basis of these data, it appears that quadruplex II in
Na+ buffer is more stable than the tetramolecular counterpart,
yet it is less stable than quadruplex I. The 1H NMR spectra of
I, II, and [d(TG4T)]4 recorded in K+ buffer displayed quite
similar signal patterns; however, it was not possible to observe
any quenching of the imino proton signals up to 85 °C (Figure
3D). This observation is in accordance with reported data about
the capability of K+ cations to form more stable quadruplex
structures in comparison with those observed in Na+ buffer (51).
As expected, 1H NMR spectra of III indicated that this com-
pound is more structured in K+ than in Na+ buffer. In K+ buffer
it was possible to detect the four imino proton signals up to 85
°C (Figure 3C and 3D), whereas in Na+ the spectrum showed
large imino proton signals at 25 °C (Figure 3A) which almost
disappeared at 85 °C (Figure 3B). The 1H NMR spectra of IV
at 25 °C showed very large and overlapped imino proton signals
both in Na+ (Figure 3A) and K+ buffers (Figure 3C). The in-
crease of temperature for 1H NMR spectra of IV led to the
sharpening of all imino proton signals both in Na+ and K+
buffers. In K+ buffer at least three imino proton signals are
clearly detectable even at 85 °C (Figure 3D), whereas in Na+
buffer all imino proton signals are completely lost since 65 °C
(data not shown). These data, which are consistent with UV
and CD experiments, indicate that both complexes III and IV
result in less stable quadruplex structures than I and II. Further-
more, III results more stable than IV especially in K+ buffer.
Molecular Modeling. To explore the capability of TEL-
ODNs 3 and 4 of adopting the parallel quadruplex structure
IIIa and IVa, respectively, a modeling study was performed.
The minimized structures obtained are shown in Figure 4.
Inspection of these structures reveals that in both IIIa and IVa,
the tetra-end-linker is able to span the distance between the 5′-
and 3′-ends of the strands assembled in parallel quadruplex
structure. It can be noted that the orientation of the linker with
respect to the helical axis is different in IIIa and IVa
Figure 3. 1H NMR (500 MHz) spectra of I-IV and [d(TG4T)]4 in Na+ and K+ buffers. The spectra were registered in H2O/D2O, (9:1, v/v) solution
at 0.5 mM of quadruplex at 25 and 85 °C. The aromatic and imino proton regions of the spectra are reported.
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quadruplexes. For both the complexes the interatomic distances
between the linker atoms and the quadruplex groove hydrogen
bonding sites suggest the possibility of favorable nonbonded
interactions. Although the integrity of the G-tetrads is maintained
after energy minimization for both complexes, a detailed analysis
of the H-bonds scheme inside the G-tetrads reveals some
differences between the quadruplexes. In particular, in IIIa, each
G-tetrad shows the same hydrogen bond scheme with an
optimum distance and angle between donor and acceptor atoms,
resulting in strong hydrogen bonds. Indeed in IVa there is a
change of hydrogen-bond distances and angles between adjacent
quartets, and, on average, two hydrogen bonds for each G-tetrad
are lost. Furthermore, the degree of coplanarity between the G
residues in each G-tetrad is greater in IIIa than in IVa. It is
important to point out that the perturbation of each G-tetrad
directly affects the stacking energy of the neighboring G-tetrads.
In summary, the TEL-ODN 3 can form a parallel quadruplex
structure IIIa without causing any distortion in the G-tetrad
region, whereas in the TEL-ODN 4, which forms the quadruplex
IVa, a major readjustment of the G-tetrads occurs. These
findings appear consistent with the experimental CD and NMR
data revealing the formation of a more stable quadruplex III in
comparison to IV.
The results described in this paper confirm the potential of
TEL-ODNs as a new class of ODN analogues prone to adopt
stable intramolecular quadruplex structures. In each case the
Tm values are higher in potassium- than in sodium-containing
buffer. It is noteworthy that, irrespective of the ends by which
the four strands are attached to the tetra-end-linker, the CD
spectra of the obtained complexes are typical of parallel
quadruplex structures, displaying positive maxima centered at
264 nm, in contrast to maxima at 295 nm observed for anti-
parallel structures. The only exception concerns the CD spectrum
of 4 in Na+ buffer, in which a positive shoulder at 295 nm is
present, indicating that a mixture of parallel and antiparallel
forms could exist (quadruplex IVa-c). The whole of data,
including molecular modeling calculations, suggest that the tetra-
end-linker used in the present study is long and flexible enough
to allow the organization of the ODN strands into a parallel
quadruplex structure and (ii) that, at least in the presence of
potassium ions, this form is favored over the antiparallel one,
even if it is at the cost of a major readjustment of G-tetrads,
which is the case of IVa. We believe that TEL-quadruplexes
with suitable sequences and predetermined strand orientations
could be used as aptamers, decoy and molecular probes, when
used in a labeled form. Furthermore, TEL-ODNs may prove to
be important tools for structural studies of alternative less stable
quartets such as A-tetrads (52, 53), C-tetrads (54), T-tetrads (55),
and mixed tetrads (56) as well as tetrads formed by modified
nucleosides (57, 58). To confirm these conclusions as well as
to get hold of a suitable tool to prepare monomolecular
quadruplex structures with a preordered strand orientation, the
syntheses of several TEL-ODNs characterized by shorter
branched spacers and/or longer DNA stretches are currently in
progress in our laboratory.
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ABSTRACT: Guanine-rich DNA sequences are widely dispersed in eukaryotic genome and 
are abundant in regions with relevant biological significance. They can form quadruplex 
structures from stacked tetrads of hydrogen-bonded guanine bases. These stable, non 
classical, secondary structures can be intermolecular or intramolecular in nature and can 
exhibit structural polymorphism based on variability in both strand polarity and loop 
geometry. However, intermolecular formation of quadruplex structure in vitro is very slow 
and may require high ODN concentrations. These unfavourable kinetic and thermodynamic 
parameters could be disadvantageous in view of their potential therapeutic use.We report here 
the syntheses and the structural studies of a set of interconnected d(TG4T) fragments which 
are tethered, with different orientations, to a tetra-end-linker in an attempt to force the 
formation of specific four-stranded DNA quadruplex structures. Two synthetic strategies have 
been used to obtain oligodeoxyribonucleotide (ODN) strands linked with their 3' or 5' ends to 
each of the four arms of the linker. The first approach allowed the synthesis of tetra end-
linked ODN (TEL-ODN) containing the four ODN strands with a parallel orientation, while, 
the latter synthetic pathway led to the synthesis of TEL-ODNs each containing antiparallel 
ODN pairs. The influence of the linker at 3' or 5'-ODN, on the quadruplex typology and 
stability, in the presence of sodium or potassium ions, has been investigated by circular 
dichroism (CD), CD thermal denaturation, 1H NMR experiments at variable temperature and 
molecular modeling. All synthesized TEL-ODNs showed to form parallel G-quadruplex 
structures. Particularly, the TEL-ODN containing all parallel ODN tracts formed very stable 
parallel G-quadruplex complexes whereas, the TEL-ODNs containing antiparallel ODN pairs 
led to relatively less stable parallel G-quadruplexes. The molecular modeling data suggested 
that the above antiparallel TEL-ODNs can adopt parallel G-quadruplex structures thanks to a 
considerable folding of the tetra-branched-linker around the whole quadruplex scaffold. 
The synthesis of a new linker with a shorter branched-spacers and or longer DNA stretches 
are currently in progress in our laboratory. We believe that TEL-quadruplexes with suitable 
sequences and predetermined strand orientations could be used as aptamers, decoy and 
molecular probes when used in a labelled form. Furthemore, TEL-ODNs may prove to be 
important tools for structural studies of alternative less stable quartets such as A-tetrads, C-
tetrads, T-tetrads mixed tetrads as well as tetrads formed by modified oligonucleotides. 
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